

SPECIFICATIONS FOR

NATIONAL KEY PERFORMANCE INDICATORS AND ONLINE SERVICES REPORTING

Maintained by Solving Health for the Department of Health and Aged Care First Nations Health Division

March 2024 | Version 16.1

Solving Health Pty Ltd ACN: 664 154 349 Postal: 3 Dove Street, Revesby, NSW 2212

Mobile: 0405 167 422

Email: info@solvinghealth.au

Copyright

© 2024 Solving Health Pty Ltd.

Any queries concerning reproduction and rights should be sent to rhayhurst@solvinghealth.au
Developed with funding from the Australian Government Department of Health and Aged Care.

Terms and codes used in the coding framework are included under licence and/or approval from the relevant parties specifically, and only, for the purposes of this project.

Document Control

Version History

Version	Date	Author	Release notes
8.2	17 September 2018	Improvement Foundation	Updates to include PI22 relating to cervical cancer and disaggregation
9.0	26 June 2019	First Nations Health Division (FNHD)	Transition activity and updates – Department of Health and Aged Care taking ownership and maintenance responsibility for the document
			Includes cut down OSR for July 2019 reporting
9.1	26 June 2019	First Nations Health Division	Inclusive of OSR Stage 2 for July 2020 reporting
10.0	03 December	NPS	Assume ownership from FNHD
	2019 to 06 April 2020	MedicineWise	Restrict scope to nKPI and OSR only
	April 2020		Modify some definitions to improve clarity
			Update system-specific lists
10.1	August 2020	NPS MedicineWise	Modifications to PI03, PI07, PI14 and PI22 and related measure codes
11.0	December 2020	NPS MedicineWise	Modifications to PI01, PI02, PI04, PI08, PI09, PI10, PI11, PI13 and PI24 and related measure codes for the June 2021 reporting period
			Added age disaggregation to OSR3a and updated related measure codes
12.0	September 2021	NPS MedicineWise	Modifications to PI12, PI15, PI18, PI19A and PI19B and related measure codes for the December 2021 reporting period Updating of visit types and health provider roles by CIS Suspended and retired nKPIs moved to Appendix C Result code tables complied (Appendix D)
12.1	December 2021	NPS MedicineWise	Addition of Condition Coding Framework (Appendix E) implemented in the December 2021 reporting period
13.0	February 2022	NPS MedicineWise	Addition of new sexual health indicator PI25 and related measure codes
			Additional modifications to PI18 and PI19 and related measure codes for the June 2022 reporting period; removal of age groups <18years
13.1	March 2022	NPS MedicineWise	Minor updates to introduction as part of regular review
13.2	March 2022	NPS MedicineWise	Best Practice condition coding correction of code 5833 to 5883 (Carotid Artery Stent)
			Modification to PI19: moderate risk ACR ranges and consistent ordering of male then female
14.0	March 2023	Solving Health	Assume ownership from NPS MedicineWise
			Update to v13.0 release notes to include PI19 age group change (from December 2022)
			Revision of narrative as part of regular review; added acronyms
			PI17 retired: moved indicator to Appendix C
			Updated measure codes: removed retired measure codes to align with current APCC_IDs
			Addition of Pathology Coding Framework for STIs; implemented prior to the July 2023 reporting round
			Removal of reference to 'rfr' to align with PI19 definition using Normal, Low, Moderate, High risk of renal disease

			Reference to 'The Framework' removed as now have both coding and STI tests.
15.0	August 2023	Solving Health	Addition of new PI26 Ear Health indicator
			New ear health coding added to the condition coding framework
			Pathology framework revision: clarification of the free text implementation, expansion of the list of LOINC terms and codes, revision of principles for inclusion and exclusion
			Removal of retired MBS items for PI03 and PI07 Updated METEOR links.
15.1	August 2023	Solving Health	Minor formatting edits
15.2	August 2023	Solving Health	Updated METEOR links
			Adjustment of age groups for PI26
			Removal of references in nKPIs to 'at the organisation' (PI01, PI09, PI16, PI23)
			Clarification in description, numerator and/or denominators of nKPIs to specify Indigenous regular clients (PI05, PI06, PI09, PI10, PI11, PI12, PI13, PI16, PI20, PI21, PI23, PI24, PI25) Revised notes for PI11, PI16, PI23, PI25
15.3	October 2023	Solving Health	Completion of the codes in the ear health condition coding framework and minor edits to the inclusion/exclusion criteria text to aid readability
15.4	December 2023	Solving Health	Vendor implementation of pathology coding framework has been updated
			Addition of CVD Cerebrovascular codes for Communicare
			Updated links to June 2023 METEOR Specifications
16.0	February 2024	Solving Health	Addition of excluded LOINC codes to pathology coding framework
			Added a note to the pathology framework regarding the need to action results in some CIS
			ICPC-2 PLUS codes for Communicare standardised and revised for:
			Renal artery code updated to U99028 (not K99028)
			 Code for Renal artery in cardiovascular surgery table clarified as K53006
			 Arteriosclerosis obliterans removed as doesn't exist in ICPC2-PLUS
			Rapid Bp removed from Best Practice coding in table – code doesn't exist
			Addition of the PI26 APCCID measure codes NKPI-26001 – NKPI-26036
			PI26 – changed word mobility to movement for clarity and clarified the association between counting rules A,B,C and indicator parts 1,2,3
			Updated links to December 2023 METEOR Specifications
16.1	March 2024	Solving Health	Ear health coding framework revised from original draft
			Communicare – addition of new visit types
			ICPC2-PLUS – added newly released codes: K92033, K90029, K90030

^{*}Solving Health acknowledges NPS MedicineWise for earlier versions of this document.

Table of Contents

Intro	duction	9
Revi	ew of the nKPIs	10
Co	oding Frameworks	10
1	Clinical Information System Requirements	11
1.	1 Report Automation	11
1.2	2 Electronic Data Submission	11
1.3	3 Functionality and Capacity	11
2	Foundation Data Concepts	12
2.	1 Clients Client Definition Regular Client	12 12 12
2.2	2 Client Demographics Indigenous Status Gender Age	13 13 13 13
2.3	3 Service Measures Visit/Client Contact Episode of Care	14 14 16
3	National Reporting	17
3.4	National Key Performance Indicators nKPI – PI01: Birthweight recorded nKPI – PI02: Birthweight result nKPI – PI03: Indigenous health assessment completed nKPI – PI05: HbA1c recorded nKPI – PI06: HbA1c result nKPI – PI07: Chronic disease management plan prepared nKPI – PI09: Smoking status recorded nKPI – PI10: Smoking status nKPI – PI11: Smoking status of females who gave birth nKPI – PI12: Body mass index of clients nKPI – PI13: First antenatal visit	18 19 20 21 23 24 26 28 29 31 33 35
	nKPI – PI14: Clients who are immunised against influenza	37

	nKPI – PI16: Alcohol consumption recorded	38
	nKPI – PI18: Kidney function testing	39
	nKPI – PI19: Kidney function test result	41
	nKPI – Pl20: CVD risk assessment factors	45
	nKPI – Pl21: CVD risk assessment result	46
	nKPI – Pl22: Female clients who have had a cervical screening (HPV) test	48
	nKPI – Pl23: Blood pressure recorded	49
	nKPI – Pl24: Blood pressure result	50
	nKPI – Pl25: STI result recorded	51
	nKPI – Pl26: Ear Health Check	52
3.2	Online Services Report	54
	OSR – CS1a: Episodes of care	54
	OSR – CS2: Client contacts (general staff)	55
	OSR – CS2: Client contacts (medical specialists)	57
	OSR – CS2: Client contacts (social and emotional wellbeing / counsellors)	59
	OSR – CS2: Client contacts (allied health professionals)	60
	OSR – CS3a: Individual clients seen	62
Acrony	yms	64
Appen	dix A – Measure code disaggregation	65
Natio	onal Key Performance Indicators	65
Onli	ne Services Report	91
Appen	dix B – Health provider roles by CIS	97
Appen	dix C – Retired and suspended indicators	102
	nKPI – PI04: Indigenous children who are fully Immunised (SUSPENDED)	102
	nKPI – Pl08: Team care arrangement claimed (RETIRED)	104
	nKPI – PI15: Type 2 diabetes or COPD clients immunised against influenza (RETIRED) 106
	nKPI – PI17: AUDIT-C result (RETIRED)	107
	nKPI – PI19-A: eGFR result (RETIRED)	109
	nKPI – PI19-B: ACR result (RETIRED)	111
Appen	dix D – Result codes	113
	Birthweight result	113
	HbA1c result	113
	Body mass index (BMI) result	113
	Gestational age recorded	113

AUDIT-C result	113
Renal function test result	114
CVD risk assessment result	114
eGFR result (not currently in use)	114
Urinary albumin and albumin/creatinine ratio (urinary ACR) (not currently in use) 114
Appendix E – Condition Coding Framework	115
1. Condition Coding Introduction	115
2. Type 2 diabetes	117
2.1 Type 2 diabetes – INCLUDED TERMS	117
2.2 Type 2 diabetes – MMEx specific inclusions	118
2.3 Type 2 diabetes – EXCLUDED TERMS	118
2.4 Type 2 diabetes – MMEx specific exclusions	118
3. Chronic Kidney Disease (CKD)	119
3.1 Chronic Kidney Disease (CKD) – INCLUDED TERMS	119
3.2 Chronic Kidney Disease (CKD) – MMEx specific inclusions	122
3.3 Chronic Kidney Disease (CKD) – EXCLUDED TERMS	123
3.4 Chronic Kidney Disease (CKD) – MMEx specific exclusions	125
4. Chronic obstructive pulmonary disease (COPD)	126
4.1 COPD – INCLUDED TERMS	126
4.2 COPD – MMEx specific inclusions – Mapping table	127
4.3 COPD – EXCLUDED TERMS	127
4.4 COPD – MMEx specific exclusions – Mapping table	128
5. Cardiovascular disease (CVD)	129
5.1 Cardiovascular Disease (CVD) – INCLUDED TERMS	129
5.2 CVD – MMEx specific inclusions – Mapping table	141
5.3 Cardiovascular Disease (CVD) – EXCLUDED SUBGROUPS AND TERMS	145
5.4 CVD - MMEx specific exclusions - Mapping table	150
6. Ear Health	151
6.1 Ear Health – INCLUDED TERMS	151
Clinical Diagnosis inclusion terms	152
Procedure inclusion terms	165
6.2 Ear Health – EXCLUDED TERMS	167
Appendix F – Pathology Coding Framework	183
Introduction	183

Principles for inclusion / exclusion	183
The Pathology Coding Framework	184
Chlamydia and gonorrhoea	186
Chlamydia and gonorrhoea – INCLUDED CODES	186
Chlamydia and gonorrhoea – EXCLUDED LOINC codes	187
Chlamydia only – INCLUDED CODES	188
Chlamydia only – EXCLUDED LOINC CODES	191
Gonorrhoea only – INCLUDED CODES	201
Gonorrhoea only – EXCLUDED LOINC CODES	202
Free text searches - Inclusion and Exclusion Terms	203
Vendor Implementation – Pathology Data Capture	205

Introduction

Approximately 200 organisations are funded by the Australian Government under its Indigenous Australians' Health Programme (IAHP) to deliver culturally appropriate primary health care services to Aboriginal and Torres Strait Islander (First Nations) people. Information reported by these organisations is available through two data collections, the national Key Performance Indicators (nKPI) and Online Services Report (OSR). These programs and managed by the First Nations Health Division (FNHD) of the Department of Health and Aged Care (DHAC).

Since 2018, reporting has been facilitated directly from organisations' clinical information systems (CIS). This document (the Specifications) details the reporting requirements for nKPI and OSR for all measures which can be generated from a complying CIS.

Intended for use by service providers and CIS vendors, the Specifications provides a single point of reference for defining the indicators. A full description of each measure and its component data elements, as well as the clinical conditions, tests, or procedures relevant to each measure are included.

Also included are references to standard national definitions such as the Australian Institute of Health and Welfare's (AIHWs) Metadata Online Registry (METEOR), additional information regarding counting rules and other notes related to variations in process and CIS functionality. The additional detail and clarification are intended to ensure high quality reporting and consistency (and thus comparability across vendors) in the reported measures.

From a privacy perspective, nKPI and OSR do not collect any personally identifying information (PII). All measures are based on aggregated practice level data and the use of data is covered in the Grant agreements between the Commonwealth and health services.

Review of the nKPIs

In 2018, the DHAC funded the AIHW to conduct a comprehensive review of the nKPI and OSR data collections. As a result of the review, some indicators were revised to better align with clinical best practice and guidelines. The indicator updates are being implemented in phases. Several indicators were retired or suspended; the specifications for these remain in the document but have been moved to Appendix C.

Following the review of the nKPIs, several new indicators were proposed. The first new indicator PI25 'Proportion of Indigenous regular clients who are tested for one or more sexually transmissible infections' was introduced in the July 2022 collection as a pilot indicator.

A second pilot indicator PI26 'Proportion of Indigenous regular clients aged 0-14 years who have a completed ear health check recorded' is being introduced for the July 2024 collection.

The Specifications are updated as indicator changes come into effect and when new indicators are released.

Coding Frameworks

The Condition Coding Framework was implemented in late 2021. As each CIS has their own coding system, the formats, and methods for producing nKPI results are specific to each. The Condition Coding Framework, included in Appendix E, accommodates the different clinical taxonomies used by each CIS including Snomed CT. The intent is to provide sufficient detail to enable a consistent definition, across all CIS, that aligns with agreed national definitions.

Ear conditions have been added to the Condition Coding Framework to support PI26 Ear Health, these are included in Appendix E.

The Pathology Coding Framework, Appendix F, was developed to aid consistent reporting of chlamydia and gonorrhoea tests in PI25.

1 Clinical Information System Requirements

1.1 Report Automation

Each vendor's software must allow users to be able to schedule the initial population of the nKPI report and OSR from the database within the CIS.

This enables users to schedule report generation overnight and reduce resource demand during normal operating hours.

1.2 Electronic Data Submission

The Health Data Portal (Data Portal) allows electronic data submission from health services.

The DHAC has extended the use of the previously developed XML schema for OCHREStreams, allowing the submission of data directly to the Data Portal via a secure data exchange. The XML data submission details are provided to each software vendor via email.

At the commencement of a reporting period, organisations required to report on their health-related data are notified via email that the reporting round has commenced.

Each organisation with a complying CIS produces and reviews the required report and then transfers this report directly to the Data Portal as a data file. This is known as direct load and automatically creates a draft data asset submission in the Data Portal.

If there are any issues with the data at the time of the direct load, the health service receive an email informing them of the issues. The health service can then log into the Data Portal and amend the data file as required before submitting the data asset for review and/or approval.

Quick reference guides are available to guide users through this process in a step-by-step manner.

1.3 Functionality and Capacity

Amendments to measures or expansion of report scope place additional demands on CIS vendors as functional changes are required to their systems. This necessitates investment of resources, financial and otherwise, and in some cases may require substantial structural database changes to allow for the appropriate capture of information.

The DHAC is committed to working with vendors and service providers to ensure that CISs remain aligned with the requirements of government and associated legislation to capture the required information.

2 Foundation Data Concepts

The following data concepts are fundamental in accurately identifying nKPI and OSR indicators and measures.

2.1 Clients

Client Definition

(Used in reporting nKPI and OSR)

A client¹ is a consumer of health services provided by the reporting organisation, for whom a client record has been created in the CIS. Where the CIS includes a 'record status', the following exclusions apply, unless specifically defined within the indicator:

Record Status		
Counted as a client	Not counted as a client	
 Active Banned Current patient Emergency contact Inactive Next of kin Past patient Transient patient 	DeceasedFictitiousNon-patient	

Regular Client

(Used in nKPI reporting)

A regular client is defined as a client who has an active medical record; that is, a client who attended² a particular primary health care provider at least 3 times in the past 2 years. Included and excluded visit types are outlined in section 2.3 below.

(METEOR link: https://meteor.aihw.gov.au/content/index.phtml/itemId/686291)

There may be minor variations between health services with respect to the way in which multiple encounters with the same provider on the same day are recorded. Where a client attends a second or subsequent encounter with the same provider on the same day, each CIS provides the user with the option of continuing to add information to the initial visit record or opening a new visit. Thus, all CISs have the capacity to capture multiple visits with the same provider on the same day.

Three of the four CISs that report directly to the Data Portal count each visit individually for the purpose of determining regular patient status. However, MMEx counts multiple visits with the same provider on the same day as a single visit, for the purpose of determining regular patient status. The impact of this variation is minimal.

¹ The definition of a regular client does not include deceased persons.

² The number of times a client 'attended' the service is equivalent to the number of visits recorded. More than one visit can be recorded on a single day.

2.2 Client Demographics

Indigenous Status

(Used in reporting nKPI and OSR)

Indigenous status is defined by whether a person identifies as being of Aboriginal or Torres Strait Islander origin.

Permissible values are:

- 1 Aboriginal but not Torres Strait Islander origin
- 2 Torres Strait Islander but not Aboriginal origin
- 3 Both Aboriginal and Torres Strait Islander origin
- 4 Neither Aboriginal nor Torres Strait Islander origin
- 9 Not stated/inadequately described

(METEOR link: https://meteor.aihw.gov.au/content/index.phtml/itemld/602543)

Note 1: Categories 1, 2 and 3 are classified as Indigenous.

Category 4 is classified as Non-Indigenous.

Note 2: Where a baby does not have a separate client record, and the mother's record is used as a source of birth details for reporting nKPI01 and nKPI02, the baby is considered Indigenous if the mother is Indigenous.

The nKPI report includes only Indigenous clients for all indicators.

The OSR includes all clients of the service including non-Indigenous clients. Each measure is disaggregated by Indigenous status (labelled 'Ethnicity') as:

- Indigenous (labelled 'Aboriginal and Torres Strait Islander')
- Non-Indigenous (labelled 'Non-Aboriginal and Torres Strait Islander')
- Not stated/inadequately described (labelled 'Aboriginal and Torres Strait Islander status not recorded').

Gender

(Used in reporting nKPI and OSR)

The distinction between male, female, and other genders which are a combination of male and female, or neither male nor female.

Permissible values are:

- 1 Male
- 2 Female
- 3 Other
- 9 Not stated/inadequately described.

Note: The nKPI report currently only includes values 1 and 2 whereas the OSR includes 1, 2 and 9.

(METEOR link: https://meteor.aihw.gov.au/content/741686)

Age

(Used in reporting nKPI and OSR)

Where the definition of a measure or disaggregation includes the client's age, this refers to the age of the client as at the census date.

The age groups listed are those defined by METEOR, for example 0-4 years. For clarity, in this age group example, all patients aged 0 to <5 years should be included.

All nKPIs are defined or disaggregated by age or age group.

Clients with unknown age are excluded from nKPI reports. Clients with unknown age are not excluded from OSR results.

(METEOR link: https://meteor.aihw.gov.au/content/index.phtml/itemId/303794)

2.3 Service Measures

Visit/Client Contact

(Used in reporting nKPI [Visit] and OSR [Client contact])

A Visit/Client contact is defined as a clinical interaction between a client and the service, that leads to either the creation of a new client record or the updating of an existing client record in the CIS. This could include clinical interactions by telephone (telehealth).

Visits/Client contacts do not include:

- Group contacts (eg, group antenatal classes, men's groups, support groups)
- Administration activities (eg, sending SMS reminder, non-clinical phone calls)
- Transport that does not involve the direct provision of health care
- Participation in programs subcontracted to other organisations and funded externally
- Routine care of clients in residential homes run by the service (where regular progress notes may be recorded in the residential aged care facility CIS).

Multiple visits/client contacts may occur on a single day.

Where the CIS includes a 'visit type' field, the following exclusions apply, unless specifically defined within the indicator:

Visit 7	Гуре
Counted as a visit	Not counted as a visit
 Home visit consultation Hospital consultation Hostel Locum service Nursing home consultation Other RACF (residential aged care facility) consultation Surgery consultation Telehealth (clinical) 	 Email Non-visit Out of office Practice admin SMS Telephone (non-clinical)*

Visit types included in four major Australian CISs (as at March 2023) are listed in Table 1 below.

^{*}Some CIS do not distinguish telephone visits as either clinical or non-clinical. Where it cannot be distinguished, it is recommended to count all 'Telephone' visit types as clinical interactions i.e. 'counted as a visit'. Note: Telehealth visits should be managed separately.

Table 1: Visit type by vendor

Best Practice	Communicare	Medical Director	MMEx*
Counted as a visit	(for reporting)	ı	
Home Hospital Hostel Locum service Out of Office RACF (residential aged care facility) Surgery Telehealth (clinical) Telephone	Aboriginal health service Client's home Clinic – consult Clinical administration – client contact Commercial setting (e.g. pharmacy) Community health centre Community services centre Court Day aged care centre Day procedure centre (free- standing) Dental room Drug and alcohol agency Health care practitioner office (any discipline) Health Service Hospital – all types Hospital – emergency department Hospital – general practice Hostel Inreach Mobile clinic Nursing home Other Outreach Prison Renal dialysis centre (free-standing) Respite care facility (non-hostel or nursing) School Supported residential accommodation Telehealth-Provider Telehealth-Provider Telehealth-recipient	Home visit consultation Hospital consultation Locum service Nursing home consultation Other Surgery consultation Telephone Telehealth	Other Progress notes with the progress note class of 'consultation' Surgery
Not counted as a v	Telephone visit (for reporting)	I	I
Email Non visit Other SMS	Administration – client contact Administration – no client contact Clinical administration – no client contact Contact Contact attempt unsuccessful – no client contact Dispensary – no client contact	Email Practice admin SMS	Admin Progress notes with the progress note class 'non-consultation'

^{*}MMEx visit types are customisable so organisations can add additional visit types to this base set as required.

Episode of Care

(Used in reporting OSR)

An episode of care comprises any client contacts occurring on a single calendar day. Multiple contacts on a single day are counted as one episode of care.

3 National Reporting

Organisations report nKPI and OSR data via the Data Portal in two reporting rounds per year:

- nKPIs are reported six-monthly (commencing 1 January and 1 July)
- OSR is reported annually in the 1 July reporting round.

This document includes only those measures (from nKPI and OSR) which can be reported directly from CISs.

For each measure, relevant information is provided in the tabular format below. Where disaggregation options are available, these are matched to measure codes in Appendix A Measure Code Disaggregation.

[indicator/measure set code]	[indicator/measure set code] – [indicator short name]		
Full name	[indicator long name]		
Description	[indicator description]		
Measure type	[indicator measure type]		
Numerator	[numerator calculation description]		
Denominator	[denominator calculation description]		
Disaggregation	[disaggregation group] [disaggregation options]		
Disaggregation points	[total number of measures]		
Measure codes	[measure codes]		
Counting rules	[specific counting instructions]		
Notes	[notes relating to the indicator]		
Definition owner	[indicator owner] ([indicator source])		
METEOR link*	[hyperlink to related METEOR definition]		

^{*}METEOR links are no longer published for OSR.

3.1 National Key Performance Indicators

The nKPIs for First Nations people focus on process of care and health outcome measures for maternal and child health, chronic disease management and preventative health. The primary purpose of the nKPIs is to provide reporting organisations with data they can use for continuous quality improvement to improve the delivery of primary health care services.

The data are also used to support policy, planning and progress, for example to monitor progress against the Council of Australian Governments' Closing the Gap health outcome targets, and support the national health goals set out in the Implementation Plan for the National Aboriginal and Torres Strait Islander Health Plan 2013–2023.

The nKPls provide measures of the extent to which various general indicators of individual health and health-related behaviours among the Indigenous population are being captured. The cohort of interest in the nKPls is the 'Indigenous regular client' population.

The following 21 nKPIs are currently reported. Note: PI26 Ear Health is in implementation phase.

Links to the currently published METEOR specifications are supplied where available, noting the content in this document may reflect a more recent unpublished version.

nKPI – Pl01: Birthweight recorded		
Full name	Proportion of Indigenous babies born within the previous 12 months, who attended the organisation more than once who have birthweight recorded	
Description	Proportion of Indigenous babies born within the previous 12 months, who have had more than one visit and whose birthweight has been recorded	
Measure type	Percentage	
Numerator	Number of Indigenous babies born within the previous 12 months who have had more than one visit and whose birthweight has been recorded	
Denominator	Total number of Indigenous babies born within the previous 12 months who have had more than one visit and had a medical record	
Disaggregation	Nil	
Disaggregation points	One (1) measure is derived from this assessment	
Counting rules	 Birthweight is defined as the first weight of a baby obtained after birth Only live births are included Results arising from measurements conducted outside of the organisation, that are known by the organisation, are included in the calculation of this indicator Where a baby does not have a separate client record, and the mother's record is used as a source of birth details, the baby is considered Indigenous if the mother is Indigenous 	
Measure Code/s	NKPI-01002	
Notes	 The birthweight is to be taken from the baby's client record where available. Where a baby does not have a separate client record, the mother's record may be used as a source of birth details. 	
Definition owner	Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care	
METEOR link	https://meteor.aihw.gov.au/content/787940 (December 2023)	

Full name Proportion of Indigenous babies born within the previous 12 months, who attended the organisation more than once who have a birthweight result within a specified category Proportion of Indigenous babies born within the previous 12 months, who had had more than one visit and whose birthweight results were categorised as one of the following: Low (less than 2,500 grams) Normal (2,500 grams to less than 4,500 grams) High (4,500 grams and over) Percentage Numerator The number of Indigenous babies born within the previous 12 months, who have had more than one visit and whose birthweight results were categorised as [Disaggregation: Birthweight] Denominator The number of Indigenous babies born within the previous 12 months, who have had more than one visit and whose birthweight has been recorded Disaggregation Birthweight: bw-1 bw-2 bw-3 Disaggregation points Three (3) measures are derived from this assessment Measure Code/s NKPI-02001 to 02003 Counting rules Birthweight is defined as the first weight of a baby obtained after birth Only live births are included Results arising from measurements conducted outside of the organisation, that are known by the organisation, are included in the calculation of this indicator Where a baby does not have a separate client record, and the mother's record is used as a source of birth details, the baby is considered Indigenous if the mother is Indigenous Notes Pefinition owner Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care METEOR link https://imeteor.aihw.gov.au/content/787945 (December 2023)	nKPI – PI02: Birthweight result		
who had had more than one visit and whose birthweight results were categorised as one of the following: Low (less than 2,500 grams) Normal (2,500 grams to less than 4,500 grams) High (4,500 grams and over) Measure type Percentage Numerator The number of Indigenous babies born within the previous 12 months, who have had more than one visit and whose birthweight results were categorised as [Disaggregation: Birthweight] Denominator The number of Indigenous babies born within the previous 12 months, who have had more than one visit and whose birthweight has been recorded Disaggregation Birthweight: bw-1 bw-2 bw-3 Disaggregation points Three (3) measures are derived from this assessment Measure Code/s NKPI-02001 to 02003 Birthweight is defined as the first weight of a baby obtained after birth Only live births are included Results arising from measurements conducted outside of the organisation, that are known by the organisation, are included in the calculation of this indicator Where a baby does not have a separate client record, and the mother's record is used as a source of birth details, the baby is considered Indigenous if the mother is Indigenous Notes Definition owner Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care	Full name	who attended the organisation more than once who have a birthweight	
Normal (2,500 grams to less than 4,500 grams) High (4,500 grams and over) Percentage Numerator The number of Indigenous babies born within the previous 12 months, who have had more than one visit and whose birthweight results were categorised as [Disaggregation: Birthweight] Denominator The number of Indigenous babies born within the previous 12 months, who have had more than one visit and whose birthweight has been recorded Birthweight: - bw-1 - bw-2 - bw-3 Disaggregation points Three (3) measures are derived from this assessment Measure Code/s NKPI-02001 to 02003 Counting rules Birthweight is defined as the first weight of a baby obtained after birth Only live births are included Results arising from measurements conducted outside of the organisation, that are known by the organisation, are included in the calculation of this indicator Where a baby does not have a separate client record, and the mother's record is used as a source of birth details, the baby is considered Indigenous if the mother is Indigenous Notes The birthweight is to be taken from the baby's client record where available. Where a baby does not have a separate client record, the mother's record may be used as a source of birth details. Definition owner Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care	Description	who had had more than one visit and whose birthweight results were	
Numerator The number of Indigenous babies born within the previous 12 months, who have had more than one visit and whose birthweight results were categorised as [Disaggregation: Birthweight] Denominator The number of Indigenous babies born within the previous 12 months, who have had more than one visit and whose birthweight has been recorded Birthweight: - bw-1 - bw-2 - bw-3 Disaggregation points Three (3) measures are derived from this assessment Measure Code/s NKPI-02001 to 02003 Counting rules Birthweight is defined as the first weight of a baby obtained after birth Only live births are included Results arising from measurements conducted outside of the organisation, that are known by the organisation, are included in the calculation of this indicator Where a baby does not have a separate client record, and the mother's record is used as a source of birth details, the baby is considered Indigenous if the mother is Indigenous Notes The birthweight is to be taken from the baby's client record where available. Where a baby does not have a separate client record, the mother's record may be used as a source of birth details. Definition owner Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care		 Normal (2,500 grams to less than 4,500 grams) 	
who have had more than one visit and whose birthweight results were categorised as [Disaggregation: Birthweight] Denominator The number of Indigenous babies born within the previous 12 months, who have had more than one visit and whose birthweight has been recorded Birthweight: - bw-1 - bw-2 - bw-3 Disaggregation points Three (3) measures are derived from this assessment Measure Code/s NKPI-02001 to 02003 Counting rules Birthweight is defined as the first weight of a baby obtained after birth Only live births are included Results arising from measurements conducted outside of the organisation, that are known by the organisation, are included in the calculation of this indicator Where a baby does not have a separate client record, and the mother's record is used as a source of birth details, the baby is considered Indigenous if the mother is Indigenous Notes Pofinition owner Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care	Measure type	Percentage	
who have had more than one visit and whose birthweight has been recorded Birthweight: - bw-1 - bw-2 - bw-3 Disaggregation points Three (3) measures are derived from this assessment Measure Code/s NKPI-02001 to 02003 Counting rules Birthweight is defined as the first weight of a baby obtained after birth - Only live births are included - Results arising from measurements conducted outside of the organisation, that are known by the organisation, are included in the calculation of this indicator - Where a baby does not have a separate client record, and the mother's record is used as a source of birth details, the baby is considered Indigenous if the mother is Indigenous Notes Notes Pefinition owner Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care	Numerator	who have had more than one visit and whose birthweight results were	
- bw-1 - bw-2 - bw-3 Disaggregation points Three (3) measures are derived from this assessment Measure Code/s NKPI-02001 to 02003 Counting rules Birthweight is defined as the first weight of a baby obtained after birth - Only live births are included - Results arising from measurements conducted outside of the organisation, that are known by the organisation, are included in the calculation of this indicator - Where a baby does not have a separate client record, and the mother's record is used as a source of birth details, the baby is considered Indigenous if the mother is Indigenous Notes - The birthweight is to be taken from the baby's client record where available Where a baby does not have a separate client record, the mother's record may be used as a source of birth details. Definition owner - Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care	Denominator	who have had more than one visit and whose birthweight has been	
Measure Code/s NKPI-02001 to 02003 Birthweight is defined as the first weight of a baby obtained after birth Only live births are included Results arising from measurements conducted outside of the organisation, that are known by the organisation, are included in the calculation of this indicator Where a baby does not have a separate client record, and the mother's record is used as a source of birth details, the baby is considered Indigenous if the mother is Indigenous The birthweight is to be taken from the baby's client record where available. Where a baby does not have a separate client record, the mother's record may be used as a source of birth details. Definition owner Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care	Disaggregation	- bw-1 - bw-2	
Birthweight is defined as the first weight of a baby obtained after birth Only live births are included Results arising from measurements conducted outside of the organisation, that are known by the organisation, are included in the calculation of this indicator Where a baby does not have a separate client record, and the mother's record is used as a source of birth details, the baby is considered Indigenous if the mother is Indigenous The birthweight is to be taken from the baby's client record where available. Where a baby does not have a separate client record, the mother's record may be used as a source of birth details. Definition owner Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care	Disaggregation points	Three (3) measures are derived from this assessment	
birth Only live births are included Results arising from measurements conducted outside of the organisation, that are known by the organisation, are included in the calculation of this indicator Where a baby does not have a separate client record, and the mother's record is used as a source of birth details, the baby is considered Indigenous if the mother is Indigenous The birthweight is to be taken from the baby's client record where available. Where a baby does not have a separate client record, the mother's record may be used as a source of birth details. Definition owner Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care	Measure Code/s	NKPI-02001 to 02003	
Notes The birthweight is to be taken from the baby's client record where available. Where a baby does not have a separate client record, the mother's record may be used as a source of birth details. Definition owner Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care	Counting rules	 birth Only live births are included Results arising from measurements conducted outside of the organisation, that are known by the organisation, are included in the calculation of this indicator Where a baby does not have a separate client record, and the 	
available. • Where a baby does not have a separate client record, the mother's record may be used as a source of birth details. Definition owner Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care		considered Indigenous if the mother is Indigenous	
of Health and Aged Care	Notes	available.Where a baby does not have a separate client record, the mother's	
METEOR link https://meteor.aihw.gov.au/content/787945 (December 2023)	Definition owner	·	
	METEOR link	https://meteor.aihw.gov.au/content/787945 (December 2023)	

nKPI – Pl03: Indigenou	s health assessment completed
Full name	Proportion of Indigenous regular clients who have a current completed Indigenous health assessment
Description	Proportion of Indigenous regular clients who have a current completed Indigenous health assessment as indicated by:
	An MBS-rebated Indigenous health assessment:
	 In-person MBS-rebated items - MBS items: 715 or 228 Telehealth MBS-rebated items - MBS items: 92004 or 92011
	For ages 0–14: an Indigenous health assessment is counted if it was completed within the previous 12 months
	For ages 15+: an Indigenous health assessment is counted if it was completed within the previous 24 months
Measure type	Percentage
Numerator	Calculation A: Number of <i>[Disaggregation: Gender]</i> Indigenous regular clients aged <i>[Disaggregation: Age]</i> who have a current completed in-person MBS-rebated Indigenous health assessment (MBS items: 715 or 228)
	Calculation B: Number of <i>[Disaggregation: Gender]</i> Indigenous regular clients aged <i>[Disaggregation: Age]</i> who have a current completed Telehealth MBS-rebated Indigenous health assessment (MBS items: 92004 or 92011)
Denominator	Calculation A and B: Total number of [Disaggregation: Gender] Indigenous regular clients aged [Disaggregation: Age]
Disaggregation	Age: - 0–4 years - 5–14 years - 15–24 years - 25–34 years - 35–44 years - 45–54 years - 55–64 years - 65 years and older Gender: - Male - Female Type of health assessment: - In-person MBS-rebated Indigenous health assessment - Telehealth MBS-rebated Indigenous health assessment
Disaggregation points	Thirty-two (32) measures are derived from this assessment
Measure Code/s	NKPI-03002 to 03006, NKPI-03008 to 03034

Counting rules	 Count is of people, not assessments Consider only the most recent assessment
Notes	 This indicator is likely to be further revised in the future to include equivalent Indigenous health assessments. A 'total' Indigenous health assessment category will be calculated for national reporting purposes based on submitted data but is not required to be collected/submitted by organisations.
Definition owner	Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care
METEOR link	https://meteor.aihw.gov.au/content/787949 (December 2023)

- "	DIOS D. A. C. II.
Full name	PI05: Proportion of Indigenous regular clients with type 2 diabetes who have had a HbA1c measurement result recorded
Description	Proportion of Indigenous regular clients with Type 2 diabetes, who have had an HbA1c measurement result recorded within the previous:
	6 months12 months
Measure type	Percentage
Numerator	The number of [Disaggregation: Gender] Indigenous regular clients with Type 2 diabetes aged [Disaggregation: Age] who have had an HbA1c test result recorded within the previous [Disaggregation: Test within previous]
Denominator	The number of [Disaggregation: Gender] Indigenous regular clients with Type 2 diabetes aged [Disaggregation: Age]
Disaggregation	Age:
	- 0–4 years
	- 5–14 years
	- 15–24 years
	25–34 years35–44 years
	- 45–54 years
	- 55–64 years
	- 65 years and over
	Gender:
	_ Male
	- Female
	Test within previous:
	- 6 months
	- 12 months
Disaggregation points	Thirty-two (32) measures are derived from this assessment
Measure Code/s	NKPI-05001 to 05032
Counting rules	Nil
Notes	 'HbA1c' – glycosylated haemoglobin. 'Type 2 diabetes' – specifically excludes Type I diabetes, secondary diabetes, gestational diabetes mellitus (GDM), previous GDM, Impaired fasting glucose, and impaired glucose tolerance.
Definition owner	Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care

nKPI – PI06: HbA1c result	
Full name	PI06: Proportion of Indigenous regular clients with Type 2 diabetes who have a HbA1c measurement result within a specified level
Description	Proportion of regular clients who are Indigenous, have Type 2 diabetes and whose HbA1c measurement result, recorded within either the previous 6 months or 12 months, was categorised as one of the following: Iess than or equal to 7% greater than 7% but less than or equal to 8% greater than 8% but less than 10% greater than or equal to 10%
Measure type	Percentage
Numerator	The number of <i>[Disaggregation: Gender]</i> Indigenous regular clients with Type 2 diabetes aged <i>[Disaggregation: Age]</i> whose most recent HbA1c measurement result, recorded within the previous <i>[Disaggregation: Test within previous]</i> , was <i>[Disaggregation: HbA1c result]</i>
Denominator	The number of <i>[Disaggregation: Gender]</i> Indigenous regular clients with Type 2 diabetes aged <i>[Disaggregation: Age]</i> who have had an HbA1c test result recorded within the previous <i>[Disaggregation: Test within previous]</i>
Disaggregation	Age: - 0-4 years - 5-14 years - 15-24 years - 25-34 years - 35-44 years - 45-54 years - 55-64 years - 65 years and over Gender: - Male - Female Test within previous: - 6 months - 12 months HbA1c result: - hr-1 - hr-2 - hr-3 - hr-4

Disaggregation points	One-hundred and twenty-eight (128) measures are derived from this assessment
Measure Code/s	NKPI-06001 to 06128
Counting rules	Nil
Notes	 'Type 2 diabetes' – specifically excludes Type I diabetes, secondary diabetes, gestational diabetes mellitus (GDM), previous GDM, Impaired fasting glucose, and impaired glucose tolerance. Conversion of HbA1c results from percentage to mmol/mol and vice-versa is performed by using the 'master equation' specified in the Medical Journal of Australia³: HbA1c (mmol/mol) = (10.93 x HbA1c (%)) – 23.50
Definition owner	Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care
METEOR link	https://meteor.aihw.gov.au/content/787957 (December 2023)

³ Jones G, Barker G, Goodall I, Schneider H-G Shephard M, Twigg S (2011) Change of HbA1c reporting to the new SI units, Medical Journal of Australia, Med J Aust 2011; 195 (1): 45-46. https://www.mja.com.au/journal/2011/195/1/change- https://www.mja.com.au/journal/2011/195/1/change- https://www.abs.gov.au/ausstats/abs@.nsf/Lookup/4363.0.55.001Chapter670222011-13

nKPI – PI07: Chronic di	sease management plan prepared
Full name	PI07: Proportion of Indigenous regular clients with a chronic disease who have a Chronic Disease Management Plan prepared
Description	Proportion of Indigenous regular clients who have a chronic disease (Type 2 diabetes) and for whom a Chronic Disease Management Plan was prepared within the previous 24 months as indicated by: • An MBS-rebated Chronic Disease Management Plan: - In-person MBS-rebated items: 721 or 229 - Telehealth MBS-rebated items: 92024 or 92055
Measure type	Percentage
Numerator	Calculation A: Number of [Disaggregation: Gender] Indigenous regular clients aged [Disaggregation: Age] who have Type 2 diabetes and for whom an in-person MBS-rebated Chronic Disease Management Plan (MBS items: 721 or 229) was prepared within the previous 24 months.
	Calculation B: Number of [Disaggregation: Gender] Indigenous regular clients aged [Disaggregation: Age] who have Type 2 diabetes and for whom a Telehealth MBS-rebated Chronic Disease Management Plan (MBS items: 92024 or 92055) was prepared within the previous 24 months
Denominator	Calculation A and B: Total number of [Disaggregation: Gender] Indigenous regular clients aged [Disaggregation: Age] who have Type 2 diabetes
Disaggregation	Age: - 0–4 years - 5–14 years - 15–24 years - 25–34 years - 35–44 years - 45–54 years - 55–64 years - 65 years and older Gender: - Male - Female Type of Chronic Disease Management Plan: - In-person MBS-rebated Chronic Disease Management Plan - Telehealth MBS-rebated Chronic Disease Management Plan
Disaggregation points	Thirty-two (32) measures are derived from this assessment
Measure Code/s	NKPI-07001 to 07032

Counting rules	Count is of people, not plansConsider only the most recent plan
Notes	 'Type 2 diabetes' – specifically excludes Type I diabetes, secondary diabetes, gestational diabetes mellitus (GDM), previous GDM, Impaired fasting glucose, and impaired glucose tolerance. This indicator is likely to be further revised in the future to include:
	equivalent Chronic Disease Management Plansother chronic diseases.
	 A 'total' Chronic Disease Management Plan category will be calculated for national reporting purposes based on submitted data but is not required to be collected/submitted by organisations.
Definition owner	Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care
METEOR link	https://meteor.aihw.gov.au/content/787961 (December 2023)

nKPI – Pl09: Smoking	status recorded
Full name	PI09: Proportion of Indigenous regular clients who have a smoking status recorded
Description	Proportion of regular clients who are Indigenous, aged 11 and over and whose smoking status has been recorded within the previous 24 months
Measure type	Percentage
Numerator	The number of <i>[Disaggregation: Gender]</i> Indigenous regular clients aged <i>[Disaggregation: Age]</i> whose smoking status has been recorded
Denominator	The number of [Disaggregation: Gender] Indigenous regular clients aged [Disaggregation: Age]
Disaggregation	Age: - 11–14 years - 15–24 years - 25–34 years - 35–44 years - 45–54 years - 55–64 years - 65 years and older Gender: - Male - Female
Disaggregation points	Fourteen (14) measures are derived from this assessment
Measure Code/s	NKPI-09001 to 09012, NKPI-09041, NKPI-09051
Counting rules	 Where the smoking status does not have an assessment date assigned within the Clinical Information System (CIS), smoking status recorded in the CIS should be treated as current (that is, as having been updated within the previous 24 months) Results arising from measurements conducted outside of the organisation that are known by the organisation should be included
Notes	Nil
Definition owner	Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care
METEOR link	https://meteor.aihw.gov.au/content/787965 (December 2023)

Full name	PI10: Proportion of Indigenous regular clients who have a smoking status result within a specified category
Description	Proportion of regular clients who are Indigenous, aged 11 and over and whose smoking status has been recorded within the previous 24 months as one of the following: current smoker ex-smoker or never smoked
Measure type	Percentage
Numerator	The number of [Disaggregation: Gender] Indigenous regular clients aged [Disaggregation: Age] whose most recent smoking status has been recorded as [Disaggregation: Smoking Status]
Denominator	The number of <i>[Disaggregation: Gender]</i> Indigenous regular clients aged <i>[Disaggregation: Age]</i> whose smoking status has been recorded
Disaggregation	Age: - 11–14 years - 15–24 years - 25–34 years - 35–44 years - 45–54 years - 55–64 years - 65 years and older Gender: - Male - Female Smoking Status: - current smoker - ex-smoker - never smoked
Disaggregation points	Forty-two (42) measures are derived from this assessment
Measure Code/s	NKPI-10001 to 10036, NKPI-10041 to 10043, NKPI-10051 to 10053
Counting rules	 Where the smoking status does not have an assessment date assigned within the Clinical Information System (CIS), smoking status recorded in the CIS should be treated as current (that is, as having been updated within the previous 24 months) Results arising from measurements conducted outside of the organisation that are known by the organisation should be included
Notes	Nil

Definition owner	Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care
METEOR link	https://meteor.aihw.gov.au/content/787969 (December 2023)

nKPI – PI11: Smoking	status of females who gave birth
Full name	PI11: Proportion of female Indigenous regular clients who gave birth within the previous 12 months who have a smoking status result within a specified category
Description	Proportion of female regular clients who are Indigenous, who gave birth within the previous 12 months and whose smoking status was recorded during pregnancy as one of the following: current smoker ex-smoker or never smoked
Measure type	Percentage
Numerator	The number of female Indigenous regular clients aged <i>[Disaggregation: Age]</i> who gave birth within the previous 12 months, and whose most recent smoking status recorded during pregnancy has been recorded as <i>[Disaggregation: Smoking Status]</i>
Denominator	The number of female Indigenous regular clients aged [Disaggregation: Age] who gave birth within the previous 12 months, and whose smoking status has been recorded
Disaggregation	Age: - less than 20 years - 20–34 years - 35 years and older Smoking Status: - current smoker - ex-smoker - never smoked
Disaggregation points	Nine (9) measures are derived from this assessment
Measure Code/s	NKPI-11004, NKPI-11008, NKPI-11012, NKPI-11021 to 11026
Counting rules	 Counts clients with a recorded smoking status, who recorded 3 or more visits within the previous 2 years Includes live births and still births if the birthweight is at least 400 grams OR the gestational age was 20 weeks or more Include only the most recent smoking status recorded prior to the completion of the latest pregnancy. Where a smoking status does not have an assessment date assigned within the CIS, smoking status should not be counted Include results arising from measurements conducted outside of the organisation that are known by the organisation
Notes	Nil

Definition owner	Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care
METEOR link	https://meteor.aihw.gov.au/content/787973 (December 2023)

nKPI – PI12: Body mas	s muex of clients
Full name	PI12: Proportion of Indigenous regular clients who have a Body Mass Index (BMI) result within a specified category.
Description	Proportion of regular clients who are Indigenous, aged 18 and over whe have had their body mass index (BMI) classified as:
	 underweight (<18.50) normal weight (≥18.50 but <25) overweight (≥25 but <30) obese (≥30) not calculated within the previous 24 months.
Measure type	Percentage
Numerator	The number of <i>[Disaggregation: Gender]</i> Indigenous regular clients aged <i>[Disaggregation: Age]</i> who have had their BMI classified as <i>[Disaggregation: BMI classification]</i> within the previous 24 months
Denominator	The number of [Disaggregation: Gender] Indigenous regular clients aged [Disaggregation: Age]
Disaggregation	Age: - 18–24 years - 25–34 years - 35–44 years - 45–54 years - 55–64 years - 65 years and older Gender: - Male - Female
	BMI classification*:
	bmi-1 overweight (≥25.00 but <30)
	bmi-2 obese (≥30)
	bmi-4 normal weight (≥18.50 but <25)
	bmi-5 underweight (<18.50)
	bmi-6 not calculated
	*Note: 'bmi-3' is not currently in use. Refer to Results Codes in Appendix for more information.
Disaggregation points	Sixty (60) measures are derived from this assessment

Measure Code/s	NKPI-12021 to 12080
Counting rules	Counts clients who recorded 3 or more visits in the previous 2 years, whose BMI was classified using a weight measurement taken within the previous 24 months and a height measurement taken since the client turned 18.
Notes	 'Constituent Elements of a BMI' – weight in kilograms, recorded within the previous 24 months; height in meters, recorded since the client turned 18 years of age. 'Body Mass Index (BMI)' – is a measure of an adult's weight (body mass) relative to height used to assess the extent of weight deficit or excess where height and weight have been measured. BMI is the weight in kilograms divided by the square of the height in metres (WHO 2000). If a client had their BMI recorded more than once in the previous 24 months, include only the most recently recorded result.
Definition owner	Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care
METEOR link	https://meteor.aihw.gov.au/content/787977 (December 2023)

nKPI – PI13: First ante	nKPI – PI13: First antenatal visit		
Full name	PI13: Proportion of female Indigenous regular clients who gave birth within the previous 12 months who have their first antenatal care visit within a specified period		
Description	 Proportion of regular clients who are Indigenous, who gave birth within the previous 12 months, and who: had gestational age recorded at their first antenatal care visit with results less than 11/40 weeks; had gestational age recorded at their first antenatal care visit with results at or after 11/40 weeks and less than 14/40 weeks; had gestational age recorded at their first antenatal care visit with results at or after 14/40 weeks and less than 20/40 weeks had gestational age recorded at their first antenatal care visit with results at or after 20/40 weeks; did not have gestational age recorded at their first antenatal care visit or; did not attend an antenatal care visit 		
Measure type	Percentage		
Numerator	The number of female Indigenous regular clients aged [Disaggregation: Age] who gave birth within the previous 12 months, who had gestational age recorded at their first antenatal care visit with results [Disaggregation: Gestational age], or who had no antenatal visit recorded		
Denominator	The number of female Indigenous regular clients aged [Disaggregation: Age] who gave birth within the previous 12 months		
Disaggregation	Age: - less than 20 years - 20–34 years - 35 years and older Gestational age: - ga-1 - ga-2 - ga-3 - ga-4 - ga-5 - ga-6		
Disaggregation points	Eighteen (18) measures are derived from this assessment		
Measure Code/s	NKPI-13007 to 13015, NKPI-13021 to 13029		
Counting rules	Nil		
Notes	'Birth' includes live births, and still births if the birthweight was at least 400 grams or the gestational age was 20 weeks or more.		

Definition owner	Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care
METEOR link	https://meteor.aihw.gov.au/content/787981 (December 2023)

nKPI – PI14: Clients wi	no are immunised against influenza	
Full name	PI14: Proportion of Indigenous regular clients aged 6 months and over who are immunised against influenza	
Description	Proportion of Indigenous regular clients aged 6 months and over who are immunised against influenza	
Measure type	Percentage	
Numerator	The number of <i>[Disaggregation: Gender]</i> Indigenous regular clients aged <i>[Disaggregation: Age]</i> who are immunised against influenza	
Denominator	The number of [Disaggregation: Gender] Indigenous regular clients aged [Disaggregation: Age]	
Disaggregation	Gender: - Male - Female Age: - 6 months-4 years - 5-14 years - 15-24 years - 25-34 years - 35-44 years - 45-54 years - 55-64 years - 65 years and older	
Disaggregation points	Sixteen (16) measures are derived from this assessment	
Measure Code/s	NKPI-14010 to 14017, NKPI-14020 to 14027	
Counting rules	Nil	
Notes	An Indigenous person aged 6 months and over is immunised against influenza if they have received an influenza vaccine within the previous year.	
Definition owner	Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care	
METEOR link	https://meteor.aihw.gov.au/content/787985 (December 2023)	

Full name	DI16: Proportion of Indigonous regular clients who have alcohol	
ruii name	PI16: Proportion of Indigenous regular clients who have alcohol consumption status recorded	
Description	Proportion of regular clients who are Indigenous, aged 15 and over and who have had their alcohol consumption status recorded within the previous 24 months	
Measure type	Percentage	
Numerator	The number of <i>[Disaggregation: Gender]</i> Indigenous regular clients aged <i>[Disaggregation: Age]</i> who have had their alcohol consumption status recorded within the previous 24 months	
Denominator	The number of [Disaggregation: Gender] Indigenous regular clients aged [Disaggregation: Age]	
Disaggregation	Age: - 15–24 years - 25–34 years - 35–44 years - 45–54 years - 55–64 years - 65 years and older Gender: - Male - Female	
Disaggregation points	Twelve (12) measures are derived from this assessment	
Measure Code/s	NKPI-16001 to 16012	
Counting rules	Nil	
Notes	 'Alcohol consumption status' – is considered recorded where the organisation has either a record of whether the client consumes alcohol, OR a record specifying the amount AND frequency of the client's alcohol consumption. Results arising from measurements conducted outside of the organisation that are known by the organisation are included in the calculation of this indicator. Where an Indigenous regular client's alcohol consumption status does not have an assessment date assigned within the Clinical Information System (CIS), alcohol consumption status as recorded in the CIS should be treated as current (that is, as having been updated within the previous 24 months). 	
Definition owner	Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care	
METEOR link	https://meteor.aihw.gov.au/content/787991 (December 2023)	

nKPI – PI18: Kidney	function testing	
Full name	PI18: Proportion of Indigenous regular clients with a selected chronic disease who have a selected kidney function test result recorded	
Description	Proportion of regular clients who are Indigenous aged 18 and over, who are recorded as having:	
	 Type 2 diabetes OR Cardiovascular disease (CVD) OR Type 2 diabetes and/or CVD 	
	AND who have had either:	
	 an estimated glomerular filtration rate (eGFR) AND an albumin/creatinine ratio (ACR) test result recorded only an eGFR test result recorded only an ACR test result recorded neither an eGFR NOR an ACR test result recorded within the previous 12 months. 	
Measure type	Percentage	
Numerator	The number of Indigenous regular [Disaggregation: Gender] clients with [Disaggregation: Chronic disease] aged [Disaggregation: Age] who have had [Disaggregation: Tests] recorded within the previous 12 months	
Denominator	The number of Indigenous regular [Disaggregation: Gender] clients with [Disaggregation: Chronic disease] aged [Disaggregation: Age]	
Disaggregation	Age: - 18–24 years - 25–34 years - 35–44 years - 45–54 years - 55–64 years - 65 years and older	
	Gender:	
	MaleFemale	
	Chronic disease:	
	 Type 2 diabetes Cardiovascular disease Either or both of the above 	
	Test:	
	 an eGFR only an ACR only both an eGFR and an ACR neither an eGFR nor an ACR 	

Disaggregation points	One hundred and forty-four (144) measures are derived from this assessment	
Measure Code/s	See appendix A for measure codes	
Counting rules	Nil	
Notes	 'Type 2 diabetes' – specifically excludes Type I diabetes, secondary diabetes, gestational diabetes mellitus (GDM), previous GDM, Impaired fasting glucose, and impaired glucose tolerance. 'ACR' – refers to an albumin/creatinine ratio. 'An eGFR only' – a recorded eGFR result, where an ACR result HAS NOT been recorded. 'An ACR only' – a recorded ACR result, where an eGFR result HAS NOT been recorded. 'Both an eGFR and an ACR' – a recorded eGFR result AND a recorded ACR result. 'Neither an eGFR NOR an ACR' – an eGFR result AND an ACR result HAS NOT been recorded. To count a test as recorded, a valid test result must be entered in the test result field of the Clinical Information System (CIS). A valid test result is a numeric value that can be used to classify test results into the risk categories specified in 'Chronic Kidney Disease (CKD) Management in Primary Care' guidelines.⁴ Negative, non-numerical and null values are not considered to be valid results (that is, are invalid and should be considered as no result recorded). 	
Definition owner	Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care	
METEOR link	https://meteor.aihw.gov.au/content/788046 (December 2023)	

⁴ Kidney Health Australia 2020. Chronic Kidney Disease (CKD) Management in Primary Care (4th edition). Melbourne: Kidney Health Australia.

nKPI – PI19: Kidn	ey function test result
Full name	PI19: Proportion of Indigenous regular clients with a selected chronic disease who have a kidney function test result within a specified category.
Description	Proportion of regular clients who are Indigenous aged 18 years and over with: type 2 diabetes, OR cardiovascular disease (CVD), OR type 2 diabetes and/or CVD
	whose estimated glomerular filtration rate (eGFR) AND albumin/creatinine ratio (ACR) recorded within the previous 12 months were categorised as:
	 normal risk low risk moderate risk high risk
	Note: Some risk groups have more than one result classification (See description of risk categories table below).
	Description of risk categories
	Normal risk eGFR greater than or equal to 60 mL/min/1.73m² AND:
	 ACR less than 2.5 mg/mmol for males OR ACR less than 3.5 mg/mmol for females.
	Low risk eGFR greater than or equal to 45 mL/min/1.73m² and less than 60 mL/min/1.73m² AND
	 ACR less than 2.5 mg/mmol for males OR ACR less than 3.5 mg/mmol for females. OR
	eGFR greater than or equal to 60 mL/min/1.73m ² AND
	 ACR greater than or equal to 2.5 mg/mmol and less than or equal to 25 mg/mmol for males OR ACR greater than or equal to 3.5 mg/mmol and less than or equal to 35 mg/mmol for females.
	Moderate risk eGFR greater than or equal to 45 mL/min/1.73m² and less than 60 mL/min/1.73m² AND
	 ACR greater than or equal to 2.5 mg/mmol and less than or equal to 25 mg/mmol for males OR

	High risk	 ACR greater than or equal to 3.5 mg/mmol and less than or equal to 35 mg/mmol for females. OR eGFR greater than or equal to 30 mL/min/1.73m² and less than 45 mL/min/1.73m² AND ACR less than or equal to 25 mg/mmol for males OR ACR less than or equal to 35 mg/mmol for females. eGFR greater than or equal to 30 mL/min/1.73m² AND ACR greater than 25mg/mmol for males OR 	
		 ACR greater than 35ml/mmol for females. OR eGFR less than 30 mL/min/1.73m² AND Any ACR result for both females and males. 	
Measure type	Percentage		
Numerator	with [Disaggre whose most re-	The number of [Disaggregation: Gender] Indigenous regular clients with [Disaggregation: Chronic disease] aged [Disaggregation: Age] whose most recent eGFR and ACR results, recorded within the previous 12 months, were [Disaggregation: Results]	
Denominator	with [Disaggre	The number of <i>[Disaggregation: Gender]</i> Indigenous regular clients with <i>[Disaggregation: Chronic disease]</i> aged <i>[Disaggregation: Age]</i> who had both eGFR and ACR results recorded within the previous 12 months	
Disaggregation	25–34 year35–44 year45–54 year55–64 year	18–24 years25–34 years35–44 years	
	Gender: Calculation A Male	Gender: Calculation A only	
	Calculation B	only	
	- Female		
	Chronic diseas	e:	
	Type 2 diabCardiovaso	oetes ular disease	

Type 2 diabetes and/or CVD Result:

	Result:		
	Risk	Range	Sex specific
	Normal	eGFR ≥60 and ACR <2.5	Male
	Normal	eGFR ≥60 and ACR <3.5	Female
	Low	eGFR ≥45 but <60 and ACR <2.5 OR, eGFR ≥60 and ACR ≥2.5 but ≤25	Male
	Low	eGFR ≥45 but <60 and ACR <3.5 OR, eGFR ≥60 and ACR ≥3.5 but ≤35	Female
	Moderate	eGFR ≥45 but <60 and ACR ≥2.5 but ≤25 OR,	Male
		eGFR ≥30 but <45 and ACR ≤25	
	Moderate	eGFR ≥45 but <60 and ACR ≥3.5 but ≤35 OR,	Female
		eGFR ≥30 but <45 and ACR ≤35	
	High	eGFR ≥30 and ACR >25 OR,	Male
		eGFR <30 and any ACR result	
	High	eGFR ≥30 and ACR >35 OR,	Female
		eGFR <30 and any ACR result	
Disaggregation points	One-hundred and forty-four (144) measures are derived from this assessment		
Measure Code/s	See appendix 1 for measure codes		
Counting rules	Consider only the most recent eGFR and ACR tests		
Notes	 'Type 2 diabetes' – specifically excludes Type I diabetes, secondary diabetes, gestational diabetes mellitus (GDM), previous GDM, Impaired fasting glucose, and impaired glucose tolerance. 'ACR' – refers to an albumin/creatinine ratio. To count a test as recorded, a valid test result must be entered in the test result field of the Clinical Information System (CIS). A valid test result is a numeric value that can be used to classify test results into the risk categories specified in 'Chronic Kidney Disease (CKD) Management in Primary Care' guidelines.⁵ Negative, non-numerical and null values are not considered to be valid results (that is, are invalid and should be considered as 'no result recorded'). Records with an invalid result recorded should be 		

⁵ Kidney Health Australia 2020. Chronic Kidney Disease (CKD) Management in Primary Care (4th edition). Melbourne: Kidney Health Australia.

	assigned to either the 'only an eGFR test result recorded', 'only an ACR test result recorded' or 'neither an eGFR nor an ACR test result recorded' as appropriate.
Definition owner	Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care
METEOR	https://meteor.aihw.gov.au/content/788072 (December 2023)

nKPI – PI20: CVD risk a	assessment factors	
Full name	PI20: Proportion of Indigenous regular clients who have the necessary risk factors recorded to assess absolute cardiovascular disease (CVD) risk	
Description	Proportion of Indigenous regular clients with no known cardiovascular disease (CVD), assessed aged 35 to 74, with information available to calculate their absolute CVD risk	
Measure type	Percentage	
Numerator	The number of <i>[Disaggregation: Gender]</i> Indigenous regular clients aged <i>[Disaggregation: Age]</i> that are not coded with a diagnosis matching the CVD definition who have had the following information recorded: • smoking status, AND • systolic blood pressure result recorded within the previous 24 months, AND • total cholesterol result recorded within the previous 24 months, AND • High Density Lipoprotein (HDL) cholesterol result recorded within the previous 24 months	
Denominator	The number of <i>[Disaggregation: Gender]</i> Indigenous regular clients aged <i>[Disaggregation: Age]</i> that are not coded with a diagnosis matching the CVD definition	
Disaggregation	Age: - 35-44 years - 45-54 years - 55-64 years - 65-74 years Gender: - Male - Female	
Disaggregation points	Eight (8) measures are derived from this assessment	
Measure Code/s	NKPI-20001 to 20008	
Counting rules	Nil	
Notes	Nil	
Definition owner	Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care	
METEOR link	https://meteor.aihw.gov.au/content/788077 (December 2023)	

nKPI – Pl21: CVD risk a	assessment result	
Full name	PI21: Proportion of Indigenous regular clients aged 35 to 74 years who have an absolute cardiovascular disease (CVD) risk assessment result within a specified level	
Description	Proportion of Indigenous regular clients, aged 35 to 74 and with no known history of cardiovascular disease (CVD), who have had an absolute CVD risk assessment recorded within the previous 24 months and whose CVD risk was categorised as one of the following:	
	 High (greater than 15% chance of a cardiovascular event in the next 5 years) Moderate (10–15% chance of a cardiovascular event in the next 5 years) Low (less than 10% chance of a cardiovascular event in the next 5 years) 	
Measure type	Percentage	
Numerator	The number of <i>[Disaggregation: Gender]</i> Indigenous regular clients aged <i>[Disaggregation: Age]</i> that are not coded with a diagnosis matching the CVD definition, who have had an absolute CVD risk assessment result recorded within the previous 24 months, whose most recent absolute CVD risk assessment result was categorised as <i>[Disaggregation: Result]</i>	
Denominator	The number of <i>[Disaggregation: Gender]</i> Indigenous regular clients aged <i>[Disaggregation: Age]</i> that are not coded with a diagnosis matching the CVD definition, who have had an absolute CVD risk assessment result recorded within the previous 24 months	
Disaggregation	Age: - 35–44 years - 45–54 years - 55–64 years - 65–74 years Gender: - Male - Female	
	Result: - ar-1 - ar-2 - ar-3	
Disaggregation points	Twenty-four (24) measures are derived from this assessment	
Measure Code/s	NKPI-21001 to 21024	
Counting rules	Nil	

Notes	'Absolute CVD risk assessment' – refers to a risk assessment performed with the National Vascular Disease Prevention Alliance (NVDPA) absolute cardiovascular disease risk calculator. Where the Central Australian Rural Practitioners Association (CARPA) CVD risk assessment calculator is used, 5% is to be deducted from the reported result.
Definition owner	Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care
METEOR link	hhttps://meteor.aihw.gov.au/content/788081 (December 2023)

nKPI – PI22: Female clients who have had a cervical screening (HPV) test		
Full name	PI22: Proportion of female Indigenous regular clients who have had a cervical screening (HPV) test	
Description	Proportion of female Indigenous regular clients aged 25–74, who have not had a hysterectomy and who have had a cervical screening (human papillomavirus (HPV)) test within the previous 5 years where the test occurred on or after 1 December 2017	
Measure type	Percentage	
Numerator	Number of female Indigenous regular clients aged 25–74 who have not had a hysterectomy and who have had a cervical screening (HPV) test within the previous 5 years where the test occurred on or after 1 December 2017	
Denominator	Number of female Indigenous regular clients aged 25–74 who have not had a hysterectomy	
Disaggregation	Age: - 25–34 years - 35–44 years - 45–54 years - 55–64 years - 65–74 years	
Disaggregation points	Five (5) measures are derived from this assessment	
Measure Code/s	NKPI-22016 to 22019, NKPI-22024	
Counting rules	Count is of women, not tests	
Notes	Include HPV tests where the sample is either collected by a health practitioner or self-collected	
Definition owner	Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care	
METEOR link	https://meteor.aihw.gov.au/content/788085 (December 2023)	

nKPI – Pl23: Blood pre	ssure recorded
Full name	PI23: Proportion of Indigenous regular clients with Type 2 diabetes who have a blood pressure measurement result recorded
Description	Proportion of regular clients who are Indigenous, have Type 2 diabetes and who have had a blood pressure measurement result recorded within the previous 6 months
Measure type	Percentage
Numerator	The number of <i>[Disaggregation: Gender]</i> Indigenous regular clients with Type 2 diabetes aged <i>[Disaggregation: Age]</i> who have had blood pressure test result recorded within the previous 6 months
Denominator	The number of <i>[Disaggregation: Gender]</i> Indigenous regular clients with Type 2 diabetes aged <i>[Disaggregation: Age]</i>
Disaggregation	Age: - 0-4 years - 5-14 years - 15-24 years - 25-34 years - 35-44 years - 45-54 years - 55-64 years - 65 years and older Gender: - Male - Female
Disaggregation points	Sixteen (16) measures are derived from this assessment
Measure Code/s	NKPI-23001 to 23016
Counting rules	Nil
Notes	 'Type 2 diabetes' – specifically excludes Type I diabetes, secondary diabetes, gestational diabetes mellitus (GDM), previous GDM, Impaired fasting glucose, and impaired glucose tolerance. Results arising from measurements conducted outside of the organisation that are known by the organisation are included in the calculation of this indicator.
Definition owner	Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care
METEOR link	https://meteor.aihw.gov.au/content/788089 (December 2023)

nKPI – Pl24: Blood pre	
Full name	PI24: Proportion of Indigenous regular clients with Type 2 diabetes who have a blood pressure measurement result within a specified category
Description	Proportion of regular clients who are Indigenous, have Type 2 diabetes and whose blood pressure measurement result, recorded within the previous 6 months, was less than or equal to 140/90 mmHg
Measure type	Percentage
Numerator	The number of [Disaggregation: Gender] Indigenous regular clients with Type 2 diabetes aged [Disaggregation: Age] who have had blood pressure test result recorded within the previous 6 months, whose most recent result was 140/90 mmHg
Denominator	The number of <i>[Disaggregation: Gender]</i> Indigenous regular clients with Type 2 diabetes aged <i>[Disaggregation: Age]</i> who have had blood pressure test result recorded within the previous 6 months
Disaggregation	Age: - 0-4 years - 5-14 years - 15-24 years - 25-34 years - 35-44 years - 45-54 years - 55-64 years - 65 years and older Gender: - Male - Female
Disaggregation points	Sixteen (16) measures are derived from this assessment
Measure Code/s	NKPI-24001 to 24016
Counting rules	Nil
Notes	 'Type 2 diabetes' – specifically excludes Type I diabetes, secondary diabetes, gestational diabetes mellitus (GDM), previous GDM, Impaired fasting glucose, and impaired glucose tolerance. 'Less than or equal to 140/90 mmHg' – the client does not have a blood pressure measurement of less than or equal to 140/90 mmHg if either the systolic or diastolic reading is above the threshold (140 and 90 respectively).
Definition owner	Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care
METEOR link	https://meteor.aihw.gov.au/content/788093 (December 2023)

nKPI – PI25: STI result	recorded
Full name	Proportion of Indigenous regular clients who have a test result for one or more sexually transmissible infections (STI)
Description	Proportion of Indigenous regular clients aged 15 to 34 years who had a STI(s) result recorded (chlamydia and/or gonorrhoea) within the previous 12 months.
Measure type	Percentage
Numerator	The number of <i>[Disaggregation: Gender]</i> Indigenous regular clients <i>[Disaggregation: Age]</i> who have had a chlamydia and/or gonorrhoea test result recorded within the previous 12 months
Denominator	The number of [Disaggregation: Gender] Indigenous regular clients [Disaggregation: Age]
Disaggregation	Age: - 15-19 years - 20-24 years - 25-29 years - 30-34 years Gender: - Male - Female
Disaggregation points	Eight (8) measures are derived from this assessment
Measure Code/s	NKPI-25001 - NKPI-25008
Counting rules	Count is of people, not tests
Notes	 Include point of care tests. Include test results copied to providers. Do not include tests that have been requested but a result has not been recorded. Include all relevant test types. Include LOINC and free text results as specified in the pathology coding framework at Appendix F.
Definition owner	Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care
METEOR link	https://meteor.aihw.gov.au/content/788097 (December 2023)

nKPI – Pl26: Ear Health Check	
Full name	Pl26: Proportion of Indigenous regular clients ages 0-14 years who have a completed ear health check recorded
	Proportion of Indigenous regular clients who, in the previous 12 months, have had a completed check, that was recorded, of the
	1. Appearance of both* ear canals and eardrums
Description	2. Movement of both* eardrums
	 Appearance of both* ear canals and ear drums AND movement of both* ear drums
	*Refer to notes for one ear
Measure type	Percentage
	Calculation A: Number of [Disaggregation: Gender] Indigenous regular clients aged [Disaggregation: Age] who have had a completed check of the appearance of both ear canals and ear drums within the previous 12 months.
Numerator	Calculation B: Number of <i>[Disaggregation: Gender]</i> Indigenous regular clients aged <i>[Disaggregation: Age]</i> who have had a completed check of the movement of both eardrums within the previous 12 months.
	Calculation C : Number of <i>[Disaggregation: Gender]</i> Indigenous regular clients aged <i>[Disaggregation: Age]</i> who have had a completed check of the appearance of both ear canals and eardrums and the movement of both eardrums within the previous 12 months.
Denominator	Calculation A, B and C: Total number of [Disaggregation: Gender] Indigenous regular clients aged [Disaggregation: Age].
Disaggregation	Age: - 0 - 11 months - 12 - 23 months - 24 - 35 months - 36 - 59 months - 5 - 9 years - 10 - 14 years Gender: - Male - Female
Disaggregation points	Thirty-six (36) measures are derived from this assessment
Measure Code/s	NKPI-26001 - NKPI-26036
Counting rules	Count is of people not checks.

Clients may be counted in one or all parts of the indicator. The indicator counts Indigenous regular clients who, in the previous 12 months, have had a completed ear check. In each of the three parts of this indicator, a completed ear check is determined from a record of the following: 1. A recorded check of the appearance of both ear canals and eardrums (Calculation A) 2. A recorded check of the movement of both eardrums (Calculation B) 3. A recorded check of the appearance of both ear canals and ear drums AND movement of both ear drums (Calculation C). Blank fields are considered 'not completed'. Sourcing data for the ear health check A recorded ear health check in the last 12 months is determined from the following workflow, in this priority order: i. Ear check recorded in the ear health section or 'module' in the CIS - if recorded here do not count 'ii' and 'iii' ii. Ear health procedures as defined in the ear health coding framework - if recorded here do not count 'iii' iii. Ear health conditions as defined in the ear health coding framework – if not recorded here then no ear health check is recorded. Note: Count only conditions and procedures recorded in the last 12 months. Include any completed ear health check recorded in the last 12 months even if a more recent check is not completed. For workflow 'ii' and 'iii', count procedures and/or conditions against either Appearance, Movement or BOTH Appearance and Movement as defined in the ear health coding framework. Within each workflow, if it is not clear which part of the check has been completed (appearance, movement, or both) count Appearance, Movement and BOTH having been completed. If it cannot be determined that a check was performed at all (that is, that any part was completed), do not count any part as completed. Both ears should be checked; however, if a person has only one ear, only one ear can be checked. If there is detail in the patient record specific to only the left or right ear the patient should still be included **Notes** in the relevant measure code. Patients with an ear health check recorded within the last 12 months, performed at any service, by any provider type, should be included. Australian Institute of Health and Welfare on behalf of the Definition owner Department of Health and Aged Care **METEOR link** Pending METEOR publication (anticipated Jul-Dec 2024)

3.2 Online Services Report

The OSR collects information on the services organisations provide, client numbers, client contacts, episodes of care and staffing levels. Contextual information about each organisation is also collected. Unlike nKPI reports, the OSR does not report on health outcomes.

Most of the questions in the OSR require manual data entry (through an online data collection instrument) however some measures can be electronically extracted directly from the organisation's CIS. The Specifications includes only those measures which are currently mandatory, and which can be extracted from the CIS.

The population of interest for the OSR is the total client population of the reporting service, regardless of Indigenous status. Activity measures report activity recorded in the last 12 months (unless otherwise specified). All measures reporting client activity are disaggregated by Indigenous status (labelled 'Ethnicity' in the OSR).

OSR – CS1a: Episodes of care	
Full name	CS1a – Episodes of care
Description	Number of episodes of care provided within the previous 12 months
Measure type	Count
Numerator	The number of episodes of care provided within the previous 12 months to [Disaggregation: Ethnicity] [Disaggregation: Gender] clients
Denominator	N/A
Disaggregation	Ethnicity: - Aboriginal and Torres Strait Islander - Non-Aboriginal and Torres Strait Islander - Aboriginal and Torres Strait Islander status not recorded Gender: - Male - Female - Other or not stated
Disaggregation points	Nine (9) measures are derived from this assessment
Measure codes	OSR-CS1a-0001 to 0009
Counting rules	Nil
Notes	Nil
Definition owner	First Nations Health Division, Australian Government Department of Health and Aged Care

OSR - CS2: Client contacts (general staff)	
Full name	CS2 – Client contacts (general)
Description	 Number of client contacts provided by: Aboriginal and Torres Strait Islander health worker Aboriginal and Torres Strait Islander health practitioner Doctor – General practitioner Nurse Midwife Substance misuse / drug and alcohol worker Tobacco worker / co-ordinator Dentists / dental therapist Dental support (eg, dental assistant / dental technician) Sexual health worker Traditional healer Other health / clinical staff Transport – health professionals who do not work for the service Transport – health professionals who work for the service within the previous 12 months
Measure type	Count
Numerator	The number of contacts provided by [Disaggregation: Worker type] within the previous 12 months to [Disaggregation: Ethnicity] [Disaggregation: Gender] clients
Denominator	N/A
Disaggregation	Worker type: - Aboriginal and Torres Strait Islander health worker - Aboriginal and Torres Strait Islander health practitioner - Doctor – General practitioner - Nurse - Midwife - Substance misuse / drug and alcohol worker - Tobacco worker / co-ordinator - Dentists / dental therapists - Dental support (eg, dental assistant / dental technician) - Sexual health worker - Traditional healer - Other health / clinical staff - Transport (health professionals who do not work for the service) - Transport (health professionals who work for the service) Ethnicity: - Aboriginal and Torres Strait Islander - Non-Aboriginal and Torres Strait Islander - Aboriginal and Torres Strait Islander status not recorded
	Gender:

	MaleFemaleOther or not stated
Disaggregation points	One hundred and twenty-six (126) measures are derived from this assessment
Measure codes	OSR-CS2-0001 to 0126
Counting rules	Nil
Notes	Nil
Definition owner	First Nations Health Division, Australian Government Department of Health and Aged Care

OSR - CS2: Client contacts (medical specialists)	
Full name	CS2 – Client contacts (medical specialists)
Description	Number of client contacts provided by: Paediatrician Endocrinologist Ophthalmologist Obstetrician / Gynaecologist Ear, nose and throat specialist Cardiologist Renal medicine specialist Psychiatrist / Psychiatric registrar Dermatologist Surgeon Specialist other or not specified within the previous 12 months
Measure type	Count
Numerator	The number of contacts provided by [Disaggregation: Worker type] within the previous 12 months to [Disaggregation: Ethnicity] [Disaggregation: Gender] clients
Denominator	N/A
Disaggregation	Worker type: Paediatrician Endocrinologist Ophthalmologist Obstetrician / Gynaecologist Ear, nose and throat specialist Cardiologist Renal medicine specialist Psychiatrist / Psychiatric registrar Dermatologist Surgeon Specialist other or not specified Ethnicity: Aboriginal and Torres Strait Islander Non-Aboriginal and Torres Strait Islander Aboriginal and Torres Strait Islander status not recorded Gender: Male Female
Disaggregation points	Other or not stated Ninety-nine (99) measures are derived from this assessment
	1

Measure codes	OSR-CS12-0127 to 0225
Counting rules	Nil
Notes	Nil
Definition owner	First Nations Health Division, Australian Government Department of Health and Aged Care

OSR - CS2: Client con	OSR – CS2: Client contacts (social and emotional wellbeing / counsellors)	
Full name	CS2 – Client contacts (social and emotional wellbeing / counsellors)	
Description	Number of client contacts provided by: Psychologist Counsellor Social worker Welfare worker Social and emotional wellbeing (SEWB) staff: Link Up caseworkers SEWB staff other or not specified within the previous 12 months	
Measure type	Count	
Numerator	The number of contacts provided by [Disaggregation: Worker type] within the previous 12 months to [Disaggregation: Ethnicity] [Disaggregation: Gender] clients	
Denominator	N/A	
Disaggregation	Worker type: - Psychologist - Counsellor - Social worker - Welfare worker - SEWB staff: Link Up caseworker - SEWB staff other or not specified Ethnicity: - Aboriginal and Torres Strait Islander - Non-Aboriginal and Torres Strait Islander - Aboriginal and Torres Strait Islander - Aboriginal and Torres Strait Islander - Male - Female - Other or not stated	
Disaggregation points	Fifty-four (54) measures are derived from this assessment	
Measure codes	OSR-CS2-0226 to 0279	
Counting rules	Nil	
Notes	Nil	
Definition owner	First Nations Health Division, Australian Government Department of Health and Aged Care	

OSR – CS2: Client contacts (allied health professionals)	
Full name	CS2 – Client contacts (allied health professionals)
Description	Number of client contacts provided by: Audiologist / Audiometrist Diabetes educator Dietician Optometrist Pharmacist Physiotherapist Podiatrist Speech pathologist Allied health other or not specified within the previous 12 months
Measure type	Count
Numerator	The number of contacts provided by [Disaggregation: Worker type] within the previous 12 months to [Disaggregation: Ethnicity] [Disaggregation: Gender] clients
Denominator	N/A
Disaggregation	Worker type: - Audiologist / Audiometrist - Diabetes educator - Dietician - Optometrist - Pharmacist - Physiotherapist - Podiatrist - Speech pathologist - Allied health other or not specified Ethnicity: - Aboriginal and Torres Strait Islander - Non-Aboriginal and Torres Strait Islander - Aboriginal and Torres Strait Islander status not recorded Gender: - Male - Female - Other or not stated
Disaggregation points	Eighty (80) measures are derived from this assessment
Measure codes	OSR-CS2-0280 to 0360
Counting rules	Counts client contacts.

Notes	Nil
Definition owner	First Nations Health Division, Australian Government Department of Health and Aged Care

OSR – CS3a: Individua	l clients seen		
Full name	CS3a – Individual clients seen		
Description	Number of clients seen within the previous 12 months		
Measure type	Count		
Numerator	The number of [Disaggregation: Ethnicity] [Disaggregation: Age] [Disaggregation: Gender] clients seen within the previous 12 months		
Denominator	N/A		
Disaggregation	Ethnicity: Aboriginal and/or Torres Strait Islander Non-Aboriginal and Torres Strait Islander Aboriginal and Torres Strait Islander status not recorded Age: 0-4 years 5-9 years 10-14 years 15-19 years 20-24 years 25-29 years 30-34 years 30-34 years 40-44 years 45-49 years 50-54 years 50-54 years 60-64 years 65 years and older Gender: Male Female Other or not stated		
Disaggregation points	One hundred and twenty-six (126) measures are derived from this assessment		
Measure codes	OSR-CS3a-0010 to 0135		
Counting rules	Counts individual / unique clients		
Notes	 'Seen' – refers to having had a client contact. Each individual client is counted once only, no matter how many times they attended in the reference period. Include visitors and transient patients 		

First Nations Health Division, Australian Government Department of Health and Aged Care
,

Acronyms

ACR Albumin-Creatinine Ratio

AIHW Australian Institute of Health and Welfare

AN Antenatal

APCCID Term given to measure codes within the Health Data Portal

BMI Body Mass Index

BP Best Practice

CDS Control Data Set

CIS Clinical Information System

COPD Chronic Obstructive Pulmonary Disease

CSV Comma Separated Values

CVD Cardiovascular Disease

DHAC Department of Health and Aged Care

eGFR Estimated Glomerular Filtration Rate

FNHD First Nations Health Division (Department of Health and Aged Care)

GA Gestational Age

HbA1c Glycosylated haemoglobin

HDP Health Data Portal

LMP Last Menstrual Period

LOINC Logical Observation Identifier Names and Codes

MBS Medicare Benefits Scheme

MD Medical Director

METEOR Metadata Online Registry

nKPI National Key Performance Indicator

OSR Online Services Report

POCT Point of Care Testing

STI Sexually Transmitted Infection

Appendix A – Measure code disaggregation

The following tables list nKPIs and OSR measure codes and the required disaggregation. Not all indicators have disaggregation. A separate measure code is allocated to each combination of disaggregation values and these are used when reporting to the Data Portal.

Caution: Measure codes are unique, they are not repurposed. For example, when there is a clinical change in the indicator a new measure code is allocated to reflect the new disaggregation values, i.e. a change in age range from 0-15 to 0-18 would result in a new measure code.

National Key Performance Indicators

Table 2: nKPI measure codes by indicator

Measure Code	Disaggregation 1	Disaggregation 2	Disaggregation 3	Disaggregation 4
PI01: Birth weight red	corded			
NKPI_01002				
PI02: Birth weight res	sult			
NKPI-02001	bw-1 (low)			
NKPI-02002	bw-2 (normal)			
NKPI-02003	bw-3 (high)			
Pl03: Indigenous hea	Ith assessment comple	ted		
NKPI-03002	25-34 years	Male	In-person	
NKPI-03003	35-44 years	Male	In-person	
NKPI-03004	45-54 years	Male	In-person	
NKPI-03005	55-64 years	Male	In-person	
NKPI-03006	65 years and older	Male	In-person	
NKPI-03008	25-34 years	Female	In-person	
NKPI-03009	35-44 years	Female	In-person	
NKPI-03010	45-54 years	Female	In-person	
NKPI-03011	55-64 years	Female	In-person	
NKPI-03012	65 years and older	Female	In-person	
NKPI-03013	0-4 years	Male	In-person	
NKPI-03014	0-4 years	Male	Telehealth	
NKPI-03015	5-14 years	Male	In-person	
NKPI-03016	5-14 years	Male	Telehealth	
NKPI-03017	0-4 years	Female	In-person	
NKPI-03018	0-4 years	Female	Telehealth	
NKPI-03019	5-14 years	Female	In-person	
NKPI-03020	5-14 years	Female	Telehealth	
NKPI-03021	15-24 years	Male	In-person	
NKPI-03022	15-24 years	Male	Telehealth	
NKPI-03023	25-34 years	Male	Telehealth	
NKPI-03024	35-44 years	Male	Telehealth	
NKPI-03025	45-54 years	Male	Telehealth	
NKPI-03026	55-64 years	Male	Telehealth	
NKPI-03027	65 years and older	Male	Telehealth	

Measure Code	Disaggregation 1	Disaggregation 2	Disaggregation 3	Disaggregation 4		
NKPI-03028	15-24 years	Female	In-person			
NKPI-03029	15-24 years	Female	Telehealth			
NKPI-03030	25-34 years	Female	Telehealth			
NKPI-03031	35-44 years	Female	Telehealth			
NKPI-03032	45-54 years	Female	Telehealth			
NKPI-03033	55-64 years	Female	Telehealth			
NKPI-03034	65 years and older	Female	Telehealth			
PI04: Indigenous chile	PI04: Indigenous children fully immunised (Retired - see Appendix C for details)					
PI05: HbA1c recorded	1					
NKPI-05001	0-4 years	Male	6 months			
NKPI-05002	5-14 years	Male	6 months			
NKPI-05003	15-24 years	Male	6 months			
NKPI-05004	25-34 years	Male	6 months			
NKPI-05005	35-44 years	Male	6 months			
NKPI-05006	45-54 years	Male	6 months			
NKPI-05007	55-64 years	Male	6 months			
NKPI-05008	65 years and older	Male	6 months			
NKPI-05009	0-4 years	Female	6 months			
NKPI-05010	5-14 years	Female	6 months			
NKPI-05011	15-24 years	Female	6 months			
NKPI-05012	25-34 years	Female	6 months			
NKPI-05013	35-44 years	Female	6 months			
NKPI-05014	45-54 years	Female	6 months			
NKPI-05015	55-64 years	Female	6 months			
NKPI-05016	65 years and older	Female	6 months			
NKPI-05017	0-4 years	Male	12 months			
NKPI-05018	5-14 years	Male	12 months			
NKPI-05019	15-24 years	Male	12 months			
NKPI-05020	25-34 years	Male	12 months			
NKPI-05021	35-44 years	Male	12 months			
NKPI-05022	45-54 years	Male	12 months			
NKPI-05023	55-64 years	Male	12 months			
NKPI-05024	65 years and older	Male	12 months			
NKPI-05025	0-4 years	Female	12 months			
NKPI-05026	5-14 years	Female	12 months			
NKPI-05027	15-24 years	Female	12 months			
NKPI-05028	25-34 years	Female	12 months			
NKPI-05029	35-44 years	Female	12 months			
NKPI-05030	45-54 years	Female	12 months			
NKPI-05031	55-64 years	Female	12 months			
NKPI-05032	65 years and older	Female	12 months			
PI06: HbA1c result						
NKPI-06001	0-4 years	Male	6 months	hr-1 (≤7%)		

Measure Code	Disaggregation 1	Disaggregation 2	Disaggregation 3	Disaggregation 4
NKPI-06002	5-14 years	Male	6 months	hr-1 (≤7%)
NKPI-06003	15-24 years	Male	6 months	hr-1 (≤7%)
NKPI-06004	25-34 years	Male	6 months	hr-1 (≤7%)
NKPI-06005	35-44 years	Male	6 months	hr-1 (≤7%)
NKPI-06006	45-54 years	Male	6 months	hr-1 (≤7%)
NKPI-06007	55-64 years	Male	6 months	hr-1 (≤7%)
NKPI-06008	65 years and older	Male	6 months	hr-1 (≤7%)
NKPI-06009	0-4 years	Female	6 months	hr-1 (≤7%)
NKPI-06010	5-14 years	Female	6 months	hr-1 (≤7%)
NKPI-06011	15-24 years	Female	6 months	hr-1 (≤7%)
NKPI-06012	25-34 years	Female	6 months	hr-1 (≤7%)
NKPI-06013	35-44 years	Female	6 months	hr-1 (≤7%)
NKPI-06014	45-54 years	Female	6 months	hr-1 (≤7%)
NKPI-06015	55-64 years	Female	6 months	hr-1 (≤7%)
NKPI-06016	65 years and older	Female	6 months	hr-1 (≤7%)
NKPI-06017	0-4 years	Male	6 months	hr-2 (>7% but ≤8%)
NKPI-06018	5-14 years	Male	6 months	hr-2 (>7% but ≤8%)
NKPI-06019	15-24 years	Male	6 months	hr-2 (>7% but ≤8%)
NKPI-06020	25-34 years	Male	6 months	hr-2 (>7% but ≤8%)
NKPI-06021	35-44 years	Male	6 months	hr-2 (>7% but ≤8%)
NKPI-06022	45-54 years	Male	6 months	hr-2 (>7% but ≤8%)
NKPI-06023	55-64 years	Male	6 months	hr-2 (>7% but ≤8%)
NKPI-06024	65 years and older	Male	6 months	hr-2 (>7% but ≤8%)
NKPI-06025	0-4 years	Female	6 months	hr-2 (>7% but ≤8%)
NKPI-06026	5-14 years	Female	6 months	hr-2 (>7% but ≤8%)
NKPI-06027	15-24 years	Female	6 months	hr-2 (>7% but ≤8%)
NKPI-06028	25-34 years	Female	6 months	hr-2 (>7% but ≤8%)
NKPI-06029	35-44 years	Female	6 months	hr-2 (>7% but ≤8%)
NKPI-06030	45-54 years	Female	6 months	hr-2 (>7% but ≤8%)
NKPI-06031	55-64 years	Female	6 months	hr-2 (>7% but ≤8%)
NKPI-06032	65 years and older	Female	6 months	hr-2 (>7% but ≤8%)
NKPI-06033	0-4 years	Male	6 months	hr-3 (>8% but <10%)
NKPI-06034	5-14 years	Male	6 months	hr-3 (>8% but <10%)
NKPI-06035	15-24 years	Male	6 months	hr-3 (>8% but <10%)
NKPI-06036	25-34 years	Male	6 months	hr-3 (>8% but <10%)
NKPI-06037	35-44 years	Male	6 months	hr-3 (>8% but <10%)
NKPI-06038	45-54 years	Male	6 months	hr-3 (>8% but <10%)
NKPI-06039	55-64 years	Male	6 months	hr-3 (>8% but <10%)
NKPI-06040	65 years and older	Male	6 months	hr-3 (>8% but <10%)
NKPI-06041	0-4 years	Female	6 months	hr-3 (>8% but <10%)
NKPI-06042	5-14 years	Female	6 months	hr-3 (>8% but <10%)
NKPI-06043	15-24 years	Female	6 months	hr-3 (>8% but <10%)
NKPI-06044	25-34 years	Female	6 months	hr-3 (>8% but <10%)

Measure Code	Disaggregation 1	Disaggregation 2	Disaggregation 3	Disaggregation 4
NKPI-06045	35-44 years	Female	6 months	hr-3 (>8% but <10%)
NKPI-06046	45-54 years	Female	6 months	hr-3 (>8% but <10%)
NKPI-06047	55-64 years	Female	6 months	hr-3 (>8% but <10%)
NKPI-06048	65 years and older	Female	6 months	hr-3 (>8% but <10%)
NKPI-06049	0-4 years	Male	6 months	hr-4 (≥10%)
NKPI-06050	5-14 years	Male	6 months	hr-4 (≥10%)
NKPI-06051	15-24 years	Male	6 months	hr-4 (≥10%)
NKPI-06052	25-34 years	Male	6 months	hr-4 (≥10%)
NKPI-06053	35-44 years	Male	6 months	hr-4 (≥10%)
NKPI-06054	45-54 years	Male	6 months	hr-4 (≥10%)
NKPI-06055	55-64 years	Male	6 months	hr-4 (≥10%)
NKPI-06056	65 years and older	Male	6 months	hr-4 (≥10%)
NKPI-06057	0-4 years	Female	6 months	hr-4 (≥10%)
NKPI-06058	5-14 years	Female	6 months	hr-4 (≥10%)
NKPI-06059	15-24 years	Female	6 months	hr-4 (≥10%)
NKPI-06060	25-34 years	Female	6 months	hr-4 (≥10%)
NKPI-06061	35-44 years	Female	6 months	hr-4 (≥10%)
NKPI-06062	45-54 years	Female	6 months	hr-4 (≥10%)
NKPI-06063	55-64 years	Female	6 months	hr-4 (≥10%)
NKPI-06064	65 years and older	Female	6 months	hr-4 (≥10%)
NKPI-06065	0-4 years	Male	12 months	hr-1 (≤7%)
NKPI-06066	5-14 years	Male	12 months	hr-1 (≤7%)
NKPI-06067	15-24 years	Male	12 months	hr-1 (≤7%)
NKPI-06068	25-34 years	Male	12 months	hr-1 (≤7%)
NKPI-06069	35-44 years	Male	12 months	hr-1 (≤7%)
NKPI-06070	45-54 years	Male	12 months	hr-1 (≤7%)
NKPI-06071	55-64 years	Male	12 months	hr-1 (≤7%)
NKPI-06072	65 years and older	Male	12 months	hr-1 (≤7%)
NKPI-06073	0-4 years	Female	12 months	hr-1 (≤7%)
NKPI-06074	5-14 years	Female	12 months	hr-1 (≤7%)
NKPI-06075	15-24 years	Female	12 months	hr-1 (≤7%)
NKPI-06076	25-34 years	Female	12 months	hr-1 (≤7%)
NKPI-06077	35-44 years	Female	12 months	hr-1 (≤7%)
NKPI-06078	45-54 years	Female	12 months	hr-1 (≤7%)
NKPI-06079	55-64 years	Female	12 months	hr-1 (≤7%)
NKPI-06080	65 years and older	Female	12 months	hr-1 (≤7%)
NKPI-06081	0-4 years	Male	12 months	hr-2 (>7% but ≤8%)
NKPI-06082	5-14 years	Male	12 months	hr-2 (>7% but ≤8%)
NKPI-06083	15-24 years	Male	12 months	hr-2 (>7% but ≤8%)
NKPI-06084	25-34 years	Male	12 months	hr-2 (>7% but ≤8%)
NKPI-06085	35-44 years	Male	12 months	hr-2 (>7% but ≤8%)
NKPI-06086	45-54 years	Male	12 months	hr-2 (>7% but ≤8%)
NKPI-06087	55-64 years	Male	12 months	hr-2 (>7% but ≤8%)

Measure Code	Disaggregation 1	Disaggregation 2	Disaggregation 3	Disaggregation 4
NKPI-06088	65 years and older	Male	12 months	hr-2 (>7% but ≤8%)
NKPI-06089	0-4 years	Female	12 months	hr-2 (>7% but ≤8%)
NKPI-06090	5-14 years	Female	12 months	hr-2 (>7% but ≤8%)
NKPI-06091	15-24 years	Female	12 months	hr-2 (>7% but ≤8%)
NKPI-06092	25-34 years	Female	12 months	hr-2 (>7% but ≤8%)
NKPI-06093	35-44 years	Female	12 months	hr-2 (>7% but ≤8%)
NKPI-06094	45-54 years	Female	12 months	hr-2 (>7% but ≤8%)
NKPI-06095	55-64 years	Female	12 months	hr-2 (>7% but ≤8%)
NKPI-06096	65 years and older	Female	12 months	hr-2 (>7% but ≤8%)
NKPI-06097	0-4 years	Male	12 months	hr-3 (>8% but <10%)
NKPI-06098	5-14 years	Male	12 months	hr-3 (>8% but <10%)
NKPI-06099	15-24 years	Male	12 months	hr-3 (>8% but <10%)
NKPI-06100	25-34 years	Male	12 months	hr-3 (>8% but <10%)
NKPI-06101	35-44 years	Male	12 months	hr-3 (>8% but <10%)
NKPI-06102	45-54 years	Male	12 months	hr-3 (>8% but <10%)
NKPI-06103	55-64 years	Male	12 months	hr-3 (>8% but <10%)
NKPI-06104	65 years and older	Male	12 months	hr-3 (>8% but <10%)
NKPI-06105	0-4 years	Female	12 months	hr-3 (>8% but <10%)
NKPI-06106	5-14 years	Female	12 months	hr-3 (>8% but <10%)
NKPI-06107	15-24 years	Female	12 months	hr-3 (>8% but <10%)
NKPI-06108	25-34 years	Female	12 months	hr-3 (>8% but <10%)
NKPI-06109	35-44 years	Female	12 months	hr-3 (>8% but <10%)
NKPI-06110	45-54 years	Female	12 months	hr-3 (>8% but <10%)
NKPI-06111	55-64 years	Female	12 months	hr-3 (>8% but <10%)
NKPI-06112	65 years and older	Female	12 months	hr-3 (>8% but <10%)
NKPI-06113	0-4 years	Male	12 months	hr-4 (≥10%)
NKPI-06114	5-14 years	Male	12 months	hr-4 (≥10%)
NKPI-06115	15-24 years	Male	12 months	hr-4 (≥10%)
NKPI-06116	25-34 years	Male	12 months	hr-4 (≥10%)
NKPI-06117	35-44 years	Male	12 months	hr-4 (≥10%)
NKPI-06118	45-54 years	Male	12 months	hr-4 (≥10%)
NKPI-06119	55-64 years	Male	12 months	hr-4 (≥10%)
NKPI-06120	65 years and older	Male	12 months	hr-4 (≥10%)
NKPI-06121	0-4 years	Female	12 months	hr-4 (≥10%)
NKPI-06122	5-14 years	Female	12 months	hr-4 (≥10%)
NKPI-06123	15-24 years	Female	12 months	hr-4 (≥10%)
NKPI-06124	25-34 years	Female	12 months	hr-4 (≥10%)
NKPI-06125	35-44 years	Female	12 months	hr-4 (≥10%)
NKPI-06126	45-54 years	Female	12 months	hr-4 (≥10%)
NKPI-06127	55-64 years	Female	12 months	hr-4 (≥10%)
NKPI-06128	65 years and older	Female	12 months	hr-4 (≥10%)
PI07: Chronic disease	⊓ e management plan clai	med		
NKPI-07001	0-4 years	Male	In-person	

Measure Code	Disaggregation 1	Disaggregation 2	Disaggregation 3	Disaggregation 4
NKPI-07002	5-14 years	Male	In-person	
NKPI-07003	15-24 years	Male	In-person	
NKPI-07004	25-34 years	Male	In-person	
NKPI-07005	35-44 years	Male	In-person	
NKPI-07006	45-54 years	Male	In-person	
NKPI-07007	55-64 years	Male	In-person	
NKPI-07008	65 years and older	Male	In-person	
NKPI-07009	0-4 years	Female	In-person	
NKPI-07010	5-14 years	Female	In-person	
NKPI-07011	15-24 years	Female	In-person	
NKPI-07012	25-34 years	Female	In-person	
NKPI-07013	35-44 years	Female	In-person	
NKPI-07014	45-54 years	Female	In-person	
NKPI-07015	55-64 years	Female	In-person	
NKPI-07016	65 years and older	Female	In-person	
NKPI-07017	0-4 years	Male	Telehealth	
NKPI-07018	5-14 years	Male	Telehealth	
NKPI-07019	15-24 years	Male	Telehealth	
NKPI-07020	25-34 years	Male	Telehealth	
NKPI-07021	35-44 years	Male	Telehealth	
NKPI-07022	45-54 years	Male	Telehealth	
NKPI-07023	55-64 years	Male	Telehealth	
NKPI-07024	65 years and older	Male	Telehealth	
NKPI-07025	0-4 years	Female	Telehealth	
NKPI-07026	5-14 years	Female	Telehealth	
NKPI-07027	15-24 years	Female	Telehealth	
NKPI-07028	25-34 years	Female	Telehealth	
NKPI-07029	35-44 years	Female	Telehealth	
NKPI-07030	45-54 years	Female	Telehealth	
NKPI-07031	55-64 years	Female	Telehealth	
NKPI-07032	65 years and older	Female	Telehealth	
Pl08: Team care arrar	ngement claimed (Retire	ed – see appendix C for de	etails)	
Pl09: Smoking status	recorded			
NKPI-09001	15-24 years	Male		
NKPI-09002	25-34 years	Male		
NKPI-09003	35-44 years	Male		
NKPI-09004	45-54 years	Male		
NKPI-09005	55-64 years	Male		
NKPI-09006	65 years and older	Male		
NKPI-09007	15-24 years	Female		
NKPI-09008	25-34 years	Female		
NKPI-09009	35-44 years	Female		
NKPI-09010	45-54 years	Female		

Measure Code	Disaggregation 1	Disaggregation 2	Disaggregation 3	Disaggregation 4
NKPI-09011	55-64 years	Female		
NKPI-09012	65 years and older	Female		
NKPI-09041	11-14 years	Male		
NKPI-09051	11-14 years	Female		
PI10: Smoking status				
NKPI-10001	15-24 years	Male	Current smoker	
NKPI-10002	25-34 years	Male	Current smoker	
NKPI-10003	35-44 years	Male	Current smoker	
NKPI-10004	45-54 years	Male	Current smoker	
NKPI-10005	55-64 years	Male	Current smoker	
NKPI-10006	65 years and older	Male	Current smoker	
NKPI-10007	15-24 years	Male	Ex-smoker	
NKPI-10008	25-34 years	Male	Ex-smoker	
NKPI-10009	35-44 years	Male	Ex-smoker	
NKPI-10010	45-54 years	Male	Ex-smoker	
NKPI-10011	55-64 years	Male	Ex-smoker	
NKPI-10012	65 years and older	Male	Ex-smoker	
NKPI-10013	15-24 years	Male	Never smoked	
NKPI-10014	25-34 years	Male	Never smoked	
NKPI-10015	35-44 years	Male	Never smoked	
NKPI-10016	45-54 years	Male	Never smoked	
NKPI-10017	55-64 years	Male	Never smoked	
NKPI-10018	65 years and older	Male	Never smoked	
NKPI-10019	15-24 years	Female	Current smoker	
NKPI-10020	25-34 years	Female	Current smoker	
NKPI-10021	35-44 years	Female	Current smoker	
NKPI-10022	45-54 years	Female	Current smoker	
NKPI-10023	55-64 years	Female	Current smoker	
NKPI-10024	65 years and older	Female	Current smoker	
NKPI-10025	15-24 years	Female	Ex-smoker	
NKPI-10026	25-34 years	Female	Ex-smoker	
NKPI-10027	35-44 years	Female	Ex-smoker	
NKPI-10028	45-54 years	Female	Ex-smoker	
NKPI-10029	55-64 years	Female	Ex-smoker	
NKPI-10030	65 years and older	Female	Ex-smoker	
NKPI-10031	15-24 years	Female	Never smoked	
NKPI-10032	25-34 years	Female	Never smoked	
NKPI-10033	35-44 years	Female	Never smoked	
NKPI-10034	45-54 years	Female	Never smoked	
NKPI-10035	55-64 years	Female	Never smoked	
NKPI-10036	65 years and older	Female	Never smoked	
NKPI-10041	11-14 years	Male	Current smoker	
NKPI-10042	11-14 years	Male	Ex-smoker	

Measure Code	Disaggregation 1	Disaggregation 2	Disaggregation 3	Disaggregation 4
NKPI-10043	11-14 years	Male	Never smoked	
NKPI-10051	11-14 years	Female	Current smoker	
NKPI-10052	11-14 years	Female	Ex-smoker	
NKPI-10053	11-14 years	Female	Never smoked	
PI11: Smoking status	of women who gave bi	rth		
NKPI-11004	35 years and older	Current smoker		
NKPI-11008	35 years and older	Ex-smoker		
NKPI-11012	35 years and older	Never smoked		
NKPI-11021	Less than 20 years	Current smoker		
NKPI-11022	20-34 years	Current smoker		
NKPI-11023	Less than 20 years	Ex-smoker		
NKPI-11024	20-34 years	Ex-smoker		
NKPI-11025	Less than 20 years	Never smoked		
NKPI-11026	20-34 years	Never smoked		
PI12: Body mass inde	ex result within specifie	d categories		
NKPI-12021	18-24 years	Male	bmi-5 (underweight)	
NKPI-12022	25-34 years	Male	bmi-5 (underweight)	
NKPI-12023	35-44 years	Male	bmi-5 (underweight)	
NKPI-12024	45-54 years	Male	bmi-5 (underweight)	
NKPI-12025	55-64 years	Male	bmi-5 (underweight)	
NKPI-12026	65 years and older	Male	bmi-5 (underweight)	
NKPI-12027	18-24 years	Female	bmi-5 (underweight)	
NKPI-12028	25-34 years	Female	bmi-5 (underweight)	
NKPI-12029	35-44 years	Female	bmi-5 (underweight)	
NKPI-12030	45-54 years	Female	bmi-5 (underweight)	
NKPI-12031	55-64 years	Female	bmi-5 (underweight)	
NKPI-12032	65 years and older	Female	bmi-5 (underweight)	
NKPI-12033	18-24 years	Male	bmi-4 (normal weight)	
NKPI-12034	25-34 years	Male	bmi-4 (normal weight)	
NKPI-12035	35-44 years	Male	bmi-4 (normal weight)	
NKPI-12036	45-54 years	Male	bmi-4 (normal weight)	
NKPI-12037	55-64 years	Male	bmi-4 (normal weight)	
NKPI-12038	65 years and older	Male	bmi-4 (normal weight)	
NKPI-12039	18-24 years	Female	bmi-4 (normal weight)	
NKPI-12040	25-34 years	Female	bmi-4 (normal weight)	
NKPI-12041	35-44 years	Female	bmi-4 (normal weight)	
NKPI-12042	45-54 years	Female	bmi-4 (normal weight)	
NKPI-12043	55-64 years	Female	bmi-4 (normal weight)	
NKPI-12044	65 years and older	Female	bmi-4 (normal weight)	
NKPI-12045	18-24 years	Male	bmi-1 (overweight)	
NKPI-12046	25-34 years	Male	bmi-1 (overweight)	
NKPI-12047	35-44 years	Male	bmi-1 (overweight)	
NKPI-12048	45-54 years	Male	bmi-1 (overweight)	

Measure Code	Disaggregation 1	Disaggregation 2	Disaggregation 3	Disaggregation 4
NKPI-12049	55-64 years	Male	bmi-1 (overweight)	
NKPI-12050	65 years and older	Male	bmi-1 (overweight)	
NKPI-12051	18-24 years	Female	bmi-1 (overweight)	
NKPI-12052	25-34 years	Female	bmi-1 (overweight)	
NKPI-12053	35-44 years	Female	bmi-1 (overweight)	
NKPI-12054	45-54 years	Female	bmi-1 (overweight)	
NKPI-12055	55-64 years	Female	bmi-1 (overweight)	
NKPI-12056	65 years and older	Female	bmi-1 (overweight)	
NKPI-12057	18-24 years	Male	bmi-2 (obese)	
NKPI-12058	25-34 years	Male	bmi-2 (obese)	
NKPI-12059	35-44 years	Male	bmi-2 (obese)	
NKPI-12060	45-54 years	Male	bmi-2 (obese)	
NKPI-12061	55-64 years	Male	bmi-2 (obese)	
NKPI-12062	65 years and older	Male	bmi-2 (obese)	
NKPI-12063	18-24 years	Female	bmi-2 (obese)	
NKPI-12064	25-34 years	Female	bmi-2 (obese)	
NKPI-12065	35-44 years	Female	bmi-2 (obese)	
NKPI-12066	45-54 years	Female	bmi-2 (obese)	
NKPI-12067	55-64 years	Female	bmi-2 (obese)	
NKPI-12068	65 years and older	Female	bmi-2 (obese)	
NKPI-12069	18-24 years	Male	bmi-6 (not calculated)	
NKPI-12070	25-34 years	Male	bmi-6 (not calculated)	
NKPI-12071	35-44 years	Male	bmi-6 (not calculated)	
NKPI-12072	45-54 years	Male	bmi-6 (not calculated)	
NKPI-12073	55-64 years	Male	bmi-6 (not calculated)	
NKPI-12074	65 years and older	Male	bmi-6 (not calculated)	
NKPI-12075	18-24 years	Female	bmi-6 (not calculated)	
NKPI-12076	25-34 years	Female	bmi-6 (not calculated)	
NKPI-12077	35-44 years	Female	bmi-6 (not calculated)	
NKPI-12078	45-54 years	Female	bmi-6 (not calculated)	
NKPI-12079	55-64 years	Female	bmi-6 (not calculated)	
NKPI-12080	65 years and older	Female	bmi-6 (not calculated)	
PI13: Antenatal Visits				
NKPI-13007	Less than 20 years	ga-4 (≥20 weeks)		
NKPI-13008	20-34 years	ga-4 (≥20 weeks)		
NKPI-13009	35 years and older	ga-4 (≥20 weeks)		
NKPI-13010	Less than 20 years	ga-5 (no GA recorded)		
NKPI-13011	20-34 years	ga-5 (no GA recorded)		
NKPI-13012	35 years and older	ga-5 (no GA recorded)		
NKPI-13013	Less than 20 years	No antenatal visit recorded		
NKPI-13014	20-34 years	No antenatal visit recorded		

Measure Code	Disaggregation 1	Disaggregation 2	Disaggregation 3	Disaggregation 4	
NKPI-13015	35 years and older	No antenatal visit recorded			
NKPI-13021	Less than 20 years	ga-1 (<11 weeks)			
NKPI-13022	20-34 years	ga-1 (<11 weeks)			
NKPI-13023	35 years and older	ga-1 (<11 weeks)			
NKPI-13024	Less than 20 years	ga-2 (≥11 but <14 weeks)			
NKPI-13025	20-34 years	ga-2 (≥11 but <14 weeks)			
NKPI-13026	35 years and older	ga-2 (≥11 but <14 weeks)			
NKPI-13027	Less than 20 years	ga-3 (≥14 but < 20 weeks)			
NKPI-13028	20-34 years	ga-3 (≥14 but < 20 weeks)			
NKPI-13029	35 years and older	ga-3 (≥14 but < 20 weeks)			
PI14: Older clients who are immunised for influenza					
NKPI-14010	6 months - 4 years	Male			
NKPI-14011	5 - 14 years	Male			
NKPI-14012	15 - 24 years	Male			
NKPI-14013	25 - 34 years	Male			
NKPI-14014	35 - 44 years	Male			
NKPI-14015	45 - 54 years	Male			
NKPI-14016	55 - 64 years	Male			
NKPI-14017	65 years and older	Male			
NKPI-14020	6 months - 4 years	Female			
NKPI-14021	5 - 14 years	Female			
NKPI-14022	15 - 24 years	Female			
NKPI-14023	25 - 34 years	Female			
NKPI-14024	35 - 44 years	Female			
NKPI-14025	45 - 54 years	Female			
NKPI-14026	55 - 64 years	Female			
NKPI-14027	65 years and older	Female			
PI15: Clients with Typ	oe 2 diabetes or COPD i	mmunised for influenza (F	Retired - see Appendix C	for details)	
PI16: Alcohol consun	nption recorded				
NKPI-16001	15-24 years	Male			
NKPI-16002	25-34 years	Male			
NKPI-16003	35-44 years	Male			
NKPI-16004	45-54 years	Male			
NKPI-16005	55-64 years	Male			
NKPI-16006	65 years and older	Male			
NKPI-16007	15-24 years	Female			
NKPI-16008	25-34 years	Female			
NKPI-16009	35-44 years	Female			
NKPI-16010	45-54 years	Female			

Measure Code	Disaggregation 1	Disaggregation 2	Disaggregation 3	Disaggregation 4
NKPI-16011	55-64 years	Female		
NKPI-16012	65 years and older	Female		
PI17: AUDIT-C result	(Retired - see Appendix	C for details)		
PI18: Chronic disease	e clients with kidney fur	ction testing		
NKPI-18183	18-24 years	Male	Type 2 diabetes	An eGFR only
NKPI-18002	25-34 years	Male	Type 2 diabetes	An eGFR only
NKPI-18003	35-44 years	Male	Type 2 diabetes	An eGFR only
NKPI-18004	45-54 years	Male	Type 2 diabetes	An eGFR only
NKPI-18005	55-64 years	Male	Type 2 diabetes	An eGFR only
NKPI-18006	65 years and older	Male	Type 2 diabetes	An eGFR only
NKPI-18184	18-24 years	Male	Type 2 diabetes	An ACR only
NKPI-18008	25-34 years	Male	Type 2 diabetes	An ACR only
NKPI-18009	35-44 years	Male	Type 2 diabetes	An ACR only
NKPI-18010	45-54 years	Male	Type 2 diabetes	An ACR only
NKPI-18011	55-64 years	Male	Type 2 diabetes	An ACR only
NKPI-18012	65 years and older	Male	Type 2 diabetes	An ACR only
NKPI-18185	18-24 years	Male	Type 2 diabetes	Both eGFR and ACR
NKPI-18014	25-34 years	Male	Type 2 diabetes	Both eGFR and ACR
NKPI-18015	35-44 years	Male	Type 2 diabetes	Both eGFR and ACR
NKPI-18016	45-54 years	Male	Type 2 diabetes	Both eGFR and ACR
NKPI-18017	55-64 years	Male	Type 2 diabetes	Both eGFR and ACR
NKPI-18018	65 years and older	Male	Type 2 diabetes	Both eGFR and ACR
NKPI-18186	18-24 years	Male	Type 2 diabetes	Neither an eGFR or ACR
NKPI-18059	25-34 years	Male	Type 2 diabetes	Neither an eGFR or ACR
NKPI-18060	35-44 years	Male	Type 2 diabetes	Neither an eGFR or ACR
NKPI-18061	45-54 years	Male	Type 2 diabetes	Neither an eGFR or ACR
NKPI-18062	55-64 years	Male	Type 2 diabetes	Neither an eGFR or ACR
NKPI-18063	65 years and older	Male	Type 2 diabetes	Neither an eGFR or ACR
NKPI-18187	18-24 years	Female	Type 2 diabetes	An eGFR only
NKPI-18026	25-34 years	Female	Type 2 diabetes	An eGFR only
NKPI-18027	35-44 years	Female	Type 2 diabetes	An eGFR only
NKPI-18028	45-54 years	Female	Type 2 diabetes	An eGFR only
NKPI-18029	55-64 years	Female	Type 2 diabetes	An eGFR only
NKPI-18030	65 years and older	Female	Type 2 diabetes	An eGFR only
NKPI-18188	18-24 years	Female	Type 2 diabetes	An ACR only
NKPI-18032	25-34 years	Female	Type 2 diabetes	An ACR only
NKPI-18033	35-44 years	Female	Type 2 diabetes	An ACR only
NKPI-18034	45-54 years	Female	Type 2 diabetes	An ACR only
NKPI-18035	55-64 years	Female	Type 2 diabetes	An ACR only
NKPI-18036	65 years and older	Female	Type 2 diabetes	An ACR only
NKPI-18189	18-24 years	Female	Type 2 diabetes	Both eGFR and ACR
NKPI-18038	25-34 years	Female	Type 2 diabetes	Both eGFR and ACR
NKPI-18039	35-44 years	Female	Type 2 diabetes	Both eGFR and ACR

Measure Code	Disaggregation 1	Disaggregation 2	Disaggregation 3	Disaggregation 4
NKPI-18040	45-54 years	Female	Type 2 diabetes	Both eGFR and ACR
NKPI-18041	55-64 years	Female	Type 2 diabetes	Both eGFR and ACR
NKPI-18042	65 years and older	Female	Type 2 diabetes	Both eGFR and ACR
NKPI-18190	18-24 years	Female	Type 2 diabetes	Neither an eGFR or ACR
NKPI-18066	25-34 years	Female	Type 2 diabetes	Neither an eGFR or ACR
NKPI-18067	35-44 years	Female	Type 2 diabetes	Neither an eGFR or ACR
NKPI-18068	45-54 years	Female	Type 2 diabetes	Neither an eGFR or ACR
NKPI-18069	55-64 years	Female	Type 2 diabetes	Neither an eGFR or ACR
NKPI-18070	65 years and older	Female	Type 2 diabetes	Neither an eGFR or ACR
NKPI-18191	18-24 years	Male	Cardiovascular disease	An eGFR only
NKPI-18073	25-34 years	Male	Cardiovascular disease	An eGFR only
NKPI-18074	35-44 years	Male	Cardiovascular disease	An eGFR only
NKPI-18075	45-54 years	Male	Cardiovascular disease	An eGFR only
NKPI-18076	55-64 years	Male	Cardiovascular disease	An eGFR only
NKPI-18077	65 years and older	Male	Cardiovascular disease	An eGFR only
NKPI-18192	18-24 years	Male	Cardiovascular disease	An ACR only
NKPI-18080	25-34 years	Male	Cardiovascular disease	An ACR only
NKPI-18081	35-44 years	Male	Cardiovascular disease	An ACR only
NKPI-18082	45-54 years	Male	Cardiovascular disease	An ACR only
NKPI-18083	55-64 years	Male	Cardiovascular disease	An ACR only
NKPI-18084	65 years and older	Male	Cardiovascular disease	An ACR only
NKPI-18193	18-24 years	Male	Cardiovascular disease	Both eGFR and ACR
NKPI-18087	25-34 years	Male	Cardiovascular disease	Both eGFR and ACR
NKPI-18088	35-44 years	Male	Cardiovascular disease	Both eGFR and ACR
NKPI-18089	45-54 years	Male	Cardiovascular disease	Both eGFR and ACR
NKPI-18090	55-64 years	Male	Cardiovascular disease	Both eGFR and ACR
NKPI-18091	65 years and older	Male	Cardiovascular disease	Both eGFR and ACR
NKPI-18194	18-24 years	Male	Cardiovascular disease	Neither an eGFR or ACR
NKPI-18094	25-34 years	Male	Cardiovascular disease	Neither an eGFR or ACR
NKPI-18095	35-44 years	Male	Cardiovascular disease	Neither an eGFR or ACR

Measure Code	Disaggregation 1	Disaggregation 2	Disaggregation 3	Disaggregation 4
NKPI-18096	45-54 years	Male	Cardiovascular disease	Neither an eGFR or ACR
NKPI-18097	55-64 years	Male	Cardiovascular disease	Neither an eGFR or ACR
NKPI-18098	65 years and older	Male	Cardiovascular disease	Neither an eGFR or ACR
NKPI-18195	18-24 years	Female	Cardiovascular disease	An eGFR only
NKPI-18101	25-34 years	Female	Cardiovascular disease	An eGFR only
NKPI-18102	35-44 years	Female	Cardiovascular disease	An eGFR only
NKPI-18103	45-54 years	Female	Cardiovascular disease	An eGFR only
NKPI-18104	55-64 years	Female	Cardiovascular disease	An eGFR only
NKPI-18105	65 years and older	Female	Cardiovascular disease	An eGFR only
NKPI-18196	18-24 years	Female	Cardiovascular disease	An ACR only
NKPI-18108	25-34 years	Female	Cardiovascular disease	An ACR only
NKPI-18109	35-44 years	Female	Cardiovascular disease	An ACR only
NKPI-18110	45-54 years	Female	Cardiovascular disease	An ACR only
NKPI-18111	55-64 years	Female	Cardiovascular disease	An ACR only
NKPI-18112	65 years and older	Female	Cardiovascular disease	An ACR only
NKPI-18197	18-24 years	Female	Cardiovascular disease	Both eGFR and ACR
NKPI-18115	25-34 years	Female	Cardiovascular disease	Both eGFR and ACR
NKPI-18116	35-44 years	Female	Cardiovascular disease	Both eGFR and ACR
NKPI-18117	45-54 years	Female	Cardiovascular disease	Both eGFR and ACR
NKPI-18118	55-64 years	Female	Cardiovascular disease	Both eGFR and ACR
NKPI-18119	65 years and older	Female	Cardiovascular disease	Both eGFR and ACR
NKPI-18198	18-24 years	Female	Cardiovascular disease	Neither an eGFR or ACR
NKPI-18122	25-34 years	Female	Cardiovascular disease	Neither an eGFR or ACR
NKPI-18123	35-44 years	Female	Cardiovascular disease	Neither an eGFR or ACR
NKPI-18124	45-54 years	Female	Cardiovascular disease	Neither an eGFR or ACR
NKPI-18125	55-64 years	Female	Cardiovascular disease	Neither an eGFR or ACR
NKPI-18126	65 years and older	Female	Cardiovascular disease	Neither an eGFR or ACR

Measure Code	Disaggregation 1	Disaggregation 2	Disaggregation 3	Disaggregation 4
NKPI-18199	18-24 years	Male	Type 2 diabetes and/or CVD	An eGFR only
NKPI-18129	25-34 years	Male	Type 2 diabetes and/or CVD	An eGFR only
NKPI-18130	35-44 years	Male	Type 2 diabetes and/or CVD	An eGFR only
NKPI-18131	45-54 years	Male	Type 2 diabetes and/or CVD	An eGFR only
NKPI-18132	55-64 years	Male	Type 2 diabetes and/or CVD	An eGFR only
NKPI-18133	65 years and older	Male	Type 2 diabetes and/or CVD	An eGFR only
NKPI-18200	18-24 years	Male	Type 2 diabetes and/or CVD	An ACR only
NKPI-18136	25-34 years	Male	Type 2 diabetes and/or CVD	An ACR only
NKPI-18137	35-44 years	Male	Type 2 diabetes and/or CVD	An ACR only
NKPI-18138	45-54 years	Male	Type 2 diabetes and/or CVD	An ACR only
NKPI-18139	55-64 years	Male	Type 2 diabetes and/or CVD	An ACR only
NKPI-18140	65 years and older	Male	Type 2 diabetes and/or CVD	An ACR only
NKPI-18201	18-24 years	Male	Type 2 diabetes and/or CVD	Both eGFR and ACR
NKPI-18143	25-34 years	Male	Type 2 diabetes and/or CVD	Both eGFR and ACR
NKPI-18144	35-44 years	Male	Type 2 diabetes and/or CVD	Both eGFR and ACR
NKPI-18145	45-54 years	Male	Type 2 diabetes and/or CVD	Both eGFR and ACR
NKPI-18146	55-64 years	Male	Type 2 diabetes and/or CVD	Both eGFR and ACR
NKPI-18147	65 years and older	Male	Type 2 diabetes and/or CVD	Both eGFR and ACR
NKPI-18202	18-24 years	Male	Type 2 diabetes and/or CVD	Neither an eGFR or ACR
NKPI-18150	25-34 years	Male	Type 2 diabetes and/or CVD	Neither an eGFR or ACR
NKPI-18151	35-44 years	Male	Type 2 diabetes and/or CVD	Neither an eGFR or ACR
NKPI-18152	45-54 years	Male	Type 2 diabetes and/or CVD	Neither an eGFR or ACR
NKPI-18153	55-64 years	Male	Type 2 diabetes and/or CVD	Neither an eGFR or ACR
NKPI-18154	65 years and older	Male	Type 2 diabetes and/or CVD	Neither an eGFR or ACR
NKPI-18203	18-24 years	Female	Type 2 diabetes and/or CVD	An eGFR only
NKPI-18157	25-34 years	Female	Type 2 diabetes and/or CVD	An eGFR only
NKPI-18158	35-44 years	Female	Type 2 diabetes and/or CVD	An eGFR only

Measure Code	Disaggregation 1	Disaggregation 2	Disaggregation 3	Disaggregation 4
NKPI-18159	45-54 years	Female	Type 2 diabetes and/or CVD	An eGFR only
NKPI-18160	55-64 years	Female	Type 2 diabetes and/or CVD	An eGFR only
NKPI-18161	65 years and older	Female	Type 2 diabetes and/or CVD	An eGFR only
NKPI-18204	18-24 years	Female	Type 2 diabetes and/or CVD	An ACR only
NKPI-18164	25-34 years	Female	Type 2 diabetes and/or CVD	An ACR only
NKPI-18165	35-44 years	Female	Type 2 diabetes and/or CVD	An ACR only
NKPI-18166	45-54 years	Female	Type 2 diabetes and/or CVD	An ACR only
NKPI-18167	55-64 years	Female	Type 2 diabetes and/or CVD	An ACR only
NKPI-18168	65 years and older	Female	Type 2 diabetes and/or CVD	An ACR only
NKPI-18205	18-24 years	Female	Type 2 diabetes and/or CVD	Both eGFR and ACR
NKPI-18171	25-34 years	Female	Type 2 diabetes and/or CVD	Both eGFR and ACR
NKPI-18172	35-44 years	Female	Type 2 diabetes and/or CVD	Both eGFR and ACR
NKPI-18173	45-54 years	Female	Type 2 diabetes and/or CVD	Both eGFR and ACR
NKPI-18174	55-64 years	Female	Type 2 diabetes and/or CVD	Both eGFR and ACR
NKPI-18175	65 years and older	Female	Type 2 diabetes and/or CVD	Both eGFR and ACR
NKPI-18206	18-24 years	Female	Type 2 diabetes and/or CVD	Neither an eGFR or ACR
NKPI-18178	25-34 years	Female	Type 2 diabetes and/or CVD	Neither an eGFR or ACR
NKPI-18179	35-44 years	Female	Type 2 diabetes and/or CVD	Neither an eGFR or ACR
NKPI-18180	45-54 years	Female	Type 2 diabetes and/or CVD	Neither an eGFR or ACR
NKPI-18181	55-64 years	Female	Type 2 diabetes and/or CVD	Neither an eGFR or ACR
NKPI-18182	65 years and older	Female	Type 2 diabetes and/or CVD	Neither an eGFR or ACR
PI19: Chronic disease	clients kidney function te	st results		
NKPI-19433	18-24 years	Male	Type 2 diabetes	Normal risk (eGFR ≥60 and ACR <2.5)
NKPI-19183	25-34 years	Male	Type 2 diabetes	Normal risk (eGFR≥60 and ACR <2.5)
NKPI-19184	35-44 years	Male	Type 2 diabetes	Normal risk (eGFR≥60 and ACR <2.5)
NKPI-19185	45-54 years	Male	Type 2 diabetes	Normal risk (eGFR≥60 and ACR <2.5)
NKPI-19186	55-64 years	Male	Type 2 diabetes	Normal risk (eGFR≥60 and ACR <2.5)

Measure Code	Disaggregation 1	Disaggregation 2	Disaggregation 3	Disaggregation 4
NKPI-19187	65 years and older	Male	Type 2 diabetes	Normal risk (eGFR≥60 and ACR <2.5)
NKPI-19437	18-24 years	Female	Type 2 diabetes	Normal risk (eGFR≥60 and ACR <3.5)
NKPI-19225	25-34 years	Female	Type 2 diabetes	Normal risk (eGFR ≥60 and ACR < 3.5)
NKPI-19226	35-44 years	Female	Type 2 diabetes	Normal risk (eGFR ≥60 and ACR <3.5)
NKPI-19227	45-54 years	Female	Type 2 diabetes	Normal risk (eGFR ≥60 and ACR <3.5)
NKPI-19228	55-64 years	Female	Type 2 diabetes	Normal risk (eGFR ≥60 and ACR <3.5)
NKPI-19229	65 years and older	Female	Type 2 diabetes	Normal risk (eGFR ≥60 and ACR <3.5)
NKPI-19434	18-24 years	Male	Type 2 diabetes	Low risk (eGFR ≥45 but <60 and ACR <2.5 OR eGFR ≥60 and ACR ≥2.5 but ≤25)
NKPI-19190	25-34 years	Male	Type 2 diabetes	Low risk (eGFR ≥45 but <60 and ACR <2.5 OR,
				eGFR ≥60 and ACR ≥2.5 but ≤25)
NKPI-19191	35-44 years	Male	Type 2 diabetes	Low risk (eGFR ≥45 but <60 and ACR <2.5 OR, eGFR ≥60 and ACR ≥2.5 but
NKPI-19192	45-54 years	Male	Type 2 diabetes	≤25) Low risk (eGFR ≥45 but <60 and ACR <2.5 OR, eGFR ≥60 and ACR ≥2.5 but ≤25)
NKPI-19193	55-64 years	Male	Type 2 diabetes	Low risk (eGFR ≥45 but <60 and ACR <2.5 OR, eGFR ≥60 and ACR ≥2.5 but ≤25)
NKPI-19194	65 years and older	Male	Type 2 diabetes	Low risk (eGFR ≥45 but <60 and ACR <2.5 OR, eGFR ≥60 and ACR ≥2.5 but ≤25)
NKPI-19438	18-24 years	Female	Type 2 diabetes	Low risk (eGFR ≥45 but <60 and ACR <3.5 OR, eGFR ≥60 and ACR ≥3.5 but
NKPI-19232	25-34 years	Female	Type 2 diabetes	≤35) Low risk (eGFR ≥45 but <60 and ACR <3.5 OR, eGFR ≥60 and ACR ≥3.5 but ≤35)
NKPI-19233	35-44 years	Female	Type 2 diabetes	Low risk (eGFR ≥45 but <60 and ACR <3.5 OR, eGFR ≥60 and ACR ≥3.5 but ≤35)
NKPI-19234	45-54 years	Female	Type 2 diabetes	Low risk (eGFR ≥45 but <60 and ACR <3.5 OR, eGFR ≥60 and ACR ≥3.5 but ≤35)
NKPI-19235	55-64 years	Female	Type 2 diabetes	Low risk (eGFR ≥45 but <60 and ACR <3.5 OR, eGFR ≥60 and ACR ≥3.5 but ≤35)

Measure Code	Disaggregation 1	Disaggregation 2	Disaggregation 3	Disaggregation 4
NKPI-19236	65 years and older	Female	Type 2 diabetes	Low risk (eGFR ≥45 but <60 and ACR <3.5 OR, eGFR ≥60 and ACR ≥3.5 but ≤35)
NKPI-19435	18-24 years	Male	Type 2 diabetes	Moderate risk (eGFR ≥45 but <60 and ACR ≥2.5 but ≤25 OR, eGFR ≥30 but <45 and ACR ≤25)
NKPI-19197	25-34 years	Male	Type 2 diabetes	Moderate risk (eGFR ≥45 but <60 and ACR ≥2.5 but ≤25 OR, eGFR ≥30 but <45 and ACR ≤25)
NKPI-19198	35-44 years	Male	Type 2 diabetes	Moderate risk (eGFR ≥45 but <60 and ACR ≥2.5 but ≤25 OR, eGFR ≥30 but <45 and ACR ≤25)
NKPI-19199	45-54 years	Male	Type 2 diabetes	Moderate risk (eGFR ≥45 but <60 and ACR ≥2.5 but ≤25 OR, eGFR ≥30 but <45 and ACR ≤25)
NKPI-19200	55-64 years	Male	Type 2 diabetes	Moderate risk (eGFR ≥45 but <60 and ACR ≥2.5 but ≤25 OR, eGFR ≥30 but <45 and ACR ≤25)
NKPI-19201	65 years and older	Male	Type 2 diabetes	Moderate risk (eGFR ≥45 but <60 and ACR ≥2.5 but ≤25 OR, eGFR ≥30 but <45 and ACR ≤25)
NKPI-19439	18-24 years	Female	Type 2 diabetes	Moderate risk (eGFR ≥45 but <60 and ACR ≥3.5 but ≤35 OR, eGFR ≥30 but <45 and ACR ≤35)
NKPI-19239	25-34 years	Female	Type 2 diabetes	Moderate risk (eGFR ≥45 but <60 and ACR ≥3.5 but ≤35 OR, eGFR ≥30 but <45 and ACR ≤35)
NKPI-19240	35-44 years	Female	Type 2 diabetes	Moderate risk (eGFR ≥45 but <60 and ACR ≥3.5 but ≤35 OR, eGFR ≥30 but <45 and ACR ≤35)
NKPI-19241	45-54 years	Female	Type 2 diabetes	Moderate risk (eGFR ≥45 but <60 and ACR ≥3.5 but ≤35 OR, eGFR ≥30 but <45 and ACR ≤35)
NKPI-19242	55-64 years	Female	Type 2 diabetes	Moderate risk (eGFR ≥45 but <60 and ACR ≥3.5 but ≤35 OR, eGFR ≥30 but <45 and ACR ≤35)
NKPI-19243	65 years and older	Female	Type 2 diabetes	Moderate risk (eGFR ≥45 but <60 and ACR ≥3.5 but ≤35 OR, eGFR ≥30 but <45 and ACR ≤35)
NKPI-19436	18-24 years	Male	Type 2 diabetes	High risk (eGFR ≥30 and ACR >25 OR, eGFR <30 and any ACR result)
NKPI-19204	25-34 years	Male	Type 2 diabetes	High risk (eGFR ≥30 and ACR >25 OR, eGFR <30 and any ACR result)

Measure Code	Disaggregation 1	Disaggregation 2	Disaggregation 3	Disaggregation 4
NKPI-19205	35-44 years	Male	Type 2 diabetes	High risk (eGFR ≥30 and ACR >25 OR,
				eGFR <30 and any ACR result)
NKPI-19206	45-54 years	Male	Type 2 diabetes	High risk (eGFR ≥30 and ACR >25 OR,
				eGFR <30 and any ACR result)
NKPI-19207	55-64 years	Male	Type 2 diabetes	High risk (eGFR ≥30 and ACR >25 OR,
				eGFR <30 and any ACR result)
NKPI-19208	65 years and older	Male	Type 2 diabetes	High risk (eGFR ≥30 and ACR >25 OR,
NICEL 40440	40.04	Familia	Towns Outlinks (see	eGFR <30 and any ACR result)
NKPI-19440	18-24 years	Female	Type 2 diabetes	High risk (eGFR ≥30 and ACR >35 OR,
NUCEL 40040	05.04	 	T 0 " 1 .	eGFR <30 and any ACR result)
NKPI-19246	25-34 years	Female	Type 2 diabetes	High risk (eGFR ≥30 and ACR >35 OR, eGFR <30 and any ACR result)
NKPI-19247	35-44 years	Female	Type 2 diabetes	High risk (eGFR ≥30 and ACR >35 OR.
				eGFR <30 and any ACR result)
NKPI-19248	45-54 years	Female	Type 2 diabetes	High risk (eGFR ≥30 and ACR >35 OR.
				eGFR <30 and any ACR result)
NKPI-19249	55-64 years	Female	Type 2 diabetes	High risk (eGFR ≥30 and ACR >35 OR,
				eGFR <30 and any ACR result)
NKPI-19250	65 years and older	Female	Type 2 diabetes	High risk (eGFR ≥30 and ACR >35 OR,
				eGFR <30 and any ACR result)
NKPI-19441	18-24 years	Male	Cardiovascular disease	Normal risk (eGFR ≥60 and ACR <2.5)
NKPI-19267	25-34 years	Male	Cardiovascular disease	Normal risk (eGFR ≥60 and ACR <2.5)
NKPI-19268	35-44 years	Male	Cardiovascular disease	Normal risk (eGFR ≥60 and ACR <2.5)
NKPI-19269	45-54 years	Male	Cardiovascular disease	Normal risk (eGFR ≥60 and ACR <2.5)
NKPI-19270	55-64 years	Male	Cardiovascular disease	Normal risk (eGFR ≥60 and ACR <2.5)
NKPI-19271	65 years and older	Male	Cardiovascular disease	Normal risk (eGFR ≥60 and ACR <2.5)
NKPI-19445	18-24 years	Female	Cardiovascular disease	Normal risk (eGFR ≥60 and ACR <3.5)
NKPI-19309	25-34 years	Female	Cardiovascular disease	Normal risk (eGFR ≥60 and ACR <3.5)
NKPI-19310	35-44 years	Female	Cardiovascular disease	Normal risk (eGFR ≥60 and ACR <3.5)
NKPI-19311	45-54 years	Female	Cardiovascular disease	Normal risk (eGFR ≥60 and ACR <3.5)
NKPI-19312	55-64 years	Female	Cardiovascular disease	Normal risk(eGFR ≥60 and ACR <3.5)
NKPI-19313	65 years and older	Female	Cardiovascular disease	Normal risk (eGFR ≥60 and ACR < 3.5)

Measure Code	Disaggregation 1	Disaggregation 2	Disaggregation 3	Disaggregation 4
NKPI-19442	18-24 years	Male	Cardiovascular disease	Low risk (eGFR ≥45 but <60 and ACR <2.5 OR, eGFR ≥60 and ACR ≥2.5 but
				<25)
NKPI-19274	25-34 years	Male	Cardiovascular disease	Low risk (eGFR ≥45 but <60 and ACR <2.5 OR,
				eGFR ≥60 and ACR ≥2.5 but <25)
NKPI-19275	35-44 years	Male	Cardiovascular disease	Low risk (eGFR ≥45 but <60 and ACR <2.5 OR, eGFR ≥60 and ACR ≥2.5 but
				<25)
NKPI-19276	45-54 years	Male	Cardiovascular disease	Low risk (eGFR ≥45 but <60 and ACR <2.5 OR,
				eGFR ≥60 and ACR ≥2.5 but <25)
NKPI-19277	55-64 years	Male	Cardiovascular disease	Low risk (eGFR ≥45 but <60 and ACR <2.5 OR,
				eGFR ≥60 and ACR ≥2.5 but <25)
NKPI-19278	65 years and older	Male	Cardiovascular disease	Low risk (eGFR ≥45 but <60 and ACR <2.5 OR,
				eGFR ≥60 and ACR ≥2.5 but <25)
NKPI-19446	18-24 years	Female	Cardiovascular disease	Low risk (eGFR ≥45 but <60 and ACR <3.5 OR,
				eGFR ≥60 and ACR ≥3.5 but ≤35)
NKPI-19316	25-34 years	Female	Cardiovascular disease	Low risk (eGFR ≥45 but <60 and ACR <3.5 OR,
				eGFR ≥60 and ACR ≥3.5 but ≤35)
NKPI-19317	35-44 years	Female	Cardiovascular disease	Low risk (eGFR ≥45 but <60 and ACR <3.5 OR,
				eGFR ≥60 and ACR ≥3.5 but ≤35)
NKPI-19318	45-54 years	Female	Cardiovascular disease	Low risk (eGFR ≥45 but <60 and ACR <3.5 OR,
				eGFR ≥60 and ACR ≥3.5 but ≤35)
NKPI-19319	55-64 years	Female	Cardiovascular disease	Low risk (eGFR ≥45 but <60 and ACR <3.5 OR,
				eGFR ≥60 and ACR ≥3.5 but ≤35)
NKPI-19320	65 years and older	Female	Cardiovascular disease	Low risk (eGFR ≥45 but <60 and ACR <3.5 OR,
				eGFR ≥60 and ACR ≥3.5 but ≤35)
NKPI-19443	18-24 years	Male	Cardiovascular disease	Moderate risk (eGFR ≥45 but <60 and ACR ≥2.5 but ≤25 OR,
				eGFR ≥30 but <45 and ACR ≤25)
NKPI-19281	25-34 years	Male	Cardiovascular disease	Moderate risk (eGFR ≥45 but <60 and ACR ≥2.5 but ≤25 OR,
				eGFR ≥30 but <45 and ACR ≤25)

Measure Code	Disaggregation 1	Disaggregation 2	Disaggregation 3	Disaggregation 4
NKPI-19282	35-44 years	Male	Cardiovascular disease	Moderate risk (eGFR ≥45 but <60 and ACR ≥2.5 but ≤25 OR,
				eGFR ≥30 but <45 and ACR ≤25)
NKPI-19283	45-54 years	Male	Cardiovascular disease	Moderate risk (eGFR ≥45 but <60 and ACR ≥2.5 but ≤25 OR,
				eGFR ≥30 but <45 and ACR ≤25)
NKPI-19284	55-64 years	Male	Cardiovascular disease	Moderate risk (eGFR ≥45 but <60 and ACR ≥2.5 but ≤25 OR, eGFR ≥30 but <45 and ACR
				≤25)
NKPI-19285	65 years and older	Male	Cardiovascular disease	Moderate risk (eGFR ≥45 but <60 and ACR ≥2.5 but ≤25 OR,
				eGFR ≥30 but <45 and ACR ≤25)
NKPI-19447	18-24 years	Female	Cardiovascular disease	Moderate risk (eGFR ≥45 but <60 and ACR ≥3.5 but ≤35 OR,
				eGFR ≥30 but <45 and ACR ≤35)
NKPI-19323	25-34 years	Female	Cardiovascular disease	Moderate risk (eGFR ≥45 but <60 and ACR ≥3.5 but ≤35 OR,
				eGFR ≥30 but <45 and ACR ≤35)
NKPI-19324	35-44 years	Female	Cardiovascular disease	Moderate risk (eGFR ≥45 but <60 and ACR ≥3.5 but ≤35 OR,
				eGFR ≥30 but <45 and ACR ≤35)
NKPI-19325	45-54 years	Female	Cardiovascular disease	Moderate risk (eGFR ≥45 but <60 and ACR ≥3.5 but ≤35 OR,
				eGFR ≥30 but <45 and ACR ≤35)
NKPI-19326	55-64 years	Female	Cardiovascular disease	Moderate risk (eGFR ≥45 but <60 and ACR ≥3.5 but ≤35 OR,
				eGFR ≥30 but <45 and ACR ≤35)
NKPI-19327	65 years and older	Female	Cardiovascular disease	Moderate risk (eGFR ≥45 but <60 and ACR ≥3.5 but ≤35 OR, eGFR ≥30 but <45 and ACR ≤35)
NKPI-19444	18-24 years	Male	Cardiovascular disease	High risk (eGFR ≥30 and ACR >25 OR,
				eGFR <30 and any ACR result)
NKPI-19288	25-34 years	Male	Cardiovascular disease	High risk (eGFR ≥30 and ACR >25 OR,
NKPI-19289	35-44 years	Male	Cardiovascular	eGFR <30 and any ACR result) High risk (eGFR ≥30 and ACR
INIXF1-13203	55-44 years	iviale	disease	>25 OR, eGFR <30 and any ACR result)
NKPI-19290	45-54 years	Male	Cardiovascular	High risk (eGFR ≥30 and ACR
			disease	>25 OR, eGFR <30 and any ACR result)
NKPI-19291	55-64 years	Male	Cardiovascular disease	High risk (eGFR ≥30 and ACR >25 OR,
				eGFR <30 and any ACR result)

Measure Code	Disaggregation 1	Disaggregation 2	Disaggregation 3	Disaggregation 4
NKPI-19292	65 years and older	Male	Cardiovascular disease	High risk (eGFR ≥30 and ACR >25 OR,
				eGFR <30 and any ACR result)
NKPI-19448	18-24 years	Female	Cardiovascular disease	High risk (eGFR ≥30 and ACR >35 OR,
				eGFR <30 and any ACR result)
NKPI-19330	25-34 years	Female	Cardiovascular disease	High risk (eGFR ≥30 and ACR >35 OR,
				eGFR <30 and any ACR result)
NKPI-19331	35-44 years	Female	Cardiovascular disease	High risk (eGFR ≥30 and ACR >35 OR, eGFR <30 and any ACR result)
NIZDI 40000	45.54	Famala	Candiavaaavlan	,
NKPI-19332	45-54 years	Female	Cardiovascular disease	High risk (eGFR ≥30 and ACR >35 OR, eGFR <30 and any ACR result)
NKPI-19333	55-64 years	Female	Cardiovascular	High risk (eGFR ≥30 and ACR
NAC1-19333	33-04 years	remale	disease	>35 OR, eGFR <30 and any ACR result)
NKPI-19334	65 years and older	Female	Cardiovascular disease	High risk (eGFR ≥30 and ACR >35 OR,
				eGFR <30 and any ACR result)
NKPI-19449	18-24 years	Male	Type 2 diabetes and/or CVD	Normal risk (eGFR ≥60 and ACR <2.5)
NKPI-19351	25-34 years	Male	Type 2 diabetes and/or CVD	Normal risk (eGFR ≥60 and ACR <2.5)
NKPI-19352	35-44 years	Male	Type 2 diabetes and/or CVD	Normal risk (eGFR ≥60 and ACR <2.5)
NKPI-19353	45-54 years	Male	Type 2 diabetes and/or CVD	Normal risk (eGFR ≥60 and ACR <2.5)
NKPI-19354	55-64 years	Male	Type 2 diabetes and/or CVD	Normal risk (eGFR ≥60 and ACR <2.5)
NKPI-19355	65 years and older	Male	Type 2 diabetes and/or CVD	Normal risk (eGFR ≥60 and ACR <2.5)
NKPI-19453	18-24 years	Female	Type 2 diabetes and/or CVD	Normal risk (eGFR ≥60 and ACR <3.5)
NKPI-19393	25-34 years	Female	Type 2 diabetes and/or CVD	Normal risk (eGFR ≥60 and ACR <3.5)
NKPI-19394	35-44 years	Female	Type 2 diabetes and/or CVD	Normal risk (eGFR ≥60 and ACR <3.5)
NKPI-19395	45-54 years	Female	Type 2 diabetes and/or CVD	Normal risk (eGFR ≥60 and ACR <3.5)
NKPI-19396	55-64 years	Female	Type 2 diabetes and/or CVD	Normal risk (eGFR ≥60 and ACR <3.5)
NKPI-19397	65 years and older	Female	Type 2 diabetes and/or CVD	Normal risk (eGFR ≥60 and ACR < 3.5)
NKPI-19450	18-24 years	Male	Type 2 diabetes and/or CVD	Low risk (eGFR ≥45 but <60 and ACR <2.5 OR,
				eGFR ≥60 and ACR ≥2.5 but <25)
NKPI-19358	25-34 years	Male	Type 2 diabetes and/or CVD	Low risk (eGFR ≥45 but <60 and ACR <2.5 OR,
				eGFR ≥60 and ACR ≥2.5 but <25)

Measure Code	Disaggregation 1	Disaggregation 2	Disaggregation 3	Disaggregation 4
NKPI-19359	35-44 years	Male	Type 2 diabetes and/or CVD	Low risk (eGFR ≥45 but <60 and ACR <2.5 OR, eGFR ≥60 and ACR ≥2.5 but <25)
NKPI-19360	45-54 years	Male	Type 2 diabetes and/or CVD	Low risk (eGFR ≥45 but <60 and ACR <2.5 OR, eGFR ≥60 and ACR ≥2.5 but <25)
NKPI-19361	55-64 years	Male	Type 2 diabetes and/or CVD	Low risk (eGFR ≥45 but <60 and ACR <2.5 OR, eGFR ≥60 and ACR ≥2.5 but <25)
NKPI-19362	65 years and older	Male	Type 2 diabetes and/or CVD	Low risk (eGFR ≥45 but <60 and ACR <2.5 OR, eGFR ≥60 and ACR ≥2.5 but <25)
NKPI-19454	18-24 years	Female	Type 2 diabetes and/or CVD	Low risk (eGFR ≥45 but <60 and ACR <3.5 OR, eGFR ≥60 and ACR ≥3.5 but ≤35)
NKPI-19400	25-34 years	Female	Type 2 diabetes and/or CVD	Low risk (eGFR ≥45 but <60 and ACR <3.5 OR, eGFR ≥60 and ACR ≥3.5 but ≤35)
NKPI-19401	35-44 years	Female	Type 2 diabetes and/or CVD	Low risk (eGFR ≥45 but <60 and ACR <3.5 OR, eGFR ≥60 and ACR ≥3.5 but ≤35)
NKPI-19402	45-54 years	Female	Type 2 diabetes and/or CVD	Low risk (eGFR ≥45 but <60 and ACR <3.5 OR, eGFR ≥60 and ACR ≥3.5 but ≤35)
NKPI-19403	55-64 years	Female	Type 2 diabetes and/or CVD	Low risk (eGFR ≥45 but <60 and ACR <3.5 OR, eGFR ≥60 and ACR ≥3.5 but ≤35)
NKPI-19404	65 years and older	Female	Type 2 diabetes and/or CVD	Low risk (eGFR ≥45 but <60 and ACR <3.5 OR, eGFR ≥60 and ACR ≥3.5 but ≤35)
NKPI-19451	18-24 years	Male	Type 2 diabetes and/or CVD	Moderate risk (eGFR ≥45 but <60 and ACR ≥2.5 but ≤25 OR, eGFR ≥30 but <45 and ACR ≤25)
NKPI-19365	25-34 years	Male	Type 2 diabetes and/or CVD	Moderate risk (eGFR ≥45 but <60 and ACR ≥2.5 but ≤25 OR, eGFR ≥30 but <45 and ACR ≤25)
NKPI-19366	35-44 years	Male	Type 2 diabetes and/or CVD	Moderate risk (eGFR ≥45 but <60 and ACR ≥2.5 but ≤25 OR, eGFR ≥30 but <45 and ACR ≤25)
NKPI-19367	45-54 years	Male	Type 2 diabetes and/or CVD	Moderate risk (eGFR ≥45 but <60 and ACR ≥2.5 but <25 OR, eGFR ≥30 but <45 and ACR ≤25)

Disaggregation 1	Disaggregation 2	Disaggregation 3	Disaggregation 4
55-64 years	Male	Type 2 diabetes and/or CVD	Moderate risk (eGFR ≥45 but <60 and ACR ≥2.5 but ≤25 OR, eGFR ≥30 but <45 and ACR ≤25)
65 years and older	Male	Type 2 diabetes and/or CVD	Moderate risk (eGFR ≥45 but <60 and ACR ≥2.5 but ≤25 OR, eGFR ≥30 but <45 and ACR ≤25)
18-24 years	Female	Type 2 diabetes and/or CVD	Moderate risk (eGFR ≥45 but <60 and ACR ≥3.5 but ≤35 OR, eGFR ≥30 but <45 and ACR ≤35)
25-34 years	Female	Type 2 diabetes and/or CVD	Moderate risk (eGFR ≥45 but <60 and ACR ≥3.5 but ≤35 OR, eGFR ≥30 but <45 and ACR ≤35)
35-44 years	Female	Type 2 diabetes and/or CVD	Moderate risk (eGFR ≥45 but <60 and ACR ≥3.5 but ≤35 OR, eGFR ≥30 but <45 and ACR ≤35)
45-54 years	Female	Type 2 diabetes and/or CVD	Moderate risk (eGFR ≥45 but <60 and ACR ≥3.5 but ≤35 OR, eGFR ≥30 but <45 and ACR ≤35)
55-64 years	Female	Type 2 diabetes and/or CVD	Moderate risk (eGFR ≥45 but <60 and ACR ≥3.5 but ≤35 OR, eGFR ≥30 but <45 and ACR ≤35)
65 years and older	Female	Type 2 diabetes and/or CVD	Moderate risk (eGFR ≥45 but <60 and ACR ≥3.5 but ≤35 OR, eGFR ≥30 but <45 and ACR ≤35)
18-24 years	Male	Type 2 diabetes and/or CVD	High risk (eGFR ≥30 and ACR >25 OR, eGFR <30 and any ACR result)
25-34 years	Male	Type 2 diabetes and/or CVD	High risk (eGFR ≥30 and ACR >25 OR, eGFR <30 and any ACR result)
35-44 years	Male	Type 2 diabetes and/or CVD	High risk (eGFR ≥30 and ACR >25 OR, eGFR <30 and any ACR result)
45-54 years	Male	Type 2 diabetes and/or CVD	High risk (eGFR ≥30 and ACR >25 OR, eGFR <30 and any ACR result)
55-64 years	Male	Type 2 diabetes and/or CVD	High risk (eGFR ≥30 and ACR >25 OR, eGFR <30 and any ACR result)
65 years and older	Male	Type 2 diabetes and/or CVD	High risk (eGFR ≥30 and ACR >25 OR, eGFR <30 and any ACR result)
18-24 years	Female	Type 2 diabetes and/or CVD	High risk (eGFR ≥30 and ACR >35 OR, eGFR <30 and any ACR result)
			, , ,
	55-64 years 65 years and older 18-24 years 25-34 years 35-44 years 55-64 years 65 years and older 18-24 years 25-34 years 55-64 years 55-64 years	55-64 years Male 65 years and older Male 18-24 years Female 25-34 years Female 45-54 years Female 55-64 years Female 18-24 years Male 18-24 years Male 45-54 years Male 55-64 years Male 55-64 years Male 45-54 years Male	55-64 years Male Type 2 diabetes and/or CVD 65 years and older Male Type 2 diabetes and/or CVD 18-24 years Female Type 2 diabetes and/or CVD 25-34 years Female Type 2 diabetes and/or CVD 35-44 years Female Type 2 diabetes and/or CVD 45-54 years Female Type 2 diabetes and/or CVD 55-64 years Female Type 2 diabetes and/or CVD 65 years and older Female Type 2 diabetes and/or CVD 18-24 years Male Type 2 diabetes and/or CVD 35-44 years Male Type 2 diabetes and/or CVD 45-54 years Male Type 2 diabetes and/or CVD 45-54 years Male Type 2 diabetes and/or CVD 55-64 years Male Type 2 diabetes and/or CVD 65 years and older Male Type 2 diabetes and/or CVD 65 years and older Male Type 2 diabetes and/or CVD 18-24 years Female Type 2 diabetes and/or CVD

Measure Code	Disaggregation 1	Disaggregation 2	Disaggregation 3	Disaggregation 4
NKPI-19415	35-44 years	Female	Type 2 diabetes and/or CVD	High risk (eGFR ≥30 and ACR >35 OR,
			and/or CVD	eGFR <30 and any ACR result)
NKPI-19416	45-54 years	Female	Type 2 diabetes	High risk (eGFR ≥30 and ACR
			and/or CVD	>35 OR, eGFR <30 and any ACR result)
NKPI-19417	55-64 years	Female	Type 2 diabetes	High risk (eGFR ≥30 and ACR
144110117	oo o i youro	- Omaio	and/or CVD	>35 OR,
				eGFR <30 and any ACR result)
NKPI-19418	65 years and older	Female	Type 2 diabetes and/or CVD	High risk (eGFR ≥30 and ACR >35 OR,
				eGFR <30 and any ACR result)
PI19A: eGFR result (F	Retired - see Appendix (C for details)		
PI19B: ACR result (R	etired – see Appendix C	for details)		
PI20: CVD risk asses	sment factors			
NKPI-20001	35-44 years	Male		
NKPI-20002	45-54 years	Male		
NKPI-20003	55-64 years	Male		
NKPI-20004	65-74 years	Male		
NKPI-20005	35-44 years	Female		
NKPI-20006	45-54 years	Female		
NKPI-20007	55-64 years	Female		
NKPI-20008	65-74 years	Female		
PI21: CVD risk asses	sment result			
NKPI-21001	35-44 years	Male	ar-1 (>15%)	
NKPI-21002	45-54 years	Male	ar-1 (>15%)	
NKPI-21003	55-64 years	Male	ar-1 (>15%)	
NKPI-21004	65-74 years	Male	ar-1 (>15%)	
NKPI-21005	35-44 years	Female	ar-1 (>15%)	
NKPI-21006	45-54 years	Female	ar-1 (>15%)	
NKPI-21007	55-64 years	Female	ar-1 (>15%)	
NKPI-21008	65-74 years	Female	ar-1 (>15%)	
NKPI-21009	35-44 years	Male	ar-2 (10-15%)	
NKPI-21010	45-54 years	Male	ar-2 (10-15%)	
NKPI-21011	55-64 years	Male	ar-2 (10-15%)	
NKPI-21012	65-74 years	Male	ar-2 (10-15%)	
NKPI-21013	35-44 years	Female	ar-2 (10-15%)	
NKPI-21014	45-54 years	Female	ar-2 (10-15%)	
NKPI-21015	55-64 years	Female	ar-2 (10-15%)	
NKPI-21016	65-74 years	Female	ar-2 (10-15%)	
NKPI-21017	35-44 years	Male	ar-3 (<10%)	
NKPI-21018	45-54 years	Male	ar-3 (<10%)	
NKPI-21019	55-64 years	Male	ar-3 (<10%)	
NKPI-21020	65-74 years	Male	ar-3 (<10%)	
NKPI-21021	35-44 years	Female	ar-3 (<10%)	

Measure Code	Disaggregation 1	Disaggregation 2	Disaggregation 3	Disaggregation 4
NKPI-21022	45-54 years	Female	ar-3 (<10%)	
NKPI-21023	55-64 years	Female	ar-3 (<10%)	
NKPI-21024	65-74 years	Female	ar-3 (<10%)	
Pl22: Female clients v	with a cervical screenin	g (HPV) test		
NKPI-22016	25-34 years			
NKPI-22017	35-44 years			
NKPI-22018	45-54 years			
NKPI-22019	55-64 years			
NKPI-22024	65-74 years			
PI23: Blood pressure	recorded			
NKPI-23001	0-4 years	Male		
NKPI-23002	5-14 years	Male		
NKPI-23003	15-24 years	Male		
NKPI-23004	25-34 years	Male		
NKPI-23005	35-44 years	Male		
NKPI-23006	45-54 years	Male		
NKPI-23007	55-64 years	Male		
NKPI-23008	65 years and older	Male		
NKPI-23009	0-4 years	Female		
NKPI-23010	5-14 years	Female		
NKPI-23011	15-24 years	Female		
NKPI-23012	25-34 years	Female		
NKPI-23013	35-44 years	Female		
NKPI-23014	45-54 years	Female		
NKPI-23015	55-64 years	Female		
NKPI-23016	65 years and older	Female		
PI24: Blood pressure	result			
NKPI-24001	0-4 years	Male		
NKPI-24002	5-14 years	Male		
NKPI-24003	15-24 years	Male		
NKPI-24004	25-34 years	Male		
NKPI-24005	35-44 years	Male		
NKPI-24006	45-54 years	Male		
NKPI-24007	55-64 years	Male		
NKPI-24008	65 years and older	Male		
NKPI-24009	0-4 years	Female		
NKPI-24010	5-14 years	Female		
NKPI-24011	15-24 years	Female		
NKPI-24012	25-34 years	Female		
NKPI-24013	35-44 years	Female		
NKPI-24014	45-54 years	Female		
NKPI-24015	55-64 years	Female		
NKPI-24016	65 years and older	Female		

Measure Code	Disaggregation 1	Disaggregation 2	Disaggregation 3	Disaggregation 4
Pl25: STI result recor	rded			
NKPI-25001	15-19 years	Male		
NKPI-25002	20-24 years	Male		
NKPI-25003	25-29 years	Male		
NKPI-25004	30-34 years	Male		
NKPI-25005	15-19 years	Female		
NKPI-25006	20-24 years	Female		
NKPI-25007	25-29 years	Female		
NKPI-25008	30-34 years	Female		
PI26: Ear Health Check				
NKPI-26001	0-11 months	Male	Appearance	
NKPI-26002	0-11 months	Male	Movement	
NKPI-26003	0-11 months	Male	Appearance and movement	
NKPI-26004	12-23 months	Male	Appearance	
NKPI-26005	12-23 months	Male	Movement	
NKPI-26006	12-23 months	Male	Appearance and movement	
NKPI-26007	24-35 months	Male	Appearance	
NKPI-26008	24-35 months	Male	Movement	
NKPI-26009	24-35 months	Male	Appearance and movement	
NKPI-26010	36-59 months	Male	Appearance	
NKPI-26011	36-59 months	Male	Movement	
NKPI-26012	36-59 months	Male	Appearance and movement	
NKPI-26013	5-9 years	Male	Appearance	
NKPI-26014	5-9 years	Male	Movement	
NKPI-26015	5-9 years	Male	Appearance and movement	
NKPI-26016	10-14 years	Male	Appearance	
NKPI-26017	10-14 years	Male	Movement	
NKPI-26018	10-14 years	Male	Appearance and movement	
NKPI-26019	0-11 months	Female	Appearance	
NKPI-26020	0-11 months	Female	Movement	
NKPI-26021	0-11 months	Female	Appearance and movement	
NKPI-26022	12-23 months	Female	Appearance	
NKPI-26023	12-23 months	Female	Movement	
NKPI-26024	12-23 months	Female	Appearance and movement	
NKPI-26025	24-35 months	Female	Appearance	
NKPI-26026	24-35 months	Female	Movement	
NKPI-26027	24-35 months	Female	Appearance and movement	

Measure Code	Disaggregation 1	Disaggregation 2	Disaggregation 3	Disaggregation 4
NKPI-26028	36-59 months	Female	Appearance	
NKPI-26029	36-59 months	Female	Movement	
NKPI-26030	36-59 months	Female	Appearance and movement	
NKPI-26031	5-9 years	Female	Appearance	
NKPI-26032	5-9 years	Female	Movement	
NKPI-26033	5-9 years	Female	Appearance and movement	
NKPI-26034	10-14 years	Female	Appearance	
NKPI-26035	10-14 years	Female	Movement	
NKPI-26036	10-14 years	Female	Appearance and movement	

Online Services Report

Table 3. OSR measure codes by indicator

Measure Code	Disaggregation Option 1	Disaggregation Option 2	Disaggregation Option 3
CS1: Episodes of care		·	'
OSR-CS1a-0001	Aboriginal and Torres Strait Islander	Male	
OSR-CS1a-0002	Non-Aboriginal and Torres Strait Islander	Male	
OSR-CS1a-0003	Aboriginal and Torres Strait Islander status not recorded	Male	
OSR-CS1a-0004	Aboriginal and Torres Strait Islander	Female	
OSR-CS1a-0005	Non-Aboriginal and Torres Strait Islander	Female	
OSR-CS1a-0006	Aboriginal and Torres Strait Islander status not recorded	Female	
OSR-CS1a-0007	Aboriginal and Torres Strait Islander	Other or not stated	
OSR-CS1a-0008	Non-Aboriginal and Torres Strait Islander	Other or not stated	
OSR-CS1a-0009	Aboriginal and Torres Strait Islander status not recorded	Other or not stated	
CS2: Client contacts			
OSR-CS2-0001	Aboriginal and Torres Strait Islander Health Workers	Aboriginal and Torres Strait Islander	Male
OSR-CS2-0002	Aboriginal and Torres Strait Islander Health Workers	Non-Aboriginal and Torres Strait Islander	Male
OSR-CS2-0003	Aboriginal and Torres Strait Islander Health Workers	Aboriginal and Torres Strait Islander status not recorded	Male
OSR-CS2-0004	Aboriginal and Torres Strait Islander Health Workers	Aboriginal and Torres Strait Islander	Female
OSR-CS2-0005	Aboriginal and Torres Strait Islander Health Workers	Non-Aboriginal and Torres Strait Islander	Female
OSR-CS2-0006	Aboriginal and Torres Strait Islander Health Workers	Aboriginal and Torres Strait Islander status not recorded	Female
OSR-CS2-0007	Aboriginal and Torres Strait Islander Health Workers	Aboriginal and Torres Strait Islander	Other or not stated

Measure Code	Disaggregation Option 1	Disaggregation Option 2	Disaggregation Option 3
OSR-CS2-0008	Aboriginal and Torres Strait Islander Health Workers	Non-Aboriginal and Torres Strait Islander	Other or not stated
OSR-CS2-0009	Aboriginal and Torres Strait Islander Health Workers	Aboriginal and Torres Strait Islander status not recorded	Other or not stated
OSR-CS2-0010 to 0018	Aboriginal and Torres Strait Islander Health Practitioners	As above	As above
OSR-CS2-0019 to 0027	Doctor – General Practitioner	As above	As above
OSR-CS2-0028 to 0036	Nurses	As above	As above
OSR-CS2-0037 to 0045	Midwives	As above	As above
OSR-CS2-0046 to 0054	Substance misuse / drug and alcohol worker	As above	As above
OSR-CS2-0055 to 0063	Tobacco worker / co-ordinator	As above	As above
OSR-CS2-0064 to 0072	Dentists / dental therapists	As above	As above
OSR-CS2-0073 to 0081	Dental support (eg, dental assistant / dental technician)	As above	As above
OSR-CS2-0082 to 0090	Sexual health worker	As above	As above
OSR-CS2-0091 to 0099	Traditional healer	As above	As above
OSR-CS2-0100 to 0108	Other health / clinical staff	As above	As above
OSR-CS2-0109 to 0117	Transport (health professionals who do not work for the service)	As above	As above
OSR-CS2-0118 to 0126	Transport (health professionals who work for the service)	As above	As above
OSR-CS2-0127 to 0135	Paediatrician	As above	As above
OSR-CS2-0136 to 0144	Endocrinologist	As above	As above
OSR-CS2-0145 to 0153	Ophthalmologist	As above	As above
OSR-CS2-0154 to 0162	Obstetrician / Gynaecologist	As above	As above
OSR-CS2-0163 to 0171	Ear, Nose and Throat Specialist	As above	As above
OSR-CS2-0172 to 0180	Cardiologist	As above	As above
OSR-CS2-0181 to 0189	Renal Medicine Specialist	As above	As above
OSR-CS2-0190 to 0198	Psychiatrist / Psychiatric Registrar	As above	As above
OSR-CS2-0199 to 0207	Dermatologist	As above	As above
OSR-CS2-0208 to 0216	Surgeon	As above	As above
OSR-CS2-0217 to 0225	Specialist other or not specified	As above	As above

Measure Code	Disaggregation Option 1	Disaggregation Option 2	Disaggregation Option 3
OCR-CS2-0226 to 0234	Psychologists	As above	As above
OCR-CS2-0235 to 0243	Counsellors	As above	As above
OCR-CS2-0244 to 0252	Social Workers	As above	As above
OCR-CS2-0253 to 0261	Welfare Workers	As above	As above
OCR-CS2-0262 to 0270	Social and Emotional Wellbeing (SEWB) staff: Link Up caseworkers	As above	As above
OCR-CS2-0271 to 0279	SEWB staff other or not specified	As above	As above
OCR-CS2-0280 to 0288	Audiologist / Audiometrists	As above	As above
OCR-CS2-0289 to 0297	Diabetes Educators	As above	As above
OCR-CS2-0298 to 0306	Dieticians	As above	As above
OCR-CS2-0307 to 0315	Optometrists	As above	As above
OCR-CS2-0316 to 0324	Pharmacists	As above	As above
OCR-CS2-0325 to 0333	Physiotherapists	As above	As above
OCR-CS2-0334 to 0342	Podiatrists	As above	As above
OCR-CS2-0343 to 0351	Speech Pathologists	As above	As above
OCR-CS2-0352 to 0360	Allied health other or not specified	As above	As above
CS3a: Individual clien	ts seen		
OSR-CS3a-0010	Aboriginal and Torres Strait Islander	Male	0-4 years
OSR-CS3a-0011	Aboriginal and Torres Strait Islander	Male	5-9 years
OSR-CS3a-0012	Aboriginal and Torres Strait Islander	Male	10-14 years
OSR-CS3a-0013	Aboriginal and Torres Strait Islander	Male	15-19 years
OSR-CS3a-0014	Aboriginal and Torres Strait Islander	Male	20-24 years
OSR-CS3a-0015	Aboriginal and Torres Strait Islander	Male	25-29 years
OSR-CS3a-0016	Aboriginal and Torres Strait Islander	Male	30-34 years
OSR-CS3a-0017	Aboriginal and Torres Strait Islander	Male	35-39 years
OSR-CS3a-0018	Aboriginal and Torres Strait Islander	Male	40-44 years
OSR-CS3a-0019	Aboriginal and Torres Strait Islander	Male	45-49 years
OSR-CS3a-0020	Aboriginal and Torres Strait Islander	Male	50-54 years
OSR-CS3a-0021	Aboriginal and Torres Strait Islander	Male	55-59 years
OSR-CS3a-0022	Aboriginal and Torres Strait Islander	Male	60-64 years
OSR-CS3a-0023	Aboriginal and Torres Strait Islander	Male	65 years and older
OSR-CS3a-0024	Aboriginal and Torres Strait Islander	Female	0-4 years
OSR-CS3a-0025	Aboriginal and Torres Strait Islander	Female	5-9 years
OSR-CS3a-0026	Aboriginal and Torres Strait Islander	Female	10-14 years

Measure Code	Disaggregation Option 1	Disaggregation Option 2	Disaggregation Option 3
OSR-CS3a-0027	Aboriginal and Torres Strait Islander	Female	15-19 years
OSR-CS3a-0028	Aboriginal and Torres Strait Islander	Female	20-24 years
OSR-CS3a-0029	Aboriginal and Torres Strait Islander	Female	25-29 years
OSR-CS3a-0030	Aboriginal and Torres Strait Islander	Female	30-34 years
OSR-CS3a-0031	Aboriginal and Torres Strait Islander	Female	35-39 years
OSR-CS3a-0032	Aboriginal and Torres Strait Islander	Female	40-44 years
OSR-CS3a-0033	Aboriginal and Torres Strait Islander	Female	45-49 years
OSR-CS3a-0034	Aboriginal and Torres Strait Islander	Female	50-54 years
OSR-CS3a-0035	Aboriginal and Torres Strait Islander	Female	55-59 years
OSR-CS3a-0036	Aboriginal and Torres Strait Islander	Female	60-64 years
OSR-CS3a-0037	Aboriginal and Torres Strait Islander	Female	65 years and older
OSR-CS3a-0038	Aboriginal and Torres Strait Islander	Unknown	0-4 years
OSR-CS3a-0039	Aboriginal and Torres Strait Islander	Unknown	5-9 years
OSR-CS3a-0040	Aboriginal and Torres Strait Islander	Unknown	10-14 years
OSR-CS3a-0041	Aboriginal and Torres Strait Islander	Unknown	15-19 years
OSR-CS3a-0042	Aboriginal and Torres Strait Islander	Unknown	20-24 years
OSR-CS3a-0043	Aboriginal and Torres Strait Islander	Unknown	25-29 years
OSR-CS3a-0044	Aboriginal and Torres Strait Islander	Unknown	30-34 years
OSR-CS3a-0045	Aboriginal and Torres Strait Islander	Unknown	35-39 years
OSR-CS3a-0046	Aboriginal and Torres Strait Islander	Unknown	40-44 years
OSR-CS3a-0047	Aboriginal and Torres Strait Islander	Unknown	45-49 years
OSR-CS3a-0048	Aboriginal and Torres Strait Islander	Unknown	50-54 years
OSR-CS3a-0049	Aboriginal and Torres Strait Islander	Unknown	55-59 years
OSR-CS3a-0050	Aboriginal and Torres Strait Islander	Unknown	60-64 years
OSR-CS3a-0051	Aboriginal and Torres Strait Islander	Unknown	65 years and older
OSR-CS3a-0052	Non-Aboriginal and Torres Strait Islander	Male	0-4 years
OSR-CS3a-0053	Non-Aboriginal and Torres Strait Islander	Male	5-9 years
OSR-CS3a-0054	Non-Aboriginal and Torres Strait Islander	Male	10-14 years
OSR-CS3a-0055	Non-Aboriginal and Torres Strait Islander	Male	15-19 years
OSR-CS3a-0056	Non-Aboriginal and Torres Strait Islander	Male	20-24 years
OSR-CS3a-0057	Non-Aboriginal and Torres Strait Islander	Male	25-29 years
OSR-CS3a-0058	Non-Aboriginal and Torres Strait Islander	Male	30-34 years
OSR-CS3a-0059	Non-Aboriginal and Torres Strait Islander	Male	35-39 years
OSR-CS3a-0060	Non-Aboriginal and Torres Strait Islander	Male	40-44 years
OSR-CS3a-0061	Non-Aboriginal and Torres Strait Islander	Male	45-49 years
OSR-CS3a-0062	Non-Aboriginal and Torres Strait Islander	Male	50-54 years
OSR-CS3a-0063	Non-Aboriginal and Torres Strait Islander	Male	55-59 years
OSR-CS3a-0064	Non-Aboriginal and Torres Strait Islander	Male	60-64 years
OSR-CS3a-0065	Non-Aboriginal and Torres Strait Islander	Male	65 years and older
OSR-CS3a-0066	Non-Aboriginal and Torres Strait Islander	Female	0-4 years
OSR-CS3a-0067	Non-Aboriginal and Torres Strait Islander	Female	5-9 years
	14011 Abongmai and Torres Strait Islander	i Ciliale	J-J years

Measure Code	Disaggregation Option 1	Disaggregation Option 2	Disaggregation Option 3
OSR-CS3a-0069	Non-Aboriginal and Torres Strait Islander	Female	15-19 years
OSR-CS3a-0070	Non-Aboriginal and Torres Strait Islander	Female	20-24 years
OSR-CS3a-0071	Non-Aboriginal and Torres Strait Islander	Female	25-29 years
OSR-CS3a-0072	Non-Aboriginal and Torres Strait Islander	Female	30-34 years
OSR-CS3a-0073	Non-Aboriginal and Torres Strait Islander	Female	35-39 years
OSR-CS3a-0074	Non-Aboriginal and Torres Strait Islander	Female	40-44 years
OSR-CS3a-0075	Non-Aboriginal and Torres Strait Islander	Female	45-49 years
OSR-CS3a-0076	Non-Aboriginal and Torres Strait Islander	Female	50-54 years
OSR-CS3a-0077	Non-Aboriginal and Torres Strait Islander	Female	55-59 years
OSR-CS3a-0078	Non-Aboriginal and Torres Strait Islander	Female	60-64 years
OSR-CS3a-0079	Non-Aboriginal and Torres Strait Islander	Female	65 years and older
OSR-CS3a-0080	Non-Aboriginal and Torres Strait Islander	Unknown	0-4 years
OSR-CS3a-0081	Non-Aboriginal and Torres Strait Islander	Unknown	5-9 years
OSR-CS3a-0082	Non-Aboriginal and Torres Strait Islander	Unknown	10-14 years
OSR-CS3a-0083	Non-Aboriginal and Torres Strait Islander	Unknown	15-19 years
OSR-CS3a-0084	Non-Aboriginal and Torres Strait Islander	Unknown	20-24 years
OSR-CS3a-0085	Non-Aboriginal and Torres Strait Islander	Unknown	25-29 years
OSR-CS3a-0086	Non-Aboriginal and Torres Strait Islander	Unknown	30-34 years
OSR-CS3a-0087	Non-Aboriginal and Torres Strait Islander	Unknown	35-39 years
OSR-CS3a-0088	Non-Aboriginal and Torres Strait Islander	Unknown	40-44 years
OSR-CS3a-0089	Non-Aboriginal and Torres Strait Islander	Unknown	45-49 years
OSR-CS3a-0090	Non-Aboriginal and Torres Strait Islander	Unknown	50-54 years
OSR-CS3a-0091	Non-Aboriginal and Torres Strait Islander	Unknown	55-59 years
OSR-CS3a-0092	Non-Aboriginal and Torres Strait Islander	Unknown	60-64 years
OSR-CS3a-0093	Non-Aboriginal and Torres Strait Islander	Unknown	65 years and older
OSR-CS3a-0094	Aboriginal and Torres Strait Islander status unknown	Male	0-4 years
OSR-CS3a-0095	Aboriginal and Torres Strait Islander status unknown	Male	5-9 years
OSR-CS3a-0096	Aboriginal and Torres Strait Islander status unknown	Male	10-14 years
OSR-CS3a-0097	Aboriginal and Torres Strait Islander status unknown	Male	15-19 years
OSR-CS3a-0098	Aboriginal and Torres Strait Islander status unknown	Male	20-24 years
OSR-CS3a-0099	Aboriginal and Torres Strait Islander status unknown	Male	25-29 years
OSR-CS3a-0100	Aboriginal and Torres Strait Islander status unknown	Male	30-34 years
OSR-CS3a-0101	Aboriginal and Torres Strait Islander status unknown	Male	35-39 years
OSR-CS3a-0102	Aboriginal and Torres Strait Islander status unknown	Male	40-44 years
OSR-CS3a-0103	Aboriginal and Torres Strait Islander status unknown	Male	45-49 years
OSR-CS3a-0104	Aboriginal and Torres Strait Islander status unknown	Male	50-54 years
OSR-CS3a-0104 OSR-CS3a-0105	Aboriginal and Torres Strait Islander status unknown	Male	55-59 years
OSR-CS3a-0105 OSR-CS3a-0106	Aboriginal and Torres Strait Islander status unknown	Male	60-64 years
OSR-CS3a-0100 OSR-CS3a-0107	Aboriginal and Torres Strait Islander status unknown	Male	65 years and older
OSR-CS3a-0107 OSR-CS3a-0108	Aboriginal and Torres Strait Islander status unknown	Female	0-4 years
OSR-CS3a-0108 OSR-CS3a-0109	Aboriginal and Torres Strait Islander status unknown Aboriginal and Torres Strait Islander status unknown	Female	5-9 years
OON-000a-0109	Apoliginal and Torres Strait Islander Status unknown	i ciliale	J-a years

Measure Code	Disaggregation Option 1	Disaggregation Option 2	Disaggregation Option 3	
OSR-CS3a-0111	Aboriginal and Torres Strait Islander status unknown	Female	15-19 years	
OSR-CS3a-0112	Aboriginal and Torres Strait Islander status unknown	Female	20-24 years	
OSR-CS3a-0113	Aboriginal and Torres Strait Islander status unknown	Female	25-29 years	
OSR-CS3a-0114	Aboriginal and Torres Strait Islander status unknown	Female	30-34 years	
OSR-CS3a-0115	Aboriginal and Torres Strait Islander status unknown	Female	35-39 years	
OSR-CS3a-0116	Aboriginal and Torres Strait Islander status unknown	Female	40-44 years	
OSR-CS3a-0117	Aboriginal and Torres Strait Islander status unknown	Female	45-49 years	
OSR-CS3a-0118	Aboriginal and Torres Strait Islander status unknown	Female	50-54 years	
OSR-CS3a-0119	Aboriginal and Torres Strait Islander status unknown	Female	55-59 years	
OSR-CS3a-0120	Aboriginal and Torres Strait Islander status unknown	Female	60-64 years	
OSR-CS3a-0121	Aboriginal and Torres Strait Islander status unknown	Female	65 years and older	
OSR-CS3a-0122	Aboriginal and Torres Strait Islander status unknown	Unknown	0-4 years	
OSR-CS3a-0123	Aboriginal and Torres Strait Islander status unknown	Unknown	5-9 years	
OSR-CS3a-0124	Aboriginal and Torres Strait Islander status unknown	Unknown	10-14 years	
OSR-CS3a-0125	Aboriginal and Torres Strait Islander status unknown	Unknown	15-19 years	
OSR-CS3a-0126	Aboriginal and Torres Strait Islander status unknown	Unknown	20-24 years	
OSR-CS3a-0127	Aboriginal and Torres Strait Islander status unknown	Unknown	25-29 years	
OSR-CS3a-0128	Aboriginal and Torres Strait Islander status unknown	Unknown	30-34 years	
OSR-CS3a-0129	Aboriginal and Torres Strait Islander status unknown	Unknown	35-39 years	
OSR-CS3a-0130	Aboriginal and Torres Strait Islander status unknown	Unknown	40-44 years	
OSR-CS3a-0131	Aboriginal and Torres Strait Islander status unknown	Unknown	45-49 years	
OSR-CS3a-0132	Aboriginal and Torres Strait Islander status unknown	Unknown	50-54 years	
OSR-CS3a-0133	Aboriginal and Torres Strait Islander status unknown	Unknown	55-59 years	
OSR-CS3a-0134	Aboriginal and Torres Strait Islander status unknown	Unknown	60-64 years	
OSR-CS3a-0135	Aboriginal and Torres Strait Islander status unknown	Unknown	65 years and older	
CS4: Clinical Activities (retired)				

Appendix B – Health provider roles by CIS

Table 4: Health provider role classifications by CISs (March 2023).

Role Classification for reporting	Best Practice	Communicare	Medical Director	MMEx
General Staff				
ATSI health worker	Aboriginal health worker	Aboriginal and TSI health worker Aboriginal family health worker	Aboriginal health worker Aboriginal and Torres Strait Islander health worker ATSI health worker	Aboriginal Health Worker
ATSI health practitioner	Aboriginal and Torres Strait Islander Health Practitioner	Aboriginal and TSI health practitioner	ATSI health practitioner Aboriginal health practitioner Aboriginal and Torres Strait Islander health practitioner	ATSI Health Practitioner
Doctor – general practitioner	Principal doctor Employee doctor	General medical practitioner	Doctor General Practitioner General Practice G.P. G.P GP	GP
Nurse practitioner	Practice nurse Nurse practitioner Child and Maternal Nurse	Child health nurse Enrolled nurse Mothercraft nurse Nurse educator Nurse manager Nurse practitioner Nurse researcher Registered nurse Registered nurse (devt'l disability) Registered nurse (mental health)	Registered nurse RN R.N. R.N Nurse Nurse practitioner	Nurse
Midwives	Midwife	Midwife	Midwife Midwive	Midwifery
Substance misuse / drug and alcohol worker	Drug and Alcohol Worker	Drug and alcohol counsellor Substance misuse worker	AOD worker Drug and alcohol Drug and alcohol counsellor Drug and alcohol worker Alcohol and drug counsellor Alcohol and drug worker Substance misuse counsellor	Drug and Alcohol Worker
Tobacco worker / co-ordinator	Tobacco Worker	Smoking cessation coordinator Smoking cessation officer	Tobacco worker / coordinator	Tobacco Worker
Dentists / dental therapists	Dentist	Dental hygienist Dental specialist Dental therapist Dentist	Dentist Dental therapist	Dentist

Role Classification for reporting	Best Practice	Communicare	Medical Director	MMEx
Dental support (eg,	Dental prosthetist	Dental – technician or	Dental hygienist	Dental Support
dental assistant / dental technician)		prosthetist Dental assistant	Dental technician	
,		Dental prosthetist		
		Dental technician		
Sexual health worker	Sexual Health Worker	Sexual health worker	Sex health worker	Sexual Health Worker
Traditional healer	Traditional Healer	Traditional healer	Traditional healer	Traditional Healer
Other health /	Medical student	Aboriginal liaison officer		Other Health / Clinical
clinical staff		Aboriginal community support worker		Staff
		Assistant in nursing		
		Ambulance officer		
		Child care worker		
		Clerical / administrative		
		worker		
		Clinical allergist Community / family		
		representative		
		Community services worker		
		Day care worker		
		Dermal clinician		
		Epidemiologist		
		Health practice manager		
		Home help worker Hospital scientist		
		Interpreter/translator		
		Meals/food services worker		
		Medical receptionist		
		Other profession / discipline		
		Pharmacy technician		
		Phlebotomist		
		Physician's assistant		
		Sonographer		
		Technician Therenist's assistant		
		Therapist's assistant Therapy aide		
		Voluntary worker		
		Health information manager		
		Health promotion officer		
		Medical intern		
		Medical practitioner in		
		training Recreation worker		
		Registered paramedic		
		Resident medical officer		
Transport – work for service		Transport worker	Transport (for practice workers)	Transport (Working for Service)
Transport – do not work for service			Transport (for non-practice workers)	Transport (Not Working for Service)
Medical specialists		<u>'</u>	<u>'</u>	
			Describerations	D 11 ()
Paediatrician		Paediatrician	Paediatrician	Paediatrics

Role Classification for reporting	Best Practice	Communicare	Medical Director	MMEx
Endocrinologist		Endocrinologist	Endocrinologist Endocrinology	Endocrinologist
Ophthalmologist		Ophthalmologist	Ophthalmologist Ophthalmology	Ophthalmology
Obstetrician / Gynecologists		Obstetrician and Gynaecologist	Obstetrician Obstetrician and gynaecologist Obstetrics Gynaecologist Gynaecology OBGYN OB/GYN OBG	Obstetrician / Gynaecologist
Ear nose and throat specialist		Ear, nose and throat specialist Otorhinolaryngologist	ENT Otorhinolaryngologist Otorhinolary surgeon ENT surgeon Ear nose throat surgeon Neck surgeon	ENT
Cardiologist		Cardiologist	Cardiologist Cardiology Cardio	Cardiologist
Renal medical specialist		Renal medicine specialist	Renal medicine specialist Renal medicine	Nephrologist
Psychiatrist/psychiat ric registrar		Psychiatrist	Psychiatrist	Psychiatrist
Dermatologist		Dermatologist	Dermatologist Dermatology	Dermatology
Surgeon		Surgeon	Surgeon Surgeon general General surgeon	Surgeon
Specialist other or not specified		Anaesthetist Cardiothoracic surgeon Clinical cytopathologist Clinical haematologist Clinical pharmacologist Emergency medicine specialist Gastroenterologist Geriatrician Gynaecological oncologist Immunologist Intensive care anaesthetist Intensive care medical specialist Medical diagnostic radiographer Medical oncologist Nephrologist Neurologist Neurosurgeon Nuclear medicine technologist		Specialist

Role Classification for reporting	Best Practice	Communicare	Medical Director	MMEx
Co. Toporaing		Oral and maxillofacial surgeon Orthopaedic surgeon Orthoptist Palliative care physician Pathologist Plastic and reconstructive surgeon Public health physician Radiation oncologist Radiotherapist Respiratory physician Rheumatologist Specialist medical practitioner Specialist physician Surgeon Urologist Vascular surgeon Veterinarian Infectious disease specialist		
Social and Emotions	 Wellbeing / Counselle			
Psychologist	Psychologist	Psychologist Clinical psychologist Neuropsychologist	Psychologist Clinical psychologist Educational psychologist Organisational psychologist Psychotherapist	Psychologist
Counsellor	Counsellor	Bth counsellor Counsellor	Counsellor	Counsellor
Social worker	Social worker	Social worker	Social worker	Social Worker
Welfare worker	Welfare Worker	Welfare worker	Welfare Worker	Welfare Worker
SEWB staff – link up caseworker			SEWB LinkUp caseworkers SEWB Link Up caseworkers Social and Emotional Well-Being Link Up caseworker	SEWB staff –Link up caseworker
SEWB staff other or not specified	SEWB Staff	Aboriginal mental health worker Emotional and social wellbeing staff Psychotherapist Team. Psychogeriatric assess team (PGAT) Youth worker		SEWB Staff Other / Not Specified
Allied Health Profess	sionals			
Audiologist/ audiometrist	Audiologist	Audiologist	Audiologist	Audiology
Diabetes educator	Diabetes educator	Diabetes educator	Diabetes educator	Diabetes Educator

Role Classification for reporting	Best Practice	Communicare	Medical Director	MMEx
			Diabetic educator	
Dietician	Dietitian	Dietitian	Dietician Dietitian	Dietetics
Optometrist	Optometrist	Optometrist	Optometrist	Optometry
Pharmacist	Clinical pharmacist	Pharmacist	Pharmacist	Pharmacist
Physiotherapist	Physiotherapist	Physiotherapist Cardiothoracic physiotherapist Respiratory physiotherapist	Physiotherapist Physio	Physiotherapist
Podiatrist	Podiatrist	Podiatrist	Podiatrist	Podiatrist
Speech pathologist	Speech pathologist	Speech pathologist	Speech pathologist Speech therapist	Speech Therapy
Allied health other or not specified	Occupational therapist Exercise physiologist Radiographer Chiropractor Osteopath Massage therapist Orthoptist	Acupuncturist Allied health aide Alternative therapist Asthma educator Attendant carer Chiropractor Community paramedical Dermal Clinician Disability services worker Environmental health officer Exercise physiologist Eye health coordinator Health diagnosis/treatment Practitioner Home care worker Homoeopath Massage therapist Music therapist Natural therapy professional Naturopath Occupational therapist Orthotist Osteopath Personal care assistant Physiologist Psychotherapist Rehabilitation aide Speech therapist Team. Aged care assessment team (ACAT) Team. Multi-disciplinary team Cardiac educator Chronic care coordinator		Allied Health

Appendix C - Retired and suspended indicators

nKPI – PI04: Indigenous children who are fully Immunised (SUSPENDED)

Note: This indicator is currently suspended - it will not be visible to health services in the health data portal from June 2021 onwards - no change required to CIS reports.

(May be revived in the future as and when the AIR can provide a data feed to clinical information systems)

systems)	
Full name	PI04: Proportion of Indigenous children who are fully immunised
Description	Proportion of children who are clients aged: 12 months to less than 24 months 24 months to less than 36 months 60 months to less than 72 months, who are 'fully immunised'
Measure type	Percentage
Numerator	The number of children who are regular clients, aged <i>[Disaggregation: Age]</i> , who are 'fully immunised'
Denominator	The number of children who are regular clients, aged <i>[Disaggregation: Age]</i>
Disaggregation	Age: - 12 months to less than 24 months - 24 months to less than 36 months - 60 months to less than 72 months
Disaggregation points	Three (3) measures are derived from this assessment
Measure Code/s	NKPI-04001 to 04003
Counting rules	 A child aged '12 months to less than 24 months' is counted as fully immunised if they have received vaccinations ascribed to the 12 month milestone A child aged '24 months to less than 36 months' is counted as fully immunised if they have received vaccinations ascribed to the 24 month milestone A child aged '60 months to less than 72 months' is counted as fully immunised if they have received vaccinations ascribed to the 60 month milestone
Notes	 'Fully immunised' – is determined in accordance with the National Immunisation Program Schedule. The childhood vaccinations essential to be considered 'fully immunised' include: DTPa (diphtheria, tetanus, pertussis) HiB (haemophilus influenza type B) Polio Hep B (hepatitis B) and

	 MMR (measles, mumps, rubella) A child is considered 'fully immunised' if they have received the following vaccinations by the specified age milestones: At 12 months: 3 doses DTPa 3 doses Polio 2 or 3 doses HiB 2 or 3 doses Hep B At 24 months: 3 doses DTPa 3 doses Polio 3 or 4 doses HiB 3 doses Hep B 1 dose MMR At 60 months: 4 doses DTPa 4 doses Polio 2 doses MMR
Definition owner	Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care
METEOR link	https://meteor.aihw.gov.au/content/717279 (June 2020)

nKPI – PI08: Team care arrangement claimed (RETIRED)

Note: This indicator is retired - it is not visible to health services in the health data portal from December 2020 onwards - no change required to CIS reports.

Full name	PI08: Proportion of regular clients with a chronic disease for whom a Team Care Arrangement (MBS Item 723) was claimed
Description	Proportion of clients with: Type 2 diabetes, OR cardiovascular disease, OR chronic obstructive pulmonary disease, OR chronic kidney disease, for whom a Team Care Arrangement (MBS Item 723) was claimed within the previous 24 months At this stage, this indicator is only calculated for Type 2 diabetes as currently this is the only relevant chronic disease type with an agreed national definition
Measure type	Percentage
Numerator	The number of <i>[Disaggregation: Gender]</i> clients with <i>[Disaggregation: Chronic disease]</i> aged <i>[Disaggregation: Age]</i> for whom a Team Care Arrangement (MBS Item 723) was claimed within the previous 24 months
Denominator	The number of [Disaggregation: Gender] clients with [Disaggregation: Chronic disease] aged [Disaggregation: Age]
Disaggregation	Age: - 0-4 years - 5-14 years - 15-24 years - 25-34 years - 35-44 years - 45-54 years - 55-64 years - 65 years and older Gender:
	MaleFemale
	Chronic disease: - Type 2 diabetes - Cardiovascular disease - Chronic obstructive pulmonary disease - Chronic kidney disease
Disaggregation points	Sixty-four (64) measures are derived from this assessment

Measure Code/s	NKPI-08001 to 08064	
Counting rules	Nil	
Notes	 'Claimed' – refers to claims or invoices prepared for presentation to Medicare for reimbursement (regardless of whether these are actually reimbursed by Medicare) 'Type 2 diabetes' – specifically excludes Type I diabetes, secondary diabetes, gestational diabetes mellitus (GDM), previous GDM, Impaired fasting glucose, and impaired glucose tolerance 	
	Note: at this stage, this indicator is only calculated for Type 2 diabetes as currently this is the only relevant chronic disease type with an agreed national definition	
Definition owner	Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care	
METEOR link	https://meteor.aihw.gov.au/content/717298 (June 2020)	

nKPI – PI15: Type 2 diabetes or COPD clients immunised against influenza (RETIRED)

Note: This indicator is retired - it is not visible to health services in the health data portal from December 2021 onwards - no change required to CIS reports.

Full name	PI15: Proportion of regular clients with Type 2 diabetes or chronic obstructive pulmonary disease (COPD) who are immunised against influenza
Description	Proportion of regular clients who are Indigenous, aged 15 to 49, are recorded as having Type 2 diabetes or chronic obstructive pulmonary disease (COPD) and are immunised against influenza
Measure type	Percentage
Numerator	The number of <i>[Disaggregation: Gender]</i> clients with <i>[Disaggregation: Chronic disease]</i> aged <i>[Disaggregation: Age]</i> who have received an influenza vaccination within the previous 12 months
Denominator	The number of [Disaggregation: Gender] regular clients with [Disaggregation: Chronic disease] aged [Disaggregation: Age]
Disaggregation	Age: - 15–24 years - 25–34 years - 35–44 years - 45–49 years Gender: - Male - Female Chronic disease: - Type 2 diabetes - Chronic obstructive pulmonary disease
Disaggregation points	Sixteen (16) measures are derived from this assessment
Measure Code/s	NKPI-15001 to 15016
Counting rules	Nil
Notes	'Type 2 diabetes' – specifically excludes Type I diabetes, secondary diabetes, gestational diabetes mellitus (GDM), previous GDM, Impaired fasting glucose, and impaired glucose tolerance
Definition owner	Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care
METEOR link	https://meteor.aihw.gov.au/content/747534 (June 2021)

nKPI - PI17: AUDIT-C result (RETIRED)

Note: This indicator is retired - it is not visible to health services in the health data portal from December 2022 onwards - no change required to CIS reports.

from December 202	22 onwards - no change required to CIS reports.
Full name	PI17: Proportion of regular clients who have an AUDIT-C with result within a specified level
Description	Proportion of clients who have had an AUDIT-C result recorded within the previous 24 months with a score of:
	 greater than or equal to 4 in males and 3 in females or less than 4 in males and 3 in females
Measure type	Percentage
Numerator	Calculation A:
	The number of <i>[Disaggregation: Gender]</i> clients aged <i>[Disaggregation: Age]</i> who have had an AUDIT-C result recorded within the previous 24 months, whose most recent AUDIT-C result was <i>[Disaggregation: Result]</i>
	Calculation B:
	The number of <i>[Disaggregation: Gender]</i> clients aged <i>[Disaggregation: Age]</i> who have had an AUDIT-C result recorded within the previous 24 months, whose most recent AUDIT-C result was <i>[Disaggregation: Result]</i>
Denominator	Calculation A:
	The number of <i>[Disaggregation: Gender]</i> clients aged <i>[Disaggregation: Age]</i> who have had an AUDIT-C result recorded within the previous 24 months
	Calculation B:
	The number of <i>[Disaggregation: Gender]</i> clients aged <i>[Disaggregation: Age]</i> who have had an AUDIT-C result recorded within the previous 24 months
Disaggregation	Age:
	_ 15–24 years
	- 25–34 years
	35–44 years45–54 years
	- 45-54 years - 55-64 years
	 65 years and older
	Gender:
	Calculation A only
	- Male
	Calculation B only
	- Female
	<u>I</u>

	Result: Calculation A only ac-1 ac-2 Calculation B only ac-3 ac-4
Disaggregation points	Twenty-four (24) measures are derived from this assessment
Measure Code/s	NKPI-17001 to 17024
Counting rules	Nil
Notes	'AUDIT-C' – is a three-item alcohol screen (modified version of the 10 question AUDIT instrument) that can help identify persons who are hazardous drinkers, or have active alcohol use disorders (including alcohol abuse or dependence)
Definition owner	Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care
METEOR link	https://meteor.aihw.gov.au/content/772332 (June 2022)

nKPI - PI19-A: eGFR result (RETIRED)

Note: From June 2021 Pl19-A and Pl19-B have been amalgamated to a single new indicator to Pl19. Pl19-A or Pl19-B will not be visible to health services in the health data portal from December 2021 onwards - no change required to CIS reports.

December 2021 onwards - no change required to old reports.		
Full name	PI19-A: Proportion of regular clients with a selected chronic disease who have had a kidney function test (eGFR) with results within specified levels	
Description	Proportion of clients with:	
	Type 2 diabetes, ORcardiovascular disease,	
	who have had an estimated glomerular filtration rate (eGFR) recorded within the previous 12 months with a result of (ml/min/1.73m2):	
	 greater than or equal to 90, OR greater than or equal to 60 but less than 90, OR greater than or equal to 45 but less than 60, OR greater than or equal to 30 but less than 45, OR greater than or equal to 15 but less than 30, OR less than 15 	
Measure type	Percentage	
Numerator	The number of [Disaggregation: Gender] clients with [Disaggregation: Chronic disease] aged [Disaggregation: Age] whose most recent eGFR result, recorded within the previous 12 months, was [Disaggregation: Result]	
Denominator	The number of <i>[Disaggregation: Gender]</i> clients with <i>[Disaggregation: Chronic disease]</i> aged <i>[Disaggregation: Age]</i> who have had an eGFR result recorded within the previous 12 months	
Disaggregation	Age: - 15–24 years - 25–34 years - 35–44 years - 45–54 years - 55–64 years - 65 years and older	
	Gender:	
	MaleFemale	
	Chronic disease:	
	Type 2 diabetescardiovascular disease	
	Result:	
	– egfr-1	

	 egfr-2 egfr-3 egfr-4 egfr-5 egfr-6
Disaggregation points	One hundred and forty-four (144) measures are derived from this assessment
Measure Code/s	NKPI-19001 to 19144
Counting rules	Nil
Notes	'Type 2 diabetes' – specifically excludes Type I diabetes, secondary diabetes, gestational diabetes mellitus (GDM), previous GDM, Impaired fasting glucose, and impaired glucose tolerance
Definition owner	Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care
METEOR	http://meteor.aihw.gov.au/content/index.phtml/itemId/739454

nKPI - PI19-B: ACR result (RETIRED)

Note: From June 2021 Pl19-A and Pl19-B have been amalgamated to a single new indicator to Pl19. Pl19-A or Pl19-B will not be visible to health services in the health data portal from December 2021 onwards - no change required to CIS reports.

December 2021 onwards - no change required to CIS reports.	
Full name	PI19-B: Proportion of clients with a selected chronic disease who have had a kidney function test with results within specified levels
Description	Proportion of clients with:
	Type 2 diabetes
	who have had an estimated albumin / creatinine ratio (ACR) recorded within the previous 12 months with a result of (mg/mmol):
	 less than 2.5 in males and 3.5 in females, OR greater than or equal to 2.5 in males and 3.5 in females, but less than or equal to 25 in males and 35 in females, OR greater than 25 in males and 35 in females
Measure type	Percentage
Numerator	Calculation A:
	The number of <i>[Disaggregation: Gender]</i> clients aged <i>[Disaggregation: Age]</i> with <i>[Disaggregation: Chronic disease]</i> who have had an ACR result recorded within the previous 12 months, whose most recent ACR result was <i>[Disaggregation: Result]</i>
	Calculation B:
	The number of <i>[Disaggregation: Gender]</i> clients aged <i>[Disaggregation: Age]</i> with <i>[Disaggregation: Chronic disease]</i> who have had an ACR result recorded within the previous 12 months, whose most recent ACR result was <i>[Disaggregation: Result]</i>
Denominator	Calculation A:
	The number of <i>[Disaggregation: Gender]</i> clients aged <i>[Disaggregation: Age]</i> with <i>[Disaggregation: Chronic disease]</i> , who have had an ACR result recorded within the previous 12 months
	Calculation B:
	The number of <i>[Disaggregation: Gender]</i> clients aged <i>[Disaggregation: Age]</i> with <i>[Disaggregation: Chronic disease]</i> , who have had an ACR result recorded within the previous 12 months
Disaggregation	Age:
	- 15–24 years
	25–34 years35–44 years
	- 35-44 years - 45-54 years
	- 55–64 years
	- 65 years and older
	Gender:

	Calculation A only
	- Male
	Calculation B only
	- Female
	Chronic disease:
	- Type 2 diabetes
	Result:
	Calculation A only
	uacr-3
	uacr-4
	- uacr-5
	Calculation B only
	uacr-6uacr-7
	- uacr-7 - uacr-8
Disaggregation points	Thirty-six (36) measures are derived from this assessment
Measure Code/s	NKPI-19145 to 19180
Counting rules	Nil
Notes	 'Type 2 diabetes' – specifically excludes Type I diabetes, secondary diabetes, gestational diabetes mellitus (GDM), previous GDM, Impaired fasting glucose, and impaired glucose tolerance 'ACR' – refers to an albumin/creatinine ratio, or other micro albumin urine test result
Definition owner	Australian Institute of Health and Welfare on behalf of the Department of Health and Aged Care
METEOR link	http://meteor.aihw.gov.au/content/index.phtml/itemId/739454

Appendix D – Result codes

Result codes used for national key performance indicators (including retired indicators).

Birthweight result	
bw-1	Low (less than 2,500 grams)
bw-2	Normal (2,500 grams to less than 4,500 grams)
bw-3	High (4,500 grams and over)

HbA1c result	
hr-1	Less than or equal to 7% (≤ 7%)
hr-2	Greater than 7% but less than or equal to 8% (>7% but ≤8%)
hr-3	Greater than 8% but less than 10% (>8% but <10%)
hr-4	Greater than or equal to 10% (≥10%)

Body mass index (BMI) result		
bmi-1	Overweight (BMI ≥25 AND <30)	
bmi-2	Obese (BMI ≥30)	
bmi-3	Other (BMI <25)	No longer in use
bmi-4	Normal (BMI ≥18.5 AND <25)	
bmi-5	Underweight (BMI <18.5)	
bmi-6	BMI not calculated	

Gestational age recorded	
ga-1	less than 11/40 weeks (<11 weeks)
ga-2	At or after 11/40 weeks and less than 14/40 weeks (≥11 but <14 weeks)
ga-3	At or after 14/40 weeks and less than 20/40 weeks (≥14 but <20 weeks)
ga-4	At or after 20/40 weeks (≥ 20 week)
ga-5	no gestational age recorded
ga-6	No antenatal visit recorded

AUDIT-C result	
ac-1	Greater than or equal to 4 (≥ 4)
ac-2	Less than <4
ac-3	Greater than or equal to 3 (≥ 3)
ac-4	Less than <3

Renal function test result	
Normal Risk	eGFR ≥60 and ACR <2.5
Normal Risk	eGFR ≥60 and ACR <3.5
Low Risk	eGFR ≥45 but <60 and ACR <2.5 OR, eGFR ≥60 and ACR ≥2.5 but ≤25
Low Risk	eGFR ≥45 but <60 and ACR <3.5 OR, eGFR ≥60 and ACR ≥3.5 but ≤35
Moderate Risk	eGFR ≥45 but <60 and ACR ≥2.5 but ≤25 OR, eGFR ≥30 but <45 and ACR ≤25
Moderate Risk	eGFR ≥45 but <60 and ACR ≥3.5 but ≤35 OR, eGFR ≥30 but <45 and ACR ≤35
High Risk	eGFR ≥30 and ACR >25 OR, eGFR <30 and any ACR result
High Risk	eGFR ≥30 and ACR >35 OR, eGFR <30 and any ACR result

CVD risk assessment result	
ar-1	High: greater than 15% chance of a CV event in next 5 years (>15)
ar-2	Moderate: 10-15% chance of a CV event in the next 5 years (10-15)
ar-3	Low: less than 10% chance of a CV event in the next 5 years (<10)

eGFR result (not currently in use)	
eGFR-1	≥90 ml/min/1.73m2
eGFR-2	≥60 but <90 ml/min/1.73m2
eGFR-3	≥45 but <60 ml/min/1.73m2
eGFR-4	≥30 but <45 ml/min/1.73m2
eGFR-5	≥15 but <30 ml/min/1.73m2
eGFR-6	<15 ml/min/1.73m2

Urinary albumin and albumin/creatinine ratio (urinary ACR) (not currently in use)				
uacr-1	≤2.6 mg/mmol			
uacr-2	≤3.6 mg/mmol			
uacr-3	<2.5 mg/mmol			
uacr-4	≥2.5 but ≤25 mg/mmol			
uacr-5	>25 mg/mmol			
uacr-6	<3.5 mg/mmol			
uacr-7	≥3.5 but ≤35 mg/mmol			
uacr-8	>35 mg/mmol			

Appendix E – Condition Coding Framework

1. Condition Coding Introduction

The nKPI Condition Coding Framework provides a flexible and sustainable model, reducing the need for frequent revision of coding lists and future proofing the nKPIs as much as possible. Initially implemented for the January 2022 reporting period, the Condition Coding Framework was established through consultation and expert advice to align with definitions in national guidelines.

The Condition Coding Framework includes coded condition terms and Global care plan names, for four CIS. Each CIS has its own coding system and the formats and methods for producing nKPI results are specific to each. The Condition Coding Framework accommodates the different clinical taxonomies used by each CIS.

The main method used by vendors to inform conditions included in nKPI results is to use a diagnosis. MMEx uses another method, specifically 'Global care plans tagged to each nKPI'.

- Best Practice (BP) Pyefinch codes and terms
- Communicare a combination of ICPC and ICPC-2 PLUS codes and terms
- Medical Director (MD) Docle codes and terms
- MMEx a Global care plan tagged to each nKPI; from 2021 onwards, it is anticipated that SNOMED-CT-AU codes and terms will be specified within each Global care plan as a list of valid conditions.

The Condition Coding Framework provides sufficient detail to enable a consistent condition definition across all CIS that aligns with agreed national definitions. The Condition Coding Framework contains a detailed list of included and excluded terms, by condition, specific to each vendor. The revised inclusion and exclusion criteria for each condition are also included.

SNOMED-CT terms are captured against MMEx. These terms should be considered by all vendors that have implemented SNOMED-CT in addition to their existing terminology.

The Condition Coding Framework does not provide an exhaustive list of codes. Rather it outlines included and excluded subgroups to enable vendors to apply new condition codes as they are implemented in the future.

Varying in complexity, the conditions included are:

- Type 2 diabetes
- Chronic kidney disease
- Chronic obstructive pulmonary disease
- Cardiovascular disease
- Ear health*.

Each condition is summarised in a table format, so it is clear which codes and terms belong to which CIS. Codes and terms that should be excluded are also listed.

For ease of navigation each CIS is denoted in a different colour:

- Best Practice is pale green, and codes displayed below are Pyefinch codes.
- Communicare is peach and codes displayed are a combination of ICPC and IPCP-2 PLUS codes.
- Medical Director is blue, and codes displayed are Docle codes and terms.
- MMEx is pale yellow, and codes displayed are SNOMED-CT codes. Global care plan names are also listed.

^{*}Ear health contains a defined list for each of conditions and procedures to facilitate reporting 'rules' of the indicator. In other conditions there is no requirement to separate them.

Please note, to avoid confusion, all clinical terms are presented in the original spelling and formats used by the vendors, directly from each vendor list, and have not been 'corrected / altered'.

A list of excluded codes and terms are supplied for transparency and to illustrate terms that are not relevant. Vendor discretion is advised; vendors are encouraged to consider whether coding the exclusion of these terms complements their implementation or whether to code inclusions only.

Terms and codes used in the coding framework are included under licence and/or approval from the relevant parties specifically, and only, for Solving Health to use for the purposes of this project.

2. Type 2 diabetes

The following principles outline the inclusion and exclusion criteria for Type 2 diabetes:

- Clinical terms have been removed where they did not explicitly define Type 2 diabetes, eg, latent autoimmune diabetes and complicated diabetes.
- Diabetic retinopathy has been removed. It was agreed that inclusion of one diabetic complication would require inclusion of ALL diabetic complications. It was recommended that all diabetic complications be omitted.
- As Diabetes Mellitus is often used by general practitioners (GPs) when referring to Type 2 diabetes it has been included in the definition.
- Tables 5 and 6 respectively provide the Type 2 diabetes clinical coding definition and then Table 7 contains a set of excluded terms.

2.1 Type 2 diabetes – INCLUDED TERMS

Table 5: Type 2 diabetes clinical coding definition

NKPI CONDITION	CONDITION SUBGROUP	CIS	CODE	CLINICAL TERM (OR GLOBAL CAREPLAN NAME)
			778	Diabetes Mellitus, NIDDM
			778	Diabetes Mellitus, Type 2
		Best Practice	778	NIDDM
			778	Non insulin dependent Diabetes Mellitus
			778	Type 2 Diabetes Mellitus
			T90005	Diabetes non insulin depend
		Communicare	T90007	Diabetes adult onset
		Communicare	T90009	Diabetes Type 2
			T90016	Diabetes Type 2 insulin treated
		TYPE 2 DIABETES Medical Director	diabm@niddm	Diabetes Mellitus - NIDDM
			diabm@niddm	Diabetes Mellitus - Type II
	TYPE 2 DIABETES		diabm@niddm	NIDDM
TYPE 2 DIABETES			diabm@niddm	NIDDM (Non Insulin dependent diabetes mellitus)
DIABETES			diabm@niddm	Non insulin dependent diabetes mellitus
			diabm@niddm℞ %insu	Diabetes Type II requiring insulin
			diabm@niddm℞ %insu	NIDDM - requiring insulin
			44054006	Diabetes mellitus type 2
			44054006	Diabetes mellitus type II
			44054006	T2DM - Type 2 diabetes mellitus
		MMEx	44054006	Type 2 diabetes mellitus
			44054006	Type II diabetes mellitus
			Global care plan name	DIABETES - type 2
	UNSPECIFIE	Best Practice	774	Diabetes Mellitus
	D DIABETES	Communicare	T90002	Diabetes mellitus

Medical Director	diabm	Diabetes Mellitus
	73211009	Diabetes mellitus
MMEx	Global care plan name	DIABETES

2.2 Type 2 diabetes – MMEx specific inclusions

The primary method used by MMEx to include a patient in a specific nKPI is to 'tag' a patient with nKPI Global Care plan. The correct clinical term and corresponding (mapped) Global care plan name for Type 2 Diabetes are shown in the table below.

Table 6: Terms to include Type 2 diabetes clinical coding definition

KPI CONDITION	CONDITION SUBGROUP	CLINICAL TERM	SNOMED CODE	GLOBAL CARE PLAN NAME
		Diabetes mellitus type 2		
		Diabetes mellitus type II		
TYPE 2	TYPE 2 DIABETES	T2DM - Type 2 diabetes mellitus	44054006	DIABETES
DIABETES		Type 2 diabetes mellitus		
		Type II diabetes mellitus		
	UNSPECIFIED	Diabetes mellitus	73211009	DIABETES
	DIABETES			

2.3 Type 2 diabetes – EXCLUDED TERMS

The following terms are excluded from the clinical coding definition of Type 2 diabetes:

- Latent autoimmune
- Diabetes complicated
- Diabetic retinopathy
- Unspecified diabetes

Table 7: Terms to exclude from Type 2 clinical coding definition

NKPI CONDITION	CONDITION SUBGROUP	CIS	CODE	CLINICAL TERM (OR GLOBAL CAREPLAN NAME)
	COMPLICATION OF DIABETES	MMEx	Global care plan name	Diabetic Retinopathy (old)
TYPE 2 DIABETES	LATENT AUTOIMMUNE	Communicare	T90017	Diabetes latent autoimmune
	UNSPECIFIED DIABETES	Communicare	T90018	Diabetes complicated

2.4 Type 2 diabetes – MMEx specific exclusions

MMEx does not have any exclusions for Type 2 Diabetes.

3. Chronic Kidney Disease (CKD)

The following principles outline the inclusion and exclusion criteria for chronic kidney disease.

True 'chronic kidney disease' for the nKPIs is defined as starting from CKD Stage 3. This is consistent with the definition of CKD in Australian guidelines 'An estimated or measured glomerular filtration rate (GFR) <60 mL/min/1.73m2 that is present for ≥3 months with or without evidence of kidney damage'.¹ This means Chronic Kidney Disease − Stage 1 and Chronic Kidney Disease − Stage 2 are excluded from the definition.

3.1 Chronic Kidney Disease (CKD) - INCLUDED TERMS

Tables 8 to 11 outline the CKD coding definition. Tables 12 to 15 outline the excluded terms.

Table 8: CKD 3 and 4 clinical coding definition

nKPI CONDITION	CONDITION SUBGROUP	CIS	CIS CODE	CLINICAL TERM (OR GLOBAL CAREPLAN NAME)
		Best Practice	7504	Chronic Kidney Disease Stage 3
			8119	Chronic Kidney Disease Stage 3a
			8120	Chronic Kidney Disease Stage 3b
				Chronic Kidney Disease Stage 3
		NA - P I	ant a al	Chronic Kidney Disease Stage 3
		Medical Director	crf:eval ctx:stag3	CKD (Chronic Kidney Disease) Stage 3
		Director	CIX.Stag5	Kidney Disease Chronic Stage 3
				Renal Disease Chronic Stage 3
			Global care	CKD Stage 3 (High Risk)
	CKD 3		plan name	CKD Stage 3 (Moderate Risk)
			piarriamo	CKD Stage 3 (Very High Risk)
		MMEx	433144002	Chronic kidney disease stage 3
		Communicare	433144002	CKD stage 3
			700378005	Chronic kidney disease stage 3A
CHRONIC			700379002	Chronic kidney disease stage 3B
KIDNEY			U99037	Chronic kidney disease stage 3
DISEASE				Disease kidney chronic stage 3
(CKD)		Communicate	U99043	Disease kidney chronic stage 3A
			U99044	Disease kidney chronic stage 3B
		Best Practice	7505	Chronic Kidney Disease Stage 4
				Chronic Kidney Disease Stage 4
				Chronic Kidney Disease Stage 4
		Medical	crf:eval	CKD (Chronic Kidney Disease) Stage 4
		Director	ctx:stag4	Kidney Disease Chronic Stage 4
				Renal Disease Chronic Stage 4
	CKD 4			Kidney Disease Chronic Stage 4
		N 40 45	Global care plan name	CKD Stage 4
		MMEx	431857002	Chronic kidney disease stage 5
			431857002	CKD stage 4
		Communication	U99038	Chronic kidney disease stage 4
		Communicare	U99038	Disease kidney chronic stage 4

 ${}^{1}Chronic\ Kidney\ Disease\ Management\ handbook\ \underline{https://kidney.org.au/health-professionals/ckd-management-handbook\ \underline{https://kidney.org.au/health$

Table 9: CKD 5 and Dialysis clinical coding definition

nKPI CONDITION	CONDITION SUBGROUP	CIS	CIS CODE	CLINICAL TERM (OR GLOBAL CAREPLAN NAME)
		Best Practice	7506	Chronic Kidney Disease Stage 5
			crf:eval ctx:stag5	Chronic Kidney Disease Stage 5
			crf:eval ctx:stag5	Chronic Kidney Disease Stage 5
		Medical Director	crf:eval ctx:stag5	CKD (Chronic Kidney Disease) Stage 5
	CKD 5		crf:eval ctx:stag5	Kidney Disease Chronic Stage 5
	0112		crf:eval ctx:stag5	Renal Disease Chronic Stage 5
		N 4N 4E	433146000	Chronic kidney disease stage 5
		MMEx	433146000	CKD stage 5
			U99039	Chronic kidney disease stage 5
		Communicare	U99039	Disease kidney chronic stage 5
			2853	Continuous Ambulatory Peritoneal Dialysis
			2853	Dialysis, peritoneal
		Best Practice	2853	Peritoneal dialysis
		Boot i idolico	2882	Dialysis
			2882	Haemodialysis
			2882	Renal dialysis
		Communicare	U59001	Dialysis; kidney (renal)
CHRONIC			U59008	Haemodialysis
KIDNEY			Global care plan	HD SATELLITE
DISEASE (CKD)				HHD (Home Haemodialysis) Nursing Care
				PD Nursing Care
			71192002	Peritoneal dialysis
			71192002	PD - Peritoneal dialysis
	DIALYSIS		302497006	Haemodialysis
				haemodialysis procedure
				HD - Haemodialysis
				Extracorporeal haemodialysis
		MMEx		Renal dialysis
				Kidney dialysis
			005704000	Artificial kidney dialysis
			265764009	Continuous Ambulatory Peritoneal Dialysis
				CAPD - Continuous ambulatory peritoneal dialysis
				Chronic kidney disease stage 5
			71.4152005	on dialysis Chronic kidney disease 5d
			714152005	CKD (chronic kidney disease)
				stage 5d
		Medical Director	ppoc@capd	CAPD (Continuous Ambulatory Peritoneal Dialysis)

			Continuous Ambulatory Peritoneal Dialysis Dialysis peritoneal Peritoneal Dialysis
		0 11 10111	Dialysis haemodialysis
			Haemodialysis
	ppoc@dial@kidn	Hemodialysis	
		Renal dialysis	

Table 10: CKD Kidney transplant clinical coding definition

nKPI CONDITION	CONDITION SUBGROUP	CIS	CIS CODE	CLINICAL TERM (OR GLOBAL CAREPLAN NAME)
				Kidney transplant
		Best Practice	3765	Renal transplant
				Transplant, renal
		Communicare	U28001	Renal transplant
CHRONIC		MMEx	70536003	Kidney transplant
KIDNEY	KIDNEY			Tx - Kidney transplantation
DISEASE	TRANSPLANT			Transplantation of kidney
(CKD)				Transplant of kidney
				Kidney transplant
		Medical	acces kida Otranania	Renal transplant
		Director	surg.kidn@transpla	Surgery - Kidney transplant
				Transplant - kidney

3.2 Chronic Kidney Disease (CKD) - MMEx specific inclusions

The primary method used by MMEx to include a patient in a specific nKPI is to 'tag' a patient with nKPI Global Care plan. The correct clinical term and corresponding (mapped) Global care plan name for CKD are shown in the table below.

Table 11: CKD MMEx specific inclusions

NKPI CONDITION	CONDITION SUBGROUP	CLINICAL TERM	SNOMED CODE	GLOBAL CARE PLAN NAME
	CKD 3	Chronic kidney disease stage 3 CKD stage 3	433144002	CKD Stage 3 (High
		Chronic kidney disease stage 3A	700378005	Risk) OR CKD Stage 3 (Moderate Risk)
		Chronic kidney disease stage 3B	700379002	
	CKD 4	Chronic kidney disease stage 4 CKD stage 4	431857002	CKD Stage 4 - Very High Risk CKD
	CKD 5	Chronic kidney disease stage 5	433146000	CKD Stage 5 - End-
		CKD stage 5	433146000	stage Renal Disease.
		PD - Peritoneal dialysis Peritoneal dialysis	71192002	
		CAPD - Continuous ambulatory peritoneal dialysis	238318009	
CHRONIC KIDNEY		Continuous Ambulatory Peritoneal Dialysis		PD Nursing Care
DISEASE		Artificial kidney dialysis		
(CKD)		Kidney dialysis	265764009	
	DIALYSIS	Renal dialysis		
		Extracorporeal haemodialysis	302497006	HD Satellite
		Haemodialysis haemodialysis procedure	000407000	HD Satellite; or
		HD - Haemodialysis	302497006	HHD Nursing Care
		Chronic kidney disease 5d		
		Chronic kidney disease stage 5 on dialysis	714152005	CKD Stage 5 - End-
		CKD (chronic kidney disease) stage 5d		stage Renal Disease.
		Kidney transplant		
		Tx - Kidney transplantation	70536003	Renal Transplant
	TRANSPLANT	Transplantation of kidney	, 3000000	
		Transplant of kidney		
		Renal replacement	398887003	

3.3 Chronic Kidney Disease (CKD) - EXCLUDED TERMS

The definition of CKD has been clearly defined as starting from Stage 3 and as such the following terms are excluded from the clinical coding definition of CKD:

- Chronic Kidney Disease Stage 1
- Chronic Kidney Disease Stage 2
- Nephropathy
- Terms that describe structural renal impairment eg, Polycystic kidney or Renal stenosis
- Terms that do not describe a 'chronic' kidney disease eg, CKD Risk, Nephritis, Acute renal failure, Renal impairment
- Chronic Kidney Disease where there is no specification as to the stage or is unspecified.

Table 12: Terms to exclude from CKD clinical coding definition – ARF, CKD1, CKD2

nKPI CONDITION	CONDITION SUBGROUP	CIS	CIS CODE	CLINICAL TERM
	ACUTE		arf	Kidney failure acute
	RENAL	Medical Director	an	Renal insufficiency acute
	FAILURE	Bircotor	cirr@arf	Cirrhosis with acute renal failure
		Best Practice	7502	Chronic Kidney Disease Stage 1
		Communicare	1100025	Chronic kidney disease stage 1
		Communicare	U99035	Disease kidney chronic stage 1
			crf:eval ctx:stag1	Chronic Kidney Disease Stage 1
	CKD 1	KD 1 Medical Director		CKD (Chronic Kidney Disease) Stage 1
CHRONIC				Kidney Disease Chronic Stage 1
KIDNEY DISEASE				Renal Disease Chronic Stage 1
(CKD)				Chronic Kidney Disease Stage 1
		Best Practice	7503	Chronic Kidney Disease Stage 2
			U99036	Chronic kidney disease stage 2
		Communicare		Disease kidney chronic stage 2
				Chronic Kidney Disease Stage 2
	CKD 2			Chronic Kidney Disease Stage 2
		Medical Director	crf:eval ctx:stag2	CKD (Chronic Kidney Disease) Stage 2
				Kidney Disease Chronic Stage 2
				Renal Disease Chronic Stage 2

Table 13: Terms to exclude from CKD clinical coding definition - CKD unspecified, Kidney disease unspecified

nKPI CONDITION	CONDITION SUBGROUP	cis	CIS CODE	CLINICAL TERM (OR GLOBAL CAREPLAN NAME)
		Best Practice	662	Chronic Kidney Disease
			1100004	Chronic kidney disease
		Communicare	U99034	Disease kidney chronic
				Chronic renal failure
		Best Practice	662	Kidney failure chronic
				Renal failure chronic
	CKD	0	1100000	Chronic renal failure
	UNSPECIFIED	Communicare	U99023	Failure renal chronic
				Chronic Renal Failure
			t	Chronic Renal Failure
		NA sulta a l	crf	Kidney failure chronic
		Medical Director		Renal insufficiency chronic
			hype@parat&sequ< crf	Chronic Renal Failure Hyperparathyroidism
CHRONIC			renaf	Kidney failure
KIDNEY DISEASE		Communicare	U85001	Polycystic kidney
(CKD)			U88001	Nephropathy
			U88002	Nephrosis
			U88003	Nephrotic syndrome
			U88004	Nephritis
			U88008	Glomerulonephritis chronic
	I (IBNE) (U88010	Nephropathy analgesic
	KIDNEY DISEASE		U88011	Nephropathy diabetic
	UNSPECIFIED		U88012	Nephrosclerosis
			U88040	Glomerulonephritis
			glomn@prolifer	Glomerulonephritis Proliferative
		Medical Director	glomn <strec< td=""><td>Glomerulonephritis Post streptococcal</td></strec<>	Glomerulonephritis Post streptococcal
			nephs	Nephrotic syndrome
			pck@adul	Polycystic kidney adult

Table 14: Terms to exclude from CKD clinical coding definition – renal artery stenosis, renal failure, renal impairment

nKPI CONDITION	CONDITION SUBGROUP	CIS	CIS CODE	CLINICAL TERM (OR GLOBAL CAREPLAN NAME)	
	RENAL	Medical	stenrenaa	Renal artery stenosis	
	ARTERY STENOSIS	Director	stenrenaa	Stenosis Renal artery	
			U99006	Necrosis renal	
			U99016	Uraemia	
		Communicare	U99024	Necrosis renal papillary	
	RENAL		U99030	Failure renal	
	FAILURE		U99031	Renal failure NOS	
	UNSPECIFIED	Medical Director	cirr@arf	Hepatorenal syndrome	
				Renal failure due to cirrhosis	
CHRONIC KIDNEY			renaf	Renal failure	
DISEASE			renaf	Uraemia	
(CKD)		Communicare	U99022	Insufficiency renal	
			U99022	Renal insufficiency	
			U99032	Impairment renal	
			U99032	Renal Impairment	
	RENAL IMPAIRMENT			Impairment Renal	
	UNSPECIFIED		impa@rena	Kidney Impairment	
		Medical	ппраштепа	Renal Damage	
		Director		Renal Impairment	
			nephp@diabm	Diabetic Nephropathy	
				pck@adul	Adult polycystic kidney

3.4 Chronic Kidney Disease (CKD) - MMEx specific exclusions

The primary method used by MMEx to include a patient in a specific nKPI is to 'tag' a patient with nKPI Global Care plan. The clinical terms and corresponding (mapped) Global care plan name for CKD that should no longer be used are shown in the table below.

Table 15: CKD MMEX specific exclusions

nKPI CONDITION	CONDITION SUBGROUP	CLINICAL TERM	SNOMED CODE	GLOBAL CARE PLAN NAME
CHRONIC KIDNEY DISEASE (CKD)	CKD RISK	CKD Risk - Macroalbinuria CKD Risk - Microalbinuria	SNOMED code does not exist	Macroalbuminuria (High Risk CKD) Microalbuminuria (Moderate Risk CKD)

4. Chronic obstructive pulmonary disease (COPD)

The COPD definition is defined as including terms relating to

- Chronic bronchitis
- COPD
- Emphysema

4.1 COPD - INCLUDED TERMS

Tables 16 and 17 outline the COPD clinical coding definition. Tables 18 and 19 list excluded terms.

Table 16: COPD clinical coding definition – Chronic bronchitis, COPD, Emphysema

nKPI CONDITION	CONDITION SUBGROUP	cis	CODE	CLINICAL TERM (OR GLOBAL CAREPLAN NAME)			
		Best Practice	E00	Bronchitis chronic			
		best Practice	598	Chronic bronchitis			
	CHRONIC	Communicare	R79002	Bronchiolitis chronic			
	BRONCHITIS	Communicate	R79003	Bronchitis chronic			
		Medical Director	bronchit@chro	Bronchitis Chronic			
		MMEx	63480004	Chronic Bronchitis			
				Chronic Obstructive Airways Disease			
		Best Practice	598	Chronic Obstructive Pulmonary Disease			
				COAD			
				COPD			
			R95001	Chronic obstr airways disease			
		Communicare	R95002	Chronic obstr pulmon disease			
			R95004	Chronic obstr lung disease			
CHRONIC			R95008	Chronic airways limitation			
OBSTRUCTIVE			R95009	Chronic airways disease			
PULMONARY DISEASE	COPD		coad	CAL (Chronic Airways Limitation)			
(COPD)	COLD			Chronic Airways Limitation			
(00.2)		Medical Director		Chronic Bronchitis			
				Chronic Obstructive Airways Disease			
				Chronic Obstructive Pulmonary			
			oodd	Disease COAD			
				COAD (Chronic Obstructive Airways Disease)			
				COPD (Chronic Obstructive			
				Pulmonary Disease)			
		MMEx	Global care plan name	COPD			
		Best Practice	598	Emphysema			
		Communicare	R95006	Emphysema			
	EMPHYSEMA	Medical Director	emph	Emphysema			
		MMEx	87433001	Emphysema of lung			
					IVIIVIEX	07 400001	Pulmonary emphysema

4.2 COPD - MMEx specific inclusions - Mapping table

The primary method used by MMEx to include a patient in a specific nKPI is to 'tag' a patient with nKPI Global Care plan. The correct clinical term and corresponding (mapped) Global care plan name for CKD are shown in the table below.

Table 17: COPD MMEx specific inclusions

NKPI CONDITION	CONDITION SUBGROUP	CLINICAL TERM	SNOMED CODE	GLOBAL CARE PLAN
CHRONIC	CHRONIC BRONCHITIS	Chronic Bronchitis	63480004	CHRONIC BRONCHITIS
OBSTRUCTIVE PULMONARY		Emphysema of lung	87433001	COPD
(COPD)	(COPD) EMPHYSEMA		87433001	OR EMPHYSEMA
	COPD	COPD	13645005	COPD

4.3 COPD - EXCLUDED TERMS

The COPD definition does not include terms relating to

- Infective or acute exacerbations
- Nonspecific respiratory

Table 18: Terms to exclude from COPD clinical coding definition – chronic bronchitis, infective exacerbation, smoker's lung, tracheitis

nKPI CONDITION	CONDITION SUBGROUP	CIS	CODE	CLINICAL TERM (OR GLOBAL CAREPLAN NAME)
	ACUTE EXACERBATION	Best Practice	7869	Acute exacerbation of COPD
				COAD Infective exacerbation
				COPD Infective exacerbation
	INFECTIVE EXACERBATION	Medical Director	ractice 929	Infective exacerbation of COAD
CHRONIC OBSTRUCTIV F				Infective exacerbation of COPD
PULMONARY DISEASE			bronchit@chro/infe	Chronic Bronchitis Infective exacerbation
(COPD)			coad/infe	COAD Infective exacerbation
(,			coad/infe	COPD Infective exacerbation
			emph/infe	Emphysema Infective exacerbation
	RESPIRATORY	MMEX	Global care plan	RESPIRATORY-
	TREGITION OF THE	IVIIVIEX	name	CHRONIC/RECURRENT
	SMOKER'S LUNG	Communicare	R79001	Smokers lung
	TRACHEITIS	Communicate	R79004	Tracheitis chronic

4.4 COPD - MMEx specific exclusions - Mapping table

The primary method used by MMEx to include a patient in a specific nKPI is to 'tag' a patient with nKPI Global Care plan. The clinical terms and corresponding (mapped) Global care plan name for COPD that should no longer be used are shown in the table below.

Table 19: COPD MMEx specific exclusions

NKPI CONDITION	CLINICAL TERM	SNOMED CODE	GLOBAL CARE PLAN NAME
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)	N/A	N/A	RESPIRATORY- CHRONIC/RECURRENT

5. Cardiovascular disease (CVD)

The definition of CVD aligns with definitions by AIHW, RACHP/NACCHO and the Heart Foundation, which all focus on atherosclerotic heart disease.

Terms that relate to other forms of heart disease and not 'atherosclerotic' heart disease, eg, cardiomyopathy, rheumatic heart disease, congenital heart conditions, heart failure etc. are excluded.

CVD subgroups were created to handle the vast number of terms contained within this chronic condition. The following subgroups are included in this definition:

- Acute coronary syndrome
- Angina
- Cardiovascular disease
- Cardiovascular surgery
- Carotid artery stenosis
- Cerebrovascular disease
- Cerebrovascular disease CVA

- Cerebrovascular disease TIA
- Cerebrovascular haemorrhage
- Coronary heart disease
- Myocardial infarction
- Peripheral vascular disease
- Renal artery stenosis
- CHD care plan (provided it refers to coronary heart disease)

5.1 Cardiovascular Disease (CVD) - INCLUDED TERMS

Tables 20 through 30 provide lists of the CVD clinical coding definition. Tables 31 through to 37 provide a list of excluded subgroups and terms.

Table 20: CVD clinical coding definition – Acute coronary syndrome/Angina

NKPI CONDITION	CONDITION SUBGROUP	CIS	CODE	CLINICAL TERM (OR GLOBAL CAREPLAN NAME)
			226	Angina
			220	Angina pectoris
		Best Practice		Acute Coronary insufficiency
		Dest Flactice	228	Angina unstable
			220	Preinfarction syndrome
				Unstable Angina
			K74001	Angina pectoris
			K74002	Pain angina
		Communicare	K74004	Unstable angina
CARDIO	ACUTE		K74006	Insufficiency coronary
VASCULAR	CORONARY		K74007	IHD with angina
DISEASE	SYNDROME		K74008	Acute coronary syndrome
(CVD)	(ACS)/ ANGINA		1774000	Acute coronary syndrome
,	ANGINA		angip	Angina
				Angina pectoris
				Acute coronary insufficiency
			angip@unst	Angina pectoris - unstable
		Medical Director	angipeunst	Preinfarction syndrome
		Wicaldar Bircotor		Unstable Angina
			angip@unst:high@risk	Unstable Angina - High risk
			angip@unst:low@risk	Unstable Angina - Low risk
			angip@unst:moderate	Unstable Angina - Moderate
			@risk	risk

			ACS (acute coronary
			syndrome)
		occl@coroa:acut	Acute coronary syndrome
			Acute Coronary Syndrome
			(ACS)
			Intermediate coronary
			syndrome
			Preinfarction angina
		4557003	Preinfarction syndrome
			Pre-infarction syndrome
			Unstable angina
			Worsening angina
			Angina
			Angina pectoris
	MMEx		Anginal syndrome
			AP - Angina pectoris
		194828000	Cardiac angina
			Ischaemic heart disease -
			angina
			Stenocardia [synonym of
			Angina]
		00.4050000	ACS - Acute coronary
		394659003	syndrome
			Acute coronary syndrome
		194823009	Acute coronary insufficiency

Table 21: CVD clinical coding definition – Myocardial infarction

NKPI CONDITIO N	CONDITION SUBGROUP	cis	CODE	CLINICAL TERM (OR GLOBAL CAREPLAN NAME)			
				Acute Myocardial infarction			
				AMI			
			2376	Heart Attack			
				MI			
		ION Best Practice		Myocardial infarction			
			2377	Anterior Myocardial infarct			
			2311	Myocardial infarction, Anterior			
						2278	Anterolateral Myocardial infarct
			2370	Myocardial infarction, Anterolateral			
CARDIO						2379	Inferior Myocardial infarction
VASCULAR	MYOCARDIAL			Myocardial infarction, inferior			
DISEASE (CVD)	INFARCTION		2380	Myocardial infarction, posterior			
(CVD)			2000	Posterior Myocardial infarct			
			0004	Myocardial infarction, subendocardial			
					2381	2381	Subendocardial infarct
				Subendocardial Myocardial infarct			
			2382	Myocardial infarction, superior			
				Superior Myocardial infarct			
			4610	Silent infarct			
			6103	Post myocardial infarction syndrome			

		6847	Myocardial infarction, Non STEMI Non ST elevation Myocardial infarction NSTEMI Myocardial infarction, STEMI ST elevation Myocardial infarction STEMI
		K75001	Infarction heart
		K75002	Infarction myocardial acute
		K75010	Infarction impending
		K75011	Postmyocardial infarct syndrome
	Communicare	K75013	Infarction myocardial
	Communicate	K75014	Heart attack
		K75015	Myocardial infarction STEMI
		K75016	Myocardial infarction non STEMI
		K76006	Infarction myocardial healed
			Infarction myocardial old

Table 21.2: CVD clinical coding definition – Myocardial infarction continued

NKPI CONDITION	CONDITION SUBGROUP	CIS	CODE	CLINICAL TERM (OR GLOBAL CAREPLAN NAME)
				Acute myocardial infarction
				AMI (Acute Myocardial Infarction)
			myoci	Myocardial Damage
		Illyoci	Myocardial Damage	
				Myocardial infarction
				Myocardial Infarction (MI)
				Myocardial infarction-without ST elevation
			myoci:sans,st@el ev	Non-ST-elevation myocardial infarction (NSTEMI)
				NSTEMI (non-ST-elevation
			myocardial infarction)	
			Myocardial Infarction-with ST elevation	
CARDIO VASCULAR	MYOCARDIAL	Medical Director	myoci:st@elev	STEMI (ST-Elevation Myocardial Infarction)
DISEASE (CVD)	INFARCTION		myoci@ante	Anterior myocardial infarct
(CVD)				Myocardial infarction-anterior
			myoci@antel	Anterolateral myocardial infarct
				Myocardial infarction-anterolateral
				Myocardial infarction-anterolateral
				Inferior myocardial infarction
			myoci@inf	Inferior myocardial infarction
			inyoci@iiii	Myocardial infarction-inferior
				Myocardial infarction-inferior
				Myocardial infarction-posterior
			myoci@posterio	Myocardial infarction-posterior
			m, sor @ postorio	Posterior myocardial infarct
				Posterior myocardial infarct
			myoci@sile	Myocardial infarction-silent

			Myocardial infarction-silent Silent myocardial infarction
			Silent myocardial infarction
			Myocardial infarction- subendocardial
	myoci@subendo c	Myocardial infarction- subendocardial	
			Subendocardial myocardial infarct
	myoci@supe	Myocardial infarction-superior	
		Myocardial infarction-superior	
			Superior myocardial infarct

Table 21.3: CVD clinical coding definition – Myocardial infarction continued

NKPI CONDITION	CONDITION SUBGROUP	CIS	CODE	CLINICAL TERM (OR GLOBAL CAREPLAN NAME)
			1755008	Old myocardial infarction
			1733008	Healed myocardial infarction
				Cardiac infarction
				Heart Attack
			22298006	Infarction of heart
			22290000	MI - myocardial infarction
				Myocardial infarct
				Myocardial infarction
				Acute anterior myocardial infarction
				Acute anterior myocardial infarction
			54329005	Acute myocardial infarction of anterior wall
			34323003	Acute myocardial infarction of anterior wall
	MYCCARRIA			Acute Myocardial infarction
				AMI - Acute myocardial infarction
			73795002	Acute inferior myocardial infarction
0.15510				Acute myocardial infarction of
CARDIO VASCULAR				diaphragmatic wall
DISEASE	MYOCARDIAL INFARCTION	MMEx	00000000	Acute myocardial infarction of inferior wall
(CVD)	INI ARCTION		233839009	Old anterior myocardial infarction
(- /			233840006	Old inferior myocardial infarction
			233843008	MI - Silent myocardial infarction
				Silent myocardial infarction
				Acute anterior ST segment elevation myocardial infarction
				Acute ST segment elevation myocardial
			703164000	infarction of anterior wall
				Acute STEMI (ST elevation myocardial
				infarction) of anterior wall
				Acute inferior ST segment elevation
				myocardial infarction
				Acute inferior ST segment elevation
			703213009	myocardial infarction Acute ST segment elevation myocardial
				infarction of inferior wall
				Acute STEMI (ST elevation myocardial
				infarction) of inferior wall
				Anterolateral Myocardial infarction

		·
	7380110001	Anterolateral myocardial infarction
	68103	Anterolateral myocardial infarction (MI)
	233841005	Old lateral myocardial infarction
	401303003	Acute ST segment elevation myocardial infarction
	401303004	STEMI - ST elevation myocardial infarction
	401314000	Acute non-ST segment elevation myocardial infarction
	401314001	NSTEMI - Non-ST segment elevation MI
	401314000	Acute non-ST segment elevation myocardial infarction
		Acute anterior ST segment elevation myocardial infarction
		Acute ST segment elevation myocardial infarction of anterior wall
		Acute STEMI (ST elevation myocardial infarction) of anterior wall
		Acute inferior ST segment elevation myocardial infarction
	703213009	Acute ST segment elevation myocardial infarction of inferior wall
		Acute STEMI (ST elevation myocardial infarction) of inferior wall
	7380610001	Inferior myocardial infarction
	68100	Inferior myocardial infarction (MI)

Table 22: CVD clinical coding definition – CHD

NKPI CONDITION	CONDITION SUBGROUP	CIS	CODE	CLINICAL TERM (OR GLOBAL CAREPLAN NAME)
			228	Acute coronary insufficiency
			220	Preinfarction syndrome
				Coronary artery disease
			1534	Coronary heart disease
			1004	IHD
		Best Practice		Ischaemic heart disease
		Dest i faction	2556	Coronary occlusion
			2000	Occlusion, Coronary Artery
			7276	Care plan, Chronic heart disease
CARDIO			7270	Chronic heart disease Care plan
VASCULAR	CORONARY		7278	Chronic heart disease Care plan review
DISEASE	HEART		11744	Cardiovascular disease
(CVD)	DISEASE		K74006	Insufficiency coronary
			K74007	IHD with angina
			K75004	Occlusion coronary
			K75008	Thrombosis artery coronary
			K76011	Disease ischaemic heart subacute
		Communicare	K76013	Coronary heart disease
			K76014	Disease ischaemic heart
			K76015	Disease ischaemic heart chronic
			K76018	IHD without angina
			K76019	Atherosclerosis coronary
			K76003	Coronary artery disease

K76005	Disease atherosclerotic heart
K76008	Ischaemia myocardial chronic
K89015	RIND syndrome
K89004	Vertebral artery syndrome
K89005	Basilar artery syndrome
K92022	Stenosis artery
K92024	Atherosclerosis
K92025	Arteriosclerosis
K92028	Insufficiency vascular
K92030	Atherosclerosis aorta
K92031	Disease small vessel
K92007	Occlusion arterial

Table 22.1: CVD clinical coding definition – CHD continued

NKPI CONDITION	CONDITION SUBGROUP	CIS	CODE	CLINICAL TERM (OR GLOBAL CAREPLAN NAME)
			atherosc	Arteriosclerosis
			allielosc	Atherosclerosis
				Atherosclerotic heart disease
				Coronary artery disease
				Coronary heart disease
			ihd	Coronary insufficiency
CARDIO		Medical	ina	IHD
VASCULAR	CORONARY	Director		IHD (Ischaemic Heart Disease)
DISEASE	HEART DISEASE			Ischaemic heart disease
(CVD				Myocardial insufficiency
			occl@coroa	Blockage Coronary Artery
				Coronary Occlusion
				Occlusion-Coronary Artery
			ppoc@reha@ihd	Coronary artery disease-Rehabilitation
		MMEx	Global care plan	Chronic heart disease - other
			name	Coronary Heart Disease (CHD)

Table 23: CVD clinical coding definition – Cerebrovascular disease

NKPI CONDITION	CONDITION SUBGROUP	CIS	CODE	CLINICAL TERM (OR GLOBAL CAREPLAN NAME)
				Cerebrovascular accident
			677	CVA
				Stroke
	CEREBRO VASCULAR DISEASE	Best Practice	678	Cerebral infarction
CARDIO				Ischaemic stroke
VASCULAR DISEASE				Stroke, ischaemic
(CVD)			679	Lacunar infarct
(0,2)				Lacunar Stroke
				Stroke, lacunar
			680	Migrainous stroke
				Stroke, Migrainous

1 1			1
		681	Stroke, thrombotic
			Thrombotic stroke
			Cerebral haemorrhage
			Haemorrhage, intracerebral
			Haemorrhagic CVA
		1522	Haemorrhagic stroke
		1022	Intracerebral bleed
			Intracerebral haemorrhage
			Intracranial haemorrhage
			Stroke, haemorrhagic
		7805	Visual cortex stroke
			Cerebral Infarction
		cva	Cerebrovascular Accident
		CVA	CVA (Cerebrovascular Accident)
			Stroke
			Ischaemic Stroke
		cva@isch	Stroke - Ischaemic
		CVa@iscri	Lacunar Stroke
			Stroke - Lacunar
		ava @ mian	Migrainous Stroke
		cva@migr	Stroke - Migrainous
		@ 4h h	Stroke - Thrombotic
		cva@thrombos	Thrombotic - Stroke
	Medic	CVI	Cerebrovascular insufficiency
	Direct		Cerebral Embolism
		embo.cere	Embolism - Cerebral
			Cerebral Haemorrhage
			Haemorrhage - intracerebral
			Haemorrhagic CVA
		ich	Haemorrhagic Stroke
			Intracerebral bleed
		Intracerebral haemorrhage	
		Stroke-Haemorrhagic	
		sah	Haemorrhage - subarachnoid
	Sall	Subarachnoid bleed	
			Subarachnoid haemorrhage

Table 23.1: CVD clinical coding definition – Cerebrovascular disease continued

NKPI CONDITIO N	CONDITION SUBGROUP	CIS	CODE	CLINICAL TERM (OR GLOBAL CAREPLAN NAME)
VASCULAR VASCUL		DISEASE	195190007	Cerebral infarction due to embolism of cerebral arteries Cerebrovascular accident
	VASCULAR			CVA - Cerebrovascular accident
	DISEASE			Stroke
			371040005	Thrombotic CVA (cerebrovascular accident)

		Thrombotic stroke
		Ischaemic CVA (cerebrovascular
	422504002	accident)
		Ischaemic stroke
		Cerebral infarction due to embolism of
		MCA (middle cerebral artery)
		Cerebral infarction due to embolism of
	705400004	middle cerebral artery CVA (cerebrovascular accident) co-
	705128004	occurrent with migraine
		Migraine-induced stroke
		Stroke and migraine
		Stroke co-occurrent with migraine
		Lacunar stroke
		Lacunar infarction
	230698000	Lacunar CVA (cerebrovascular accident)
		LI - Lacunar infarction
		LACI - Lacunar infarction
	371040005	Thrombotic stroke
	371040006	Thrombotic CVA (cerebrovascular accident)
	788884002	Cerebral ischaemic stroke due to subarachnoid haemorrhage
	788884003	Cerebral ischaemic stroke co-occurrent with subarachnoid haemorrhage
	K90029	Stroke; lacunar
	K90030	Stroke; migrainous
	K89008	Insufficiency vertebrobasilar
	K89011	Insufficiency cerebrovascular
	K90002	Cerebrovascular accident
	K90004	Haemorrhage;subarachnoid
	K90006	Haemorrhage cerebral
	K90010	Infarction cerebral
	K90011	Occlusion cerebral
	K90012	Paralysis poststroke/CVA
Communica	K90017	Stroke
Continuality	K90018	Thrombosis artery cerebral
	K90025	Paresis poststroke/CVA
	K90026	Hemiparesis post stroke/CVA
	K91006	Disease cerebrovascular
	K91007	Cerebral artery aneurysm
	K91008	Occlusion precerebral
	K91009	Ischaemia cerebral
	K91010	Stroke/cva old
	K91011	Stenosis arterial precerebral
	K91012	Thrombosis artery precerebral
	K91015	Atherosclerosis cerebral

Table 24: CVD clinical coding definition – Cerebrovascular disease, TIA and PVD

NKPI CONDITION	CONDITION SUBGROUP	CIS	CODE	CLINICAL TERM (OR GLOBAL CAREPLAN NAME)
		Best Practice	4253	TIA
		Dest Flactice	4200	Syncope, TIA
		Communicare	K89013	Insufficiency basilar
		Communicate	K89001	Transient ischaemic attack
				Arterial Embolism - minor
				Cerebral TIA
	CEREBRO	Medical		Cerebral Transient Ischaemia
	VASCULAR DISEASE -	Director	tia	Cerebral Transient Ischaemic Attacks
	TIA			TIA (Transient Ischaemic Attack)
				Transient Ischaemic Attack
		MMEx	266257000	Temporary cerebral vascular dysfunction
				TIA
CARDIO				TIA - Transient ischaemic attack
VASCULAR				Transient cerebral ischaemia
DISEASE				Transient ischaemic attack
(CVD)			3083	Arteriosclerosis obliterans
		Best Practice		Peripheral arterial disease
				Peripheral vascular disease
				PVD
		Communicare	K92003	Disease peripheral vascular
	PERIPHERAL	Madiaal		Arteriosclerosis obliterans
	VASCULAR	Medical Director	pvd	Peripheral Vascular Disease
	DISEASE	Director		PVD
	(PVD)		361133006	Arteriosclerosis obliterans
			400047006	PVD - peripheral vascular disease
		MMEx		Peripheral arterial disease
		IVIIVI⊏X	840580004	Peripheral arterial disease
				Peripheral artery disease
			400047006	Peripheral vascular disease

Table 25: CVD clinical coding definition – Carotid stenosis, Renal artery stenosis, Surgery, cardiovascular, carotid

NKPI CONDITION	CONDITION SUBGROUP	CIS	CODE	CLINICAL TERM (OR GLOBAL CAREPLAN NAME)
		Best Practice	5340	Carotid artery occlusion
		Dest Flactice	5540	Carotid artery stenosis
	CAROTID ARTERY STENOSIS	Communicare	K91014	Stenosis artery carotid
CARDIO				Stenosis, artery, carotid
VASCULAR			K91016	Disease carotid
DISEASE		0.200.0	Medical Director	sten.caroa
(CVD)		MMEx	64586002	Carotid artery narrowing
				Carotid artery stenosis
		Doot Desetion	2200	Renal artery stenosis
		Best Practice	e 3398	Stenosis of renal artery

	Communicare	U99028	Stenosis artery renal
RENAL	. Medical Director	sten.renaa	Renal Artery Stenosis
ARTER'	7	Sterriteriaa	Stenosis - Renal artery
STENOS	IS MMEx	302233006	RAS - Renal artery stenosis
	IVIIVIEX	302233000	Renal artery stenosis
	Best Practice	5883	Carotid artery stent
	Dest Fractice	0000	Stent, carotid artery
	Communicare	K52008	Endarterectomy internal carotid
	Communicare	K53007	Stent(s) carotid
		surg.caroa@bypa	Corotid orten, bypass surgen,
SURGER		@graf surg.caroa@enda	Carotid Endarters stemy
CARDIO	_		Carotid Endarterectomy
VASCUL/	modical Biloctor		Endarterectomy - Carotid
- CAROT			Arterial stent - Carotid artery
		surg.caroa@stent	Carotid artery stent
			Stent - Carotid artery
			Carotid endarterectomy
	MMEx	66951008	Carotid thromboendarterectomy
			CEA - Carotid endarterectomy

Table 26: CVD clinical coding definition – Surgery, Cardiovascular, coronary

NKPI CONDITION	CONDITION SUBGROUP	CIS	CODE	CLINICAL TERM (OR GLOBAL CAREPLAN NAME)
				Angioplasty, Coronary
				Balloon Coronary Angioplasty
				Coronary Angioplasty
			3576	PCTA
				Percutaneous transluminal
				Angioplasty Percutaneous transluminal
		Best Practice		Coronary Angioplasty
		20011 1001100	3577	Coronary Artery endarterectomy
			3377	Coronary endarterectomy
			3578	CABG
			0070	Coronary Artery Bypass graft
				Coronary Angioplasty with stent
			3579	Coronary Artery stent
			1/	Stent, Coronary Artery
			K53003	Angioplasty; artery; coronary
		Communicare	K53009	Stent(s)coronary
			K54007	Graft coronary artery bypass
			surg.coroa	Coronary artery surgery
			•	Surgery - Coronary artery
	SURGERY - CARDIOVAS CULAR - CORONARY			Angioplasty - coronary Balloon coronary angioplasty
0.55.0				Coronary artery balloon
CARDIO			surg.coroa@balloon	angioplasty
VASCULAR DISEASE				PCTA
(CVD)				Percutaneous transluminal
				angioplasty
				Surgery - Coronary artery balloon angioplasty
				Coronary artery endarterectomy
			surg.coroa@enda	Surgery - Coronary artery
				endarterectomy
			surg.coroa@graf	Bypass - coronary
				CABG (Coronary Artery Bypass
				graft)
				Coronary artery bypass graft
				Surgery - Coronary artery bypass graft
				Coronary Angiography and Stent
				Coronary artery stent
				Stent - Coronary artery
			surg.coroa@stent	Surgery - Coronary artery stent
				Angioplasty - coronary (with stent)
			surg.coroa@stent@ eluting	Arterial stent - Coronary artery,
				drug-eluting
				Coronary artery, drug-eluting stent
				Stent - Coronary Artery, drug- eluting

			Arterial stent - Coronary artery, not drug-eluting Coronary artery, not drug-eluting stent Stent - Coronary artery, not drug-
			eluting Insertion of coronary artery stent
			Placement of stent in coronary artery Dotter operation for transluminal angioplasty
		36969009	PCA - Percutaneous angioplasty Percutaneous angioplasty
			Percutaneous balloon angioplasty
	MMEx		Percutaneous transluminal balloon angioplasty
		232717009	CABG (Coronary artery bypass graft)
			CAG - Coronary artery graft
			CBG - Coronary bypass graft
			Coronary artery bypass graft
			Coronary artery bypass grafting
		5431005	Percutaneous transluminal angioplasty

Table 27: CVD clinical coding definition – Cardiovascular surgery, Renal artery

NKPI CONDITIO N	CONDITION SUBGROUP	CIS	CODE	CLINICAL TERM (OR GLOBAL CAREPLAN NAME)	
		Best Practice	6456	Renal artery stent	
		Communicare	K53006	Renal artery angioplasty	
CARDIO	SURGERY – CARDIO VASCULAR - RENAL ARTERY	Medical Director	surg.renaa	Angioplasty - renal	
			surg.renaa@stent	Arterial stent - Renal artery	
				Renal artery stent	
VASCULAR				Stent - Renal artery	
DISEASE			344990004	Balloon angioplasty of renal artery	
(CVD)			346007006	Angioplasty of renal artery	
		MMEx	414512008	Insertion of renal artery stent	
			419827000	Fluoroscopic angioplasty of renal	
				artery	
				Fluoroscopy and angioplasty of renal artery	

5.2 CVD - MMEx specific inclusions - Mapping table

Table 28: MMEx specific inclusions – ACS, Angina, Carotid Artery Stenosis, Cerebrovascular disease

NKPI CONDITION	CONDITION SUBGROUP	CLINICAL TERM	SNOMED CODE	GLOBAL CARE PLAN NAME (and suggestions)
		Intermediate coronary syndrome	4557003	
		Preinfarction angina	4557003	
		Preinfarction syndrome	4557003	
		Pre-infarction syndrome	4557003	
		Unstable angina	4557003	
		Worsening angina [synonym of Unstable angina]	4557003	
	ACUTE	Angina	194828000	ACUTE
	CORONARY	Angina pectoris	194828000	CORONARY
	SYNDROME (ACS)/ANGINA	Anginal syndrome [synonym of Angina Pectoris and Angina)	194828000	SYNDROME (ACS)/ANGINA
		AP - Angina pectoris	194828000	
		Cardiac angina	194828000	
		Ischaemic heart disease - angina	194828000	
		Stenocardia [synonym of Angina]	194828000	
		ACS - Acute coronary syndrome	394659003	
		Acute coronary syndrome	394659003	
		Acute coronary insufficiency	194823009	
	CAROTID	Carotid artery narrowing	64586002	CAROTID
CARRIOVAG	ARTERY STENOSIS	Carotid artery stenosis	64586002	ARTERY STENOSIS
CARDIOVAS CULAR		Cerebral infarction due to embolism of cerebral arteries	195190007	
DISEASE		Cerebrovascular accident	195190007	
(CVD)		CVA - Cerebrovascular accident	195190007	
		Stroke	195190007	
	CEREBROVAS CULAR DISEASE	Thrombotic CVA (cerebrovascular accident)	371040005	
		Thrombotic stroke	371040005	
		Ischaemic CVA (cerebrovascular accident)	422504002	
		Ischaemic stroke	422504002	
		Cerebral infarction due to embolism of MCA (middle cerebral artery)	705128004	CEREBRO VASCULAR
		Cerebral infarction due to embolism of middle cerebral artery	705128004	DISEASE
		CVA (cerebrovascular accident) co- occurrent with migraine	724429004	
		Migraine-induced stroke	724429004	
		Stroke and migraine	724429004	
		Stroke co-occurrent with migraine	724429004	
		Lacunar stroke	230698000	
		Lacunar infarction	230698000	
		Lacunar CVA (cerebrovascular accident)	230698000	
		LI - Lacunar infarction	230698000	

LACI - Lacunar infarction	230698000	
Thrombotic stroke	371040005	
Thrombotic CVA (cerebrovascular accident)	371040005	
Cerebral ischaemic stroke due to subarachnoid haemorrhage	788884002	
Cerebral ischaemic stroke co- occurrent with subarachnoid haemorrhage	788884002	
Arterial embolism	54687002	

Table 29: MMEx specific inclusions – Cerebrovascular disease – TIA, Coronary Heart disease, Myocardial infarction

NKPI CONDITION	CONDITION SUBGROUP	CLINICAL TERM	SNOMED CODE	GLOBAL CARE PLAN NAME (and suggestions)
		Temporary cerebral vascular dysfunction	266257000	
	CEREBRO	TIA	266257000	CEREBRO
	VASCULAR	TIA - Transient ischaemic attack	266257000	VASCULAR
	DISEASE - TIA	Transient cerebral ischaemia	266257000	DISEASE - TIA
		Transient ischaemic attack	266257000	
	CORONARY HEART	Chronic heart disease - other	128238001	CORONARY HEART
	DISEASE	Coronary Heart Disease (CHD)	53741008	DISEASE
		Old myocardial infarction	1755008	
		Healed myocardial infarction	1755008	
		Cardiac infarction	22298006	
		Heart Attack	22298006	
		Infarction of heart	22298006	
		MI - myocardial infarction	22298006	
CARDIO		Myocardial infarct	22298006	
VASCULAR		Myocardial infarction	22298006	
DISEASE		Acute anterior myocardial infarction	54329005	
(CVD)		Acute anterior myocardial infarction	54329005	
	MYOCARDIAL INFARCTION	Acute myocardial infarction of anterior wall	54329005	MYOCARDIAL
		Acute myocardial infarction of anterior wall	54329005	INFARCTION
		Acute Myocardial infarction	54329005	
		AMI - Acute myocardial infarction	54329005	
		Acute inferior myocardial infarction	73795002	
		Acute myocardial infarction of diaphragmatic wall	73795002	
		Acute myocardial infarction of inferior wall	73795002	
		Old anterior myocardial infarction	233839009	
		Old inferior myocardial infarction	233840006	
		MI - Silent myocardial infarction	233843008	
		Silent myocardial infarction	233843008	

Acute anterior ST segment	703164000	
elevation myocardial infarction		
Acute ST segment elevation	703164000	
myocardial infarction of anterior		
wall		
Acute STEMI (ST elevation	703164000	
myocardial infarction) of anterior	700104000	
wall	- 00040000	
Acute inferior ST segment elevation	703213009	
myocardial infarction		
Acute inferior ST segment elevation	703213009	
myocardial infarction		
Acute ST segment elevation	703213009	
myocardial infarction of inferior wall		
Acute STEMI (ST elevation	703213009	
	703213009	
myocardial infarction) of inferior		
wall		
	738011000	
Anterolateral Myocardial infarction	168103	
	738011000	
Anterolateral myocardial infarction	168103	
Anterolateral myocardial infarction	738011000	
(MI)	168103	
• •	233841005	
Old lateral myocardial infarction		
Acute ST segment elevation	401303003	
myocardial infarction		
STEMI - ST elevation myocardial	401303003	
infarction		
Acute non-ST segment elevation	401314000	
myocardial infarction		
NSTEMI - Non-ST segment	401314001	
elevation MI	.0.0.	
Acute non-ST segment elevation	401314002	
myocardial infarction	101014002	
Acute anterior ST segment	703164000	
	703104000	
elevation myocardial infarction	70040400	
Acute ST segment elevation	703164000	
myocardial infarction of anterior		
wall		
Acute STEMI (ST elevation	703164000	
myocardial infarction) of anterior		
wall		
Acute inferior ST segment elevation		
myocardial infarction	703213009	
	703213009	
Acute ST segment elevation	703213009	
myocardial infarction of inferior wall	=00045555	
Acute STEMI (ST elevation	703213009	
myocardial infarction) of inferior		
wall		
	738061000	
Inferior myocardial infarction	168100	
	/.38UD TUUU	
Inferior myocardial infarction (MI)	738061000 168100	

Table 30: MMEx specific inclusions – Peripheral vascular disease, Renal artery stenosis, Surgery – Cardiovascular – Carotid, Coronary, Renal Artery

NKPI CONDITIO N	CONDITION SUBGROUP	CLINICAL TERM	SNOMED CODE	GLOBAL CARE PLAN NAME (and suggestions)
		Arteriosclerosis obliterans	361133006	
		PVD - peripheral vascular disease	400047006	
	PERIPHERAL	Peripheral arterial disease	840580004	PERIPHERAL
	VASCULAR DISEASE (PVD)	Peripheral arterial disease	840580004	VASCULAR DISEASE (PVD)
	BIOLINOL (I VD)	Peripheral artery disease	840580004	BIOL/IOL (I VD)
		Peripheral vascular disease	400047006	
	RENAL ARTERY	RAS - Renal artery stenosis	302233006	RENAL
	STENOSIS	Renal artery stenosis	302233006	ARTERY STENOSIS
	SURGERY -	Carotid endarterectomy	66951008	
	CARDIO VASCULAR -	Carotid thromboendarterectomy	66951008	
	CAROTID	CEA - Carotid endarterectomy	66951008	
		Insertion of coronary artery stent	36969009	
	SURGERY – CARDIO VASCULAR - CORONARY	Placement of stent in coronary artery	36969009	
CARRIO		Dotter operation for transluminal angioplasty	68457009	
CARDIO VASCULAR		PCA - Percutaneous angioplasty	68457009	
DISEASE		Percutaneous angioplasty	68457009	
(CVD)		Percutaneous balloon angioplasty	68457009	
		Percutaneous transluminal balloon angioplasty	68457009	CARDIO
		CABG (Coronary artery bypass graft)	232717009	VASCULAR DISEASE (CVD)
		CAG - Coronary artery graft	232717009	SURGERY
		CBG - Coronary bypass graft	232717009	
		Coronary artery bypass graft	232717009	
		Coronary artery bypass grafting	232717009	
		Percutaneous transluminal angioplasty	5431005	
	SURGERY – CARDIO VASCULAR - RENAL ARTERY	Balloon angioplasty of renal artery	344990004	
		Angioplasty of renal artery	346007006	
		Insertion of renal artery stent	414512008	
		Fluoroscopic angioplasty of renal artery	419827000	
		Fluoroscopy and angioplasty of renal artery	419827000	

5.3 Cardiovascular Disease (CVD) – EXCLUDED SUBGROUPS AND TERMS

The following subgroups are excluded from the clinical coding definition of CVD:

- Angina Prinzmetal
- Angina prescription
- Apoplexy
- Arrythmia
- Atrial fibrillation
- Atrial flutter
- Cardiomyopathy
- Congenital condition
- Gangrene

- Heart block
- Heart failure
- Hypertension
- Rheumatic heart disease
- Rupture
- Syncope
- Tachycardia
- Valve disease
- Venous embolism.

Table 31: Terms to exclude from CVD clinical coding definition – Angina, Apoplexy and Arrythmia

NKPI CONDITION	CONDITION SUBGROUP	CIS	CIS CODE	CLINICAL TERM (OR GLOBAL CAREPLAN NAME)
	ANGINA -	Medical		Anti-angina agent prescription
	PRESCRIPTIO N	Director	pres@angip	Prescription-Angina pectoris
	ANGINA -	Best Practice	227	Prinzmetal Angina
	PRINZMETAL	Medical Director	angip@prin	Prinzmetal angina
	APOPLEXY	Communicare	K90015	Seizure apoplectic
	AI OI LEXT	Communicate	K90024	Apoplexy
			7	Cardioversion - failed
				Arrhythmia, Bradycardia
			260	Bradyarrhythmia
				Cardiac Bradyarrhythmia
			1079	Arrhythmia, Atrial fibrillation
			1079	Rapid AF
		Best Practice	1086	Arrhythmia, ventricular fibrillation
CARDIO				Fibrillation, ventricular
VASCULAR				Ventricular fibrillation
DISEASE			2527	Arrhythmia, Nodal tachycardia
(CVD)			2321	Tachycardia, Nodal
			2854	Cardioversion
	ARRYTHMIA		4172	Arrhythmia, SVT
				SVT
			4208	Arrhythmia, tachycardia
				Tachycardia
			4474	Ectopics, ventricular
			4474	Premature ventricular Contractions
			4475	Arrhythmia, ventricular tachycardia
			4475	Tachycardia, ventricular
				Pre excitation syndrome
			4557	Wolff Parkinson White syndrome
				WPW
			4605	Tachycardia, supraventricular
			6298	Triatrial heart

		6708	Autosomal recessive long QT syndrome
		7828	Bigeminy
			Ventricular Bigeminy
		8252	Cardioversion, elective
			Elective Cardioversion

Table 32: Terms to exclude from CVD clinical coding definition – Atrial fibrillation, Atrial flutter, and Cardiomyopathy

NKPI CONDITION	CONDITION SUBGROUP	cis	CIS CODE	CLINICAL TERM (OR GLOBAL CAREPLAN NAME)					
	ATDIAL			AF					
	ATRIAL FIBRILLATION	Best Practice	1079	Atrial fibrillation					
				Fibrillation, Atrial					
	ATRIAL	Root Prootice	1113	Arrhythmia, Atrial flutter					
	FLUTTER	Best Practice	1113	Atrial flutter					
			496	Cardiomyopathy					
				Cardiomyopathy, Congestive					
			497	Cardiomyopathy, dilated					
			497	Congestive Cardiomyopathy					
				Dilated Cardiomyopathy					
			498	Cardiomyopathy, hypertrophic					
			490	Hypertrophic Cardiomyopathy					
			499	Cardiomyopathy, restrictive					
			499	Restrictive Cardiomyopathy					
			2080	Cardiomyopathy, selenium deficiency					
			4738	Cardiomyopathy, Congenital					
			4730	Congenital Cardiomyopathy					
0.4.0.0.10			5179	Cardiomyopathy, ischaemic					
CARDIO	CARDIO-	Best Practice		Ischaemic Cardiomyopathy					
VASCULAR DISEASE	MYOPATHY	Desi Fractice	5180	Alcoholic Cardiomyopathy					
(CVD)							310	3100	Cardiomyopathy, Alcoholic
()			5181	Amyloid Cardiomyopathy					
			3101	Cardiomyopathy, Amyloid					
			5182	Cardiomyopathy, idiopathic					
			0102	Idiopathic Cardiomyopathy					
			5183	Cardiomyopathy, peripartum					
			3103	Peripartum Cardiomyopathy					
			5184	Cardiomyopathy, haemochromatosis					
			3104	Haemochromatosis Cardiomyopathy					
			6915	Cardiomyopathy, hypertensive					
			0913	Hypertensive Cardiomyopathy					
			74.45	Stress-induced Cardiomyopathy					
			7145	Takotsubo Cardiomyopathy					
			521	Congenital heart defect					
			4739	Congenital heart disease					
	CONGENITAL	Best Practice	4866	Hypoplastic left heart syndrome					
	CONDITION	Dest Flactice	6261	Cardiofaciocutaneous syndrome					
			6298	Cor Triatriatum					
			0230	Cardio auditory syndrome					

		Jervell And Lange-Nielsen syndrome
		Cardiocutaneous syndrome
		Cardiomyopathic lentiginosis
	6516	LEOPARD syndrome
		Multiple lentigines syndrome
		Progressive Cardiomyopathic lentiginosis
	7635	Congenital heart Block

Table 33: Terms to exclude from CVD clinical coding definition – Embolism, Gangrene and Heart failure

NKPI CONDITION	CONDITION SUBGROUP	CIS	CIS CODE	CLINICAL TERM (OR GLOBAL CAREPLAN NAME)
	EMBOLISM		K75009	Embolism artery coronary
		Communicare	K90020	Embolism cerebral
	LIVIDOLISIVI	Communicate	K91013	Embolism precerebral
			K92018	Embolism arterial
	GANGRENE	Communicare	K92004	Gangrene
	GANGRENE	Communicate	K92006	Ischaemia limb (gangrene)
			628	Intraventricular Block
			020	Intraventricular Heart Block
				Atrio-Ventricular Block
			1341	AV Block
			1341	Heart Block
				Sino-Atrial heart Block
			1342	First degree heart Block
			1342	Heart Block, first degree
	HEART BLOCK	Best Practice		Heart Block, second degree
	TIEART BLOCK	Dest Flactice	1343	Mobitz type 1A-VBlock
				Second degree heart Block
CARDIO			1344	Complete heart Block
VASCULAR				Heart Block, third degree
DISEASE				Third degree heart Block
(CVD)			1357	Split heart Sounds
			3390	Sinus Node dysfunction
			7594	Mobitz type 2A-VBlock
			7635	Heart Block, Congenital
			1086	VF
			1345	Cardiac failure
			1040	Heart failure
				Acute Cardiac failure
			1346	Acute heart failure
			1040	Cardiac failure, Acute
	HEART	Best Practice		Heart failure, Acute
	FAILURE	Dest Fractice		Biventricular heart failure
			1347	CCF
			1341	Congestive Cardiac failure
				Congestive heart failure
				Heart failure, left
			1348	Left heart failure
				Left Ventricular Failure

			LUE
			LHF
			LVF
			Heart failure, high output
		1349	High output Cardiac failure
			High output heart failure
			Cor pulmonale
			RHF
		1350	Right heart failure
			Right ventricular failure
			RVF
		1475	Hypertensive heart failure
		6178	Diastolic Cardiac dysfunction
			Diastolic heart failure
			Heart failure - preserved ejection
			fraction
			HFpEF
			Ventricular diastolic dysfunction
		6179	Heart failure - reduced ejection fraction
			HFrEF
			Systolic Cardiac dysfunction
		11800	Heart failure -Mid range ejection fraction
		11600	HFmrEF
	MMEx	Global care plan name	CHRONIC HEART FAILURE

Table 34: Terms to exclude from CVD clinical coding definition – Hypertension, RHD, Rupture and Syncope

NKPI CONDITION	CONDITION SUBGROUP	CIS	CIS CODE	CLINICAL TERM (OR GLOBAL CAREPLAN NAME)
	HYPERTENSIO N	MMEx	Global care plan name	HYPERTENSION
				Rheumatic heart disease
		Best Practice	3167	Rheumatic Myocarditis
		Dest Flactice	3107	Rheumatic pancarditis
	RHEUMATIC			Rheumatic valve disease
	HEART			ACUTE RHEUMATIC FEVER
	DISEASE	MMEx	Global care plan name	RHD (Priority 1) - Severe RHD
CARDIO				RHD (Priority 2) - Moderate RHD
VASCULAR DISEASE				RHD (Priority 3) - ARF (No RHD) or Mild RHD
(CVD)				RHD (Priority 4) - Inactive
(-)	RUPTURE		K75005	Rupture myocardium
			K75006	Rupture heart
		Communicare	K75007	Rupture artery coronary
			K90013	Rupture blood vessel brain
			K90014	Rupture intracranial
				Neuro cardiogenic syncope
	SYNCOPE	Best Practice	4191	Syncope, vasovagal
				Vaso vagal syncope

Table 35: Terms to exclude from CVD clinical coding definition – Tachycardia, Valve disease, Other

NKPI CONDITIO N	CONDITION SUBGROUP	CIS	CIS CODE	CLINICAL TERM (OR GLOBAL CAREPLAN NAME)
			2527	Nodal tachycardia
			4470	Atrial tachycardia
	TACHYCARDIA		4172	Supraventricular tachycardia
			4475	Ventricular Tachycardia
			4475	VT
			1589	Prosthetic heart valve endocarditis
			3167	Post streptococcal heart disease
				Post streptococcal valve disease
	VALVE		3692	Heart valve replacement
	DISEASE		0002	Prosthetic heart valve
				Heart disease, valvular
			4479	Valvular disease of heart
				Valvular heart disease
			227	Coronary Artery spasm
			260	Bradycardia
			683	Organic Heart Disease
			1343	Wenckebach phenomenon
			1351	Cardiomegaly
				Heart enlarged
			1357	Heart sounds - Split
			1358	Heart sounds - Triple rhythm
CARDIO			0000	Triple rhythm heart sounds
VASCULAR		Best Practice	2080	Keshan disease
DISEASE (CVD)		3265	3265	Cardiogenic shock
(CVD)			2200	Shock, Cardiogenic
	OTHER		3390	Sick Sinus Syndrome
				Heart surgery
			3687	Heart surgery
				Open heart surgery
				Open heart surgery
			3691	Heart transplant Transplant, heart
				· · ·
			4191	Collapse Vasovagal Attack
			4208	Rapid pulse
				Ventricular ectopics
			4474	Ventricular ectopics Ventricular extra systoles
			4557	Accessory Atrioventricular pathways
			4628	Abnormal heart chamber dimensions
				Dressler's syndrome
			6103	Post pericardiotomy syndrome
			6498	Surdo cardiac Syndrome
				Broken heart syndrome
			7145	Transient Apical Ballooning
			7810	Cyanotic heart disease
			8067	Hypertensive heart disease

8294	Post cardiotomy syndrome
11744	Heart disease

Table 36: Terms to exclude from CVD clinical coding definition – Other

NKPI CONDITION	CONDITION SUBGROUP	CIS	CIS CODE	CLINICAL TERM (OR GLOBAL CAREPLAN NAME)
			L99098	Necrosis aseptic
			K74003	Spasm artery coronary
			K74005	Cardiac vasospasm
			K76001	Coronary artery aneurysm
			K76020	Ventricular aneurysm
			K89003	Subclavian steal syndrome
			K89009	Spasm artery cerebral
			K09009	Vasospasm cerebral
	OTHER		K89010	Attack(s) drop
			K89014	Amaurosis fugax
CARDIO		Communicare	K89016	Transient global amnesia
VASCULAR		Communicate	K90008	Haemorrhage epidural
DISEASE			K92001	Disease Buergers
			K92002	Disease Raynaud's
				Raynaud's phenomenon
			K92005	Ischaemia contracture
			K92014	Thrombosis arterial
			K92016	Vasospasm peripheral
			K92017	Claudication intermittent
			K92021	Thromboangitis obliterans
			K92026	Atheroma
			K92029	Vasospasm nipple
		Medical Director	raynp	Raynaud's phenomenon

5.4 CVD - MMEx specific exclusions - Mapping table

Table 37: MMEX specific exclusions for CVD

NKPI CONDITION	CONDITION SUBGROUP	CLINICAL TERM	GLOBAL CARE PLAN NAME	
	HEART FAILURE	CHRONIC HEART FAILURE		
	HYPERTENSION	Hypertension		
CARDIO	RHEUMATIC HEART DISEASE	ACUTE RHEUMATIC FEVER		
VASCULAR DISEASE (CVD)		RHD (Priority 1) - Severe RHD	CVD	
		RHD (Priority 2) - Moderate RHD		
		RHD (Priority 3) - ARF (No RHD) or Mild RHD		
		RHD (Priority 4) - Inactive		

6. Ear Health

The preferred method for counting a recorded ear health check is via a dedicated section/module in the CIS. Where this is incomplete the counting rules should be applied, see nKPI – PI26: Ear Health Check. The ear health coding framework is designed to assist in the interpretation of the counting rules to assess diagnostic and procedural fields for inclusion/ exclusion.

The terms and codes for ear health are relevant to the principal intent of the indicator i.e. regular and accurate assessment of ear health.

The following principles outline the inclusion and exclusion criteria for Ear Health:

- Procedural terms are included where the procedure/clinical test includes assessment of the appearance of both ear canals and ear drums AND/OR the movement of both eardrums.
- Surgical procedures are included where it is reasonable to assume clinically that appearance and/or movement have been checked.
- Diagnostic clinical terms are included where in the process of obtaining a diagnosis best practice would require an assessment of the appearance of both ear canals and ear drums AND/OR the movement of both eardrums.
- Hearing loss diagnoses are excluded.
- Terminology that is too broad is excluded as it is not possible to determine which, if any, ear health assessment could be applied.

Notes: The codes and terms listed against MMEx are SNOMED-CT. This provides other CIS vendors with flexibility to include these terms as relevant, now or in the future.

It is assumed that tympanic membrane movement is checked (as much as one can) even when there is a perforation.

6.1 Ear Health - INCLUDED TERMS

Tables 38 to 46 outline the Ear Health coding terms for conditions and procedures. The allocation of each term to the disaggregation points of either appearance (App.), movement (Move.) or both (Both) is noted in the last column.

Note: No conditions have been identified that specifically relate to movement.

Included conditions are defined within the following sub-groups:

- Otitis externa
- Otitis media
- Myringitis
- Perforation of tympanic membrane
- Tympano-sclerosis
- Cholesteatoma
- Otorrhoea
- Bleeding from ear

Note: Excluded terms relating to the ear health coding framework are listed in Tables 47 to 54.

Clinical Diagnosis inclusion terms

Table 38: Ear Health – Otitis Externa

NKPI CONDITION	CONDITION SUBGROUP	cis	CIS CODE	CLINICAL TERM (OR GLOBAL CAREPLAN NAME)	APP./ MOVE./ BOTH
			2591	Otitis externa	Both
			27702	Otitis externa, circumscribed	Both
			27701	Otitis externa, diffuse	Both
			1587	Otitis externa, fungal	Both
		Best Practice	27703	Otitis externa, malignant	Both
			27703	Otitis externa, necrotising	Both
			2592	Otitis externa, Recurrent	Both
			2592	Recurrent Otitis externa	Both
			2591	Swimmer's ear	Both
		Communicare	H70002	Otitis externa	Both
		Communicate	H70003	Swimmers ear	Both
		Medical	otite	Otitis Externa	Both
		Director	otite@recu	Otitis Externa - Recurrent	Both
		2 0010.	otite	Outer ear infection	Both
			3135009	Otitis externa Acute actinic otitis	Both
	Otitis externa	MMEx	21543000	externa	Both
			232234000	Acute allergic otitis externa	Both
Ear Health			700220003	Acute bacterial otitis externa	Both
			79150005	Acute chemical otitis externa	Both
			18953001	Acute contact otitis externa	Both
			54272002	Acute eczematoid otitis externa	Both
			232223003	Acute fungal otitis externa	Both
			267665002	Acute infective otitis externa	Both
			232233006	Acute irritant otitis externa	Both
			232232001	Acute non-infective otitis externa	Both
			30250000	Acute otitis externa	Both
			194217007	Acute radiation otitis externa	Both
			402207002	Acute seborrhoeic otitis externa	Both
			232235004	Acute traumatic otitis externa	Both
			232222008	Acute viral otitis externa	Both
			405821001	Allergic otitis externa	Both
			1082971000119100	Bilateral acute non- infective otitis externa	Both

	1083361000119100	Bilateral auditory canal chronic non-infective otitis externa	Both
	1083341000119100	Bilateral chronic otitis externa of external auditory canals caused by fungus	Both
	1083471000119100	Bilateral diffuse otitis externa	Both
	1083381000119100	Bilateral external auditory canal chronic otitis externa	Both
	15983071000119100	Bilateral herpes simplex otitis externa	Both
	1084121000119100	Bilateral otitis externa of external auditory canals caused by fungus	Both
	16681000	Candidal otitis externa	Both
	232240007	Chronic allergic otitis externa	Both
	232225005	Chronic bacterial otitis externa	Both
	232224009	Chronic infective otitis externa	Both
	232239005	Chronic irritant otitis externa	Both
	111898002	Chronic mycotic otitis externa	Both
	232236003	Chronic non-infective otitis externa	Both
	1088491000119100	Chronic non-infective otitis externa of left external auditory canal	Both
	1091101000119100	Chronic non-infective otitis externa of right external auditory canal	Both
	53295002	Chronic otitis externa	Both
	194207002	Chronic otitis externa due to aspergillosis	Both
	194208007	Chronic otitis externa due to moniliasis	Both
	1088511000119100	Chronic otitis externa of left external auditory canal	Both
	1088471000119100	Chronic otitis externa of left external auditory canal caused by fungus	Both
	1091121000119100	Chronic otitis externa of right external auditory canal	Both
	1091081000119100	Chronic otitis externa of right external auditory canal caused by fungus	Both
	232237007	Chronic radiation otitis externa	Both

	Chronic seborrhoeic otitis	
402208007	externa	Both
232241006	Chronic traumatic otitis externa	Both
232226006	Chronic viral otitis externa	Both
79972006	Circumscribed otitis externa	Both
34723002	Diffuse otitis externa	Both
232229004	Granulomatous otitis externa	Both
33934002	Haemorrhagic otitis externa	Both
1088901000119100	Haemorrhagic otitis externa of left external auditory canal	Both
1091511000119100	Haemorrhagic otitis externa of right external auditory canal	Both
111856000	Herpes simplex otitis externa	Both
86981007	Infective otitis externa	Both
194202008	Infective otitis externa due to erysipelas	Both
194203003	Infective otitis externa due to impetigo	Both
1088081000119100	Left acute non-infective otitis externa	Both
1088621000119100	Left diffuse otitis externa	Both
94146005	Malignant otitis externa	Both
232230009	Malignant otitis externa caused by Pseudomonas aeruginosa	Both
1089021000119100	Malignant otitis externa of left external auditory canal	Both
1091631000119100	Malignant otitis externa of right external auditory canal	Both
773955003	Necrotising otitis externa of left external auditory canal	Both
773951007	Necrotising otitis externa of right external auditory canal	Both
232231008	Non-infective otitis externa	Both
280221000009107	Otitis externa caused by bacteria	Both
36292003	Otitis externa caused by Herpes zoster	Both
1089181000119100	Otitis externa of left external auditory canal caused by fungus	Both
1091791000119100	Otitis externa of right external auditory canal caused by fungus	Both

	1090701000119100	Right acute non-infective otitis externa	Both
	1091231000119100	Right diffuse otitis externa	Both
	232243009	Seborrhoeic otitis externa	Both

Table 39: Ear Health - Otitis Media

NKPI CONDITION	CONDITION SUBGROUP	CIS	CIS CODE	CLINICAL TERM (OR GLOBAL CAREPLAN NAME)	APP./ MOVE./ BOTH	
			905	Chronic secretory otitis media	Both	
			4305	Ear Tuberculosis	Both	
			905	Glue ear	Both	
			2593	Middle ear infection	Both	
			2593	Otitis media	Both	
		Best Practice	2594	Otitis media, recurrent	Both	
		Dest Flactice	905	Otitis media, serous	Both	
			7194	Otitis media, suppourative	Both	
			2594	Recurrent Otitis media	Both	
			905	Secretory otitis media	Both	
			905	Serous otitis media	Both	
			7194	Suppurative otitis media	Both	
			H72001	Effusion;middle ear	Both	
			H72002	Glue ear	Both	
			H71003	Otitis media	Both	
			H72005	Otitis media (with);effusion	Both	
			H71002	Otitis media;acute	Both	
	Otitis media		H71020	Otitis media;acute;no perforat	Both	
		Communicare	H71021	Otitis media;acute;perforation	Both	
			H74006	Otitis media;chronic	Both	
			H72003	Otitis media;nonsuppurative	Both	
			H71004	Otitis media;perforated	Both	
			H72004	Otitis media;serous	Both	
			H71009	Otitis media;suppurative;acute	Both	
			H74006	Otitis media;suppurative;chron	Both	
			otitm&ctx@ill,recu	Chronic Suppurative Otitis Media	Both	
		Medical	Medical	otitm	Middle ear infection	Both
		Director	otitm	Otitis Media	Both	
			otitm&ctx@ill,recu	Otitis Media - Recurrent	Both	
			tube.ear	Ear tuberculosis	Both	
			65363002	Otitis media	Both	
		MMEx	8326008	Acute allergic mucoid otitis media	Both	

1087981000119100	Acute allergic otitis media of left middle ear	Both
1090601000119100	Acute allergic otitis media of right middle ear	Both
17866004	Acute allergic sanguinous otitis media	Both
59275002	Acute allergic serous otitis media	Both
194290005	Acute bilateral otitis media	Both
7271000119107	Acute bilateral otitis media with effusion	Both
19399000	Acute exudative otitis media	Both
194288009	Acute left otitis media	Both
52353000	Acute mucoid otitis media	Both
1088061000119100	Acute mucoid otitis media of left middle ear	Both
1090681000119100	Acute mucoid otitis media of right middle ear	Both
360595002	Acute necrotising otitis media	Both
194240006	Acute non-suppurative serous otitis media	Both
3110003	Acute otitis media	Both
270490007	Acute otitis media with effusion	Both
84261000119106	Acute persistent otitis media	Both
194289001	Acute right otitis media	Both
77478005	Acute sanguinous otitis media	Both
359609001	Acute secretory otitis media	Both
8304007	Acute seromucinous otitis media	Both
194281003	Acute suppurative otitis media	Both
86279000	Acute suppurative otitis media with spontaneous rupture of ear drum	Both
14948001	Acute suppurative otitis media without spontaneous rupture of ear drum	Both
35183001	Acute transudative otitis media	Both
85108007	Acute tubotympanic catarrh	Both
7699004	Adhesive middle ear disease	Both
31700001	Adhesive middle ear disease with adhesions of drum head to incus	Both

Idle ear adhesions I to Both
Idle ear adhesions Both to stapes
is media of Both
is media of Both
media Both
s media Both
e allergic f middle Both
esive otitis dle ears
nic allergic f middle Both
nic otitis is following impanic be
nic eous otitis Both dle ears
nic serous Both
nic otitis media Both s
dle ear bid otitis Both
oid otitis dle ears
rrent acute media of Both
rrent acute otitis media Both s
Durative Both
is media Both
ranuloma Both
ranuloma and Both
gic otitis Both
pantral Stitis media

1088401000119100	Chronic atticoantral suppurative otitis media of left middle ear	Both
1091011000119100	Chronic atticoantral suppurative otitis media of right middle ear	Both
43561008	Chronic exudative otitis media	Both
78868004	Chronic mucoid otitis media	Both
1088461000119100	Chronic mucoid otitis media of left middle ear	Both
1091071000119100	Chronic mucoid otitis media of right middle ear	Both
232254004	Chronic non-suppurative otitis media	Both
232257006	Chronic non-suppurative otitis media without effusion	Both
21186006	Chronic otitis media	Both
429767005	Chronic otitis media after insertion of tympanic ventilation tube	Both
1088531000119100	Chronic otitis media of left ear following insertion of tympanic ventilation tube	Both
1091141000119100	Chronic otitis media of right ear following insertion of tympanic ventilation tube	Both
38394007	Chronic otitis media with perforation	Both
449839003	Chronic otitis media with sanguineous effusion	Both
58194007	Chronic seromucinous otitis media	Both
81564005	Chronic serous otitis media	Both
765152004	Chronic serous otitis media of left ear	Both
765153009	Chronic serous otitis media of right ear	Both
1163148001	Chronic suppurative otitis media caused by Aspergillus	Both
1088571000119100	Chronic suppurative otitis media of left middle ear	Both
1091181000119100	Chronic suppurative otitis media of right middle ear	Both
38596008	Chronic tubotympanic catarrh	Both

	34790005	Chronic tubotympanic disease with anterior perforation of ear drum	Both
	87665008	Chronic tubotympanic suppurative otitis media	Both
	1088581000119100	Chronic tubotympanic suppurative otitis media of left middle ear	Both
	1091191000119100	Chronic tubotympanic suppurative otitis media of right middle ear	Both
	32760002	Exudative otitis media	Both
	19021002	Haemophilus influenzae otitis media	Both
	312218008	Infective otitis media	Both
	1088551000119100	Left chronic serosanguineous otitis media	Both
	16664009	Malignant otitis media	Both
	6485001	Mucosanguinous chronic otitis media	Both
	275481002	Non-suppurative otitis media	Both
	194237006	Non-suppurative otitis media with eustachian tube disorder	Both
	10624911000119100	Otitis media caused by H1N1 influenza	Both
	10624951000119100	Otitis media caused by influenza	Both
	10674911000119100	Otitis media caused by Influenza A virus	Both
	721742004	Otitis media caused by Streptococcus pneumoniae	Both
	1240521000000100	Otitis media due to COVID-19	Both
	1090001000119100	Otitis media due to scarlet fever	Both
	232256002	Otitis media with effusion - sanguinous	Both
	13420004	Post measles otitis media	Both
	39288006	Purulent otitis media	Both
	232252000	Recurrent acute non- suppurative otitis media	Both
	194287004	Recurrent acute otitis media	Both
	232251007	Recurrent acute suppurative otitis media	Both
	1082561000119104	Recurrent acute suppurative otitis media with spontaneous rupture of ear drum	Both
_		·	

1091161000119104	Right chronic serosanguineous otitis media	Both
1980003	Seromucinous otitis media	Both
86850004	Serosanguineous chronic otitis media	Both
80327007	Serous otitis media	Both
28795002	Subacute exudative otitis media	Both
6965008	Subacute nonsuppurative otitis media	Both
86359006	Subacute transudative otitis media	Both
89145009	Subacute tubotympanic catarrh	Both
789057009	Tuberculosis of middle ear	Both
85940005	Tuberculous otitis media	Both

Table 40: Ear Health – Myringitis

NKPI CONDITION	CONDITION SUBGROUP	CIS	CIS CODE	CLINICAL TERM (OR GLOBAL CAREPLAN NAME)	APP./ MOVE./ BOTH
		Best Practice	7825	Myringitis bullosa	Арр.
		Dest Flactice	7667	Bullous myringitis	App.
			H71001	Myringitis	App.
			H74002	Myringitis;chronic	App.
		Communicare	H71006	Inflammation;tympanic membra	Арр.
			H71005	Tympanitis	App.
		Medical Director	myringit <viru< td=""><td>Myringitis</td><td>Арр.</td></viru<>	Myringitis	Арр.
Ear Health	Myringitis	Myringitis	14852000	Myringitis	App.
Lai Health			297009	Acute myringitis	App.
			194311006	Acute myringitis without otitis media	Арр.
		MMEx	1083351000119100	Bilateral chronic tympanitis	App.
			33528003	Bullous myringitis	App.
			1088481000119106	Chronic left tympanitis	Арр.
			1091091000119105	Chronic right tympanitis	App.
			89723004	Chronic tympanitis	Арр.
		232245002	Granular myringitis	App.	

Table 41: Ear Health – Perforation of tympanic membrane

NKPI CONDITION	CONDITION SUBGROUP	CIS	CIS CODE	CLINICAL TERM (OR GLOBAL CAREPLAN NAME)	APP./ MOVE./ BOTH
			2688	Ear drum perforation	Арр.
		Best Practice	2688	Perforated tympanic membrane	App.
			2688	Ear drum perforation	Арр.
			H77002	Perforation;ear drum	Арр.
		Communicare	H77001	Perforation;tympanic membran	Арр.
			H79003	Rupture(trauma/pres); eardrum	Арр.
			perf.eard	Tympanic perforation	App.
		Medical	perf.eard	Ear drum perforation	App.
		Director	perf.eard	Perforation - eardrum	Арр.
			perf.eard	Perforation of eardrum	Арр.
			60442001	Perforation of tympanic membrane	Арр.
			194315002	Attic perforation of tympanic membrane	App.
	Perforation of tympanic membrane	ympanic	1083971000119100	Bilateral marginal perforation of tympanic membranes	Арр.
			1083171000119100	Bilateral perforation of pars flaccida of tympanic membranes	Арр.
Ear Health			1084361000119100	Bilateral perforation of tympanic membranes	App.
		MMEx	1083061000119100	Bilateral spontaneous rupture of tympanic membranes of ears co-occurrent and due to recurrent acute suppurative otitis media	Арр.
		IVIIVIEX	1083231000119100	Bilateral tympanic membrane central perforation	Арр.
			1088361000119100	Central perforation of left eardrum	App.
			1090971000119100	Central perforation of right eardrum	Арр.
			40723007	Central perforation of tympanic membrane	Арр.
			48523008	Healed perforation of ear drum	Арр.
			1089031000119100	Left tympanic membrane marginal perforation	Арр.
			39895008	Marginal perforation of tympanic membrane	Арр.
			44933002	Multiple perforations of tympanic membrane	App.

7361000119105	Perforation of tympanic membrane due to otitis media	Арр.
95813007	Perforation of tympanic membrane with proliferation of keratinised epithelium from middle to external ear	App.
111539002	Persistent posttraumatic perforation of ear drum	Арр.
82143003	Postinflammatory perforation of ear drum	Арр.
1091641000119100	Right tympanic membrane marginal perforation	Арр.
1088181000119100	Spontaneous rupture of tympanic membrane of left ear co-occurrent and due to recurrent acute suppurative otitis media	Арр.
1090791000119100	Spontaneous rupture of tympanic membrane of right ear co-occurrent and due to recurrent acute suppurative otitis media	Арр.
1089681000119100	Total perforation of left tympanic membrane	Арр.
1092291000119100	Total perforation of right tympanic membrane	Арр.
307497002	Traumatic tympanic membrane perforation	Арр.
232247005	Tympanic membrane - total perforation	Арр.
194318000	Tympanic membrane perforation - less than 50 percent	Арр.
267672001	Tympanic membrane perforation more than 50 percent	Арр.

Table 42: Ear Health – Tympanosclerosis

NKPI CONDITION	CONDITION SUBGROUP	CIS	CIS CODE	CLINICAL TERM (OR GLOBAL CAREPLAN NAME)	APP./ MOVE./ BOTH
		Best Practice	12042	Tympanosclerosis	Both
Ear Health Tympano- sclerosis		23606001	23606001	Tympanosclerosis	Both
			15979031000119107	Bilateral tympanosclerosis	Both Both
	MMEx	35100001	Tympanosclerosis involving tympanic membrane AND ear ossicles	Both	

35522004	Tympanosclerosis involving tympanic membrane only	Both
89058008	Tympanosclerosis involving tympanic membrane, ear ossicles AND middle ear	Both
15978951000119105	Tympanosclerosis of left middle ear	Both
15978991000119100	Tympanosclerosis of right middle ear	Both

Table 43: Ear Health - Cholesteatoma

NKPI CONDITION	CONDITION SUBGROUP	CIS	CIS CODE	CLINICAL TERM (OR GLOBAL CAREPLAN NAME)	APP./ MOVE./ BOTH
		Best Practice	571	Cholesteatoma	Арр.
		Communicare	H74005	Cholesteatoma	App.
		Medical Director	cholstea	Cholesteatoma	Арр.
			35247001	Cholesteatoma of external ear	Арр.
			1088831000119107	Cholesteatoma of left external ear	Арр.
			1089101000119100	Cholesteatoma of left middle ear	Арр.
Ear Health	Cholesteatoma		1088701000119100	Cholesteatoma of left tympanic membrane	Арр.
		MMEx	87688009	Cholesteatoma of middle ear	Арр.
			194339007	Cholesteatoma of middle ear and mastoid	Арр.
			1091441000119107	Cholesteatoma of right external ear	Арр.
			1091711000119103	Cholesteatoma of right middle ear	Арр.
			1091311000119104	Cholesteatoma of right tympanic membrane	Арр.

Table 44: Ear Health – Otorrhoea

NKPI CONDITION	CONDITION SUBGROUP	CIS	CIS CODE	CLINICAL TERM (OR GLOBAL CAREPLAN NAME)	APP./ MOVE./ BOTH
			871	Ear discharge	App.
		Best Practice	871	Otorrhoea	Арр.
		Dest Flactice	871	Discharge from ear	Арр.
Ear Health	Otorrhoea		905	Ear effusion	App.
		0	H04001	Discharge;ear	App.
	Communicare	H04002	Pus (from);ear	App.	
			effu.ear	Ear effusion	Арр.

	Medical	ear@disc	Ear - Discharge	Арр.
	Director	ear@disc	Otorrhoea	Арр.
		65668001	Otorrhoea	Арр.
		68382005	Cerebrospinal fluid otorrhoea	Арр.
		1259114008	Cerebrospinal fluid otorrhoea due to congenital deformity of labyrinth	Арр.
		1259117001	Cerebrospinal fluid otorrhoea due to encephalocele	Арр.
	MMEx	1259112007	Cerebrospinal fluid otorrhoea due to giant arachnoid granulation	Арр.
		1259113002	Cerebrospinal fluid otorrhoea due to otitis media	Арр.
		232280003	Post-traumatic cerebrospinal otorrhoea	Арр.
		232281004	Postoperative cerebrospinal otorrhoea	Арр.
		95804005	Purulent drainage from external ear canal	App.
		95803004	Serous drainage from external ear canal	Арр.

Table 45: Ear Health – Bleeding from Ear

NKPI CONDITION	CONDITION SUBGROUP	CIS	CIS CODE	CLINICAL TERM (OR GLOBAL CAREPLAN NAME)	APP./ MOVE./ BOTH		
		Best Practice	869	Bleeding from ear	App.		
		Communicare	H05001	Bleeding;ear	App.		
		Medical	ear@blee	Ear - Bleeding	Арр.		
		Director	ear@blee	Bleeding from ear	Арр.		
			26322001	Bleeding from ear	App.		
For Hoolth	Bleeding		1083791000119109	Bilateral haemotympanum	Арр. Арр. Арр.		
Ear Health	from ear		111536009	Haematotympanum	App.		
		N 4 N 4 T	1088911000119108	Haematympanum of left tympanic cavity	МОVЕ./ ВОТН Арр. Арр. Арр. Арр. Арр. Арр. Арр. Арр		
		MMEx	1091521000119102	Haematympanum of right tympanic cavity	App.		
			1089381000119105	Otorrhagia of left ear	App.		
			1091991000119109	Otorrhagia of right ear	App.		
					232249008	Traumatic haemotympanum	App.

Procedure inclusion terms

There is a limited list of terms for procedures relevant to primary care.

Note: There are no subgroups and the allocation to appearance and/or movement in this table is in column 2.

Table 46: Ear Health – Procedure Inclusion Terms

NKPI CONDITI ON	PROCEDU RE SUBGROU P	CIS	CIS CODE	CLINICAL TERM	APP./ MOVE ./ BOTH
	Communica re	H40001	Endoscopy;diagnostic;ear	App.	
			76517002	Endoscopy of ear	App.
			108164009	External ear endoscopy	Арр.
		MMEx	164770006	Magnifying otoscopy	Арр.
		IVIIVIEX	274803000	Examination of tympanic membrane (procedure)	App.
			445974009	Microscopy of middle ear	App.
		Communica re	H39007	Test;tympanometry	Move.
			91573000	Tympanometry testing	Move.
			258063008	Pneumatic otoscopy	Move.
		MMEx	278320003	Acoustic reflectometry	Move.
		IVIIVIEX	277404009	High frequency tympanometry	Move.
		91573000	Tympanometry testing	Move.	
			8245	Check ear	Both
			8245	Ear check	Both
			3593	Ear, grommet removal	Both
Ear Health	Procedure		3593	Grommet removal	Both
			7455	Grommet	Both
			3601	Myringotomy	Both
			3602	Suction myringotomy	Both
			3592	Myringotomy and ventilation tubes	Both
			7217	Myringoplasty	Both
		Best	3603	Tympanoplasty	Both
		Practice	3593	Tympanostomy tube removal	Both
			3592	Tympanostomy tube insertion	Both
			3592	Grommet insertion	Both
			3593	Grommet removal	Both
			3592	Insertion of grommets	Both
			3592	Insertion of tympanostomy tubes	Both
			3593	Removal of grommets	Both
			3593	Removal of tympanostomy tubes	Both

		3600	Tympanic membrane surgery	Both
		3600	Surgery - Ear - tympanic membrane	Both
		H30001	Check up;complete;ear	Both
		H30002	Exam;complete;ear	Both
		H30003	Assessment;complete;he aring	Both
		H51010	Myringotomy	Both
	Communica	H53003	Grommet(s)	Both
	re	H53004	Drainage tube(s);middle ear	Both
		H54006	Myringoplasty	Both
		H54007	Tympanoplasty	Both
		H72007	Otorrhoea;tympanostomy tube	Both
		surg.ear@tympm@perf	Myringoplasty	Both
		surg.ear@tympm@inci	Myringotomy	Both
		surg.ear@tympm	Tympanic membrane surgery	Both
		surg.ear@tympm@perf	Tympanoplasty	Both
		surg.ear@grom	Tympanostomy tube insertion	Both
		surg.ear@grom@remo	Tympanostomy tube removal	Both
		surg.ear@grom	Insertion of grommets	Both
		surg.ear@grom	Ear - grommet insertion	Both
		surg.ear@grom	Grommet insertion	Both
	Medical	surg.ear@grom	Surgery - Ear - Grommet insertion	Both
	Director	surg.ear@grom	Ear Grommets	Both
		surg.ear@grom	Tubes - middle ear - insertion	Both
		surg.ear@grom@remo	Removal of grommets	Both
		surg.ear@grom@remo	Ear - grommet removal	Both
		surg.ear@grom@remo	Grommet removal	Both
		surg.ear@grom@remo	Surgery - Ear - Grommet removal	Both
		surg.ear@grom@remo	Tubes - middle ear - removal	Both
		surg.ear@tympm@inci@ suct	Suction Myringotomy	Both
		surg.ear@tympm	Surgery - Ear - tympanic membrane	Both

	surg.ear@tympm@perf	Surgery - Ear - Tympanic membrane - Perforation repair	Both
	53555003	Basic comprehensive audiometry testing	Both
	396490007	Myringoplasty	Both
	75176001	Tympanectomy	Both
	397862008	Tympanostomy	Both
	397760009	Tympanotomy	Both
	397926008	Myringotomy and drainage of middle ear	Both
	172679002	Myringotomy and insertion of T tube	Both
	284532000	Myringotomy and insertion of tympanic ventilation tube	Both
MMEx	275001008	Myringotomy and insertion of long-term ventilation tube	Both
	172676009	Myringotomy and insertion of short-term tympanic ventilation tube	Both
	275002001	Removal of grommet from tympanic membrane	Both
	429440003	Insertion of tympanic ventilation tube in tympanic membrane	Both
	1156757008	Exploration of tympanic membrane	Both
	63027006	Exploration of tympanum by transtympanic route	Both

6.2 Ear Health - EXCLUDED TERMS

Table 47: Ear Health – Best Practice Excluded Conditions

NKPI CONDITION	CONDITION SUBGROUP	CIS	CIS CODE	CLINICAL TERM
			2595	Barotrauma to ear
			870	Blocked ear
CI		Best Practice	4263	Buzzing in ear Ear - Tophus
			873	
	Clinical		1339	Ear buzzing
Ear Health	Diagnosis		7542	Ear dermatitis
			1127	Ear foreign body
	5365 Ear injury	Ear injury		
			872	Ear pain
			5298	Ear polyp

4262	Ear ringing
4522	Ear wax
872	Earache
10551	Earlobe infection
856	Eustachian tube dysfunction
1127	Foreign body in ear
4832	Glomus Tympanicum
5365	Injured ear
6637	Labyrinthine positional nystagmus
1922	Labyrinthitis
13590	Myoclonus, tensor tympani
2595	Otitic barotrauma
1587	Otomycosis
5703	Otophyma
2596	Otosclerosis
872	Pain in ear
4262	Ringing in ear
13590	Tensor tympani myoclonus
1922	Viral labyrinthitis
4522	Wax in ear
713	Hearing impaired
713	Deafness
714	Deafness, conduction
715	Deafness, industrial
9410	Deafness, mixed
716	Deafness, sensorineural
713	Hearing loss
13515	Hearing loss, asymmetrical
716	Hearing loss, sensorineural
713	Loss of hearing
715	Noise induced hearing loss
1558	Hearing - Impaired
713	Impaired hearing
715	Occupational hearing loss
6245	Pili Torti-Sensorineural Hearing Loss
716	Sensorineural hearing loss
13515	Asymmetrical hearing loss
714	Conduction deafness
715	Industrial deafness
716	Sensorineural deafness
9410	Mixed deafness
13275	High frequency deafness
1925	Mastoiditis
7648	Perichondritis of the pinna
5755	Presbycusis
5756	Presbycusis
0.00	

Table 48: Ear Health – Communicare Excluded Conditions

NKPI CONDITION	CONDITION SUBGROUP	CIS	CIS CODE	CLINICAL TERM
			H01001	Earache
			H01002	Pain;ear
			H01005	Pain;mastoid area
			H01007	Otalgia
			H02007	Hyperacusis
			H02008	Disorder;auditory discriminati
			H02009	Diplacusis
			H03001	Buzzing (in);ear
			H03003	Noises in;ear
			H03004	Ringing (in);ear
			H03006	Tinnitus
			H03007	Abnormal;sensation;hearing
			H03008	Echo in;ear
			H13001	Congestion;ear
			H13002	Blocked;ear
			H13004	Clogged;ear
			H13005	Plugged feeling;ear
			H15001	Abnormal;ear;shape
			H15002	Abnormal;ear;size
			H15003	Abnormal;ear;sticking out
			H15007	Concern;appearance;ear
Ear Health	Clinical Diagnosis	Communicare	H27001	Fear (of);deafness
	Diagnosis		H27002	Fear (of);disease;ear
			H29001	Crackling;ear
			H29002	Itching;ear
			H29003	Picking at;ear
			H29004	Popping;ear
			H29005	Pulling at;ear
			H29007	Abnormal;sensation;ear
			H29010	Sympt/complaint;ear
			H29011	Pressure;ear
			H29012	Problem;ear
			H70001	Eczema;ext auditory meatus
			H70006	Tropical ear
			H70007	Boil;external auditory meatus
			H70008	Otomycosis
			H71018	Abscess;ear
			H71019	Mastoiditis
			H73001	Blocked;eustachian tube
			H73002	Dysfunction; eustachian tube
			H73003	Catarrh;eustachian tube
			H73004	Infection;eustachian tube
			H73005	Obstruction; eustachian tube

H74008 Mastoididis;chronic H75001 Neoplasm benign;ear H75002 Neoplasm malig;ear H75003 Carcinoma;ear H75006 Neoplasm;ear H75006 Neoplasm;ear H75007 Neoplasm;ear H75001 Foreign body (in);ear H76001 Injury;ear;superficial H79001 Injury;ear;superficial H79002 Injury;ear;deep H79002 Injury;ear;deep H80001 Accessory auricle H80002 Cyst;branchial H80003 Darwins tubercle H80004 Congenital anomaly;ear H80005 Bat ear H81001 Excessive;cerumen H81001 Excessive;cerumen H81002 Excessive;ear wax H82001 Disorder;labyrinth H82002 Disorder;vestibular system H82004 Vertigio, sur H82006 Vertigio, sur H82006 Vertigio, sur H82007 Vertigo; denieres H82009 Vertigo; otogenic H82010 Labyrinthitis H82011 Vestibuliris; ear H82014 Neuronitis; ear H82014 Neuronitis; ear H82014 Neuronitis; ear H82014 Presbycusis H82014 Presbycusis H82015 Presbycusis H84001 Presbycusis Presbycusis H84001 Presbycusis	H73006	Salpingitis;eustachian
H75001 Neoplasm benign;ear H75002 Neoplasm malig;ear H75003 Carcinoma;ear H75006 Neoplasm;ear H75007 Neoplasm;uncert nature;ear H76001 Foreign body (in);ear H78001 Injury;ear;superficial H79001 Barotrauma;ear H79002 Injury;ear H79004 Injury;pinna H79005 Injury;ear,deep H80001 Accessory auricle H80002 Cyst;branchial H80003 Darwins tubercle H80004 Congenital anomaly;ear H81006 Bat ear H81007 Excessive;cerumen H81008 Excessive;cerumen H81009 Excessive;cerumen H82000 Disorder,labyrinth H82001 Disorder,labyrinth H82002 Disorder,vestibular system H82004 Vertig;oarral H82006 Vertig;orarral H82007 Vertig;oarral H82008 Vertig;of,Menieres H82010 Labyrinthitis H82011 Vestibulitis;ear H82012 Vestibular neuritis H82013 Vertig;obenign positional H82014 Neuronitis;vestibular H82015 Presbycusis H84001 Presbycusis;enile H84002 Presbycusis H99004 Polyp(s);ear(s) H99005 Disease;ear H99006 Dysfunction,middle ear		
H75002 Neoplasm malig;ear H75003 Carcinoma;ear H75006 Neoplasm;ear H75007 Neoplasm;uncert nature;ear H76001 Foreign body (in);ear H76001 Foreign body (in);ear H76001 Harotrauma;ear H79001 Barotrauma;ear H79002 Injury;ears.uperficial H79004 Injury;pinna H79005 Injury;ear H80001 Accessory auricle H80002 Cyst;branchial H80003 Darwins tubercle H80004 Congenital anomaly;ear H80005 Bat ear H810001 Excessive;ear wax H82001 Disorder;labyrinth H82002 Disorder;vestibular system H82003 Vertigious syndrome H82004 Vertiginous syndrome H82007 Vertigo;aural H82008 Vertigio;totgenic H82010 Labyrinthitis H82011 Labyrinthitis H82012 Vestibular neurilis H82013 Vertigo;benign positional H82014 Neuronitis;vestibular H82015 Presbycusis H84001 Presbycusis H84001 Presbycusis H84001 Presbycusis H84001 Presbycusis H84001 Presbycusis H84001 Disease;ear H99004 Polyp(s);ear(s) H99005 Disease;ear H99006 Dysfunction;middle ear		
H75003 Carcinoma;ear	-	· · ·
H75006 Neoplasm;uncert nature;ear		
H75007 Neoplasm;uncert nature;ear H76001 Foreign body (in);ear H78001 Injury;ear;superficial H79001 Barotrauma;ear H79002 Injury;ear;deep H79002 Injury;ear;deep H80001 Accessory auricle H80002 Cyst;branchial H80003 Darwins tubercle H80004 Congenital anomaly;ear H80005 Bat ear H81001 Excessive;cerumen H81002 Excessive;cerumen H81002 Excessive;ear wax H82001 Disorder;labyrinth H82002 Disorder;vestibular system H82003 Disease;Menieres H82006 Vertigo;usural H82007 Vertigo;aural H82008 Vertigo;usural H82009 Vertigo;usural H82009 Vertigo;usperic H82011 Vestibulitis;ear H82011 Vestibulitis;ear H82012 Vestibular neuritis H82014 Neuronitis;vestibular H82014 Neuronitis;vestibular H83001 Presbycusis H84001 Presbycusis H84001 Presbycusis H84001 Presbycusis H84001 Presbycusis H84001 Presbycusis H85001 Trauma;acoustic H99004 Polyp(s);ear(s) Disease;ear H99006 Dysfunction;middle ear H99006 H99006 Dysfunction;middle ear H99006 Dysfunction;m		
H76001 Foreign body (in);ear H78001 Injury;ear;superficial H79001 Barotrauma;ear H79002 Injury;ear H79002 Injury;ear H79004 Injury;ear,deep H80001 Accessory auricle H80002 Cyst;branchial H80003 Darwins tubercle H80004 Congenital anomaly;ear H80005 Bat ear H81001 Excessive;cerumen H81002 Excessive;cerumen H81002 Excessive;ear wax H82001 Disorder;labyrinth H82002 Disorder;restibular system H82003 Disease;Menieres H82006 Vertigo;aural H82007 Vertigo;aural H82009 Vertigo;aural H82009 Vertigo;denieres H82009 Vertigo;denieres H82010 Labyrinthitis H82011 Vestibulitis;ear H82012 Vestibuliar neuritis H82014 Neuronitis;vestibular H82014 Neuronitis;vestibular H82014 Neuronitis;vestibular H82014 Presbycusis H84001 Presbycusis;senile H84001 Presbycusis;senile H85001 Trauma;acoustic H99004 Polyp(s);ear(s) H99005 Disease;ear H99006 Dysfunction;middle ear	-	· · · · · · · · · · · · · · · · · · ·
H78001		
H79001 Barotrauma,ear H79002 Injury;ear H79004 Injury;ear H79004 Injury;ear H79005 Injury;ear;deep H80001 Accessory auricle H80002 Cyst,branchial H80003 Darwins tubercle H80004 Congenital anomaly;ear H80005 Bat ear H81001 Excessive;cerumen H81001 Excessive;cerumen H82001 Disorder; estibular system H82002 Disorder; estibular system H82003 Disease; Menieres H82006 Vertiginous syndrome H82007 Vertigo; aural H82008 Vertigo; Menieres H82009 Vertigo; otogenic H82010 Labyrinthitis H82011 Vestibulitis; ear H82012 Vestibular neuritis H82013 Vertigo; benign positional H82014 Neuronitis; vestibular H82014 Neuronitis; vestibular H83001 Presbycusis; senile H84001 Presbycusis; senile H84002 Presbycusis H85001 Trauma; acoustic H99004 Polyp(s); ear(s) H99005 Disease; ear H99006 Dysfunction; middle ear		
H79002	-	
H79004		
H79005		
H80001 Accessory auricle		
H80002 Cyst;branchial H80003 Darwins tubercle H80004 Congenital anomaly;ear H80005 Bat ear H81001 Excessive;cerumen H81002 Excessive;ear wax H82001 Disorder;labyrinth H82002 Disorder;vestibular system H82003 Disease;Menieres H82006 Vertigo;oural H82007 Vertigo;aural H82008 Vertigo;denieres H82009 Vertigo;otogenic H82010 Labyrinthitis H82011 Vestibulitis;ear H82012 Vestibular neuritis H82013 Vertigo;benign positional H82014 Neuronitis;vestibular H82014 Neuronitis;vestibular H83001 Otosclerosis H84001 Presbycusis H84001 Trauma;acoustic H99004 Polyp(s);ear(s) H99005 Disease;ear H99006 Dysfunction;middle ear		
H80003 Darwins tubercle		
H80004 Congenital anomaly;ear		
H80005 Bat ear H81001 Excessive;cerumen H81002 Excessive;ear wax H82001 Disorder;labyrinth H82002 Disorder;vestibular system H82003 Disease;Menieres H82006 Vertiginous syndrome H82007 Vertigo;aural H82008 Vertigo;Menieres H82009 Vertigo;otogenic H82010 Labyrinthitis H82011 Vestibulitis;ear H82012 Vestibular neuritis H82013 Vertigo;benign positional H82014 Neuronitis;vestibular H83001 Otosclerosis H84001 Presbycusis;senile H84002 Presbycusis H85001 Trauma;acoustic H99004 Polyp(s);ear(s) H99005 Disease;ear H99006 Dysfunction;middle ear		
H81001 Excessive;cerumen H81002 Excessive;ear wax H82001 Disorder;labyrinth H82002 Disorder;vestibular system H82003 Disease;Menieres H82006 Vertiginous syndrome H82007 Vertigo;aural H82008 Vertigo;Menieres H82009 Vertigo;otogenic H82010 Labyrinthitis H82011 Vestibulitis;ear H82012 Vestibular neuritis H82013 Vertigo;benign positional H82014 Neuronitis;vestibular H83001 Otosclerosis H84001 Presbycusis;senile H84002 Presbycusis H85001 Trauma;acoustic H99004 Polyp(s);ear(s) H99005 Disease;ear H99006 Dysfunction;middle ear		
H81002 Excessive;ear wax H82001 Disorder;labyrinth H82002 Disorder;vestibular system H82003 Disease;Menieres H82006 Vertiginous syndrome H82007 Vertigo;aural H82008 Vertigo;Menieres H82009 Vertigo;otogenic H82010 Labyrinthitis H82011 Vestibulitis;ear H82012 Vestibular neuritis H82013 Vertigo;benign positional H82014 Neuronitis;vestibular H83001 Otosclerosis H84001 Presbycusis;senile H84002 Presbycusis H85001 Trauma;acoustic H99004 Polyp(s);ear(s) H99005 Disease;ear H99006 Dysfunction;middle ear		
H82001 Disorder;labyrinth H82002 Disorder;vestibular system H82003 Disease;Menieres H82006 Vertiginous syndrome H82007 Vertigo;aural H82008 Vertigo;Menieres H82009 Vertigo;otogenic H82010 Labyrinthitis H82011 Vestibulitis;ear H82012 Vestibular neuritis H82013 Vertigo;benign positional H82014 Neuronitis;vestibular H83001 Otosclerosis H84001 Presbycusis;senile H84002 Presbycusis H85001 Trauma;acoustic H99004 Polyp(s);ear(s) H99005 Disease;ear H99006 Dysfunction;middle ear		
H82002 Disorder;vestibular system H82003 Disease;Menieres H82006 Vertiginous syndrome H82007 Vertigo;aural H82008 Vertigo;Menieres H82009 Vertigo;otogenic H82010 Labyrinthitis H82011 Vestibulitis;ear H82012 Vestibular neuritis H82013 Vertigo;benign positional H82014 Neuronitis;vestibular H83001 Otosclerosis H84001 Presbycusis;senile H84002 Presbycusis H85001 Trauma;acoustic H99004 Polyp(s);ear(s) H99005 Disease;ear H99006 Dysfunction;middle ear		
H82003 Disease;Menieres		
H82006 Vertiginous syndrome H82007 Vertigo;aural H82008 Vertigo;Menieres H82009 Vertigo;otogenic H82010 Labyrinthitis H82011 Vestibulitis;ear H82012 Vestibular neuritis H82013 Vertigo;benign positional H82014 Neuronitis;vestibular H83001 Otosclerosis H84001 Presbycusis;senile H84002 Presbycusis H85001 Trauma;acoustic H99004 Polyp(s);ear(s) H99005 Disease;ear H99006 Dysfunction;middle ear		·
H82007 Vertigo; aural H82008 Vertigo; Menieres H82009 Vertigo; otogenic H82010 Labyrinthitis H82011 Vestibulitis; ear H82012 Vestibular neuritis H82013 Vertigo; benign positional H82014 Neuronitis; vestibular H83001 Otosclerosis H84001 Presbycusis; senile H84002 Presbycusis H85001 Trauma; acoustic H99004 Polyp(s); ear(s) H99005 Disease; ear H99006 Dysfunction; middle ear		
H82008 Vertigo;Menieres H82009 Vertigo;otogenic H82010 Labyrinthitis H82011 Vestibulitis;ear H82012 Vestibular neuritis H82013 Vertigo;benign positional H82014 Neuronitis;vestibular H83001 Otosclerosis H84001 Presbycusis;senile H84002 Presbycusis H85001 Trauma;acoustic H99004 Polyp(s);ear(s) H99005 Disease;ear H99006 Dysfunction;middle ear		
H82009 Vertigo;otogenic H82010 Labyrinthitis H82011 Vestibulitis;ear H82012 Vestibular neuritis H82013 Vertigo;benign positional H82014 Neuronitis;vestibular H83001 Otosclerosis H84001 Presbycusis;senile H84002 Presbycusis H85001 Trauma;acoustic H99004 Polyp(s);ear(s) H99005 Disease;ear H99006 Dysfunction;middle ear		
H82010 Labyrinthitis H82011 Vestibulitis;ear H82012 Vestibular neuritis H82013 Vertigo;benign positional H82014 Neuronitis;vestibular H83001 Otosclerosis H84001 Presbycusis;senile H84002 Presbycusis H85001 Trauma;acoustic H99004 Polyp(s);ear(s) H99005 Disease;ear H99006 Dysfunction;middle ear		
H82011 Vestibulitis;ear H82012 Vestibular neuritis H82013 Vertigo;benign positional H82014 Neuronitis;vestibular H83001 Otosclerosis H84001 Presbycusis;senile H84002 Presbycusis H85001 Trauma;acoustic H99004 Polyp(s);ear(s) H99005 Disease;ear H99006 Dysfunction;middle ear		
H82012 Vestibular neuritis H82013 Vertigo;benign positional H82014 Neuronitis;vestibular H83001 Otosclerosis H84001 Presbycusis;senile H84002 Presbycusis H85001 Trauma;acoustic H99004 Polyp(s);ear(s) H99005 Disease;ear H99006 Dysfunction;middle ear		-
H82013 Vertigo;benign positional H82014 Neuronitis;vestibular H83001 Otosclerosis H84001 Presbycusis;senile H84002 Presbycusis H85001 Trauma;acoustic H99004 Polyp(s);ear(s) H99005 Disease;ear H99006 Dysfunction;middle ear		
H82014 Neuronitis;vestibular H83001 Otosclerosis H84001 Presbycusis;senile H84002 Presbycusis H85001 Trauma;acoustic H99004 Polyp(s);ear(s) H99005 Disease;ear H99006 Dysfunction;middle ear		
H83001 Otosclerosis H84001 Presbycusis;senile H84002 Presbycusis H85001 Trauma;acoustic H99004 Polyp(s);ear(s) H99005 Disease;ear H99006 Dysfunction;middle ear		
H84001 Presbycusis;senile H84002 Presbycusis H85001 Trauma;acoustic H99004 Polyp(s);ear(s) H99005 Disease;ear H99006 Dysfunction;middle ear		
H84002 Presbycusis H85001 Trauma;acoustic H99004 Polyp(s);ear(s) H99005 Disease;ear H99006 Dysfunction;middle ear	H03001	Otoscierosis
H85001 Trauma;acoustic H99004 Polyp(s);ear(s) H99005 Disease;ear H99006 Dysfunction;middle ear	H84001	Presbycusis;senile
H99004 Polyp(s);ear(s) H99005 Disease;ear H99006 Dysfunction;middle ear	H84002	Presbycusis
H99005 Disease;ear H99006 Dysfunction;middle ear	H85001	Trauma;acoustic
H99006 Dysfunction;middle ear	H99004	Polyp(s);ear(s)
	H99005	Disease;ear
H99007 Perichondritis;ear	H99006	Dysfunction;middle ear
	H99007	Perichondritis;ear

	H99008	Infection;ear
	H99009	Inflammation;ear
	H99010	Stenosis;external canal;ear
	H99011	Chondrodermatitis nodularis
	H02001	Unable (to);hear
	H02002	Disturbed;hearing
	H02003	Diminished;hearing
	H02004	Loss (of);hearing
	H02006	Problem;hearing
	H28001	Disability;hearing
	H28002	Impairment;hearing
	H28003	Deafness;temporary
	H28004	Deafness;partial;one ear
	H28005	Deafness;total;one ear
	H28006	Deafness;one ear
	H28007	Limited function;ear
	H85002	Deafness;noise induced
	H86001	Deaf mutism
	H86002	Deafness;sensorineural
	H86003	Deafness
	H86004	Deafness;conductive
	H86005	Deafness;mixed
	H86007	Deafness;partial;bilateral
	H86008	Deafness;total;bilateral
	H86009	Deafness;congenital

Table 49: Ear Health – Medical Director Excluded Conditions

NKPI CONDITION	CONDITION SUBGROUP	CIS	CIS CODE	CLINICAL TERM
		hear@buzz	Ear - buzzing	
		Medical Director	tinn	ear ringing
Ear Health Clinical Diagnosi	Clinical		tinn@symp	buzzing in ear
	Diagnosis		ear@pain	Ear - Pain
			ear@toph	Ear - Tophus

	ear@tophus	Ear - Tophus
	ear@bloc	Ear blockage
	ear@bloc@feel	Ear blocked feeling
	foreb.ear	Ear foreign body
	ear@itch	Ear itch
	ear@pain	Ear pain
	hear@buzz	Ear ringing
	surg.ear	Ear surgery
	otitm@baro	Barotrauma;ear
	inju.ear	Ear trauma
	wax.ear	Ear wax
	ear@pain	Earache
	dysf.eustt	Eustachian tube dysfunction
	paragang.ear	Glomus Tympanicum
	infl.laby	Labyrinthitis
	infe.ear <fung< td=""><td>Otomycosis</td></fung<>	Otomycosis
	otos	Otosclerosis
	otos@preg	Otosclerosis during pregnancy
	otos@preg	Otosclerosis of pregnancy
	otos@preg	Pregnancy Otosclerosis
	infl.laby	Viral labyrinthitis
	deaf	Hearing loss
	deaf@cond	Conduction deafness
	deaf	Deafness
	deaf@cond	Deafness - conduction
	deaf@cong	Deafness - congenital
	deaf@deve	Deafness - developmental
	deaf@fami	Deafness - familial
	deaf@idio	Deafness - idiopathic
	deaf@sensn	Deafness - sensorineural
	hear*	Hearing - abnormal
	impa@hear	Hearing - Impaired
	deaf	Hearing Disorder(s) - Deafness
	deaf	Hearing impaired
	deaf@sensn	Sensorineural deafness
	deaf	Impaired hearing
	deaf@occu	Occupational hearing loss
	deaf@occu	Deafness - industrial
	deaf@occu	Industrial deafness
	infl.mast	Mastoiditis

	perichon	Perichondritis
	perichon.ear	Chondrodermatitis nodularis helicis
	perichon.ear	Perichondritis - of pinna
	presbyac	Presbycusis

Table 50: Ear Health – MMEx Excluded Conditions

NKPI CONDITIO N	CONDITION SUBGROU P	CIS	SNOMED CODE	CLINICAL TERM
			232212002	Abscess of external ear
			55989009	Acquired stenosis of external ear canal
			194268005	Acute eustachian tube salpingitis
			386034005	Acute mastoiditis
			232270002	Acute mastoiditis with labyrinthitis
			45855004	Acute perichondritis of pinna
			419957005	Allergic contact dermatitis of external auditory canal
			419121001	Allergic contact dermatitis of pinna
			302905001	Aspergillus otomycosis
			232308006	Autoimmune disorder of inner ear
			1088321000119100	Autoimmune disorder of left inner ear
			1090931000119100	Autoimmune disorder of right inner ear
			111541001	Benign paroxysmal positional vertigo
Ear Health	Clinical	MMEx	1082911000119100	Bilateral acute eustachian salpingitis
Lai Health	Diagnosis	IVIIVIEX	1083291000119100	Bilateral chronic perichondritis of external ears
			1083521000119100	Bilateral dermatitis of external ear canals
			1083251000119100	Bilateral ears chondrodermatitis nodularis helicis
			1083711000119100	Bilateral external ears chondritis
			1083951000119100	Bilateral inflammation of labyrinth structures
			1084711000119100	Bilateral inflammation of labyrinth structures caused by virus
			1083731000119100	Bilateral perichondritis of external ears
			63767001	Carbuncle of ear
			232214001	Cellulitis of pinna
			1088841000119100	Chondritis of left external ear
			1091451000119100	Chondritis of right external ear
			402699002	Chondrodermatitis nodularis
			76583009	Chondrodermatitis nodularis helicis

1088381000119100 left ear 1090991000119100 Chondrodermatitis nodularis helicis of right ear 403432008 Chondrodermatitis nodularis of antihelix 403433003 Chondrodermatitis nodularis of tragus 427348001 Chronic eczema of external auditory canal 194269002 Chronic eustachian tube salpingitis 737147003 Chronic inflammation of mastoid cavity 80645004 Chronic perichondritis of left external ear 45431004 Chronic perichondritis of pinna 1091031000119100 Chronic perichondritis of pinna 1091031000119100 Chronic perichondritis of pinna 1091031000119100 Chronic perichondritis of right external ear 61794006 Circumscribed labyrinthitis 91108004 Cochlear otosclerosis 724635009 Contact dermatitis of external ear 427404005 Dermatitis of external auditory canal 402698005 Dermatitis of external ear canal 1091261000119100 Dermatitis of left external ear canal 1091261000119100 Dermatitis of left external ear canal 89537006 Diffuse labyrinthitis 77949003 Disorders of acoustic nerve 95809000 Eczema of earlobe 95812002 Eczema of external auditory canal 232311007 Endocochlear cytomegalovirus infection 69494008 Eustachian tube disorder 270491006 Eustachian tube disorder 270491006 Eustachian tube salpingitis 71591001 Furuncle of ear 194204009 Furunculosis of external auditory meatus 271946002 Granulations of mastoid cavity 21954000 Herpes zoster auricularis 18070006 Impacted cerumen 1089011000119100 Inflammation of left labyrinth structure 1091621000119100 Inflammation of of external ear 5239005 Labyrinthitis ossificans 1088021000119100 Left acute eustachian salpingitis			Chondrodermatitis nodularis helicis of
right ear 403432008 Chondrodermatitis nodularis of antihelix 403433003 Chondrodermatitis nodularis of tragus Chronic eczema of external auditory canal 194269002 Chronic eustachian tube salpingitis 737147003 Chronic mastoiditis Chronic perichondritis of left external ear 45431004 Chronic perichondritis of left external ear 45431004 Chronic perichondritis of pinna Chronic perichondritis of right external ear 61794006 Circumscribed labyrinthitis 91108004 Cochlear otosclerosis 724635009 Contact dermatitis of external ear 427404005 Dermatitis of external ear 1088651000119100 Dermatitis of left external ear canal 1091261000119100 Dermatitis of ight external ear canal 1091261000119100 Dermatitis of ight external ear canal 89537006 Diffuse labyrinthitis 77949003 Disorders of acoustic nerve 95809000 Eczema of earlobe 95812002 Eczema of earlobe 95812002 Eczema of external auditory canal Endocochlear cytomegalovirus infection 69494008 Eustachian tube disorder 270491006 Eustachian tube disorder 270491006 Eustachian tube disorder 270491006 Eustachian tube salpingitis 71591001 Furuncle of ear 194204009 Furunculosis of external auditory meatus 271946002 Granulations of mastoid cavity 21954000 Herpes zoster auricularis 18070006 Impacted cerumen 1089011000119100 Inflammation of left labyrinth structure 1091621000119100 Inflammation of right labyrinth structure 788971005 Irritant contact dermatitis of external ear 5239005 Labyrinthitis 449832007 Labyrinthitis ossificans		1088381000119100	left ear
antihelix 403433003 Chondrodermatitis nodularis of tragus Chronic eczema of external auditory canal 194269002 Chronic eustachian tube salpingitis Chronic inflammation of mastoid cavity 80645004 Chronic mastoiditis 1088421000119100 Chronic perichondritis of left external ear 45431004 Chronic perichondritis of pinna Chronic perichondritis of right external ear 61794006 Circumscribed labyrinthitis 91108004 Cochlear otosclerosis 724635009 Contact dermatitis of external ear 427404005 Dermatitis of external ear 1088651000119100 Dermatitis of ight external ear 1088651000119100 Dermatitis of ight external ear canal 1091261000119100 Dermatitis of right external ear canal 89537006 Diffuse labyrinthitis 77949003 Disorders of acoustic nerve 95809000 Eczema of earlobe 95812002 Eczema of external auditory canal 232311007 Endocochlear cytomegalovirus infection 69494008 Eustachian tube disorder 270491006 Eustachian tube disorder 270491006 Eustachian tube salpingitis 71591001 Furuncle of ear 194204009 Furunculosis of external auditory meatus 271946002 Granulations of mastoid cavity 1954000 Herpes zoster auricularis 18070006 Impacted cerumen 1089011000119100 Inflammation of left labyrinth structure 1091621000119100 Inflammation of right labyrinth structure 1091621000119100 Irritant contact dermatitis of external ear 5239005 Labyrinthine dysfunction 66410001 Labyrinthine fistula of combined sites 23919004 Labyrinthitis ossificans		1090991000119100	
427348001 Chronic eczema of external auditory canal 194269002 Chronic eustachian tube salpingitis 737147003 Chronic inflammation of mastoid cavity 80645004 Chronic mastoiditis 1088421000119100 ear 45431004 Chronic perichondritis of left external ear 61794006 Circumscribed labyrinthitis 91108004 Cochlear otosclerosis 724635009 Contact dermatitis of external ear 427404005 Dermatitis of external auditory canal 402698005 Dermatitis of external ear canal 1091261000119100 Dermatitis of right external ear canal 1091261000119100 Dermatitis of external ear canal 89537006 Diffuse labyrinthitis 77949003 Disorders of acoustic nerve 95809000 Eczema of earlobe 95812002 Eczema of external auditory canal 232311007 Endocochlear cytomegalovirus infection 69494008 Eustachian tube disorder 270491006 Eustachian tube salpingitis 71591001 Furuncle of ear 194204009 Furunculosis of external auditory meatus 271946002 Granulations of mastoid cavity 21954000 Herpes zoster auricularis 18070006 Impacted cerumen 1089011000119100 Inflammation of left labyrinth structure 1091621000119100 Inflammation of right labyrinth structure 1091621000119100 Inflammation of right labyrinth structure 1091621000119100 Inflammation of right labyrinth structure 1091621000119100 Labyrinthine fistula of combined sites 23919004 Labyrinthitis		403432008	
194269002 Chronic eustachian tube salpingitis Chronic inflammation of mastoid cavity 80645004 Chronic mastoiditis 1088421000119100 Chronic perichondritis of left external ear 45431004 Chronic perichondritis of pinna Chronic perichondritis of right external ear 61794006 Circumscribed labyrinthitis 91108004 Cochlear otosclerosis 724635009 Contact dermatitis of external ear 427404005 Dermatitis of external ear 1088651000119100 Dermatitis of left external ear canal 1091261000119100 Dermatitis of left external ear canal 1091261000119100 Dermatitis of left external ear canal 89537006 Diffuse labyrinthitis 77949003 Disorders of acoustic nerve 95809000 Eczema of earlobe 95812002 Eczema of earlobe 95812002 Eczema of external auditory canal 232311007 Endocochlear cytomegalovirus infection 69494008 Eustachian tube disorder 270491006 Eustachian tube disorder 270491006 Eustachian tube salpingitis 71591001 Furuncle of ear 194204009 Furunculosis of external auditory meatus 271946002 Granulations of mastoid cavity 21954000 Herpes zoster auricularis 18070006 Impacted cerumen 1089011000119100 Inflammation of left labyrinth structure 1091621000119100 Inflammation of right labyrinth structure 1091621000119100 Inflammation of right labyrinth structure 1091621000119100 Inflammation of right labyrinth structure 1091621000119100 Inflammation of studios of external ear 1091621000119100 Inflammation of right labyrinth structure 1091621000119100 Labyrinthine dysfunction 66410001 Labyrinthine fistula of combined sites 23919004 Labyrinthitits		403433003	Chondrodermatitis nodularis of tragus
Chronic inflammation of mastoid cavity 80645004 Chronic mastoiditis 1088421000119100 Chronic perichondritis of left external ear 45431004 Chronic perichondritis of pinna 1091031000119100 Chronic perichondritis of right external ear 61794006 Circumscribed labyrinthitis 91108004 Cochlear otosclerosis 724635009 Contact dermatitis of external ear 427404005 Dermatitis of external auditory canal 402698005 Dermatitis of external ear 1088651000119100 Dermatitis of left external ear canal 1091261000119100 Dermatitis of right external ear canal 89537006 Diffuse labyrinthitis 77949003 Disorders of acoustic nerve 95809000 Eczema of earlobe 95812002 Eczema of external auditory canal 232311007 Endocochlear cytomegalovirus infection 69494008 Eustachian tube disorder 270491006 Eustachian tube salpingitis 71591001 Furuncle of ear 194204009 Furunculosis of external auditory meatus 271946002 Granulations of mastoid cavity Herpes zoster auricularis 18070006 Impacted cerumen 1089011000119100 Inflammation of left labyrinth structure 191621000119100 Inflammation of right labyrinth structure 1091621000119100 Inflammation of right labyrinth structure 123919004 Labyrinthitis ossificans		427348001	
Cavity		194269002	Chronic eustachian tube salpingitis
1088421000119100 Chronic perichondritis of left external ear 45431004 Chronic perichondritis of pinna 1091031000119100 Chronic perichondritis of right external ear 61794006 Circumscribed labyrinthitis 91108004 Cochlear otosclerosis 724635009 Contact dermatitis of external ear 427404005 Dermatitis of external auditory canal 402698005 Dermatitis of external ear canal 1091261000119100 Dermatitis of right external ear canal 1091261000119100 Dermatitis of right external ear canal 89537006 Diffuse labyrinthitis 77949003 Disorders of acoustic nerve 95809000 Eczema of earlobe 95812002 Eczema of external auditory canal 232311007 Endocochlear cytomegalovirus infection 69494008 Eustachian tube disorder 270491006 Eustachian tube salpingitis 71591001 Furuncle of ear 194204009 Furunculosis of external auditory meatus 271946002 Granulations of mastoid cavity 21954000 Herpes zoster auricularis 18070006 Impacted cerumen 1089011000119100 Inflammation of left labyrinth structure 1091621000119100 Inflammation of right labyrinth structure 1091621000119100 Iritant contact dermatitis of external ear 5239005 Labyrinthine dysfunction 66410001 Labyrinthitis 449832007 Labyrinthitis ossificans		737147003	
45431004 Chronic perichondritis of pinna 1091031000119100 Chronic perichondritis of right external ear 61794006 Circumscribed labyrinthitis 91108004 Cochlear otosclerosis 724635009 Contact dermatitis of external ear 427404005 Dermatitis of external auditory canal 402698005 Dermatitis of left external ear canal 1091261000119100 Dermatitis of left external ear canal 1091261000119100 Dermatitis of ight external ear canal 89537006 Diffuse labyrinthitis 77949003 Disorders of acoustic nerve 95809000 Eczema of earlobe 95812002 Eczema of external auditory canal 232311007 Endocochlear cytomegalovirus infection 69494008 Eustachian tube disorder 270491006 Eustachian tube salpingitis 71591001 Furuncle of ear 194204009 Furunculosis of external auditory meatus 271946002 Granulations of mastoid cavity 21954000 Herpes zoster auricularis 18070006 Impacted cerumen 1089011000119100 Inflammation of left labyrinth structure 1091621000119100 Inflammation of right labyrinth structure 788971005 Irritant contact dermatitis of external ear 5239005 Labyrinthine fistula of combined sites 23919004 Labyrinthitis Labyrinthitis		80645004	Chronic mastoiditis
1091031000119100 Chronic perichondritis of right external ear 61794006 Circumscribed labyrinthitis 91108004 Cochlear otosclerosis 724635009 Contact dermatitis of external ear 427404005 Dermatitis of external auditory canal 402698005 Dermatitis of left external ear canal 1088651000119100 Dermatitis of left external ear canal 1091261000119100 Dermatitis of right external ear canal 89537006 Diffuse labyrinthitis 77949003 Disorders of acoustic nerve 95809000 Eczema of earlobe 95812002 Eczema of external auditory canal 232311007 Endocochlear cytomegalovirus infection 69494008 Eustachian tube disorder 270491006 Eustachian tube salpingitis 71591001 Furuncle of ear 194204009 Furunculosis of external auditory meatus 271946002 Granulations of mastoid cavity 18070006 Impacted cerumen 1089011000119100 Inflammation of left labyrinth structure 1091621000119100 Inflammation of right labyrinth structure 788971005 Irritant contact dermatitis of external ear 5239005 Labyrinthine dysfunction 66410001 Labyrinthitis 449832007 Labyrinthitis ossificans		1088421000119100	•
external ear 61794006 Circumscribed labyrinthitis 91108004 Cochlear otosclerosis 724635009 Contact dermatitis of external ear 427404005 Dermatitis of external auditory canal 402698005 Dermatitis of left external ear canal 1088651000119100 Dermatitis of left external ear canal 1091261000119100 Dermatitis of right external ear canal 89537006 Diffuse labyrinthitis 77949003 Disorders of acoustic nerve 95809000 Eczema of earlobe 95812002 Eczema of external auditory canal 232311007 Endocochlear cytomegalovirus infection 69494008 Eustachian tube disorder 270491006 Eustachian tube salpingitis 71591001 Furuncle of ear 194204009 Furunculosis of external auditory meatus 271946002 Granulations of mastoid cavity 18070006 Impacted cerumen 1089011000119100 Inflammation of left labyrinth structure 1091621000119100 Inflammation of right labyrinth structure 788971005 Irritant contact dermatitis of external ear 5239005 Labyrinthine dysfunction 66410001 Labyrinthitis 449832007 Labyrinthitis ossificans		45431004	Chronic perichondritis of pinna
91108004 Cochlear otosclerosis 724635009 Contact dermatitis of external ear 427404005 Dermatitis of external auditory canal 402698005 Dermatitis of external ear 1088651000119100 Dermatitis of left external ear canal 1091261000119100 Dermatitis of right external ear canal 89537006 Diffuse labyrinthitis 77949003 Disorders of acoustic nerve 95809000 Eczema of earlobe 95812002 Eczema of external auditory canal Endocochlear cytomegalovirus infection 69494008 Eustachian tube disorder 270491006 Eustachian tube salpingitis 71591001 Furuncle of ear 194204009 Furunculosis of external auditory meatus 271946002 Granulations of mastoid cavity 21954000 Herpes zoster auricularis 18070006 Impacted cerumen 1089011000119100 Inflammation of left labyrinth structure 1091621000119100 Inflammation of right labyrinth structure 788971005 Irritant contact dermatitis of external ear 5239005 Labyrinthine dysfunction 66410001 Labyrinthitis 449832007 Labyrinthitis ossificans		1091031000119100	
724635009 Contact dermatitis of external ear 427404005 Dermatitis of external auditory canal 402698005 Dermatitis of external ear 1088651000119100 Dermatitis of left external ear canal 1091261000119100 Dermatitis of right external ear canal 89537006 Diffuse labyrinthitis 77949003 Disorders of acoustic nerve 95809000 Eczema of earlobe 95812002 Eczema of external auditory canal 232311007 Endocochlear cytomegalovirus infection 69494008 Eustachian tube disorder 270491006 Eustachian tube salpingitis 71591001 Furuncle of ear 194204009 Furunculosis of external auditory meatus 271946002 Granulations of mastoid cavity 21954000 Herpes zoster auricularis 18070006 Impacted cerumen 1089011000119100 Inflammation of left labyrinth structure 1091621000119100 Inflammation of right labyrinth structure 1091621000119100 Irritant contact dermatitis of external ear 5239005 Labyrinthine dysfunction 66410001 Labyrinthine fistula of combined sites 23919004 Labyrinthitis		61794006	Circumscribed labyrinthitis
427404005 Dermatitis of external auditory canal 402698005 Dermatitis of external ear 1088651000119100 Dermatitis of left external ear canal 1091261000119100 Dermatitis of right external ear canal 89537006 Diffuse labyrinthitis 77949003 Disorders of acoustic nerve 95809000 Eczema of earlobe 95812002 Eczema of external auditory canal 232311007 Endocochlear cytomegalovirus infection 69494008 Eustachian tube disorder 270491006 Eustachian tube salpingitis 71591001 Furuncle of ear 194204009 Furunculosis of external auditory meatus 271946002 Granulations of mastoid cavity 21954000 Herpes zoster auricularis 18070006 Impacted cerumen 1089011000119100 Inflammation of left labyrinth structure 1091621000119100 Inflammation of right labyrinth structure 788971005 Irritant contact dermatitis of external ear 5239005 Labyrinthine dysfunction 66410001 Labyrinthitis 449832007 Labyrinthitis ossificans		91108004	Cochlear otosclerosis
402698005 Dermatitis of external ear 1088651000119100 Dermatitis of left external ear canal 1091261000119100 Dermatitis of right external ear canal 89537006 Diffuse labyrinthitis 77949003 Disorders of acoustic nerve 95809000 Eczema of earlobe 95812002 Eczema of external auditory canal 232311007 Endocochlear cytomegalovirus infection 69494008 Eustachian tube disorder 270491006 Eustachian tube salpingitis 71591001 Furuncle of ear 194204009 Furunculosis of external auditory meatus 271946002 Granulations of mastoid cavity 21954000 Herpes zoster auricularis 18070006 Impacted cerumen 1089011000119100 Inflammation of left labyrinth structure 1091621000119100 Inflammation of right labyrinth structure 788971005 Irritant contact dermatitis of external ear 5239005 Labyrinthine dysfunction 66410001 Labyrinthine fistula of combined sites 23919004 Labyrinthitis		724635009	Contact dermatitis of external ear
1088651000119100 Dermatitis of left external ear canal 1091261000119100 Dermatitis of right external ear canal 89537006 Diffuse labyrinthitis 77949003 Disorders of acoustic nerve 95809000 Eczema of earlobe 95812002 Eczema of external auditory canal 232311007 Endocochlear cytomegalovirus infection 69494008 Eustachian tube disorder 270491006 Eustachian tube salpingitis 71591001 Furuncle of ear 194204009 Furunculosis of external auditory meatus 271946002 Granulations of mastoid cavity 21954000 Herpes zoster auricularis 18070006 Impacted cerumen 1089011000119100 Inflammation of left labyrinth structure 1091621000119100 Irritant contact dermatitis of external ear 5239005 Labyrinthine dysfunction 66410001 Labyrinthine fistula of combined sites 23919004 Labyrinthitis		427404005	Dermatitis of external auditory canal
1091261000119100 Dermatitis of right external ear canal 89537006 Diffuse labyrinthitis 77949003 Disorders of acoustic nerve 95809000 Eczema of earlobe 95812002 Eczema of external auditory canal 232311007 Endocochlear cytomegalovirus infection 69494008 Eustachian tube disorder 270491006 Eustachian tube salpingitis 71591001 Furuncle of ear 194204009 Furunculosis of external auditory meatus 271946002 Granulations of mastoid cavity 21954000 Herpes zoster auricularis 18070006 Impacted cerumen 1089011000119100 Inflammation of left labyrinth structure 1091621000119100 Irritant contact dermatitis of external ear 5239005 Labyrinthine dysfunction 66410001 Labyrinthitis 449832007 Labyrinthitis ossificans		402698005	Dermatitis of external ear
89537006 Diffuse labyrinthitis 77949003 Disorders of acoustic nerve 95809000 Eczema of earlobe 95812002 Eczema of external auditory canal 232311007 Endocochlear cytomegalovirus infection 69494008 Eustachian tube disorder 270491006 Eustachian tube salpingitis 71591001 Furuncle of ear 194204009 Furunculosis of external auditory meatus 271946002 Granulations of mastoid cavity 21954000 Herpes zoster auricularis 18070006 Impacted cerumen 1089011000119100 Inflammation of left labyrinth structure 1091621000119100 Irritant contact dermatitis of external ear 5239005 Labyrinthine dysfunction 66410001 Labyrinthitis 23919004 Labyrinthitis ossificans		1088651000119100	Dermatitis of left external ear canal
77949003 Disorders of acoustic nerve 95809000 Eczema of earlobe 95812002 Eczema of external auditory canal 232311007 Endocochlear cytomegalovirus infection 69494008 Eustachian tube disorder 270491006 Eustachian tube salpingitis 71591001 Furuncle of ear 194204009 Furunculosis of external auditory meatus 271946002 Granulations of mastoid cavity 21954000 Herpes zoster auricularis 18070006 Impacted cerumen 1089011000119100 Inflammation of left labyrinth structure 1091621000119100 Inflammation of right labyrinth structure 788971005 Irritant contact dermatitis of external ear 5239005 Labyrinthine dysfunction 66410001 Labyrinthitis 23919004 Labyrinthitis ossificans		1091261000119100	Dermatitis of right external ear canal
95809000 Eczema of earlobe 95812002 Eczema of external auditory canal 232311007 Endocochlear cytomegalovirus infection 69494008 Eustachian tube disorder 270491006 Eustachian tube salpingitis 71591001 Furuncle of ear 194204009 Furunculosis of external auditory meatus 271946002 Granulations of mastoid cavity 21954000 Herpes zoster auricularis 18070006 Impacted cerumen 1089011000119100 Inflammation of left labyrinth structure 1091621000119100 Inflammation of right labyrinth structure 788971005 Irritant contact dermatitis of external ear 5239005 Labyrinthine dysfunction 66410001 Labyrinthitis 23919004 Labyrinthitis Labyrinthitis Labyrinthitis ossificans		89537006	Diffuse labyrinthitis
95812002 Eczema of external auditory canal 232311007 Endocochlear cytomegalovirus infection 69494008 Eustachian tube disorder 270491006 Eustachian tube salpingitis 71591001 Furuncle of ear 194204009 Furunculosis of external auditory meatus 271946002 Granulations of mastoid cavity 21954000 Herpes zoster auricularis 18070006 Impacted cerumen 1089011000119100 Inflammation of left labyrinth structure 1091621000119100 Inflammation of right labyrinth structure 788971005 Irritant contact dermatitis of external ear 5239005 Labyrinthine dysfunction 66410001 Labyrinthine fistula of combined sites 23919004 Labyrinthitis 449832007 Labyrinthitis ossificans		77949003	Disorders of acoustic nerve
Endocochlear cytomegalovirus infection 69494008 Eustachian tube disorder 270491006 Eustachian tube salpingitis 71591001 Furuncle of ear 194204009 Furunculosis of external auditory meatus 271946002 Granulations of mastoid cavity 21954000 Herpes zoster auricularis 18070006 Impacted cerumen 1089011000119100 Inflammation of left labyrinth structure 1091621000119100 Inflammation of right labyrinth structure 788971005 Irritant contact dermatitis of external ear 5239005 Labyrinthine dysfunction 66410001 Labyrinthitis 23919004 Labyrinthitis 449832007 Labyrinthitis ossificans		95809000	Eczema of earlobe
infection 69494008 Eustachian tube disorder 270491006 Eustachian tube salpingitis 71591001 Furuncle of ear 194204009 Furunculosis of external auditory meatus 271946002 Granulations of mastoid cavity 21954000 Herpes zoster auricularis 18070006 Impacted cerumen 1089011000119100 Inflammation of left labyrinth structure 1091621000119100 Irritant contact dermatitis of external ear 5239005 Labyrinthine dysfunction 66410001 Labyrinthitis 23919004 Labyrinthitis Labyrinthitis ossificans		95812002	Eczema of external auditory canal
270491006 Eustachian tube salpingitis 71591001 Furuncle of ear 194204009 Furunculosis of external auditory meatus 271946002 Granulations of mastoid cavity 21954000 Herpes zoster auricularis 18070006 Impacted cerumen 1089011000119100 Inflammation of left labyrinth structure 1091621000119100 Inflammation of right labyrinth structure 788971005 Irritant contact dermatitis of external ear 5239005 Labyrinthine dysfunction 66410001 Labyrinthine fistula of combined sites 23919004 Labyrinthitis 449832007 Labyrinthitis ossificans		232311007	
71591001 Furuncle of ear 194204009 Furunculosis of external auditory meatus 271946002 Granulations of mastoid cavity 21954000 Herpes zoster auricularis 18070006 Impacted cerumen 1089011000119100 Inflammation of left labyrinth structure 1091621000119100 Irritant contact dermatitis of external ear 5239005 Labyrinthine dysfunction 66410001 Labyrinthine fistula of combined sites 23919004 Labyrinthitis 449832007 Labyrinthitis ossificans		69494008	Eustachian tube disorder
Furunculosis of external auditory meatus 271946002 Granulations of mastoid cavity 21954000 Herpes zoster auricularis 18070006 Impacted cerumen 1089011000119100 Inflammation of left labyrinth structure 1091621000119100 Irritant contact dermatitis of external ear 5239005 Labyrinthine dysfunction 66410001 Labyrinthitis 23919004 Labyrinthitis 449832007 Labyrinthitis ossificans		270491006	Eustachian tube salpingitis
meatus 271946002 Granulations of mastoid cavity 21954000 Herpes zoster auricularis 18070006 Impacted cerumen 1089011000119100 Inflammation of left labyrinth structure 1091621000119100 Inflammation of right labyrinth structure 788971005 Irritant contact dermatitis of external ear 5239005 Labyrinthine dysfunction 66410001 Labyrinthine fistula of combined sites 23919004 Labyrinthitis 449832007 Labyrinthitis ossificans		71591001	Furuncle of ear
21954000 Herpes zoster auricularis 18070006 Impacted cerumen 1089011000119100 Inflammation of left labyrinth structure 1091621000119100 Inflammation of right labyrinth structure 788971005 Irritant contact dermatitis of external ear 5239005 Labyrinthine dysfunction 66410001 Labyrinthine fistula of combined sites 23919004 Labyrinthitis 449832007 Labyrinthitis ossificans		194204009	-
18070006 Impacted cerumen 1089011000119100 Inflammation of left labyrinth structure 1091621000119100 Inflammation of right labyrinth structure 788971005 Irritant contact dermatitis of external ear 5239005 Labyrinthine dysfunction 66410001 Labyrinthine fistula of combined sites 23919004 Labyrinthitis 449832007 Labyrinthitis ossificans		271946002	Granulations of mastoid cavity
1089011000119100 Inflammation of left labyrinth structure 1091621000119100 Inflammation of right labyrinth structure 788971005 Irritant contact dermatitis of external ear 5239005 Labyrinthine dysfunction 66410001 Labyrinthine fistula of combined sites 23919004 Labyrinthitis 449832007 Labyrinthitis ossificans		21954000	Herpes zoster auricularis
1091621000119100 Inflammation of right labyrinth structure 788971005 Irritant contact dermatitis of external ear 5239005 Labyrinthine dysfunction 66410001 Labyrinthine fistula of combined sites 23919004 Labyrinthitis 449832007 Labyrinthitis ossificans		18070006	Impacted cerumen
tructure 788971005 Irritant contact dermatitis of external ear 5239005 Labyrinthine dysfunction 66410001 Labyrinthine fistula of combined sites 23919004 Labyrinthitis 449832007 Labyrinthitis ossificans		1089011000119100	-
ear 5239005 Labyrinthine dysfunction 66410001 Labyrinthine fistula of combined sites 23919004 Labyrinthitis 449832007 Labyrinthitis ossificans		1091621000119100	-
66410001 Labyrinthine fistula of combined sites 23919004 Labyrinthitis 449832007 Labyrinthitis ossificans		788971005	
23919004 Labyrinthitis 449832007 Labyrinthitis ossificans		5239005	Labyrinthine dysfunction
449832007 Labyrinthitis ossificans		66410001	Labyrinthine fistula of combined sites
· ·		23919004	Labyrinthitis
1088021000119100 Left acute eustachian salpingitis		449832007	Labyrinthitis ossificans
		1088021000119100	Left acute eustachian salpingitis

10	88411000119100	Left chronic eustachian salpingitis
13	445001	Ménière disease
27	1945003	Mucinous cyst of mastoid cavity
73	6949008	Mucosal cyst of mastoid cavity
23	2242004	Neurodermatitis of external ear
48	145001	Obstruction of Eustachian tube
53	316003	Otomycosis
11	543004	Otosclerosis
10	566007	Otosclerosis involving round window
30	1354004	Pain of ear
30	280005	Patulous Eustachian tube
23	6871000119109	Perichondritis of external ear
10	88861000119100	Perichondritis of left external ear
34	129005	Perichondritis of pinna
10	91471000119100	Perichondritis of right external ear
	438001	Peripheral vertigo
	997001	Petrositis
	103007	Polyp of middle ear
	102009	Postmastoidectomy complication
	526009	Presbycusis
	6909000	Recurrent cholesteatoma of mastoid cavity
12	9628007	Recurrent labyrinthitis
<u> </u>	90641000119100	Right acute eustachian salpingitis
<u> </u>	91021000119100	Right chronic eustachian salpingitis
	674001	Serous labyrinthitis
	2934006	Streptococcal cellulitis of external ear
 	4636005	Sudden idiopathic hearing loss
	817009	Suppurative labyrinthitis
	862001	Tinnitus
 	44003	Toxic labyrinthitis
	9056000	Tuberculosis of inner ear
	2258001	Tympanic atelectasis
	9711008	Viral labyrinthitis
	188001	Hearing loss
SN	IOMED code does t exist	Chronic Ear Disease / Hearing Loss
	8614006	Acquired deaf mutism
	1294001	Acquired hearing loss
-	9125008	Acquired rearing loss Acquired sensorineural hearing loss
	310008	Air conduction deafness
l —	7772009	Asymmetrical hearing loss
	8887009	Asymmetrical nearing loss Asymmetrical sensorineural hearing loss
42	8470000	Autoimmune sensorineural hearing loss
42	7644005	Bilateral central hearing loss
		-

		Dileteral conductive bearing loss of
	1084051000119100	Bilateral conductive hearing loss of middle ears
	162344009	Bilateral deafness
	95820000	Bilateral hearing loss
	1084151000119100	Bilateral hearing loss of ears caused by noise
	1083811000119100	Bilateral high frequency sensorineural hearing loss of ears
	1598451100011910 0	Bilateral impairment of hearing of ears co-occurrent and due to congenital ear malformation
	430977001	Bilateral neural hearing loss
	430985005	Bilateral sensory hearing loss
	129631008	Birth trauma deafness
	46050004	Bone conduction deafness
	68467004	Central hearing loss
	232325008	Chronic deafness
	194419007	Combined conductive hearing loss
	194426007	Combined perceptive hearing loss
	8531006	Complete deafness
	783742004	Conductive deafness, malformed external ear syndrome
	44057004	Conductive hearing loss
	194413008	Conductive hearing loss due to disorder of external ear
	194416000	Conductive hearing loss due to disorder of inner ear
	194415001	Conductive hearing loss due to disorder of middle ear
	194414002	Conductive hearing loss due to disorder of tympanic membrane
	2061000	Conductive hearing loss of combined sites
	1010238005	Conductive hearing loss of left ear
	1010439000	Conductive hearing loss of left ear with normal hearing on right side
	1010236009	Conductive hearing loss of right ear
	1010440003	Conductive hearing loss of right ear with normal hearing on left side
	194417009	Conductive hearing loss, bilateral
	737344003	Congenital conductive hearing loss
	698615007	Congenital deaf mutism
	95828007	Congenital deafness
	700453005	Congenital sensorineural hearing loss
	61947007	Deaf mutism
	473422006	Deafness of left ear
	473421004	Deafness of right ear
	272033007	Deafness symptom
		· 1

		232333009	Hearing loss associated with syndrome
		473424007	Hearing loss of left ear
		1089221000119100	Hearing loss of left ear caused by noise
		473423001	Hearing loss of right ear
		1091831000119100	Hearing loss of right ear caused by noise
		232326009	High frequency deafness
		48758008	High frequency hearing loss
		3820005	Inner ear conductive hearing loss
		42538001	Low frequency deafness
		61743004	Middle ear conductive hearing loss
		737047001	Mild acquired hearing loss
		955621000168101	Mild hearing loss
		21451000119101	Mild to moderate hearing loss
		77507001	Mixed conductive and sensorineural hearing loss
		1052205008	Mixed conductive and sensorineural hearing loss of left ear with normal hearing on right side
		1052206009	Mixed conductive and sensorineural hearing loss of right ear with normal hearing on left side
		194429000	Mixed conductive and sensorineural hearing loss, bilateral
		737048006	Moderate acquired hearing loss
		955631000168103	Moderate hearing loss
		95821001	Neonatal hearing loss
		1179362008	Neonatal sensorineural hearing loss
		73371001	Neural hearing loss
		1010229008	Neural hearing loss of left ear
		1010230003	Neural hearing loss of right ear
		267677007	Ototoxicity - deafness
		343087000	Partial deafness
		737050003	Profound acquired hearing loss
		1230412003	Profound hearing loss
		60700002	Sensorineural hearing loss
		65680009	Sensorineural hearing loss of combined sites
		1119387004	Sensorineural hearing loss of left ear
		1010442006	Sensorineural hearing loss of left ear with normal hearing on right side
		1119386008	Sensorineural hearing loss of right ear
		1010441004	Sensorineural hearing loss of right ear with normal hearing on left side
		194424005	Sensorineural hearing loss, bilateral
		85571008	Sensory hearing loss
		737049003	Severe acquired hearing loss

0504000440400	
3561000119106	Severe hearing loss
84063009	Traumatic deafness, occupational
49252004	Otitic barotrauma
103281005	Sensation of blocked ear
1653870100011910 3	Sensation of blocked left ear
1653865100011910 0	Sensation of blocked right ear
1653875100011910 4	Bilateral sensation of blocked ears
75441006	Foreign body in ear
32874004	Foreign body in auditory canal
1084766100011910 0	Foreign body in left ear
302907009	Foreign body in middle ear
1084762100011910 5	Foreign body in right ear
40401000087103	Foreign body in left auditory canal
40461000087104	Foreign body in right auditory canal
2999009	Injury of ear
285059008	Injury of external ear
262762001	Injury of inner ear
1184431100011910 8	Injury of left ear
765194001	Injury of middle ear
1184427100011910 8	Injury of right ear
126946000	Excessive cerumen in ear canal
271739002	Wax in ear canal
253031000	Glomus tympanicum tumour
427789001	Myoclonus of tensor tympani muscle
699392007	Itching of ear

Table 51: Ear Health – Best Practice Excluded Procedures

NKPI CONDITION	PROCEDURE SUBGROUP	CIS	CIS CODE	CLINICAL TERM
			2828	Ear syringe
			2828	Syringe ear
			2829	Ear toilet
			2830	Ear toilet - curette
			2831	Ear toilet - dry mopping
			2832	Ear toilet - suction
Ear Health	Procedure	Best Practice	3588	Ear surgery
Ear Health	Procedure		3590	Ear, foreign body removal
			3590	Foreign body removal from ear
			3590	Removal of foreign body from ear
			3594	Ear laceration repair
			3599	Ear polyp removal
			3604	Ear, wedge excision
			3604	Wedge excision from ear

Table 52: Ear Health – Communicare Excluded Procedures

NKPI CONDITION	CONDITION SUBGROUP	CIS	CIS CODE	CLINICAL TERM
Ear Health	Procedure	Communicare	H31001	Check up;partial;ear
			H31002	Exam;partial;ear
			H31003	Assessment;partial;hearing
			H39001	Test;audiometry
			H39002	Test;caloric
			H39003	Test;hearing
			H39004	Test;vestibular
			H39008	Test;physical function;ear
			H41001	Radiology;diagnostic;ear
			H41002	X-ray;ear
			H41003	CT scan;ear
			H42001	Electrical tracings;ear
			H43001	Procedures;diagnostic;ear
			H45001	Observe/wait;ear
			H45002	Advice/education;ear
			H46001	Consult;other GP/AHP;ear
			H47001	Consult;specialist;ear
			H48001	Discuss;pt RFE;ear
			H49001	Prevent procedure;ear
			H50001	Medications;ear
			H50002	Medication;renew;ear
			H50003	Medication;request;ear

H50005	Prescription;ear		
H50006	Injection;ear		
H51001	Clean ear		
H51002	Removal;wax;ear		
H51004	Syringe ear;for wax		
H51005	Aspiration;ear		
H51006	Incise;body fluids;ear		
H51007	Drain;body fluids;ear		
H51008	Aspirate;body fluids;ear		
H51009	Syringe ear		
H52001	Excision;ear		
H52002	Remove;ear		
H52003	Destruction;ear		
H52004	Cauterise;ear		
H52005	Mastoidectomy		
H54001	Adjusting;hearing aid		
H54002	Fitting (of);hearing aid		
H54003	Repair;ear		
H54004	Fixate;ear		
H54005	Implant;cochlear		
H55001	Infiltrate;ear		
H56001	Packing;ear		
H56003	Compression;ear		
H56004	Dressing;ear		
H57001	Rehab;physical;ear		
H57002	Epley manoeuvre		
H58001	Counselling;problem;ear		
H59001	Piercing;ear		
H59002	Therapeutic proced;ear		
H59003	Valsalvas manoeuvre;ear		
H59004	Removal;foreign body;ear		
H60001	Test;result(s);ear		
H60002	Results;procedures;ear		
H62001	Administrative;ear		
H64001	Check up;post-op;ear		
H64002	Encounter;Dr initiated;ear		
H66002	Referral;acoustic testing		
H66003	Referral;audiologist		
H69001	Encounter;other;ear		
H69002	Assist at operation;ear		

Table 53: Ear Health – Medical Director Excluded Procedures

NKPI CONDITION	CONDITION SUBGROUP	CIS	CIS CODE	CLINICAL TERM
			ppoc.ear@syri	Ear syringe
			ppoc.ear@toil	Ear toilet
			ppoc.ear@toil@curettag	Ear toilet - curette
			ppoc.ear@toil@dry	Ear toilet - dry mopping
	Procedure	Medical Director	ppoc.ear@toil@suct	Ear toilet - suction
			ppoc.ear@syri	Ear wax - syringed
			surg.ear@lace	Ear laceration repair
			surg.ear@wedg@exci	Ear, wedge excision
Ear Health			surg.ear@polyp	Ear polyp removal
			surg.ear@foreb@remo	Ear, foreign body removal
			surg.eustt	Eustachian tube surgery
			surg.laby	Labyrinth surgery
			surg.ear@midd@absc	Middle ear abscess drainage
			surg.ear@midd@clea	Middle ear clearance
			surg.ear@midd@expl	Middle ear exploration
			surg.ear@midd	Middle ear surgery
			surg.ear@cosm	Otoplasty

Table 54: Ear Health – MMEx Excluded Procedures

NKPI CONDITION	PROCEDURE SUBGROUP	CIS	SNOMED CODE	CLINICAL TERM (OR GLOBAL CAREPLAN NAME)
Ear Health	Procedure	MMEx	SNOMED code does not exist. 386350007 398230002 128393005 69727009 429926006 71769006 36995006 31489003 281558001 128392000 225670007 172747000 172748005 68327001	
			363158006 36511008	Incision of ear Injection into inner ear

		, , ,
	63772005	Injection of eustachian tube with inert material
	26059007	Injection of inner ear for destruction
	37127001	Injection of inner ear with alcohol
	61186007	Injection of middle ear
	52006006	Injection of semicircular canals for destruction
	182649002	Injection of tympanic cavity for local action
	79289006	Injection of tympanum
	73819002	Injection of vestibule for destruction
	232172001	Instillation of ear drops or spray
	120140002	Middle ear closure
	287497001	Non-surgical ear biopsy
	68265005	Operation on the ear
	118891001	Procedure on ear
	225675002	Putting on hearing aid
	736514007	Reconstruction of ear
	385904005	Removal of ear wax
	52577005	Repair of auricle of ear
	1162813001	Repair of bat ear
	33901004	Repair of external ear
	386556002	Repair of middle ear
	274338009	Surgical biopsy of ear
	172630005	Syringing ear to remove wax
	172592009	Wedge resection of pinna
	420068003	X-ray of ear

Appendix F – Pathology Coding Framework

The Pathology Coding Framework for the nKPIs was implemented for the July 2023 reporting period replacing the interim coding method originally implemented by vendors. This framework was revised in August 2023.

Introduction

The Pathology Coding Framework facilitates consistent collection of data for *Pl25 – Proportion of Indigenous regular clients who are tested for one or more sexually transmissible infections (STIs)* for the two relevant STIs:

- Chlamydia
- Gonorrhoea

Like the Condition Coding Framework, the Pathology Coding Framework provides a flexible and sustainable model, reducing the need for frequent formal revision, and future proofing the nKPIs as much as possible by providing sufficient guidance for vendor revision as appropriate.

The framework was established through consultation and expert clinical advice to align with definitions in STI national guidelines. Detailed consideration was given to the intent of the indicator, inclusion of tests specifically relevant to STIs, additional available information such as the test location site and review of each individual test or term to confirm inclusion in the final coding list.

Principles for inclusion / exclusion

- Focus is on tests that are specifically relevant to STIs
- The indicator intent is to screen young adults and young people, not neonates
- Nucleic acid amplification tests (NAAT tests) are highly sensitive and the recommended, most commonly used, diagnostic tests in Australia (DNA/RNA amplification testing)
- Antigen (Ag) tests are included to account for an older method of testing
- Anatomical location of specimen / sample is an important consideration to determine inclusion / exclusion. Where a location is unspecified the LOINC code should be included provided it also meets the principles for inclusion / exclusion. Locations that do not relate to sexual health should be excluded, as per guidance in the following table:

Included specimens	Excluded specimens
 Anal Anorectal Cervix Cervical mucus Donor Endometrium Genital Nasopharynx Nose Semen Throat Urine Urine sediment Urethra 	 Aspirate Blood Body fluid Bronchial Conjunctiva/conjunctival CSF - cerebral spinal fluid Peritoneal Serum Sputum Stool (fecal) Synovial Tissue
NoseSemenThroatUrineUrine sediment	SputumStool (fecal)Synovial
UrethraVaginal	

- The following principles apply to LOINC status:
 - o Discouraged LOINC codes are included (although discouraged they may still be in use)
 - Deprecated LOINC codes are only included if the status has changed in the last 12 months and are therefore still relevant for the data capture time period
 - Trial LOINC codes are excluded.
- LOINC codes determined to be relevant to specific projects outside Australia are not included.

Specific inclusions

- Penicillinase producing Neisseria gonorrhoeae
- Treated for Chlamydia trachomatis or Neisseria gonorrhoeae in last 3 to 12 months
- Sexual activity with known Chlamydia trachomatis and/or Neisseria gonorhoeae case.

Specific exclusions

- Tests for some Chlamydia species are out of scope and therefore excluded (refer to Table 63 below for details), e.g. 'chlamydia pneumoniae', 'chlamydia psittaci' etc.
- Although text terms should be as specific as possible and include any potential
 misspellings, care needs to be taken to exclude text search terms which are too broad,
 e.g. 'Neisseria Sp.' (no mention of gonorhoeae)
- Antibody (Ab) and immunoglobulin (IgA, IgG, IgM) tests are excluded (not recommended for STI screening)
- Neonatal tests
- Children's Preventative Health System (CPHS) tests.

The Pathology Coding Framework

The Pathology Coding Framework is designed to cover all scenarios for data entry regardless of how it is captured or entered including capture of point of care testing (POCTs).

There are multiple ways an STI test result can be recorded in a Clinical Information System:

- Direct receipt of test result into the CIS via electronic means using LOINC[®] (Logical Observation Identifier Names and Codes) or case insensitive text to indicate the STI test result.
- Manual data entry by GP of the STI test result into the CIS selecting the type of STI from a drop-down list made up of SNOMED CT-AU terms.
- Manual data entry by GP of the STI test result into the CIS using free text.

Caution is advised with the implementation of free text searches; further guidance is provided in below under 'Free Text'.

Some LOINC codes are relevant to <u>both</u> chlamydia and gonorrhoea. To simplify interpretation and aid implementation, the codes containing <u>both</u> tests are listed separately. For avoidance of doubt tests from all three sections need to be included:

- Both chlamydia and gonorrhoea
- Chlamydia only
- Gonorrhoea only.

It is noted that over time the list of LOINC codes will need review to confirm the status of the LOINC code. Vendors have licence to remove codes from the lists below and to add new codes providing they meet the principles outlined above and the inclusion and exclusion criteria.

Some LOINC codes are excluded based on the inclusion/exclusion criteria above. A list of excluded LOINC codes is supplied for transparency and, where needed, to compensate for

potential over inclusion from the free text wild card searches. Vendor discretion is advised; vendors are encouraged to consider whether coding the exclusion of these codes complements their implementation or whether to code inclusions only.

The variability in local and/or private pathology provider allocation of test naming convention and codes is acknowledged. To accommodate this, vendors have licence to include known local tests providing the inclusion and exclusion principles outlined in the framework have been considered.

Local codes (test numbers or test names) that have been confirmed by one or more pathology labs are included in the framework. Vendors are encouraged to advise Solving Health of additional codes so these can also be added.

Note: In some clinical information systems, pathology results must be actioned in the holding file before they drop into the clinical record. In these circumstances unactioned results may not be captured in reports.

Chlamydia and gonorrhoea

Chlamydia and gonorrhoea – INCLUDED CODES

The LOINC codes in Table 55 are relevant to both chlamydia and gonorrhoea.

Table 55: Included LOINC codes – both Chlamydia + Gonorrhoea

LOINC number	LOINC long common name
100356-5	Chlamydia trachomatis and Neisseria gonorrhoeae and Trichomonas vaginalis DNA
100710-3	[Identifier] in Specimen by NAA with probe detection Chlamydia trachomatis and Neisseria gonorrhoeae rRNA panel - Throat by NAA with
101172-5	probe detection Chlamydia trachomatis and Neisseria gonorrhoeae and Trichomonas vaginalis rRNA
	panel - Specimen by NAA with probe detection
36902-5	Chlamydia trachomatis+Neisseria gonorrhoeae DNA [Presence] in Specimen by NAA with probe detection
36903-3	Chlamydia trachomatis and Neisseria gonorrhoeae DNA [Identifier] in Specimen by NAA with probe detection
43405-0	Chlamydia trachomatis and Neisseria gonorrhoeae DNA [Identifier] in Specimen by Probe with signal amplification
43406-8	Chlamydia trachomatis+Neisseria gonorrhoeae DNA [Presence] in Specimen by Probe with signal amplification
44806-8	Chlamydia trachomatis + Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection
44807-6	Chlamydia trachomatis + Neisseria gonorrhoeae DNA [Presence] in Genital specimen by NAA with probe detection
45067-6	Chlamydia trachomatis+Neisseria gonorrhoeae rRNA [Presence] in Cervix by Probe
45068-4	Chlamydia trachomatis + Neisseria gonorrhoeae DNA [Presence] in Cervix by NAA with probe detection
45069-2	Chlamydia trachomatis + Neisseria gonorrhoeae rRNA [Presence] in Genital specimen by Probe
45070-0	Chlamydia trachomatis+Neisseria gonorrhoeae rRNA [Presence] in Vaginal fluid by Probe
45072-6	Chlamydia trachomatis + Neisseria gonorrhoeae rRNA [Presence] in Anal by Probe
45074-2	Chlamydia trachomatis+Neisseria gonorrhoeae rRNA [Presence] in Urethra by Probe
45075-9	Chlamydia trachomatis + Neisseria gonorrhoeae rRNA [Presence] in Urethra by Probe
45076-7	Chlamydia trachomatis+Neisseria gonorrhoeae rRNA [Presence] in Specimen by Probe
47362-9	Chlamydia trachomatis+Neisseria gonorrhoeae rRNA [Presence] in Specimen from Donor by NAA with probe detection
64017-7	Chlamydia trachomatis and Neisseria gonorrhoeae rRNA panel - Specimen by NAA with probe detection
70161-5	Chlamydia trachomatis and Neisseria gonorrhoeae rRNA panel - Urine by NAA with probe detection
70162-3	Chlamydia trachomatis and Neisseria gonorrhoeae rRNA panel - Urethra by NAA with probe detection
70163-1	Chlamydia trachomatis and Neisseria gonorrhoeae rRNA panel - Cervix by NAA with probe detection
70164-9	Chlamydia trachomatis and Neisseria gonorrhoeae rRNA panel - Vaginal fluid by NAA with probe detection
72828-7	Chlamydia trachomatis and Neisseria gonorrhoeae DNA panel - Specimen
77577-5	Chlamydia trachomatis and Neisseria gonorrhoeae DNA panel - Urethra by NAA with probe detection

80360-1	Chlamydia trachomatis + Neisseria gonorrhoeae rRNA [Presence] in Urine by NAA with probe detection
80361-9	Chlamydia trachomatis + Neisseria gonorrhoeae rRNA [Presence] in Cervix by NAA with probe detection
80362-7	Chlamydia trachomatis + Neisseria gonorrhoeae rRNA [Presence] in Vaginal fluid by NAA with probe detection
80365-0	Chlamydia trachomatis + Neisseria gonorrhoeae rRNA [Presence] in Anorectal by NAA with probe detection
85687-2	Treated for Chlamydia trachomatis or Neisseria gonorrhoeae in last 3 to 12 months
85689-8	Sexual activity with known Chlamydia trachomatis And Or Neisseria gonorhoeae case
90357-5	Chlamydia trachomatis and Neisseria gonorrhoeae rRNA panel - Nasopharynx by NAA with probe detection
90358-3	Chlamydia trachomatis and Neisseria gonorrhoeae rRNA panel - Anorectal by NAA with probe detection
92683-2	Chlamydia trachomatis and Neisseria gonorrhoeae and Trichomonas vaginalis DNA panel - Genital specimen by NAA with probe detection
92684-0	Chlamydia trachomatis and Neisseria gonorrhoeae and Trichomonas vaginalis DNA panel - Urine by NAA with probe detection
96612-7	Chlamydia trachomatis and Neisseria gonorrhoeae and Trichomonas vaginalis DNA panel - Specimen by NAA with probe detection

Included Non-LOINC codes

The following local codes are confirmed local pathology codes or test names relevant to both chlamydia and gonorrhoea; these may have a code or a name but are unlikely to have a LOINC code. Where relevant, search for the full name within the test field.

Table 56: Included non-LOINC codes – chlamydia and gonorrhoea

Туре	Code or number	Name – search for complete string
POCT name for TTANGO project results via GeneXpert*	N/A	Chlamydia+Gnrrh
Pathology lab term		C. trachomatis / N. gonorrhoeae PCR

^{*}Only used for testing genitourinary specimens so appropriate to include.

Chlamydia and gonorrhoea – EXCLUDED LOINC codes

The list of excluded LOINC codes in Table 57 are relevant to both chlamydia and gonorrhoea.

Table 57: Excluded LOINC codes - chlamydia and gonorrhoea

LOINC number	LOINC long common name
45071-8	Deprecated Chlamydia trachomatis+Neisseria gonorrhoeae rRNA [Presence] in Penis by DNA probe
45073-4	Chlamydia trachomatis+Neisseria gonorrhoeae rRNA [Presence] in Tissue by Probe
62864-4	Deprecated PhenX measure - assay for chlamydia - gonorrhea
62865-1	PhenX - assay for chlamydia - gonorrhea protocol 160101
69865-4	Process variables for assays - gonorrhea-chlamydia PhenX
86661-6	Chlamydia trachomatis+Neisseria gonorrhoeae tests - FPAR 2.0 set

Chlamydia only – INCLUDED CODES

The LOINC codes in Table 58 are relevant only to chlamydia.

Table 58: Included LOINC codes - Chlamydia only

LOINC number	LOINC long common name
14463-4	Chlamydia trachomatis [Presence] in Cervix by Organism specific culture
14464-2	Chlamydia trachomatis [Presence] in Vaginal fluid by Organism specific culture
14465-9	Chlamydia trachomatis [Presence] in Urethra by Organism specific culture
14467-5	Chlamydia trachomatis [Presence] in Urine sediment by Organism specific culture
14470-9	Chlamydia trachomatis Ag [Presence] in Cervix by Immunoassay
14471-7	Chlamydia trachomatis Ag [Presence] in Vaginal fluid by Immunoassay
14472-5	Chlamydia trachomatis Ag [Presence] in Urethra by Immunoassay
14474-1	Chlamydia trachomatis Ag [Presence] in Urine sediment by Immunoassay
14509-4	Chlamydia trachomatis Ag [Presence] in Cervix by Immunofluorescence
14510-2	Chlamydia trachomatis Ag [Presence] in Vaginal fluid by Immunofluorescence
14511-0	Chlamydia trachomatis Ag [Presence] in Urethra by Immunofluorescence
14513-6	Chlamydia trachomatis Ag [Presence] in Urine sediment by Immunofluorescence
16593-6	Chlamydia sp Ag [Presence] in Urine
16600-9	Chlamydia trachomatis rRNA [Presence] in Genital specimen by Probe
16601-7	Chlamydia trachomatis rRNA [Presence] in Urine by Probe
21189-6	Chlamydia trachomatis DNA [Presence] in Cervical mucus by NAA with probe detection
21190-4	Chlamydia trachomatis DNA [Presence] in Cervix by NAA with probe detection
21191-2	Chlamydia trachomatis DNA [Presence] in Urethra by NAA with probe detection
21192-0	Chlamydia trachomatis rRNA [Presence] in Urethra by Probe
21613-5	Chlamydia trachomatis DNA [Presence] in Specimen by NAA with probe detection
23838-6	Chlamydia trachomatis rRNA [Presence] in Genital fluid by Probe
31765-1	Chlamydia sp Ag [Presence] in Genital specimen
31767-7	Chlamydia sp Ag [Presence] in Specimen
31771-9	Chlamydia trachomatis Ag [Presence] in Cervix
31772-7	Chlamydia trachomatis Ag [Presence] in Vaginal fluid
31775-0	Chlamydia trachomatis Ag [Presence] in Urine sediment
31776-8	Chlamydia trachomatis Ag [Presence] in Urethra
31777-6	Chlamydia trachomatis Ag [Presence] in Specimen
32001-0	Chlamydia sp Ag [Presence] in Vaginal fluid by Immunoassay
32004-4	Chlamydia sp Ag [Presence] in Urine by Immunoassay
32671-0	Chlamydia sp Ag [Presence] in Vaginal fluid
32774-2	Chlamydia sp DNA [Presence] in Genital specimen by NAA with probe detection
34708-8	Chlamydia sp DNA [Presence] in Urine by NAA with probe detection
34709-6	Chlamydia trachomatis Ag [Presence] in Nasopharynx
34710-4	Chlamydia trachomatis Ag [Presence] in Anal
35412-6	Chlamydia sp DNA [Presence] in Nose by NAA with probe detection
35711-1	Chlamydia sp DNA [Presence] in Anal by NAA with probe detection
35713-7	Chlamydia sp DNA [Presence] in Cervix by NAA with probe detection
35714-5	Chlamydia sp rRNA [Presence] in Cervix by Probe

35715-2	Chlamydia sp rRNA [Presence] in Genital specimen by Probe
35716-0	Chlamydia sp DNA [Presence] in Vaginal fluid by NAA with probe detection
35717-8	Chlamydia sp rRNA [Presence] in Vaginal fluid by Probe
35718-6	Chlamydia sp rRNA [Presence] in Nose by Probe
35721-0	Chlamydia sp rRNA [Presence] in Anal by Probe
35724-4	Chlamydia sp DNA [Presence] in Throat by NAA with probe detection
35725-1	Chlamydia sp rRNA [Presence] in Throat by Probe
35726-9	Chlamydia sp rRNA [Presence] in Urine by Probe
35727-7	Chlamydia sp DNA [Presence] in Urethra by NAA with probe detection
35728-5	Chlamydia sp rRNA [Presence] in Urethra by Probe
35729-3	Chlamydia sp DNA [Presence] in Specimen by NAA with probe detection
35730-1	Chlamydia sp rRNA [Presence] in Specimen by Probe
35736-8	Chlamydia sp rRNA [Presence] in Nasopharynx by Probe
42931-6	Chlamydia trachomatis rRNA [Presence] in Urine by NAA with probe detection
43304-5	Chlamydia trachomatis rRNA [Presence] in Specimen by NAA with probe detection
43404-3	Chlamydia trachomatis DNA [Presence] in Specimen by Probe with signal amplification
45078-3	Chlamydia trachomatis rRNA [Presence] in Cervix by Probe
45080-9	Chlamydia trachomatis rRNA [Presence] in Vaginal fluid by Probe
45084-1	Chlamydia trachomatis DNA [Presence] in Vaginal fluid by NAA with probe detection
45085-8	Chlamydia trachomatis rRNA [Presence] in Nasopharynx by Probe
45086-6	Chlamydia trachomatis DNA [Presence] in Nasopharynx by NAA with probe detection
45089-0	Chlamydia trachomatis rRNA [Presence] in Anal by Probe
45090-8	Chlamydia trachomatis DNA [Presence] in Anal by NAA with probe detection
45091-6	Chlamydia trachomatis Ag [Presence] in Genital specimen
45092-4	Chlamydia trachomatis Ag [Presence] in Nasopharynx by Immunoassay
45093-2	Chlamydia trachomatis [Presence] in Anal by Organism specific culture
45095-7	Chlamydia trachomatis [Presence] in Genital specimen by Organism specific culture
45096-5	Chlamydia trachomatis [Presence] in Nasopharynx by Organism specific culture
45097-3	Chlamydia sp identified in Anal by Organism specific culture
45098-1	Chlamydia sp identified in Cervix by Organism specific culture
45100-5	Chlamydia sp identified in Vaginal fluid by Organism specific culture
45101-3	Chlamydia sp identified in Nasopharynx by Organism specific culture
45103-9	Chlamydia sp Ag [Presence] in Anal by Immunofluorescence
45104-7	Chlamydia sp Ag [Presence] in Anal by Immunoassay
45105-4	Chlamydia sp Ag [Presence] in Anal
45106-2	Chlamydia sp Ag [Presence] in Cervix by Immunoassay
45107-0	Chlamydia sp Ag [Presence] in Cervix
45108-8	Chlamydia sp Ag [Presence] in Cervix by Immunofluorescence
45112-0	Chlamydia sp Ag [Presence] in Urine by Immunofluorescence
45113-8	Chlamydia sp Ag [Presence] in Urethra by Immunoassay
45114-6	Chlamydia sp Ag [Presence] in Urethra
45115-3	Chlamydia sp Ag [Presence] in Urethra by Immunofluorescence
45131-0	Chlamydia sp Ag [Presence] in Nasopharynx by Immunofluorescence
45132-8	Chlamydia sp Ag [Presence] in Nasopharynx by Immunoassay
45133-6	Chlamydia sp Ag [Presence] in Nasopharynx
47211-8	Chlamydia trachomatis L2 DNA [Presence] in Specimen by NAA with probe detection

47212-6	Chlamydia trachomatis DNA [Identifier] in Specimen by NAA with probe detection
49096-1	Chlamydia trachomatis DNA [Units/volume] in Specimen by NAA with probe detection
4993-2	Chlamydia trachomatis rRNA [Presence] in Specimen by Probe
50311-0	Chlamydia trachomatis DNA [Presence] in Specimen from Donor by NAA with probe detection
50387-0	Chlamydia trachomatis rRNA [Presence] in Cervix by NAA with probe detection
50411-8	Chlamydia trachomatis rRNA [Presence] in Specimen from Donor by NAA with probe detection
51578-3	Chlamydia trachomatis DNA [Presence] in Semen by NAA with probe detection
53925-4	Chlamydia trachomatis rRNA [Presence] in Urethra by NAA with probe detection
53926-2	Chlamydia trachomatis rRNA [Presence] in Vaginal fluid by NAA with probe detection
557-9	Chlamydia sp identified in Genital specimen by Organism specific culture
558-7	Chlamydia sp identified in Throat by Organism specific culture
559-5	Chlamydia sp identified in Urethra by Organism specific culture
560-3	Chlamydia sp identified in Specimen by Organism specific culture
561-1	Chlamydia sp Ag [Presence] in Specimen by Immunofluorescence
57287-5	Chlamydia trachomatis rRNA [Presence] in Anal by NAA with probe detection
57288-3	Chlamydia trachomatis rRNA [Presence] in Nasopharynx by NAA with probe detection
6345-3	Chlamydia sp Ag [Presence] in Genital specimen by Immunoassay
6346-1	Chlamydia sp Ag [Presence] in Genital specimen by Immunofluorescence
6347-9	Chlamydia sp Ag [Presence] in Specimen by Immunoassay
6349-5	Chlamydia trachomatis [Presence] in Specimen by Organism specific culture
6354-5	Chlamydia trachomatis Ag [Presence] in Specimen by Immunoassay
6355-2	Chlamydia trachomatis Ag [Presence] in Specimen by Immunofluorescence
6356-0	Chlamydia trachomatis DNA [Presence] in Genital specimen by NAA with probe detection
6357-8	Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection
80363-5	Chlamydia trachomatis DNA [Presence] in Anorectal by NAA with probe detection
80364-3	Chlamydia trachomatis rRNA [Presence] in Anorectal by NAA with probe detection
80367-6	Chlamydia trachomatis [Presence] in Anorectal by Organism specific culture
82306-2	Chlamydia trachomatis rRNA [Presence] in Throat by NAA with probe detection
88221-7	Chlamydia trachomatis DNA [Presence] in Throat by NAA with probe detection
89648-0	Chlamydia trachomatis [Presence] in Throat by Organism specific culture
91860-7	Chlamydia trachomatis Ag [Presence] in Genital specimen by Immunofluorescence
91873-0	Chlamydia trachomatis Ag [Presence] in Throat by Immunofluorescence
L	

Included Non-LOINC codes

The following local codes are confirmed local pathology codes or test names relevant to chlamydia; these may have a code or a name but are unlikely to have a LOINC code. Where relevant search for the full name within the test field.

Table 59: Included non-LOINC codes – chlamydia

Туре	Code or number	Name – search for complete string
Pathology lab term	N/A	Chlamydia trachomatis DNA
Pathology lab term	N/A	Chlamydia RNA PCR

Chlamydia only - EXCLUDED LOINC CODES

The list of excluded LOINC codes that follows is extensive. Refer to guidance notes above to determine by vendor how to implement.

Due to the volume they are separated into categories in multiple tables; all are exclusions for chlamydia:

- Chlamydia trichomatis
- Chlamydia species (sp.)
- Chlamydophila pneumoniae
- Chlamydophila psittaci
- Both chlamydophila pneumoniae and chlamydophila psittaci
- Chlamydia other / unspecified

Table 60: Excluded LOINC codes – chlamydia only (chlamydia trichomatis)

LOINC number	LOINC long common name
100120-5	Chlamydia trachomatis Ab panel - Serum
100121-3	Chlamydia trachomatis IgA Ab [Presence] in Serum by Immunoassay
13217-5	Chlamydia trachomatis B Ab [Units/volume] in Serum
13218-3	Chlamydia trachomatis C Ab [Units/volume] in Serum
13219-1	Chlamydia trachomatis G+F+K Ab [Units/volume] in Serum
13220-9	Chlamydia trachomatis C IgM Ab [Units/volume] in Serum
13221-7	Chlamydia trachomatis G+F+K IgM Ab [Units/volume] in Serum
13222-5	Deprecated Chlamydia trachomatis C Ab [Units/volume] in Serum
13223-3	Deprecated Chlamydia trachomatis B Ab [Units/volume] in Serum
13224-1	Deprecated Chlamydia trachomatis G+F+K Ab [Units/volume] in Serum
14199-4	Chlamydia trachomatis B IgA Ab [Titer] in Serum by Immunofluorescence
14200-0	Chlamydia trachomatis B IgG Ab [Titer] in Serum by Immunofluorescence
14201-8	Chlamydia trachomatis B IgM Ab [Titer] in Serum by Immunofluorescence
14202-6	Chlamydia trachomatis C IgA Ab [Titer] in Serum by Immunofluorescence
14203-4	Chlamydia trachomatis C IgG Ab [Titer] in Serum by Immunofluorescence
14204-2	Chlamydia trachomatis C IgM Ab [Titer] in Serum by Immunofluorescence
14461-8	Chlamydia trachomatis [Presence] in Blood by Organism specific culture
14462-6	Chlamydia trachomatis [Presence] in Cerebral spinal fluid by Organism specific culture
14466-7	Deprecated Chlamydia trachomatis [Presence] in Penis by Organism specific culture
14468-3	Chlamydia trachomatis Ag [Presence] in Blood by Immunoassay
14469-1	Chlamydia trachomatis Ag [Presence] in Cerebral spinal fluid by Immunoassay
14473-3	Deprecated Chlamydia trachomatis Ag [Presence] in Penis by Immunoassay
14507-8	Chlamydia trachomatis Ag [Presence] in Blood by Immunofluorescence
14508-6	Chlamydia trachomatis Ag [Presence] in Cerebral spinal fluid by Immunofluorescence
14512-8	Deprecated Chlamydia trachomatis Ag [Presence] in Penis by Immunofluorescence
16594-4	Chlamydia trachomatis IgA Ab [Titer] in Cerebral spinal fluid by Immunofluorescence
16595-1	Chlamydia trachomatis IgG Ab [Units/volume] in Cerebral spinal fluid by Immunofluorescence
16596-9	Chlamydia trachomatis IgM Ab [Units/volume] in Cerebral spinal fluid by Immunofluorescence
16597-7	Chlamydia trachomatis B IgG Ab [Units/volume] in Serum
16598-5	Chlamydia trachomatis C IgG Ab [Units/volume] in Serum

16599-3	Chlamydia trachomatis DNA [Presence] in Blood by NAA with probe detection
16602-5	Deprecated Chlamydia trachomatis rRNA [Presence] in Urine by DNA probe
18490-3	Chlamydia trachomatis G+F+K IgA Ab [Titer] in Serum by Immunofluorescence
18491-1	Chlamydia trachomatis G+F+K IgG Ab [Titer] in Serum by Immunofluorescence
18492-9	Chlamydia trachomatis G+F+K IgM Ab [Titer] in Serum by Immunofluorescence
20993-2	Deprecated Chlamydia trachomatis DNA [Presence] in Unspecified specimen by DNA probe
	Chlamydia trachomatis DNA [Presence] in Conjunctival specimen by NAA with probe
21187-0	detection
21188-8	Chlamydia trachomatis rRNA [Presence] in Conjunctival specimen by Probe
22187-9	Chlamydia trachomatis Ab [Titer] in Serum
22188-7	Chlamydia trachomatis IgA Ab [Titer] in Cerebral spinal fluid
22189-5	Chlamydia trachomatis IgA Ab [Titer] in Serum
22190-3	Chlamydia trachomatis IgG Ab [Units/volume] in Cerebral spinal fluid
22191-1	Chlamydia trachomatis IgG Ab [Titer] in Serum
22192-9	Chlamydia trachomatis IgM Ab [Units/volume] in Cerebral spinal fluid
22193-7	Chlamydia trachomatis IgM Ab [Titer] in Serum
22194-5	Chlamydia trachomatis B IgA Ab [Titer] in Serum
22195-2	Chlamydia trachomatis B IgG Ab [Titer] in Serum
22196-0	Chlamydia trachomatis B IgM Ab [Titer] in Serum
22197-8	Chlamydia trachomatis C IgA Ab [Titer] in Serum
22198-6	Chlamydia trachomatis C IgG Ab [Titer] in Serum
22199-4	Chlamydia trachomatis C IgM Ab [Titer] in Serum
22200-0	Chlamydia trachomatis G+F+K IgA Ab [Titer] in Serum
22201-8	Chlamydia trachomatis G+F+K IgG Ab [Titer] in Serum
22202-6	Chlamydia trachomatis G+F+K IgM Ab [Titer] in Serum
26626-2	Chlamydia trachomatis L2 Ab [Presence] in Serum
26663-5	Chlamydia trachomatis D Ab [Presence] in Serum
26664-3	Chlamydia trachomatis E Ab [Presence] in Serum
26665-0	Chlamydia trachomatis F Ab [Presence] in Serum
26666-8	Chlamydia trachomatis H Ab [Presence] in Serum
26667-6	Chlamydia trachomatis I Ab [Presence] in Serum
26668-4	Chlamydia trachomatis L1 Ab [Presence] in Serum
26715-3	Chlamydia trachomatis IgG Ab [Units/volume] in Serum by Immunoassay
27167-6	Chlamydia trachomatis IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence
27185-8	Chlamydia trachomatis IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence
27368-0	Chlamydia trachomatis B Ab [Titer] in Serum by Immunofluorescence
27370-6	Chlamydia trachomatis C Ab [Titer] in Serum by Immunofluorescence
27371-4	Chlamydia trachomatis G+F+K Ab [Titer] in Serum by Immunofluorescence
28556-9	Chlamydia trachomatis D+K IgG Ab [Titer] in Serum by Immunofluorescence
28557-7	Chlamydia trachomatis D+K IgA Ab [Titer] in Serum by Immunofluorescence
28558-5	Chlamydia trachomatis D+K IgM Ab [Titer] in Serum by Immunofluorescence
30204-2	Chlamydia trachomatis Ab [Presence] in Serum
31293-4	Chlamydia trachomatis IgA Ab [Units/volume] in Serum
31294-2	Chlamydia trachomatis B IgA Ab [Units/volume] in Serum
31295-9	Chlamydia trachomatis B IgM Ab [Units/volume] in Serum

31297-5	Chlamydia trachomatis D+K IgG Ab [Units/volume] in Serum
31298-3	Chlamydia trachomatis D+K IgM Ab [Units/volume] in Serum
31768-5	Chlamydia trachomatis Ag [Presence] in Blood
31769-3	Chlamydia trachomatis Ag [Presence] in Conjunctival specimen
31770-1	Chlamydia trachomatis Ag [Presence] in Cerebral spinal fluid
31773-5	Deprecated Chlamydia trachomatis Ag [Presence] in Penis
31774-3	Chlamydia trachomatis Ag [Presence] in Stool
32005-1	Chlamydia trachomatis B Ab [Titer] in Serum
32006-9	Chlamydia trachomatis C Ab [Titer] in Serum
32007-7	Chlamydia trachomatis G+F+K Ab [Titer] in Serum
33574-5	Chlamydia trachomatis I IgM Ab [Titer] in Serum by Immunofluorescence
33575-2	Chlamydia trachomatis I Ab [Titer] in Serum by Immunofluorescence
33604-0	Chlamydia trachomatis I IgM Ab [Titer] in Serum
33605-7	Chlamydia trachomatis I Ab [Titer] in Serum
38469-3	Chlamydia trachomatis rRNA [Presence] in Blood by Probe
40710-6	Chlamydia trachomatis IgM Ab [Presence] in Serum by Immunoassay
40854-2	Chlamydia trachomatis L2 IgG Ab [Titer] in Serum
40855-9	Chlamydia trachomatis L2 IgA Ab [Titer] in Serum
40856-7	Chlamydia trachomatis L2 IgM Ab [Titer] in Serum
41157-9	Chlamydia trachomatis IgM Ab [Presence] in Serum
43058-7	Chlamydia trachomatis D+K IgM Ab [Titer] in Serum
43059-5	Chlamydia trachomatis D+K IgG Ab [Titer] in Serum
43060-3	Chlamydia trachomatis D+K IgA Ab [Titer] in Serum
43061-1	Chlamydia trachomatis IgM Ab [Titer] in Cerebral spinal fluid
43062-9	Chlamydia trachomatis IgG Ab [Titer] in Cerebral spinal fluid
43173-4	Chlamydia trachomatis L2 IgG Ab [Titer] in Serum by Immunofluorescence
43174-2	Chlamydia trachomatis L2 IgA Ab [Titer] in Serum by Immunofluorescence
43175-9	Chlamydia trachomatis L2 IgM Ab [Titer] in Serum by Immunofluorescence
43355-7	Chlamydia trachomatis D+E+F+G+H+I+J+K IgG Ab [Titer] in Serum by Immunofluorescence
	Chlamydia trachomatis D+E+F+G+H+I+J+K IgA Ab [Titer] in Serum by
43356-5	Immunofluorescence
43357-3	Chlamydia trachomatis D+E+F+G+H+I+J+K IgM Ab [Titer] in Serum by Immunofluorescence
43848-1	Chlamydia trachomatis IgG Ab [Presence] in Serum
44005-7	Chlamydia trachomatis D and K IgA and IgG and IgM [Interpretation] in Serum
44079-2	Chlamydia trachomatis IgA and IgG and IgM [Interpretation] in Serum
44983-5	Chlamydia trachomatis L2 IgM Ab [Presence] in Serum
44984-3	Chlamydia trachomatis L2 IgG Ab [Presence] in Serum
44985-0	Chlamydia trachomatis L2 IgA Ab [Presence] in Serum
44986-8	Chlamydia trachomatis G+F+K IgM Ab [Presence] in Serum
44987-6	Chlamydia trachomatis G+F+K IgA Ab [Presence] in Serum
44988-4	Chlamydia trachomatis D+K IgM Ab [Presence] in Serum
44989-2	Chlamydia trachomatis D+K IgG Ab [Presence] in Serum
44990-0	Chlamydia trachomatis D+K IgA Ab [Presence] in Serum
44991-8	Chlamydia trachomatis C IgM Ab [Presence] in Serum
44992-6	Chlamydia trachomatis C IgG Ab [Presence] in Serum

44993-4	Chlamydia trachomatis C IgA Ab [Presence] in Serum
44994-2	Chlamydia trachomatis B IgM Ab [Presence] in Serum
44995-9	Chlamydia trachomatis B IgG Ab [Presence] in Serum
44996-7	Chlamydia trachomatis B IgA Ab [Presence] in Serum
44997-5	Chlamydia trachomatis Ab [Units/volume] in Serum2nd specimen
44998-3	Chlamydia trachomatis Ab [Presence] in Serum1st specimen
44999-1	Chlamydia trachomatis IgM Ab [Presence] in Cerebral spinal fluid
45000-7	Chlamydia trachomatis IgM Ab [Titer] in Serum by Immunoassay
45001-5	Chlamydia trachomatis IgM Ab [Units/volume] in Serum by Immunoassay
45002-3	Chlamydia trachomatis IgG Ab [Presence] in Cerebral spinal fluid
45003-1	Chlamydia trachomatis IgG Ab [Titer] in Serum by Immunoassay
45004-9	Chlamydia trachomatis IgA Ab [Presence] in Cerebral spinal fluid
45005-6	Chlamydia trachomatis IgA Ab [Presence] in Serum
45006-4	Chlamydia trachomatis IgA Ab [Units/volume] in Serum by Immunoassay
45007-2	Chlamydia trachomatis Ab [Units/volume] in Serum by Immunoassay
45008-0	Chlamydia trachomatis Ab [Presence] in Serum by Complement fixation
45009-8	Chlamydia trachomatis Ab [Presence] in Serum by Immunofluorescence
45077-5	Deprecated Chlamydia trachomatis rRNA [Presence] in Conjunctival specimen by DNA probe
45079-1	Deprecated Chlamydia trachomatis rRNA [Presence] in Genital specimen by DNA probe
45081-7	Deprecated Chlamydia trachomatis rRNA [Presence] in Urethra by DNA probe
45082-5	Deprecated Chlamydia trachomatis rRNA [Presence] in Cervix by DNA probe
45083-3	Deprecated Chlamydia trachomatis rRNA [Presence] in Vaginal fluid by DNA probe
45087-4	Deprecated Chlamydia trachomatis DNA [Presence] in Penis by Probe and target amplification method
45088-2	Deprecated Chlamydia trachomatis rRNA [Presence] in Penis by DNA probe
45094-0	Chlamydia trachomatis [Presence] in Conjunctival specimen by Organism specific culture
45130-2	Chlamydia trachomatis Ab [Presence] in Body fluid
45135-1	Chlamydia trachomatis IgG Ab [Presence] in Serum by Immunoassay
46176-4	Chlamydia trachomatis D+E+F+G+H+I+J+K IgA Ab [Titer] in Serum
46177-2	Chlamydia trachomatis D+E+F+G+H+I+J+K IgG Ab [Titer] in Serum
46178-0	Chlamydia trachomatis D+E+F+G+H+I+J+K IgM Ab [Titer] in Serum
47234-0	Chlamydia trachomatis Ag [Presence] in Body fluid
5087-2	Chlamydia trachomatis Ab [Titer] in Serum by Complement fixation
5088-0	Chlamydia trachomatis Ab [Titer] in Serum by Immunofluorescence
5089-8	Chlamydia trachomatis IgG Ab [Units/volume] in Serum
5090-6	Chlamydia trachomatis IgM Ab [Units/volume] in Serum
51734-2	Chlamydia trachomatis L2 IgA and IgG and IgM [Interpretation] in Serum
6350-3	Chlamydia trachomatis Ag [Presence] in Conjunctival specimen by Immunoassay
6351-1	Chlamydia trachomatis Ag [Presence] in Conjunctival specimen by Immunofluorescence
6352-9	Chlamydia trachomatis Ag [Presence] in Stool by Immunofluorescence
6353-7	Chlamydia trachomatis Ag [Presence] in Tissue by Immunofluorescence
6358-6	Deprecated Chlamydia trachomatis rRNA [Presence] in Unspecified specimen by DNA probe
6918-7	Chlamydia trachomatis IgA Ab [Titer] in Serum by Immunofluorescence
6919-5	Chlamydia trachomatis IgG Ab [Titer] in Serum by Immunofluorescence
6920-3	Chlamydia trachomatis IgM Ab [Titer] in Serum by Immunofluorescence

7824-6	Chlamydia trachomatis Ab [Units/volume] in Serum
87949-4	Chlamydia trachomatis DNA [Presence] in Tissue by NAA with probe detection
87950-2	Chlamydia trachomatis [Presence] in Tissue by Organism specific culture
90361-7	Chlamydia trachomatis L1 IgA Ab [Titer] in Serum by Immunoassay
90362-5	Chlamydia trachomatis L1 IgG Ab [Titer] in Serum by Immunoassay
90363-3	Chlamydia trachomatis L1 IgM Ab [Titer] in Serum by Immunoassay
90365-8	Chlamydia trachomatis L1 Ab.lgG+lgA+lgM Interpretation in Serum by Immunoassay
91861-5	Chlamydia trachomatis Ag [Presence] in Aspirate by Immunofluorescence
99105-9	Chlamydia trachomatis Ag [Presence] in Serum or Plasma by Immunoassay
99778-3	Chlamydia trachomatis rRNA [Presence] in Conjunctival specimen by NAA with probe detection

Table 61: Excluded LOINC codes – chlamydia only (chlamydia sp.)

LOINC number	LOINC long common name
10848-0	Chlamydia sp IgG Ab [Titer] in Serum by Immunofluorescence
10849-8	Chlamydia sp IgM Ab [Titer] in Serum by Immunofluorescence
16589-4	Chlamydia sp Ab [Units/volume] in Serum by Immunofluorescence
16590-2	Chlamydia sp Ab [Units/volume] in Serum by Complement fixation
16591-0	Chlamydia sp IgG Ab [Units/volume] in Cerebral spinal fluid by Immunofluorescence
16592-8	Chlamydia sp IgM Ab [Units/volume] in Cerebral spinal fluid by Immunofluorescence
20755-5	Chlamydia sp Ag [Presence] in Body fluid by Immunoassay
20756-3	Chlamydia sp Ag [Presence] in Stool by Immunoassay
20757-1	Chlamydia sp Ag [Presence] in Tissue by Immunofluorescence
21185-4	Chlamydia sp IgG Ab [Presence] in Serum
21186-2	Chlamydia sp IgM Ab [Presence] in Serum
22182-0	Chlamydia sp Ab [Titer] in Serum
22183-8	Chlamydia sp IgG Ab [Units/volume] in Cerebral spinal fluid
22184-6	Chlamydia sp IgG Ab [Titer] in Serum
22185-3	Chlamydia sp IgM Ab [Units/volume] in Cerebral spinal fluid
22186-1	Chlamydia sp IgM Ab [Titer] in Serum
23967-3	Chlamydia sp Ab [Titer] in Cerebral spinal fluid
23990-5	Chlamydia sp Ab [Titer] in Cerebral spinal fluid by Complement fixation
24005-1	Chlamydia sp identified in Bronchial specimen by Organism specific culture
24238-8	Chlamydia sp IgG Ab [Units/volume] in Serum1st specimen
24239-6	Chlamydia sp IgG Ab [Units/volume] in Serum2nd specimen
25369-0	Chlamydia sp IgA Ab [Units/volume] in Serum
27273-2	Chlamydia sp Ab [Titer] in Cerebral spinal fluid by Immunofluorescence
29664-0	Chlamydia sp IgA Ab [Presence] in Serum by Immunoassay
29677-2	Chlamydia sp IgA Ab [Presence] in Serum
31292-6	Chlamydia sp Ab [Units/volume] in Cerebral spinal fluid
31763-6	Chlamydia sp Ag [Presence] in Conjunctival specimen
31764-4	Chlamydia sp Ag [Presence] in Body fluid
31766-9	Chlamydia sp Ag [Presence] in Stool
32002-8	Deprecated Chlamydia sp Ag [Presence] in Penis by Immunoassay
32003-6	Chlamydia sp Ag [Presence] in Peritoneal fluid by Immunoassay

33410-2	Chlamydia sp IgG Ab [Units/volume] in Serum by Immunoassay
34264-2	Chlamydia sp IgA Ab [Titer] in Serum by Immunofluorescence
35710-3	Chlamydia sp DNA [Presence] in Conjunctival specimen by NAA with probe detection
35712-9	Chlamydia sp rRNA [Presence] in Conjunctival specimen by Probe
	Deprecated Chlamydia sp DNA [Presence] in Penis by Probe and target amplification
35719-4	method
35720-2	Deprecated Chlamydia sp rRNA [Presence] in Penis by DNA probe
35722-8	Chlamydia sp DNA [Presence] in Serum by NAA with probe detection
35723-6	Chlamydia sp rRNA [Presence] in Serum by Probe
38467-7	Chlamydia sp IgG Ab [Presence] in Body fluid
38468-5	Chlamydia sp Ab [Presence] in Cerebral spinal fluid
41482-1	Chlamydia sp IgG and IgM panel [Titer] - Serum
43063-7	Chlamydia sp IgA Ab [Titer] in Serum
43846-5	Chlamydophila sp Ab [Interpretation] in Serum
43847-3	Chlamydophila sp Ab [Presence] in Serum by Immunofluorescence
45010-6	Chlamydia sp IgG Ab [Presence] in Cerebral spinal fluid
45011-4	Chlamydia sp Ab [Units/volume] in Cerebral spinal fluid by Immunoassay
45012-2	Chlamydia sp Ab [Presence] in Serum
45099-9	Chlamydia sp identified in Body fluid by Organism specific culture
45102-1	Deprecated Chlamydia sp identified in Penis by Organism specific culture
45109-6	Chlamydia sp Ag [Presence] in Body fluid by Immunofluorescence
45110-4	Deprecated Chlamydia sp Ag [Presence] in Penis
45111-2	Deprecated Chlamydia sp Ag [Presence] in Penis by Immunofluorescence
46179-8	Chlamydophila sp Ab [Presence] in Serum
5082-3	Chlamydia sp Ab [Units/volume] in Serum by Immunoassay
5083-1	Chlamydia sp Ab [Titer] in Serum by Complement fixation
5084-9	Chlamydia sp Ab [Titer] in Serum by Immunofluorescence
5085-6	Chlamydia sp IgG Ab [Units/volume] in Serum
5086-4	Chlamydia sp IgM Ab [Units/volume] in Serum
556-1	Chlamydia sp identified in Conjunctival specimen by Organism specific culture
56909-5	Chlamydia sp IgG Ab [Presence] in Serum by Immunoassay
56910-3	Chlamydia sp IgG Ab [Units/volume] in Serum by Immunoassay1st specimen
56911-1	Chlamydia sp IgG Ab [Units/volume] in Serum by Immunoassay2nd specimen
57679-3	Chlamydia sp IgG Ab [Presence] in Serum by Immunoassay1st specimen
57680-1	Chlamydia sp IgG Ab [Presence] in Serum by Immunoassay2nd specimen
6342-0	Deprecated Chlamydia sp Ab [Titer] in Serum by Complement fixation
6343-8	Chlamydia sp Ag [Presence] in Conjunctival specimen by Immunoassay
6344-6	Chlamydia sp Ag [Presence] in Conjunctival specimen by Immunofluorescence
6348-7	Chlamydia sp identified in Sputum by Organism specific culture
75757-5	Chlamydia sp Ab [Presence] in Serum by Complement fixation
77166-7	Chlamydia sp IgG and IgM panel [Titer] - Serum by Immunofluorescence
7823-8	Chlamydia sp Ab [Units/volume] in Serum
86659-0	Chlamydia sp tests - FPAR 2.0 set

Table 62: Excluded LOINC codes – chlamydia only (chlamydophila pneumoniae)

LOINC number	LOINC long common name
100122-1	Chlamydophila pneumoniae Ab panel - Serum
100123-9	Chlamydophila pneumoniae IgA Ab [Presence] in Serum by Immunoassay
100124-7	Chlamydophila pneumoniae IgA Ab [Units/volume] in Serum by Immunoassay
10651-8	Chlamydophila pneumoniae Ag [Presence] in Sputum or Bronchial
10652-6	Chlamydophila pneumoniae DNA [Presence] in Sputum or Bronchial by Probe with amplification
11254-0	Chlamydophila pneumoniae Ab [Titer] in Serum
16581-1	Chlamydophila pneumoniae IgA Ab [Titer] in Cerebral spinal fluid by Immunofluorescence
16582-9	Chlamydophila pneumoniae IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence
16583-7	Chlamydophila pneumoniae IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence
16584-5	Chlamydophila pneumoniae rRNA [Presence] in Sputum by Probe
16585-2	Chlamydophila pneumoniae rRNA [Presence] in Serum or Plasma by Probe
21184-7	Chlamydophila pneumoniae [Presence] in Specimen by Organism specific culture
22169-7	Chlamydophila pneumoniae IgA Ab [Titer] in Cerebral spinal fluid
22170-5	Chlamydophila pneumoniae IgA Ab [Titer] in Serum
22171-3	Chlamydophila pneumoniae IgG Ab [Titer] in Cerebral spinal fluid
22172-1	Chlamydophila pneumoniae IgG Ab [Titer] in Serum
22173-9	Chlamydophila pneumoniae IgM Ab [Titer] in Cerebral spinal fluid
22174-7	Chlamydophila pneumoniae IgM Ab [Titer] in Serum
24004-4	Chlamydophila pneumoniae IgM Ab [Presence] in Serum
29722-6	Chlamydophila pneumoniae Ag [Presence] in Specimen by Immunofluorescence
30205-9	Chlamydophila pneumoniae Ab [Presence] in Serum
31299-1	Chlamydophila pneumoniae IgA Ab [Units/volume] in Cerebral spinal fluid
31300-7	Chlamydophila pneumoniae IgA Ab [Units/volume] in Serum
31301-5	Chlamydophila pneumoniae IgG Ab [Units/volume] in Cerebral spinal fluid
31302-3	Chlamydophila pneumoniae IgG Ab [Units/volume] in Serum
31303-1	Chlamydophila pneumoniae IgM Ab [Units/volume] in Cerebral spinal fluid
31304-9	Chlamydophila pneumoniae IgM Ab [Units/volume] in Serum
31778-4	Chlamydophila pneumoniae Ag [Presence] in Specimen
34645-2	Chlamydophila pneumoniae DNA [Presence] in Specimen by NAA with probe detection
34707-0	Chlamydophila pneumoniae rRNA [Presence] in Specimen by Probe
43844-0	Chlamydophila pneumoniae IgM Ab [Presence] in Serum by Immunofluorescence
43845-7	Chlamydophila pneumoniae Ab [Titer] in Serum by Immunofluorescence
44080-0	Chlamydophila pneumoniae IgG and IgM [Interpretation] in Serum
44979-3	Chlamydophila pneumoniae Ab [Presence] in Serum2nd specimen
44980-1	Chlamydophila pneumoniae Ab [Presence] in Serum1st specimen
44981-9	Chlamydophila pneumoniae IgG Ab [Presence] in Serum
44982-7	Chlamydophila pneumoniae IgA Ab [Presence] in Serum
47052-6	Chlamydophila pneumoniae Ab [Units/volume] in Serum by Immunofluorescence
50612-1	Chlamydophila pneumoniae IgA and IgG and IgM [Interpretation] in Serum
5078-1	Chlamydophila pneumoniae Ab [Units/volume] in Serum
51806-8	Chlamydophila pneumoniae IgG Ab [Units/volume] in Serum by Immunoassay
51807-6	Chlamydophila pneumoniae IgM Ab [Units/volume] in Serum by Immunoassay

58758-4	Chlamydophila pneumoniae IgG Ab [Units/volume] in Cerebral spinal fluid by Immunoassay
6912-0	Chlamydophila pneumoniae IgA Ab [Titer] in Serum by Immunofluorescence
6913-8	Chlamydophila pneumoniae IgG Ab [Titer] in Serum by Immunofluorescence
6914-6	Chlamydophila pneumoniae IgM Ab [Titer] in Serum by Immunofluorescence
7821-2	Chlamydophila pneumoniae rRNA [Presence] in Serum by NAA with probe detection
82178-5	Chlamydophila pneumoniae DNA [Presence] in Nasopharynx by NAA with non-probe detection
88546-7	Chlamydophila pneumoniae DNA [Presence] in Aspirate by NAA with probe detection
88547-5	Chlamydophila pneumoniae DNA [Presence] in Lower respiratory specimen by NAA with probe detection
88718-2	Chlamydophila pneumoniae DNA [Presence] in Nasopharynx by NAA with probe detection
89640-7	Chlamydophila pneumoniae IgM Ab [Presence] in Serum by Immunoassay
89641-5	Chlamydophila pneumoniae IgG Ab [Presence] in Serum by Immunoassay
92133-8	Chlamydophila pneumoniae DNA [Presence] in Respiratory specimen by NAA with probe detection
92577-6	Chlamydophila pneumoniae DNA [Presence] in Upper respiratory specimen by NAA with probe detection
92859-8	Chlamydophila pneumoniae and Mycoplasma pneumoniae DNA panel - Lower respiratory specimen by NAA with probe detection
92860-6	Chlamydophila pneumoniae and Mycoplasma pneumoniae DNA panel - Upper respiratory specimen by NAA with probe detection
92986-9	Chlamydophila pneumoniae DNA [Presence] in Lower respiratory specimen by NAA with non-probe detection

Table 63: Excluded LOINC codes – chlamydia only (chlamydophila psittaci)

LOINC number	LOINC long common name
100125-4	Chlamydophila psittaci Ab panel - Serum
14198-6	Chlamydophila psittaci Ab [Titer] in Serum by Immunofluorescence
16586-0	Chlamydophila psittaci IgA Ab [Titer] in Cerebral spinal fluid by Immunofluorescence
16587-8	Chlamydophila psittaci IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence
16588-6	Chlamydophila psittaci IgM Ab [Units/volume] in Cerebral spinal fluid
20752-2	Chlamydophila psittaci [Presence] in Specimen by Organism specific culture
20753-0	Chlamydophila psittaci Ag [Presence] in Tissue by Immunofluorescence
20754-8	Chlamydophila psittaci Ab [Presence] in Serum by Complement fixation
22175-4	Chlamydophila psittaci Ab [Presence] in Serum
22176-2	Chlamydophila psittaci Ab [Titer] in Serum
22177-0	Chlamydophila psittaci IgA Ab [Titer] in Cerebral spinal fluid
22178-8	Chlamydophila psittaci IgA Ab [Titer] in Serum
22179-6	Chlamydophila psittaci IgG Ab [Titer] in Cerebral spinal fluid
22180-4	Chlamydophila psittaci IgG Ab [Titer] in Serum
22181-2	Chlamydophila psittaci IgM Ab [Titer] in Serum
22992-2	Chlamydophila psittaci [Presence] in Specimen by Giemsa stain
22993-0	Chlamydophila psittaci [Presence] in Placenta by Electron microscopy
22994-8	Chlamydophila psittaci Ab [Presence] in Serum by Agglutination
22995-5	Chlamydophila psittaci Ab [Presence] in Serum by Immune diffusion (ID)

22996-3 Chlamydophila psittaci Ab [Presence] in Serum by Immunoassay 22997-1 Chlamydophila psittaci Ag [Presence] in Specimen by Immune stain 22998-9 Chlamydophila psittaci Ag [Presence] in Tissue by Immune stain 23000-3 Chlamydophila psittaci Ag [Presence] in Stool by Immune stain 23000-3 Chlamydophila psittaci Ag [Presence] in Exudate by Immune stain 23001-1 Chlamydophila psittaci DNA [Presence] in Exudate by Immune stain 23001-1 Chlamydophila psittaci IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence 31305-6 Chlamydophila psittaci IgA Ab [Units/volume] in Cerebral spinal fluid 31306-4 Chlamydophila psittaci IgA Ab [Units/volume] in Cerebral spinal fluid 31307-2 Chlamydophila psittaci IgG Ab [Units/volume] in Cerebral spinal fluid 31379-2 Chlamydophila psittaci IgG Ab [Presence] in Genital specimen 31780-0 Chlamydophila psittaci IgG Ab [Presence] in Specimen 31780-0 Chlamydophila psittaci IgG Ab [Presence] in Serum 44081-8 Chlamydophila psittaci IgG Ab [Presence] in Serum 44081-8 Chlamydophila psittaci IgA and IgG and IgM [Interpretation] in Serum 44977-7 Chlamydophila psittaci IgA Ab [Presence] in Serum 5079-9 Chlamydophila psittaci IgA Ab [Presence] in Serum 5080-7 Chlamydophila psittaci IgA Ab [Inter] in Serum by Complement fixation 5080-7 Chlamydophila psittaci IgA Ab [Inter] in Serum by Complement fixation 5080-7 Chlamydophila psittaci IgA Ab [Units/volume] in Serum 51808-4 Chlamydophila psittaci IgA Ab [Units/volume] in Serum 51809-2 Chlamydophila psittaci IgA Ab [Units/volume] in Serum by Immunoassay 51809-2 Chlamydophila psittaci IgA Ab [Units/volume] in Serum by Immunoassay 6338-8 Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunoassay 6339-6 Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunofluorescence 6340-4 Chlamydophila psittaci Ag [Presence] in Serum by Immunofluorescence 6315-3 Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence 6316-1 Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence 6317-9 Chlamydophila psittaci		
Chlamydophila psittaci Ag [Presence] in Tissue by Immune stain Chlamydophila psittaci Ag [Presence] in Stool by Immune stain Chlamydophila psittaci Ag [Presence] in Exudate by Immune stain Chlamydophila psittaci DNA [Presence] in Specimen by NAA with probe detection Chlamydophila psittaci IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence Chlamydophila psittaci IgA Ab [Units/volume] in Cerebral spinal fluid Chlamydophila psittaci IgA Ab [Units/volume] in Cerebral spinal fluid Chlamydophila psittaci IgA Ab [Units/volume] in Cerebral spinal fluid Chlamydophila psittaci IgA Ab [Units/volume] in Cerebral spinal fluid Chlamydophila psittaci IgA Ab [Units/volume] in Cerebral spinal fluid Chlamydophila psittaci Ag [Presence] in Genital specimen Chlamydophila psittaci Ag [Presence] in Specimen Chlamydophila psittaci IgA Ab [Titer] in Cerebral spinal fluid Chlamydophila psittaci IgA Ab [Titer] in Cerebral spinal fluid Chlamydophila psittaci IgA Ab [Presence] in Serum Chlamydophila psittaci IgA and IgA and IgA Interpretation] in Serum Chlamydophila psittaci IgA Ab [Presence] in Serum Chlamydophila psittaci IgA Ab [Presence] in Serum Chlamydophila psittaci IgA Ab [Presence] in Serum Chlamydophila psittaci IgA Ab [Interpretation] in Serum by Immunoassay Chlamydophila psittaci IgA Ab [Interpretation] in Serum by Immunoassay Chlamydophila psittaci IgA Ab [Interpretation] in Serum by Immunoassay Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunoassay Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunoassay Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunoassay Chlamydophila psittaci Ag [Presence] in Serum by Immunofluorescence Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescenc	22996-3	Chlamydophila psittaci Ab [Presence] in Serum by Immunoassay
22999-7 Chlamydophila psittaci Ag [Presence] in Stool by Immune stain 23000-3 Chlamydophila psittaci Ag [Presence] in Exudate by Immune stain 23001-1 Chlamydophila psittaci DNA [Presence] in Specimen by NAA with probe detection 27404-3 Chlamydophila psittaci IgA Ab [Inits/volume] in Cerebral spinal fluid by Immunofluorescence 31305-6 Chlamydophila psittaci IgA Ab [Units/volume] in Cerebral spinal fluid 31306-4 Chlamydophila psittaci IgA Ab [Units/volume] in Cerebral spinal fluid 31307-2 Chlamydophila psittaci IgG Ab [Units/volume] in Cerebral spinal fluid 31779-2 Chlamydophila psittaci Ag [Presence] in Genital specimen 31780-0 Chlamydophila psittaci Ag [Presence] in Specimen 31780-0 Chlamydophila psittaci IgA Ab [Titer] in Cerebral spinal fluid 43868-9 Chlamydophila psittaci IgA Ab [Presence] in Serum 44081-8 Chlamydophila psittaci IgA Ab [Presence] in Serum 44977-7 Chlamydophila psittaci IgA Ab [Presence] in Serum 44978-5 Chlamydophila psittaci IgA Ab [Presence] in Serum 5079-9 Chlamydophila psittaci IgA Ab [Presence] in Serum 5080-7 Chlamydophila psittaci IgA Ab [Units/volume] in Serum 5081-5 Chlamydophila psittaci IgG Ab [Units/volume] in Serum 51808-4 Chlamydophila psittaci IgG Ab [Units/volume] in Serum by Immunoassay 51809-2 Chlamydophila psittaci IgG Ab [Units/volume] in Serum by Immunoassay 51809-2 Chlamydophila psittaci IgG Ab [Units/volume] in Serum by Immunoassay 51809-2 Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunoassay 51809-2 Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunoassay 51809-2 Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunofluorescence 638-8 Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunofluorescence 6404-4 Chlamydophila psittaci Ag [Presence] in Serum by Immunofluorescence 6540-4 Chlamydophila psittaci Ag [Presence] in Secimen by Immunofluorescence 6615-3 Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence 6616-1 Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence	22997-1	Chlamydophila psittaci Ag [Presence] in Specimen by Immune stain
Chlamydophila psittaci Ag [Presence] in Exudate by Immune stain Chlamydophila psittaci DNA [Presence] in Specimen by NAA with probe detection C7404-3 Chlamydophila psittaci IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence Chlamydophila psittaci IgA Ab [Units/volume] in Cerebral spinal fluid Chlamydophila psittaci IgA Ab [Units/volume] in Cerebral spinal fluid Chlamydophila psittaci IgA Ab [Units/volume] in Cerebral spinal fluid Chlamydophila psittaci IgA Ab [Units/volume] in Cerebral spinal fluid Chlamydophila psittaci IgA (Presence] in Genital specimen Chlamydophila psittaci Ag [Presence] in Genital specimen Chlamydophila psittaci Ag [Presence] in Specimen Chlamydophila psittaci IgM Ab [Titer] in Cerebral spinal fluid Chlamydophila psittaci IgA Ab [Presence] in Serum Chlamydophila psittaci IgA and IgA and IgA in Serum Chlamydophila psittaci IgA Ab [Presence] in Serum Chlamydophila psittaci IgA Ab [Units/volume] in Serum by Immunoassay Chlamydophila psittaci IgA Ab [Units/volume] in Serum by Immunoassay Chlamydophila psittaci IgA Ab [Units/volume] in Serum by Immunoassay Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunoassay Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunoassay Chlamydophila psittaci Ag [Presence] in Specimen by Immunoassay Chlamydophila psittaci Ag [Presence] in Specimen by Immunoassay Chlamydophila psittaci Ag [Presence] in Specimen by Immunoassay Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence	22998-9	Chlamydophila psittaci Ag [Presence] in Tissue by Immune stain
23001-1 Chlamydophila psittaci DNA [Presence] in Specimen by NAA with probe detection 27404-3 Chlamydophila psittaci IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence 31305-6 Chlamydophila psittaci IgA Ab [Units/volume] in Cerebral spinal fluid 31306-4 Chlamydophila psittaci IgA Ab [Units/volume] in Serum 31307-2 Chlamydophila psittaci IgG Ab [Units/volume] in Cerebral spinal fluid 31779-2 Chlamydophila psittaci Ag [Presence] in Genital specimen 31780-0 Chlamydophila psittaci Ag [Presence] in Specimen 43057-9 Chlamydophila psittaci IgM Ab [Titer] in Cerebral spinal fluid 43868-9 Chlamydophila psittaci IgM Ab [Titer] in Cerebral spinal fluid 43868-9 Chlamydophila psittaci IgM Ab [Presence] in Serum 44081-8 Chlamydophila psittaci IgM Ab [Presence] in Serum 44977-7 Chlamydophila psittaci IgM Ab [Presence] in Serum 44978-5 Chlamydophila psittaci IgM Ab [Presence] in Serum 5079-9 Chlamydophila psittaci IgM Ab [Inter] in Serum by Complement fixation 5080-7 Chlamydophila psittaci IgM Ab [Units/volume] in Serum 5081-5 Chlamydophila psittaci IgM Ab [Units/volume] in Serum 51808-4 Chlamydophila psittaci IgM Ab [Units/volume] in Serum by Immunoassay 51809-2 Chlamydophila psittaci IgM Ab [Units/volume] in Serum by Immunoassay 51809-2 Chlamydophila psittaci IgM Ab [Units/volume] in Serum by Immunoassay 6338-8 Chlamydophila psittaci Ag [Presence] in Bronchial brush by Organism specific culture 6338-8 Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunoassay 6341-2 Chlamydophila psittaci Ag [Presence] in Specimen by Immunofluorescence 6915-3 Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence 6916-1 Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence	22999-7	Chlamydophila psittaci Ag [Presence] in Stool by Immune stain
27404-3 Chlamydophila psittaci IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence 31305-6 Chlamydophila psittaci IgA Ab [Units/volume] in Cerebral spinal fluid 31306-4 Chlamydophila psittaci IgA Ab [Units/volume] in Serum 31307-2 Chlamydophila psittaci IgG Ab [Units/volume] in Cerebral spinal fluid 31779-2 Chlamydophila psittaci Ag [Presence] in Genital specimen 31780-0 Chlamydophila psittaci Ag [Presence] in Serum 43057-9 Chlamydophila psittaci IgM Ab [Titer] in Cerebral spinal fluid 43668-9 Chlamydophila psittaci IgG Ab [Presence] in Serum 44081-8 Chlamydophila psittaci IgA and IgG and IgM [Interpretation] in Serum 44977-7 Chlamydophila psittaci IgM Ab [Presence] in Serum 44978-5 Chlamydophila psittaci IgA Ab [Presence] in Serum 5079-9 Chlamydophila psittaci IgA Ab [Inter] in Serum by Complement fixation 5080-7 Chlamydophila psittaci IgA Ab [Units/volume] in Serum 5081-5 Chlamydophila psittaci IgM Ab [Units/volume] in Serum 51808-4 Chlamydophila psittaci IgM Ab [Units/volume] in Serum by Immunoassay 51809-2 Chlamydophila psittaci IgM Ab [Units/volume] in Serum by Immunoassay 59065-3 Chlamydophila psittaci IgM Ab [Units/volume] in Serum by Immunoassay 6338-8 Chlamydophila psittaci IgPresence] in Genital specimen by Immunoassay 6339-6 Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunoassay 6341-2 Chlamydophila psittaci Ag [Presence] in Serum by Immunofluorescence 6915-3 Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence 6916-1 Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence 6917-9 Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence	23000-3	Chlamydophila psittaci Ag [Presence] in Exudate by Immune stain
31305-6 Chlamydophila psittaci IgA Ab [Units/volume] in Cerebral spinal fluid 31306-4 Chlamydophila psittaci IgA Ab [Units/volume] in Serum 31307-2 Chlamydophila psittaci IgG Ab [Units/volume] in Cerebral spinal fluid 31779-2 Chlamydophila psittaci Ag [Presence] in Genital specimen 31780-0 Chlamydophila psittaci Ag [Presence] in Specimen 43057-9 Chlamydophila psittaci IgM Ab [Titer] in Cerebral spinal fluid 43868-9 Chlamydophila psittaci IgG Ab [Presence] in Serum 44081-8 Chlamydophila psittaci IgA and IgG and IgM [Interpretation] in Serum 44977-7 Chlamydophila psittaci IgM Ab [Presence] in Serum 44978-5 Chlamydophila psittaci IgA Ab [Presence] in Serum 5079-9 Chlamydophila psittaci IgA Ab [Titer] in Serum by Complement fixation 5080-7 Chlamydophila psittaci IgM Ab [Units/volume] in Serum 5081-5 Chlamydophila psittaci IgM Ab [Units/volume] in Serum 51808-4 Chlamydophila psittaci IgG Ab [Units/volume] in Serum by Immunoassay 51809-2 Chlamydophila psittaci IgM Ab [Units/volume] in Serum by Immunoassay 59065-3 Chlamydophila psittaci [Presence] in Bronchial brush by Organism specific culture 6338-8 Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunoassay 639-6 Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunoassay 6341-2 Chlamydophila psittaci Ag [Presence] in Specimen by Immunofluorescence 6915-3 Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence 6916-1 Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence 6917-9 Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence	23001-1	Chlamydophila psittaci DNA [Presence] in Specimen by NAA with probe detection
31306-4 Chlamydophila psittaci IgA Ab [Units/volume] in Serum 31307-2 Chlamydophila psittaci IgG Ab [Units/volume] in Cerebral spinal fluid 31779-2 Chlamydophila psittaci Ag [Presence] in Genital specimen 31780-0 Chlamydophila psittaci Ag [Presence] in Specimen 43057-9 Chlamydophila psittaci IgM Ab [Titer] in Cerebral spinal fluid 43868-9 Chlamydophila psittaci IgA and IgG and IgM [Interpretation] in Serum 44081-8 Chlamydophila psittaci IgA and IgG and IgM [Interpretation] in Serum 44977-7 Chlamydophila psittaci IgA Ab [Presence] in Serum 5079-9 Chlamydophila psittaci IgA Ab [Presence] in Serum 5080-7 Chlamydophila psittaci Ab [Titer] in Serum by Complement fixation 5080-7 Chlamydophila psittaci IgA Ab [Units/volume] in Serum 5081-5 Chlamydophila psittaci IgA Ab [Units/volume] in Serum 51808-4 Chlamydophila psittaci IgA Ab [Units/volume] in Serum by Immunoassay 51809-2 Chlamydophila psittaci IgA Ab [Units/volume] in Serum by Immunoassay 59065-3 Chlamydophila psittaci IgA Ab [Units/volume] in Serum by Immunoassay 6338-8 Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunofluorescence 6340-4 Chlamydophila psittaci Ag [Presence] in Specimen by Immunofluorescence 6341-2 Chlamydophila psittaci Ag [Presence] in Specimen by Immunofluorescence 6915-3 Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence 6916-1 Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence 6917-9 Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence	27404-3	Chlamydophila psittaci IgM Ab [Titer] in Cerebral spinal fluid by Immunofluorescence
Chlamydophila psittaci IgG Ab [Units/volume] in Cerebral spinal fluid 31779-2 Chlamydophila psittaci Ag [Presence] in Genital specimen 31780-0 Chlamydophila psittaci Ag [Presence] in Specimen 43057-9 Chlamydophila psittaci IgM Ab [Titer] in Cerebral spinal fluid 43868-9 Chlamydophila psittaci IgG Ab [Presence] in Serum 44081-8 Chlamydophila psittaci IgA and IgG and IgM [Interpretation] in Serum 44977-7 Chlamydophila psittaci IgA Ab [Presence] in Serum 44978-5 Chlamydophila psittaci IgA Ab [Presence] in Serum 5079-9 Chlamydophila psittaci Ab [Titer] in Serum by Complement fixation 5080-7 Chlamydophila psittaci IgA Ab [Units/volume] in Serum 5081-5 Chlamydophila psittaci IgA Ab [Units/volume] in Serum by Immunoassay 51808-4 Chlamydophila psittaci IgA Ab [Units/volume] in Serum by Immunoassay 51809-2 Chlamydophila psittaci IgM Ab [Units/volume] in Serum by Immunoassay 5065-3 Chlamydophila psittaci [Presence] in Bronchial brush by Organism specific culture 6338-8 Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunoassay 6339-6 Chlamydophila psittaci Ag [Presence] in Specimen by Immunofluorescence 6340-4 Chlamydophila psittaci Ag [Presence] in Specimen by Immunofluorescence 6915-3 Chlamydophila psittaci Ag [Presence] in Specimen by Immunofluorescence 6915-3 Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence 6916-1 Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence 6917-9 Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence	31305-6	Chlamydophila psittaci IgA Ab [Units/volume] in Cerebral spinal fluid
Chlamydophila psittaci Ag [Presence] in Genital specimen Chlamydophila psittaci Ag [Presence] in Specimen Chlamydophila psittaci IgM Ab [Titer] in Cerebral spinal fluid Chlamydophila psittaci IgM Ab [Presence] in Serum Chlamydophila psittaci IgA and IgG and IgM [Interpretation] in Serum Chlamydophila psittaci IgM Ab [Presence] in Serum Chlamydophila psittaci IgM Ab [Presence] in Serum Chlamydophila psittaci IgM Ab [Presence] in Serum Chlamydophila psittaci IgA Ab [Presence] in Serum Chlamydophila psittaci IgA Ab [Interpretation] in Serum by Immunoassay Chlamydophila psittaci IgA Ab [Interpretation] in Serum by Immunoassay Chlamydophila psittaci IgA [Presence] in Genital specimen by Immunoassay Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunofluorescence Chlamydophila psittaci Ag [Presence] in Specimen by Immunofluorescence Chlamydophila psittaci Ag [Presence] in Specimen by Immunofluorescence Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence	31306-4	Chlamydophila psittaci IgA Ab [Units/volume] in Serum
Chlamydophila psittaci Ag [Presence] in Specimen Chlamydophila psittaci IgM Ab [Titer] in Cerebral spinal fluid Chlamydophila psittaci IgG Ab [Presence] in Serum Chlamydophila psittaci IgG And IgM [Interpretation] in Serum Chlamydophila psittaci IgM Ab [Presence] in Serum Chlamydophila psittaci IgM Ab [Presence] in Serum Chlamydophila psittaci IgM Ab [Presence] in Serum Chlamydophila psittaci IgA Ab [Presence] in Serum Chlamydophila psittaci Ab [Titer] in Serum by Complement fixation Chlamydophila psittaci IgG Ab [Units/volume] in Serum Chlamydophila psittaci IgG Ab [Units/volume] in Serum Chlamydophila psittaci IgG Ab [Units/volume] in Serum by Immunoassay Chlamydophila psittaci IgM Ab [Units/volume] in Serum by Immunoassay Chlamydophila psittaci IgM Ab [Units/volume] in Serum by Immunoassay Chlamydophila psittaci [Presence] in Bronchial brush by Organism specific culture Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunoassay Chlamydophila psittaci Ag [Presence] in Specimen by Immunofluorescence Chlamydophila psittaci Ag [Presence] in Specimen by Immunofluorescence Chlamydophila psittaci Ag [Presence] in Specimen by Immunofluorescence Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence Chlamydophila psittaci IgG Ab [Titer] in Serum by Immunofluorescence Chlamydophila psittaci IgG Ab [Titer] in Serum by Immunofluorescence Chlamydophila psittaci IgG Ab [Titer] in Serum by Immunofluorescence	31307-2	Chlamydophila psittaci IgG Ab [Units/volume] in Cerebral spinal fluid
Chlamydophila psittaci IgM Ab [Titer] in Cerebral spinal fluid 43868-9 Chlamydophila psittaci IgG Ab [Presence] in Serum 44081-8 Chlamydophila psittaci IgA and IgG and IgM [Interpretation] in Serum 44977-7 Chlamydophila psittaci IgM Ab [Presence] in Serum 44978-5 Chlamydophila psittaci IgA Ab [Presence] in Serum 5079-9 Chlamydophila psittaci Ab [Titer] in Serum by Complement fixation 5080-7 Chlamydophila psittaci IgG Ab [Units/volume] in Serum 5081-5 Chlamydophila psittaci IgM Ab [Units/volume] in Serum 51808-4 Chlamydophila psittaci IgG Ab [Units/volume] in Serum by Immunoassay 51809-2 Chlamydophila psittaci IgM Ab [Units/volume] in Serum by Immunoassay 5065-3 Chlamydophila psittaci IgM Ab [Units/volume] in Serum by Immunoassay 6338-8 Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunoassay 6340-4 Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunoassay 6341-2 Chlamydophila psittaci Ag [Presence] in Specimen by Immunofluorescence 6915-3 Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence 6916-1 Chlamydophila psittaci IgM Ab [Titer] in Serum by Immunofluorescence 6917-9 Chlamydophila psittaci IgM Ab [Titer] in Serum by Immunofluorescence	31779-2	Chlamydophila psittaci Ag [Presence] in Genital specimen
Chlamydophila psittaci IgG Ab [Presence] in Serum Chlamydophila psittaci IgA and IgG and IgM [Interpretation] in Serum Chlamydophila psittaci IgA Ab [Presence] in Serum Chlamydophila psittaci Ab [Titer] in Serum by Complement fixation Chlamydophila psittaci IgG Ab [Units/volume] in Serum Chlamydophila psittaci IgG Ab [Units/volume] in Serum Chlamydophila psittaci IgG Ab [Units/volume] in Serum by Immunoassay Chlamydophila psittaci IgM Ab [Units/volume] in Serum by Immunoassay Chlamydophila psittaci IgM Ab [Units/volume] in Serum by Immunoassay Chlamydophila psittaci IgM Ab [Units/volume] in Serum by Immunoassay Chlamydophila psittaci IgM Ab [Presence] in Genital specimen by Immunoassay Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunoassay Chlamydophila psittaci Ag [Presence] in Specimen by Immunofluorescence Chlamydophila psittaci Ag [Presence] in Specimen by Immunofluorescence Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence Chlamydophila psittaci IgG Ab [Titer] in Serum by Immunofluorescence Chlamydophila psittaci IgG Ab [Titer] in Serum by Immunofluorescence Chlamydophila psittaci IgG Ab [Titer] in Serum by Immunofluorescence	31780-0	Chlamydophila psittaci Ag [Presence] in Specimen
Chlamydophila psittaci IgA and IgG and IgM [Interpretation] in Serum Chlamydophila psittaci IgM Ab [Presence] in Serum Chlamydophila psittaci IgA Ab [Presence] in Serum Chlamydophila psittaci IgA Ab [Presence] in Serum Chlamydophila psittaci Ab [Titer] in Serum by Complement fixation Chlamydophila psittaci IgG Ab [Units/volume] in Serum Chlamydophila psittaci IgM Ab [Units/volume] in Serum Chlamydophila psittaci IgG Ab [Units/volume] in Serum by Immunoassay Chlamydophila psittaci IgM Ab [Units/volume] in Serum by Immunoassay Chlamydophila psittaci IgM Ab [Units/volume] in Serum by Immunoassay Chlamydophila psittaci IgM Ab [Units/volume] in Serum by Immunoassay Chlamydophila psittaci IgM Ab [Presence] in Genital specimen by Immunoassay Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunofluorescence Chlamydophila psittaci Ag [Presence] in Specimen by Immunofluorescence Chlamydophila psittaci Ag [Presence] in Specimen by Immunofluorescence Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence Chlamydophila psittaci IgG Ab [Titer] in Serum by Immunofluorescence Chlamydophila psittaci IgM Ab [Titer] in Serum by Immunofluorescence Chlamydophila psittaci IgM Ab [Titer] in Serum by Immunofluorescence	43057-9	Chlamydophila psittaci IgM Ab [Titer] in Cerebral spinal fluid
44977-7 Chlamydophila psittaci IgM Ab [Presence] in Serum 44978-5 Chlamydophila psittaci IgA Ab [Presence] in Serum 5079-9 Chlamydophila psittaci Ab [Titer] in Serum by Complement fixation 5080-7 Chlamydophila psittaci IgG Ab [Units/volume] in Serum 5081-5 Chlamydophila psittaci IgM Ab [Units/volume] in Serum 51808-4 Chlamydophila psittaci IgG Ab [Units/volume] in Serum by Immunoassay 51809-2 Chlamydophila psittaci IgM Ab [Units/volume] in Serum by Immunoassay 59065-3 Chlamydophila psittaci [Presence] in Bronchial brush by Organism specific culture 6338-8 Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunoassay 6339-6 Chlamydophila psittaci Ag [Presence] in Specimen by Immunofluorescence 6340-4 Chlamydophila psittaci Ag [Presence] in Specimen by Immunofluorescence 6915-3 Chlamydophila psittaci Ag [Presence] in Specimen by Immunofluorescence 6915-3 Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence 6916-1 Chlamydophila psittaci IgG Ab [Titer] in Serum by Immunofluorescence 6917-9 Chlamydophila psittaci IgM Ab [Titer] in Serum by Immunofluorescence	43868-9	Chlamydophila psittaci IgG Ab [Presence] in Serum
Chlamydophila psittaci IgA Ab [Presence] in Serum Chlamydophila psittaci Ab [Titer] in Serum by Complement fixation Chlamydophila psittaci IgG Ab [Units/volume] in Serum Chlamydophila psittaci IgM Ab [Units/volume] in Serum Chlamydophila psittaci IgG Ab [Units/volume] in Serum Chlamydophila psittaci IgG Ab [Units/volume] in Serum by Immunoassay Chlamydophila psittaci IgM Ab [Units/volume] in Serum by Immunoassay Chlamydophila psittaci [Presence] in Bronchial brush by Organism specific culture Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunoassay Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunofluorescence Chlamydophila psittaci Ag [Presence] in Specimen by Immunofluorescence Chlamydophila psittaci Ag [Presence] in Specimen by Immunofluorescence Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence Chlamydophila psittaci IgG Ab [Titer] in Serum by Immunofluorescence Chlamydophila psittaci IgM Ab [Titer] in Serum by Immunofluorescence Chlamydophila psittaci IgM Ab [Titer] in Serum by Immunofluorescence	44081-8	Chlamydophila psittaci IgA and IgG and IgM [Interpretation] in Serum
Chlamydophila psittaci Ab [Titer] in Serum by Complement fixation Chlamydophila psittaci IgG Ab [Units/volume] in Serum Chlamydophila psittaci IgM Ab [Units/volume] in Serum Chlamydophila psittaci IgG Ab [Units/volume] in Serum by Immunoassay Chlamydophila psittaci IgM Ab [Units/volume] in Serum by Immunoassay Chlamydophila psittaci IgM Ab [Units/volume] in Serum by Immunoassay Chlamydophila psittaci [Presence] in Bronchial brush by Organism specific culture Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunoassay Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunofluorescence Chlamydophila psittaci Ag [Presence] in Specimen by Immunossay Chlamydophila psittaci Ag [Presence] in Specimen by Immunofluorescence Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence Chlamydophila psittaci IgG Ab [Titer] in Serum by Immunofluorescence Chlamydophila psittaci IgM Ab [Titer] in Serum by Immunofluorescence Chlamydophila psittaci IgM Ab [Titer] in Serum by Immunofluorescence	44977-7	Chlamydophila psittaci IgM Ab [Presence] in Serum
Chlamydophila psittaci IgG Ab [Units/volume] in Serum Chlamydophila psittaci IgM Ab [Units/volume] in Serum Chlamydophila psittaci IgG Ab [Units/volume] in Serum by Immunoassay Chlamydophila psittaci IgM Ab [Units/volume] in Serum by Immunoassay Chlamydophila psittaci IgM Ab [Units/volume] in Serum by Immunoassay Chlamydophila psittaci [Presence] in Bronchial brush by Organism specific culture Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunoassay Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunofluorescence Chlamydophila psittaci Ag [Presence] in Specimen by Immunoassay Chlamydophila psittaci Ag [Presence] in Specimen by Immunofluorescence Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence Chlamydophila psittaci IgG Ab [Titer] in Serum by Immunofluorescence Chlamydophila psittaci IgG Ab [Titer] in Serum by Immunofluorescence Chlamydophila psittaci IgM Ab [Titer] in Serum by Immunofluorescence	44978-5	Chlamydophila psittaci IgA Ab [Presence] in Serum
Chlamydophila psittaci IgM Ab [Units/volume] in Serum Chlamydophila psittaci IgG Ab [Units/volume] in Serum by Immunoassay Chlamydophila psittaci IgM Ab [Units/volume] in Serum by Immunoassay Chlamydophila psittaci IgM Ab [Units/volume] in Serum by Immunoassay Chlamydophila psittaci [Presence] in Bronchial brush by Organism specific culture Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunoassay Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunofluorescence Chlamydophila psittaci Ag [Presence] in Specimen by Immunoassay Chlamydophila psittaci Ag [Presence] in Specimen by Immunofluorescence Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence Chlamydophila psittaci IgG Ab [Titer] in Serum by Immunofluorescence Chlamydophila psittaci IgM Ab [Titer] in Serum by Immunofluorescence Chlamydophila psittaci IgM Ab [Titer] in Serum by Immunofluorescence	5079-9	Chlamydophila psittaci Ab [Titer] in Serum by Complement fixation
Chlamydophila psittaci IgG Ab [Units/volume] in Serum by Immunoassay Chlamydophila psittaci IgM Ab [Units/volume] in Serum by Immunoassay Chlamydophila psittaci [Presence] in Bronchial brush by Organism specific culture Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunoassay Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunofluorescence Chlamydophila psittaci Ag [Presence] in Specimen by Immunoassay Chlamydophila psittaci Ag [Presence] in Specimen by Immunofluorescence Chlamydophila psittaci Ag [Presence] in Specimen by Immunofluorescence Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence Chlamydophila psittaci IgG Ab [Titer] in Serum by Immunofluorescence Chlamydophila psittaci IgM Ab [Titer] in Serum by Immunofluorescence Chlamydophila psittaci IgM Ab [Titer] in Serum by Immunofluorescence	5080-7	Chlamydophila psittaci IgG Ab [Units/volume] in Serum
Chlamydophila psittaci IgM Ab [Units/volume] in Serum by Immunoassay Chlamydophila psittaci [Presence] in Bronchial brush by Organism specific culture Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunoassay Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunofluorescence Chlamydophila psittaci Ag [Presence] in Specimen by Immunoassay Chlamydophila psittaci Ag [Presence] in Specimen by Immunofluorescence Chlamydophila psittaci Ag [Presence] in Specimen by Immunofluorescence Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence Chlamydophila psittaci IgG Ab [Titer] in Serum by Immunofluorescence Chlamydophila psittaci IgM Ab [Titer] in Serum by Immunofluorescence Chlamydophila psittaci IgM Ab [Titer] in Serum by Immunofluorescence	5081-5	Chlamydophila psittaci IgM Ab [Units/volume] in Serum
Chlamydophila psittaci [Presence] in Bronchial brush by Organism specific culture Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunoassay Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunofluorescence Chlamydophila psittaci Ag [Presence] in Specimen by Immunoassay Chlamydophila psittaci Ag [Presence] in Specimen by Immunofluorescence Chlamydophila psittaci Ag [Presence] in Specimen by Immunofluorescence Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence Chlamydophila psittaci IgG Ab [Titer] in Serum by Immunofluorescence Chlamydophila psittaci IgM Ab [Titer] in Serum by Immunofluorescence	51808-4	Chlamydophila psittaci IgG Ab [Units/volume] in Serum by Immunoassay
6338-8 Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunoassay 6339-6 Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunofluorescence 6340-4 Chlamydophila psittaci Ag [Presence] in Specimen by Immunoassay 6341-2 Chlamydophila psittaci Ag [Presence] in Specimen by Immunofluorescence 6915-3 Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence 6916-1 Chlamydophila psittaci IgG Ab [Titer] in Serum by Immunofluorescence 6917-9 Chlamydophila psittaci IgM Ab [Titer] in Serum by Immunofluorescence	51809-2	Chlamydophila psittaci IgM Ab [Units/volume] in Serum by Immunoassay
6339-6 Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunofluorescence 6340-4 Chlamydophila psittaci Ag [Presence] in Specimen by Immunoassay 6341-2 Chlamydophila psittaci Ag [Presence] in Specimen by Immunofluorescence 6915-3 Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence 6916-1 Chlamydophila psittaci IgG Ab [Titer] in Serum by Immunofluorescence 6917-9 Chlamydophila psittaci IgM Ab [Titer] in Serum by Immunofluorescence	59065-3	Chlamydophila psittaci [Presence] in Bronchial brush by Organism specific culture
6340-4 Chlamydophila psittaci Ag [Presence] in Specimen by Immunoassay 6341-2 Chlamydophila psittaci Ag [Presence] in Specimen by Immunofluorescence 6915-3 Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence 6916-1 Chlamydophila psittaci IgG Ab [Titer] in Serum by Immunofluorescence 6917-9 Chlamydophila psittaci IgM Ab [Titer] in Serum by Immunofluorescence	6338-8	Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunoassay
6341-2 Chlamydophila psittaci Ag [Presence] in Specimen by Immunofluorescence 6915-3 Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence 6916-1 Chlamydophila psittaci IgG Ab [Titer] in Serum by Immunofluorescence 6917-9 Chlamydophila psittaci IgM Ab [Titer] in Serum by Immunofluorescence	6339-6	Chlamydophila psittaci Ag [Presence] in Genital specimen by Immunofluorescence
6915-3 Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence 6916-1 Chlamydophila psittaci IgG Ab [Titer] in Serum by Immunofluorescence 6917-9 Chlamydophila psittaci IgM Ab [Titer] in Serum by Immunofluorescence	6340-4	Chlamydophila psittaci Ag [Presence] in Specimen by Immunoassay
6916-1 Chlamydophila psittaci IgG Ab [Titer] in Serum by Immunofluorescence 6917-9 Chlamydophila psittaci IgM Ab [Titer] in Serum by Immunofluorescence	6341-2	Chlamydophila psittaci Ag [Presence] in Specimen by Immunofluorescence
6917-9 Chlamydophila psittaci IgM Ab [Titer] in Serum by Immunofluorescence	6915-3	Chlamydophila psittaci IgA Ab [Titer] in Serum by Immunofluorescence
	6916-1	Chlamydophila psittaci IgG Ab [Titer] in Serum by Immunofluorescence
7822-0 Chlamydophila psittaci Ab [Units/volume] in Serum	6917-9	Chlamydophila psittaci IgM Ab [Titer] in Serum by Immunofluorescence
	7822-0	Chlamydophila psittaci Ab [Units/volume] in Serum

Table 64: Excluded LOINC codes – chlamydia only (both chlamydophila pneumoniae and chlamydophila psittaci)

LOINC number	LOINC long common name
24402-0	Chlamydophila pneumoniae+Chlamydophila psittaci DNA [Presence] in Specimen by Probe with amplification
33943-2	Chlamydophila pneumoniae+Chlamydophila psittaci DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
35639-4	Chlamydophila pneumoniae+Chlamydophila psittaci DNA [Presence] in Tissue by NAA with probe detection
43216-1	Chlamydophila pneumoniae+Chlamydophila psittaci DNA [Presence] in Throat by NAA with probe detection

Table 65: Excluded LOINC codes – chlamydia only (both chlamydophila pneumoniae and chlamydophila psittaci)

LOINC number	LOINC long common name
39224-1	Chlamydia screen test status CPHS
54044-3	HEDIS 2009 Codes to identify Chlamydia screening (CHL-C)
57817-9	HEDIS 2010-2013 Codes to identify Chlamydia screening (CHL-C)
74241-1	HEDIS 2014-2016 Value Set - Chlamydia Tests
82957-2	HEDIS 2017, 2018 Value Set - Chlamydia Tests
90763-4	HEDIS 2019-2020 Value Set - Chlamydia Tests
96075-7	HEDIS MY 2020 Value Set - Chlamydia Tests

Gonorrhoea only – INCLUDED CODES

The LOINC codes in Table 66 are relevant only to gonorrhoea.

Table 66: Included LOINC codes – Gonorrhoea only

LOINC code	LOINC long common name
14127-5	Neisseria gonorrhoeae [Presence] in Anal by Organism specific culture
21414-8	Neisseria gonorrhoeae DNA [Presence] in Cervical mucus by NAA with probe detection
21415-5	Neisseria gonorrhoeae DNA [Presence] in Urethra by NAA with probe detection
21416-3	Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection
24111-7	Neisseria gonorrhoeae DNA [Presence] in Specimen by NAA with probe detection
29311-8	Neisseria gonorrhoeae Ag [Presence] in Specimen by Immunofluorescence
31905-3	Neisseria gonorrhoeae Ag [Presence] in Genital specimen
31906-1	Neisseria gonorrhoeae Ag [Presence] in Specimen
32198-4	Neisseria gonorrhoeae rRNA [Presence] in Cervix by Probe
32199-2	Neisseria gonorrhoeae rRNA [Presence] in Urethra by Probe
32705-6	Neisseria gonorrhoeae DNA [Presence] in Vaginal fluid by NAA with probe detection
43305-2	Neisseria gonorrhoeae rRNA [Presence] in Specimen by NAA with probe detection
43403-5	Neisseria gonorrhoeae DNA [Presence] in Specimen by Probe with signal amplification
47387-6	Neisseria gonorrhoeae DNA [Presence] in Genital specimen by NAA with probe detection
5028-6	Neisseria gonorrhoeae rRNA [Presence] in Specimen by Probe
50326-8	Neisseria gonorrhoeae DNA [Presence] in Specimen from Donor by NAA with probe detection
50388-8	Neisseria gonorrhoeae rRNA [Presence] in Cervix by NAA with probe detection
50412-6	Neisseria gonorrhoeae rRNA [Presence] in Specimen from Donor by NAA with probe detection
53879-3	Neisseria gonorrhoeae rRNA [Presence] in Vaginal fluid by NAA with probe detection
53927-0	Neisseria gonorrhoeae rRNA [Presence] in Urethra by NAA with probe detection
57180-2	Neisseria gonorrhoeae DNA [Presence] in Nasopharynx by NAA with probe detection
57289-1	Neisseria gonorrhoeae rRNA [Presence] in Nasopharynx by NAA with probe detection
57458-2	Neisseria gonorrhoeae rRNA [Presence] in Anal by NAA with probe detection
60255-7	Neisseria gonorrhoeae rRNA [Presence] in Throat by NAA with probe detection
60256-5	Neisseria gonorrhoeae rRNA [Presence] in Urine by NAA with probe detection
6487-3	Neisseria gonorrhoeae Ag [Presence] in Genital specimen by Immunoassay
6488-1	Neisseria gonorrhoeae Ag [Presence] in Genital specimen by Immunofluorescence
6489-9	Neisseria gonorrhoeae Ag [Presence] in Genital specimen by Latex agglutination
6490-7	Neisseria gonorrhoeae Ag [Presence] in Urethra
688-2	Neisseria gonorrhoeae [Presence] in Cervix by Organism specific culture
690-8	Neisseria gonorrhoeae [Presence] in Endometrium by Organism specific culture
691-6	Neisseria gonorrhoeae [Presence] in Genital specimen by Organism specific culture
692-4	Neisseria gonorrhoeae [Presence] in Genital lochia by Organism specific culture
693-2	Neisseria gonorrhoeae [Presence] in Vaginal fluid by Organism specific culture
694-0	Neisseria gonorrhoeae [Presence] in Semen by Organism specific culture
696-5	Neisseria gonorrhoeae [Presence] in Throat by Organism specific culture
697-3	Neisseria gonorrhoeae [Presence] in Urethra by Organism specific culture
698-1	Neisseria gonorrhoeae [Presence] in Specimen by Organism specific culture
80366-8	Neisseria gonorrhoeae rRNA [Presence] in Anorectal by NAA with probe detection

80368-4	Neisseria gonorrhoeae [Presence] in Anorectal by Organism specific culture
88224-1	Neisseria gonorrhoeae DNA [Presence] in Anorectal by NAA with probe detection
88225-8	Neisseria gonorrhoeae DNA [Presence] in Throat by NAA with probe detection
96599-6	Neisseria gonorrhoeae DNA [Presence] in Cervix by NAA with probe detection

Included Non-LOINC codes

The following local codes are confirmed local pathology codes or test names relevant to gonorrhoea; these may have a code or a name but are unlikely to have a LOINC code. Where relevant search for the full name within the test field.

Table 67: Included non-LOINC codes – gonorrhoea

Туре	Code or number	Name – search for complete string
Pathology lab term	N/A	Neisseria gonorrhoeae DNA
Pathology lab term	N/A	Gonorrhoeae RNA PCR

Gonorrhoea only - EXCLUDED LOINC CODES

The list of excluded LOINC codes in Table 68 are relevant to gonorrhoea.

Table 68: Excluded LOINC codes – gonorrhoea only

LOINC number	LOINC long common name
22430-3	Neisseria gonorrhoeae Ab [Titer] in Serum
23908-7	Deprecated Neisseria gonorrhoeae DNA [Presence] in Unspecified specimen by DNA probe
27021-5	Neisseria gonorrhoeae Ab [Titer] in Cerebral spinal fluid by Complement fixation
30099-6	Neisseria gonorrhoeae [Presence] in Conjunctival specimen by Organism specific culture
31525-9	Neisseria gonorrhoeae Ab [Units/volume] in Cerebral spinal fluid
32704-9	Neisseria gonorrhoeae Ab [Presence] in Serum
33904-4	Neisseria gonorrhoeae rRNA [Presence] in Conjunctival specimen by Probe
35735-0	Neisseria gonorrhoeae DNA [Presence] in Conjunctival specimen by NAA with probe detection
39557-4	Deprecated Neisseria gonorrhoeae rRNA [Presence] in Cervix by DNA probe
42987-8	Neisseria gonorrhoeae Ab [Titer] in Cerebral spinal fluid
43387-0	Neisseria sp identified in Specimen by Organism specific culture
5261-3	Neisseria gonorrhoeae Ab [Units/volume] in Serum
53762-1	Neisseria gonorrhoeae IgG Ab [Titer] in Serum
53878-5	Deprecated Neisseria gonorrhoeae rRNA [Presence] in Penis by Probe and target amplification method
6491-5	Deprecated Neisseria gonorrhoeae rRNA [Presence] in Unspecified specimen by DNA probe
689-0	Deprecated Neisseria gonorrhoeae [Presence] in Cervix by Organism specific culture
695-7	Neisseria gonorrhoeae [Presence] in Synovial fluid by Organism specific culture
86660-8	Neisseria gonorrhoeae tests - FPAR 2.0 set
91781-5	Neisseria gonorrhoeae [Presence] in Aspirate by Organism specific culture
9568-7	Neisseria gonorrhoeae Ab [Titer] in Serum by Complement fixation
97626-6	Neisseria gonorrhoeae DNA [Presence] in Synovial fluid by NAA with non-probe detection
99779-1	Neisseria gonorrhoeae rRNA [Presence] in Conjunctival specimen by NAA with probe detection

Free text searches - Inclusion and Exclusion Terms

To capture tests that do not have a LOINC code, inclusion of free text searches is recommended. However, it is important to minimise overcounting through inclusion of terms that may sound appropriate but are not clinically relevant to STIs e.g. some tests include the word 'chlamydia' but are not STI tests.

To mitigate this risk, searches for free text terms should consider both inclusion and exclusion terms within the term name/field. Ideally the principles listed above will also be considered, for example, anatomical location.

Free text terms may only exist as a component of the free text instance searched. To account for this, <u>any instance of these terms</u> should be counted (i.e. a wildcard search), unless an excluded term also appears in the same test name field. Terms should be searched as complete terms as listed e.g. 'ct main' or 'NG and CT'.

Specific types of Chlamydia need to be excluded to ensure non-STI variants of these conditions are not included in the calculation of PI25; these terms are listed in a separate table.

Note: There are no exclusions for Gonorrhoea as all types of Gonorrhoea are considered STIs.

All terms MUST be case-insensitive (i.e. both lower and upper case or a combination of case).

Table 69: STI coding - INCLUDED text search terms

Туре	Chlamydia	Gonorrhoea
Free text	Chlamydial infection	Gono
Free text	Chlamydial STI	Gonno
Free text	Chlamydia trachomati	Neisseria gonorrhoea
Free text	Chlamydia trachomatis	Gonococcus
Free text	Chlamydial trachomatis	Gonorrhea
Free text	c trachom	N gonorrhoea
Free text	Chlamydial	Gonorrhoea
Free text	Chlamydia	Gonorrhoeae
Free text	Chlam	Gnrrh
Free text	ct main	ng main
Free text	CTNG	CTNG
Free text	CT/NG	CT/NG
Free text	CHL/GON	CHL/GON
Free text	U-CHL/GON	U-CHL/GON
Free text	NG and CT	NG and CT

Table 70: STI coding - EXCLUDED text search terms

Chlamydia	Gonorrhoea
Pneumoniae	None
Pneum	
Psittaci	
Ornithosis	
Orni	

Vendor Implementation – Pathology Data Capture

Table 71 describes current search methods being used by each CIS to capture pathology results for STIs.

Where CIS vendors have customised features to support more rigorous data capture these are outlined below.

Table 71: STI search methods by vendor (current as of December 2023)

CIS	Search method
Best Practice	Search for LOINC codes and case insensitive free text
	2. Exclusion by excluded LOINCs
	3. Exclusion by wildcard search of 'Ab', 'IgA', 'IgG', 'IgM' and non-STI test terms eg psittaci.
Communicare	Check for LOINCs as specified in the Pathology Coding Framework, excluding those with specimen types defined as 'Excluded specimens'
	Check results with no LOINC that have any of the defined strings in the test name returned by the lab
	3. If nothing found from 1 and 2 look for qualifiers* that are evidence of a Chlamydia or Gonorrhoea result being received. These are those Boolean qualifiers with a system code of XCL or XGN, reference type qualifiers with an export code of CT- RSLT or NG-RSLT and reference type qualifiers 'TTANGO Chlamydia' or 'TTANGO Gonorrhoea'.
	Note: Free text synonyms will not be searched.
	*Qualifiers are coded both centrally and locally by organisations.
Medical Director	LOINC codes and case insensitive free text
	2. Wild card exclusion by free text excluded terms.
MMEx	LOINC and valid local codes
	System tag that can denote an observation as an STI result with or without a code.
	Note: Free text synonyms will not be searched.